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Abstract 
Approximately 550,000–570,000 women are alive in the UK who have had a 
diagnosis of breast cancer with further predictions that this will rise by 3% 
annually. Most of these women will be receiving follow-up care in a hospital 
setting and the value of this approach has been questioned for a number of 
years. Women transition from a very individual, personalised treatment plan to 
follow-up care which is not organised around individual patient need. Rather a 
blanket approach is used which does not consider age, risk profile, treatment or 
need. There is evidence that the current out-patient follow-up provision does not 
meet the physical, psychological and information needs of women with breast 
cancer, with women leaving the clinic with unmet needs. While the aim of follow-
up is multifactorial, including the provision of psychosocial care, there is little 
evidence of how this service assesses and addresses unmet needs. 
Aim  
The current study sought to examine the effectiveness of providing patient 
reported needs and psychosocial information to the Specialist Breast Care Nurse 
at the breast cancer follow-up clinic in reducing cancer needs and improving 
quality of life compared to standard care. The primary outcome was a change in 
needs scored at baseline (time 1) and 12 months (time 2). The study also aimed 
to investigate a number of secondary outcomes namely changes in quality of life 
at baseline and 12 months, as well as looking at possible effects of the 
intervention on variables such as age, severity of treatment and time since 
diagnosis.   
 
Method 
This study was a prospective single blind randomised controlled trial (RCT) 
involving 93 women who had completed primary treatment for breast cancer and 
were attending follow-up in a hospital setting.  Women were randomised to 
receive standard follow-up care (control) or a nurse-delivered intervention.  The 
intervention was structured and guided by the self-reported needs and 
psychosocial information provided by the woman and coupled with a person-
iv 
 
centred conversation. This conversation explored the options for the intervention, 
desire of the woman for assistance and best way to provide it. 
 
Results 
There were high levels of need, anxiety and depression among women attending 
the follow-up clinic. There was a statistically significant fall in level of need, 
anxiety and depression in both groups after the intervention. However, no 
differences between groups in relation to the primary outcome; changes in needs 
between baseline and time 2, were seen.  Quality of life scores fell in both groups; 
however only the overall quality of life score showed a statistically significant 
difference between groups in relation to the secondary outcome, changes in 
quality of life over time. 
 
Conclusion 
The results of this study have shown that using patient-reported needs and 
psychological information by the specialist breast care nurse in the follow-up clinic 
to inform an intervention proved to be no better than standard care, but neither is 
there sufficient evidence to state it was worse. This study has contributed to the 
methodological evidence base regarding the development and measurement of 
complex interventions in nursing practice.     
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Glossary 
Adjuvant treatment (also known as postoperative chemotherapy):  This 
usually refers to systemic chemotherapy, hormonal treatment, or both, given to 
people after removal of a primary tumour (in this case, surgery for early breast 
cancer), with the aim of killing any remaining micrometastatic tumour cells and 
thus preventing recurrence. 
 
Axillary clearance:  Clearance of level I, II, and usually level III axillary lymph 
nodes. Level I nodes are lateral to the pectoralis minor muscle, level II nodes are 
under it, and level III nodes are medial to it at the apex of the axilla. 
 
Axillary sampling: Aims to remove the four largest, most easily palpable axillary 
lymph nodes for histological examination. 
 
Breast conserving surgery: Surgery consisting of lumpectomy (minimal cancer 
free margins), wide local excision (wider free margins) 
 
Disease free survival: Means being alive with no local or distant recurrence or 
contralateral disease. 
 
Early invasive breast cancer: (stage I or II) is M0 with T1 or T2 (tumour 
diameter ≤ 5 cm, no involvement of skin or chest wall) and N0 or N1 (mobile 
axillary nodes); or M0 with T3 (tumour diameter > 5 cm, no skin or chest wall 
involvement), but only N0. 
 
Follow-up: care after primary treatment of women with breast cancer to promote 
physical and psychosocial rehabilitation, monitor treatment effectiveness 
including short and long term toxicity, and detect recurrence or new cancers 
 
Mastectomy:  Removal of the breast  
 
xxi 
 
Metastatic breast cancer: (stage IV) is M1 (any supraclavicular fossa node 
involvement or distant metastases to bone, lung, liver, etc.) with any combination 
of tumour and node parameters. 
 
Needs: ‘the requirement of some action or resource necessary, desirable, or 
useful, to attain optimal well-being’ Sanson-Fisher et al (2000: p  227) 
 
Non-invasive breast cancer (stage 0) is Tis (carcinoma in situ, intraductal 
carcinoma, lobular carcinoma in situ, or Paget’s disease of the nipple with no 
associated tumour); N0 (no axillary nodal involvement); and M0 (no metastases). 
 
Sentinel node biopsy:  A procedure whereby the first nodes in the draining 
lymphatic basin are removed and examined by a pathologist for cancer cells. 
 
Staging of breast cancer: A detailed description of the tumour, node status and, 
metastatic parameters at a particular time (TNM).  These are amalgamated into 
broader categories called stages (0–IV). Stages can be aggregated into even 
broader categories (non-invasive, early invasive and advanced breast cancer). 
 
Breast cancer survivor: Defined as women who have completed primary 
treatment (Surgery, chemotherapy, radiotherapy and Herceptin) and may be up to 
and beyond 5 years following diagnosis 
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Chapter 1: Introduction to the thesis 
1.1 Introduction 
Breast cancer is the most common cancer among women in the United Kingdom 
(UK) and relative 5 year survival is 85% (Cancer Research UK, 2012).  
Approximately 550,000 – 570,000 women are alive in the UK who have had a 
diagnosis of breast cancer with further predictions that this will rise by 3% 
annually (Maddams et al. 2009).  While the biomedical definition of cancer 
survival refers to the population of cancer patients who live disease-free for at 
least 5 years after treatment, for an individual woman, it is the quality of the 
survival leading up to this, or any, milestone that impacts on their unmet needs, 
recovery and adaptation. After primary treatment for breast cancer, women 
usually attend regular follow-up examinations, irrespective of age, risk profile or 
treatment. In the UK frequency is no longer defined in current guidelines (Scottish 
Intercollegiate Guidelines Network (SIGN), 2013; National Institute of Clinical 
Excellence (NICE), 2009), but many units still see women in follow-up clinics up 
to 5 years and beyond following their diagnosis. It is this period, follow-up, and 
specifically the appointment within the hospital setting, which is the focus of this 
thesis. 
The aim of follow-up is not only to detect new cancer or recurrence through 
examination but also to provide physical, and psychosocial rehabilitation, and 
monitoring of treatment effectiveness including short and long term toxicity (Rojas 
et al. 2009).  Research and practice based literature has been critical of follow-up, 
questioning its cost-effectiveness in providing optimum care and its ability to 
achieve its many aims within a short consultation (Sakorafas, Tsiotou & Pavlakis,. 
2000; Emens & Davidson, 2003; Collins, Bekker & Dodwell, 2004; Rutgers, 2004; 
Roche, 2006; European Society for Medical Oncology (ESMO) 2007; Tolaney & 
Winer, 2007; Beaver, Williamson & Chalmers, 2009; Rose & Watson, 2009; van 
Hezewijk et al. 2012). 
Studies that report womens views of follow-up care suggest they are largely 
positive about this appointment and few women would recommend moving away 
2 
 
from the status quo with some expressing a wish to attend more frequently 
(Montgomery et al. 2008; Kimman et al. 2010).  While the debate continues about 
the merits of providing follow-up care, a number of research studies suggest that 
women have multiple unmet psychological, physical and information needs post-
treatment (Raupach & Hiller, 2002; de Bock et al. 2004a; Thewes et al. 2004; 
Beaver et al. 2006; McCaughan & McSorley, 2007), and that these are neither 
assessed nor addressed adequately through follow-up care. Unmet needs closely 
correlate with distress according to Carey et al. (2012), add to the burden of 
suffering and interfere with a person’s ability to move on (Folkman & Greer, 
2000).  Therefore to aid recovery, the means to identify and intervene to improve 
and reduce perceived cancer needs would appear a logical goal of healthcare 
service.  
 
“Human needs” does not lend itself to a clear and unambiguous definition as it 
has two major and competing facets namely: the motivational approach that 
directs human behaviour (Maslow, 1987) and that of a force which is politically 
driven; shaped by social and cultural influences (Marx, 1964). The idea that 
nursing should be dedicated to meeting patients’ needs is a dominant theme that 
has emerged among nursing theorists (Tomey & Alligood, 2002). Within the multi 
professional arena of breast cancer, it could not and should not be considered 
solely a nursing remit. 
 
Marx (1964) was one of the early theorists linking needs to social and political 
forces.  He espoused that the ideal society was one which recognised the needs 
of the people and fulfilled them. This increased interest in human needs was 
closely related to the allocation of resources in society and fundamental fairness.  
Holmes & Warelow (1997) proposed that expressed and perceived needs are 
moulded by dominant political ideologies and social practices, and it is 
questionable whether these needs can be distinguished from desires, wants and 
rights.  Farrell provides a tentative distinction between… “a need which must be 
satisfied and a want that can be deferred” (1991, p.1063).   Similarly, Plant, 
Lesser & Taylor-Gooby (1980) suggest that wants are articulated and satisfied 
within the context of the marketplace, whereas needs ought to be met within the 
context of welfare services. These authors agree that the term “need” carries 
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persuasive connotations particularly in relation to health needs, but some 
ambiguity exists within healthcare whether we fulfill needs or wants.   
 
In contrast, Maslow’s scientific philosophy reflected a belief that man is a “whole 
functioning, adjusting individual”(1987, p.25) who is best understood from a 
holistic approach. All humans possess basic needs which must be satisfied for 
the sake of physical health. Maslow (1943) suggests that human needs are 
arranged in hierarchies of pre-potency, with the appearance of one dependent 
upon the satisfaction of a more pre-potent need.  Maslow (1943) moves from 
physiological needs to those of safety, esteem and self-actualisation and 
suggests the influence of knowledge and understanding, motivation and 
behaviour on the acquisition of basic need, is fundamental to this process. If a 
need has been identified, action is recognised as favourable by an individual or 
professional as inaction can cause persistence of need and dissatisfaction 
(Schmid-Buchi et al. 2008).  In their work with cancer patients, Sanson-Fisher et 
al. describes the process to address this deficit as “the requirement of some 
action or resource necessary, desirable, or useful, to attain optimal well-being”. 
(2000, p.227). 
 
While this is an outcome most Healthcare professionals (HCPs) would hope to 
achieve, the action or resource must recognise that humans have different sets of 
needs that have arisen out of specific contexts of life experiences before their 
cancer diagnosis, as a result of their diagnosis and beyond. Whether or not a 
woman is able to meet her own needs during a cancer experience is influenced 
by a variety of factors including; her psychological, physical, emotional, social, 
informational, spiritual and social experiences (Fitch, Porter & Page, 2009). While 
follow-up care may currently seek to provide psychosocial support, evidence 
suggests broader assessment may better identify and offer strategies to improve 
this. For many women, follow-up care is another important phase in their 
recovery.   
 
Research into different models of delivering follow-up care have largely focused 
on reducing hospital-based appointments through telephone-based follow-up 
(Beaver, Williamson & Chalmers, 2009; Koinberg, 2004, 2009), self-referral or 
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point of need (Chapman et al. 2009; Sheppard et al. 2009) and delivery by a 
General Practitioner (GP) (Grunfeld et al. 2006) rather than the actual structure of 
the follow-up appointment in meeting the needs of the women. This distinction is 
important follow-up care would certainly be offered for at least some time after 
treatment completion and therefore making changes to the structure of the 
appointment may prepare women better for eventual discharge. 
 
In UK practices, some of these models have been adopted in local settings, but 
not universally. There remains unease and a lack of consensus among HCP’s 
about the best approach to use moving forward, with a paucity of evidence to 
convince both patients and clinicians that traditional approaches that involve a 
face to face consultation and clinical examination, are no longer necessary 
(Fallowfield & George, 2008; Molino, 2008). The picture emerging is a wide 
variation in follow-up practices: some units continue to offer traditional follow-up 
appointments for 3 - 5 years in the hospital setting, employing specialist breast 
cancer nurses (SBCN) and/or advanced nurse practitioners (ANP) to deliver this 
service in conjunction with their medical colleagues, while others have chosen to 
discharge women at 2, 3 or 4 years and provide some support over the 
telephone.   
 
While curative intent remains the most important goal of treatment, it is of 
increasing importance how this goal is achieved (Ewart & Jenson, 2011). 
Intensive therapy is balanced with knowledge that breast cancer can keep 
recurring for up to and beyond 20 years following initial diagnosis (Early Breast 
Cancer Trialists Collaborative Group (EBCTCG), 2005). Screening for the risks 
associated with recurrence are evident in the current model of follow-up through 
mammography and clinical examination, however, screening of psychological 
well-being: a concept which encapsulates anxiety, depression, distress, needs 
and quality of life (Carlson, Waller & Mitchell, 2012) are less obvious.  
 
Research by Zabora et al. (2001) reported that distress (anxiety and depression) 
among breast cancers survivors (n =1249) is as high as 32%, with Coyne et al. 
(2004) also reporting that distress and psychiatric morbidity continues for women 
over many years post-treatment. There is some evidence that an association 
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exists between unmet needs, anxiety, depression and quality of life among 
women who survive breast cancer (Karakoyun-Celik et al. 2010).  Sanson-Fisher 
et al. (2000) reported an association between unmet needs, age, time since 
diagnosis and treatment modality used among cancer patients. Screening for, 
and offering appropriate interventions to address these unmet needs of cancer 
patients offer challenges to HCPs.  In breast cancer, large numbers of patients 
are seen in follow-up clinics and there are fears that screening may increase the 
pressures on an already pressured service. This may be the reason that there is 
little evidence of HCPs using formal questionnaires to screen patients and tailor 
their care accordingly within many of these clinics settings (Mitchell et al. 2008).   
 
Individualising supportive care interventions, particularly around diagnosis and 
treatment, has often been seen as the primary role of the SBCN (Cruickshank et 
al. 2008). The transfer of their skills into the follow-up setting has increased the 
focus on psychological well-being of women at this time. The National Cancer 
survivorship initiative (NCSI) has stated that, “alternative approaches to aftercare 
and support for people who have reached the transition from treatment to living 
with and after breast cancer” (at low/moderate risk of recurrence) are required” 
Davies & Batehup, 2009, p.28).  While it may seem natural to stratify women 
according to their risk of recurrence to manage the large numbers attending 
follow-up care, there is to date, no evidence to suggest unmet needs differ or are 
associated with a woman’s individual risk of recurrence.   
 
Indeed, the wider personal influences highlighted by Fitch, Porter & Page (2009) 
make this area highly complex. Measures of unmet need place a greater weight 
on the patients, rather than the professionals’, perspective and recognises that 
they are the best judge of their psychosocial well-being.  It moves away from 
restricting interventions to those who meet criteria “cases” and towards those who 
want help. Indeed, it encourages patients to interact with services in a proactive 
rather than passive way, and reflects a person-centred care approach advocated 
widely in cancer policy across the UK (Scottish Government, 2010a; Department 
of Health, 2011). 
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Previous research undertaken in a hospital clinic setting were unable to 
demonstrate statistical significant changes in unmet needs between the groups 
studied or that the intervention was directly attributable to the actions of the 
clinicians who viewed the patient reported outcomes: needs assessment and 
psychological questionnaires (McLachlan et al. 2001; Aranda et al. 2006; Boyes 
et al. 2006). However none of the studies included women with breast cancer 
attending follow-up clinics where unmet needs have been reported. This 
approach though offered possibilities within the hospital-based setting: an area 
not previously researched. This, and the suggestion by Thewes (2000) regarding 
the possible advantage of using the breast cancer survivor specific needs 
questionnaire she developed as a screening tool (known throughout this thesis as 
BCNQ) in a clinic setting, provided the basis for the work presented in this thesis.  
This led to the research aim: To determine the effectiveness of providing patient –
reported needs and psychosocial information to the SBCN at the follow-up clinic 
in reducing cancer needs and improving quality of life over time compared to 
standard care.  
The intention of this thesis is to describe a randomised controlled trial (RCT) that 
compared the effectiveness of a SBCN-delivered intervention with standard 
follow-up care. The trial was conceived to be an easily reproducible approach for 
women with breast cancer attending follow-up clinics.  As one of the first reported 
RCT’s of a specialist breast care nurse-delivered intervention to address the 
perceived needs and quality of life of women with breast cancer attending 
hospital follow-up, it is hoped that the results presented in it, constitute a 
significant contribution regarding the usefulness of this approach to both the 
understanding, and management of breast cancer patients within this setting, 
contributing also to new knowledge within this area. 
A recent report by Eccles et al. (2013, p.17) titled “the critical research gaps and 
translational priorities for the successful prevention and treatment of breast 
cancer” has given increased weight to the work reported in this thesis. They 
confirm what the author believed that the current system of aftercare does not 
meet the needs of patients. They suggest that incorporating standardised patient-
reported outcome measures (PROMs) into everyday practice is required. In 
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addition, they recommend studies that investigate how unmet psychosocial needs 
and psychological morbidity during diagnosis and treatment relate to quality of 
life, sexuality and physical well-being.  This thesis presents research into an 
intervention which sought to address unmet needs and psychological morbidity 
among breast cancer survivors attending follow-up care.   
 
The thesis has been divided into seven chapters. Chapter 1 has the objective of 
giving the reader some brief background and context to the work. Chapter 2 aims 
to review the field of breast cancer with particular attention to the area that bears 
most relevance to this thesis, follow- up care. Chapter 3 presents a systematic 
review of perceived unmet needs reported by women with breast cancer post-
treatment, and the use, and effectiveness of using needs assessment tools in this 
area. It informs the rationale for the work undertaken and launches the specific 
aims and hypothesis that drove this thesis. Chapter 4 sets out the methodological 
approach taken to address the aim and hypothesis outlined in the previous 
chapter with details of the design, protocol, assessment, procedures and 
statistical analyses used in this study. Chapter 5 presents the results including 
descriptive and inferential statistics, and regression analyses. Chapter 6 
interprets and discusses the findings and places them in the context of current 
practice.   Chapter 7 presents a conclusion along with key findings and 
recommendations  
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1.2 Personal position 
My interest in this area began many years ago when I worked as a specialist 
breast care nurse (SBCN) between 1996 and 2003 and my involvement in the 
writing group on follow-up within the Scottish Management of Breast Cancer 
Guideline Group (SIGN 2005). In my role as a SBCN, I met women at diagnosis 
and became involved in many aspects of their care.  This involved the provision 
of a range of supportive care aspects: psychosocial, emotional, practical, 
information and support. I observed women attending the clinic and immediately 
seeking me out to talk through softer issues associated with body image, side 
effects and relationships, to name a few.  I felt there was some duplication of 
effort on the part of myself and the doctor involved in the follow-up clinic, but also 
the appointment appeared to miss important areas of concern among women 
recovering from treatment. However, those who sought my support were not 
predictable. I had developed a strong therapeutic relationship with many women 
and they confidently accessed me.  For others though, who did not know me as 
well, it seemed less easy and they were referred through community services or 
other agencies. It was this latter group of women who appeared to have multiple 
unmet needs, remaining undisclosed despite attending regular follow-up care 
clinics. 
 
These experiences led me to question the effectiveness of traditional follow-up to 
meet the diverse needs of women after curative treatment, and identify those who 
required help from those who spoke loudest. Despite my observations, and 
indeed those voiced in the literature, hospital-based follow-up had remained 
largely unchanged, despite increasing numbers of SBCNs undertaking these 
clinics as part of their extended role. I sought to develop a study which took 
account of a woman’s individual and unique set of needs and provided supportive 
care in a person-centred way, while still offering clinical examination and 
mammography. As I started this research I was employed as a Lecturer in Cancer 
Nursing at Edinburgh Napier University.  Further reflections of the learning gained 
by the researcher are attached in Appendix 1. 
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Chapter 2 Breast cancer: A review of the 
literature 
2.1 Introduction  
There is a significant amount of research in the field of breast cancer, covering 
pre-diagnosis to end of life. So, this chapter aims to present a summary of what 
are the most relevant issues in breast cancer, with particular emphasis on those 
aspects which may impact on the present research within follow-up care.  Women 
with breast cancer are reported by Lindop & Cannon (2001) and Minstrell et al. 
(2008) as a particular patient group who report high levels of unmet need 
associated with their diagnosis and treatment side effects. They are also high 
users of healthcare services (Carlson & Bultz, 2004). 
 
This review will start by addressing questions about the relationship between the 
incidence, patho-physiology, diagnosis, treatment and survival of breast cancer.  
The spectrum of experiences and side effects associated with each of these 
areas can impact on both survival outcomes and the recovery of women over 
time.  It was historically one of the main reasons follow-up care was offered. 
Breast cancer is not only a physical disease but also has a profound 
psychological impact on a woman and her family. A psychosocial account of 
breast cancer will be reviewed with particular attention to factors which may 
impact on mental distress and quality of life after treatment is complete. 
 
2.2 Pathophysiology, incidence and survival 
Breast cancer is a heterogeneous, highly variable disease composed of different 
types, each with its own specific biological characteristic and prognostic indicators 
(Reddy & Given-Wilson, 2006). It is these features that make it difficult to define 
cure, but also to assess definitively all risk factors for recurrence (Weigelt. 
Peterse & van’t Veer, 2005), making it unclear why some women with apparently 
similar disease recur while others do not. The incidence of breast cancer in the 
UK is 48,975, with a lifetime risk of 1 in 8 among females (Cancer Research UK, 
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2012).  The age range of women diagnosed with breast cancer in the UK is 
illustrated in Figure 2.1. Unlike patterns seen in most cancers whereby survival 
improves with age, women in their 50s and 60s at diagnosis have higher survival 
than younger or older women. 
 
Figure 2.1: Breast cancer, average number of new cases per year and age 
specific incidence rates, Female, UK 2008-2010 Prepared by Cancer Research 
UK, 2012.  Data source: Office of National Statistics, England, 2008, Welsh Cancer 
Intelligence Unit and Surveillance Unit, 2008, Information and Statistics Division NHS 
Scotland, 2010, Northern Ireland Cancer Registry, 2008.   
The improvements in survival, as shown in Table 2.1, are one of the reasons 
there are increased pressures on follow-up services. Approximately 550,000-
570,000 women are alive in the UK who have had a diagnosis of breast cancer 
and this group constitutes 25% of all those treated and living with cancer in the 
UK (Maddams et al. 2009).   
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Table 2.1: Breast cancer age standardised 1, 5, 10 and 20 year relative survival 
England 2005-2009, England and Wales 2007 (Maddams et al. 2009). 
 
Relative survival (%) 
1 year 5 year 10 year 20 year 
2005-2009 2005-2009 2007 2001-2003 
95.8 85.1 77 64.5 
 
Reducing the risk of breast cancer recurring is the main treatment goal. A 
combination of early diagnosis and treatment has played a significant factor in the 
improved survival outcomes seen today (Early Breast Cancer Trialists’ 
Collaborative Group, (EBCTCG), 2005, 2011). However, these results are not the 
sole reason for success, better co-ordination of care among cancer specialists, 
increased specialisation among clinical staff and the introduction and extension of 
screening have also played an important role. Risks associated with survival 
outcomes are difficult to quantify and explain to women and Watson et al. wrote. 
”a risk is something that might happen in the future” (2012, p.1).  This is so true of 
breast cancer with recurrences peaking in the first 2-3 years after diagnosis (10-
15%) (Dixon & Montgomery, 2008), but remaining a constant risk between 3- 5 
years (4.3%), and 5-9 years (4.6%) (Gligorov, Pritchard & Goss, 2007).  Breast 
cancer, unlike other cancers, can continue to recur up to and beyond 20 years 
(EBCTG, 2005).   
 
There are two types of recurrence:  local or distant recurrence. The type is 
important as survival following discovery is considerably different:  Women with 
local recurrence have an 80% 5-year relative survival rate, while women with 
distant recurrence, including bones, liver, lungs or brain, have a 25% 5-year 
relative survival (Isasi et al. 2005).   
 
There is no evidence that informing women of the risks of the cancer recurring 
impacts on their well-being. Yet, Corter et al. (2013) have suggested that an 
association between illness perceptions, side effects and fear of recurrence does 
exist. In their study, women (n=153) who took endocrine therapy associated their 
side effects of treatment with symptoms of a possible recurrence. In particular, 
the women searched for a cause for their physical symptoms, and through their 
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perceptions of illness, feared they had a recurrence. This constant risk of 
recurrence creates fear, uncertainty and emotional difficulties for women and acts 
as a constant reminder (Oxlad et al. 2008). Despite these fears, statistics indicate 
that many women are surviving and doing well. It is therefore important that risk is 
balanced with optimism whereever possible. This fear is described by many 
women as one of the main reasons they want on-going follow-up care (Beaver & 
Luker, 2005; Montgomery et al. 2008). However, the data suggests that women 
attending a clinic are less likely to present with a recurrence than out with follow-
up (Beaver & Luker, 2005; Rojas et al. 2009).  
2.3 Diagnosis 
In a qualitative study by Boehmke & Dickerson (2006), diagnosis is described by 
women as a transition period from health to illness, a pattern of healthy women 
transitioning to a state of illness within a short period of time following test results.  
Advances in diagnostic procedures mean this period can be as short as a few 
hours. These authors and Knobf (2001), Ganz et al. (2004) and Halkett (2007) 
indicate that how women approach their diagnosis and subsequent treatments 
affects how they deal with later symptoms and distress, a time when they may be 
receiving follow-up care. Insight into what a diagnosis may feel for a woman is 
described in the words of Brooks;  
 
“Breast cancer is life changing, one you cannot anticipate or plan for and 
one in which you have no choice. How we deal with living with it differs, 
from one person to another” (2006, p. 31) 
 
Figure 2.2 illustrates the key points in the cancer journey as a woman enters the 
breast cancer service worldwide, receives a diagnosis and moves through the 
different stages towards follow-up and long-term monitoring, the focus of this 
thesis. Following diagnosis, women follow a personalised treatment plan 
according to the characteristics of their tumour, fitness for treatment and 
preference. The complexity of treatment decisions is heightened with each 
treatment modality added into the plan.  
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Depending on the plan, women can transition from diagnosis to long-term 
monitoring and follow-up in a matter of months, while others embark on treatment 
regimens which can last well over a year.   
Figure 2.2: Pathway of care for breast cancer (adapted from Fitch, Porter & Page, 
2002, p.15). 
2.4 Treatment 
Breast cancer is a cancer whereby most women present feeling well and healthy. 
Therefore it is the treatment, and specifically the complications of treatment, 
adverse effects of drugs and their impact on co-morbidities that creates unwanted 
symptoms which last after treatment is complete (Budin, Cartwright-Alcarase & 
Hoskins, 2008). This, according to Bloom et al. (1998) is one of the reasons 
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women find it difficult to understand and distinguish between what are normal and 
abnormal symptoms.  
 
The goal of treatments is: 
 Local control with optimum cosmesis 
 Reduction of risk of developing local and distant metastases 
 Minimisation of short and long-term treatment related morbidity 
(Neal & Hoskin, 2009, p.100)  
 
Surgery remains the first treatment choice for early breast cancer (Blowers & Foy, 
2009). Once the important prognostic information is obtained, additional 
radiotherapy and systemic therapies such as chemotherapy, endocrine therapy, 
and/or biological treatments are recommended (Veronesi et al. 2006).   
 
Historically in the UK there has been a strong reliance on the TNM (T=tumour, 
N=node, M=metastases) model developed by Veronesi, Cascinelli & Bufalino, 
(1983) to classify the stage of breast cancer and inform treatment decisions. It 
has a strong focus on the pathological characterisation of lymph node status, 
tumour size and histological grade to understand the stage of disease. It is now 
known that this is no longer sufficient as it does not recognise biological features, 
so necessary in predicting outcomes (Aapro, 2006; Veronesi et al. 2006). Since 
2005, the St Gallen Consensus panel (Goldhirsh et al. 2005) recommended that 
pathological assessment of oestrogen receptor (ER), progesterone receptor 
(PgR) and HER2/neu status of all early breast cancers should also be done, and 
predicted that this would substantially improve results from systemic therapies by 
ensuring proper targeting of therapies to the patients who need it. Future direction 
in gene expression profiling and tracking micro metastases offers opportunities to 
target treatments even more effectively (Dinh, Sotiriou & Piccart, 2007). 
 
It is important to recognise the role of ER and /or PgR and HER2: ER positivity 
reflects responsiveness to tamoxifen and aromatase inhibitors and HER2 
positivity, a response to trastuzumab (Baum, 2002; Dinh, Sotiriou & Piccart, 
2007).   
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Increasing knowledge about newer biological factors such as HER2/neu 
receptors and proliferative index (rate of cell division in the tumour) have altered 
the way adjuvant treatments are prescribed and are increasingly used to predict 
prognosis.  An over expression of the HER-2/neu protein is observed in 15%–
20% of breast cancers (Slamon, Clark & Wong, 1987), and it is now accepted that 
high levels of expression of HER-2/neu identify those patients most likely to 
respond to trastuzumab in the adjuvant setting (Dinh, Sotiriou & Piccart, 2007).   
 
Estimates of prognosis are common when managing early invasive breast cancer 
(Andersson et al. 2008). The Nottingham prognostic index is one method used to 
help guide treatment decisions and determine prognosis. It is calculated using the 
formula; 0.2 x the tumour size (cm) + grade of tumour (1, 2, or 3) + lymph node 
status (1= no nodes, 2 = 1 - 3 nodes, 3 = 3 or more nodes are involved). 
Information of this nature is regularly shared with women and their families. The 
combination of using prognostic and needs assessment information has been 
suggested by Watson et al. (2012) as an approach which may offer better 
personalised cancer follow-up care. 
 
However, although prognostic data informs decision making it is also necessary 
that HCP’s gain a better insight into what the consequences are of improved 
survival on an individual’s life (McPhail, 1999; Ganz et al. 2000; Knobf, 2001; 
Harris et al. 2002; Thewes, 2003; Biglia et al. 2003; Neal & Hoskins, 2009; Shultz 
2005; Walshe, Denduluri & Swain, 2006; Stricker, 2007). 
2.4.1 Surgery 
The majority of women undergo some form of surgery quickly after diagnosis to 
provide local control of the disease, although increasingly chemotherapy and 
endocrine therapy are being used first to shrink the tumour prior to surgery.  
Surgery involves breast conserving surgery, mastectomy alone, or mastectomy 
with immediate or delayed breast reconstruction.  Despite knowledge gained in 
an early study about the reduced psychological morbidity associated with breast- 
conserving surgery (McArdle et al. 1990), up to 50% of women will undergo a 
mastectomy (Thompson & Wells, 2006). This may be due to tumour size, position 
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of the tumour or a woman’s preference. The removal of the entire breast will 
cause loss of symmetry, likely coupled with increased psychological morbidity 
and dissatisfaction. To improve the psychological morbidity associated with 
mastectomy, breast reconstruction is routinely offered to women.  An audit in 
England of 18,216 women who had a mastectomy (NHS Information Centre for 
Health and Social Care, 2011) reported that 21% of these had immediate 
reconstruction and 10% delayed. 
 
Survival outcomes are improved following axillary surgery compared to no 
treatment (Rodger, Stebbing & Thompson, 2006). Indeed the pathologic status of 
the axillary lymph nodes is an important prognostic indicator and determinant of 
adjuvant treatment. Axillary surgery involves an axillary clearance, sampling or 
sentinel lymph node biopsy (SLNB). Axillary surgery, particularly clearances, are 
associated with complications including: seroma formation (a collection of serous 
fluid that is evident within a surgical cavity) and lymphoedema (a condition 
whereby the lymphatic routes are damaged during surgical resection) (Armer et 
al. 2008) and damage to the intercostobrachial nerve or reduced arm movement 
(Houssami, Cuzick & Dixon, 2006).   
 
Newer techniques favour fewer axillary clearances and more sentinal lymph node 
biopsies (SLNB), an accurate less invasive procedure which has lower morbidity 
then previous techniques (Houssami, Cuzick & Dixon, 2006). It is also used as a 
diagnostic procedure prior to clearance. Results report less morbidity and a high 
degree of histological accuracy when undertaken by an experienced multi-
disciplinary team (Filippakis & Zografos, 2007). A study by Delon et al. (2008) 
found that 18.8% (n =133) of women following breast cancer surgery, reviewed 
over a 12 month period, had some degree of lymphoedema and another study by 
Franks, Williams & Moffat, (2006) found this to be as high as 20.7% (n=251) in a 
similar group of women following axillary node clearance. Mansell et al. (2006) 
have suggested that SLNB reduced arm morbidity and improved the quality of life 
of women more than standard axillary treatment.  The improvements will be 
welcome by women because the physical impact of lymphoedema can be 
problematic, with fitting clothing, carrying out activities of daily living as well as, an 
emotional impact on self -esteem, body image and quality of life (Armer et al. 
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2008).  Follow-up provides some opportunity to instigate education with women 
who may be unaware of the risks, and monitor for signs and symptoms.    
 
Pain after surgery is common. In a study by Lee et al. (2008), the prevalence of 
pain in the arm and shoulder varied from between 9 and 68%, and in the breast 
area of between 15 and 72%. This pain can be transient but if nerve damage 
occurs, this problem can become more persistent and last many years.  
 
A study by Pelusi (2006) which interviewed breast cancer survivors’ adaptation to 
sexuality and body image concluded that baseline assessments in this area can 
identify those women with a poor body image, thus initiating discussion. Indeed 
Perreault & Fothergill Bourbonnais (2005) argue that body image is such an 
important area in the field of breast cancer that it should be part of a formal 
assessment, something which does not currently occur in most follow-up clinics.   
2.4.2 Radiotherapy 
The use of radiotherapy is integral to the local disease management of breast 
cancer.  Approximately 70% of breast cancer patients in Scotland are suitable to 
receive radiotherapy (Scottish Executive, 2006).  Radiotherapy is offered to all 
patients after breast conserving surgery for invasive breast cancer, and to others 
according to their risks of a local recurrence. Following a meta-analysis 
(EBCTCG, 2011), data suggested that whole irradiation following breast 
conserving surgery halves the annual rate of local disease recurrence (RR 0.52, 
0.48 - 0.56) and reduces annual breast cancer deaths by one sixth (RR 0.82, 0.75 
- 0.90), with variations occurring according to prognostic subgroups. All women 
receiving radiotherapy are at risk of skin damage in the short and long-term and 
irradiated skin can be changed permanently through loss of pigmentation, 
indentation or telangiectasia, with resultant poor healing (Scottish Government, 
2010a).  Other complications include arm and shoulder problems and pain (Ewert 
& Jensen, 2011).  
18 
 
2.4.3 Chemotherapy  
Chemotherapy is associated with acute side effects; myelo-suppression, 
alopecia, nausea and vomiting, skin and nail growth problems, weight gain, 
fatigue and stomatitis (Neal & Hoskins, 2009), and late side effects: cardiac 
toxicity (Stegall Moss et al. 2009), vasomotor symptoms and premature 
menopause (Fenlon, Corner & Haviland, 2009), fatigue and cognitive dysfunction 
(Bower et al. 2000), risk of secondary cancers, skeletal toxicities (Shapiro & 
Recht, 2001), with many of these side effects evident once treatment is complete 
and follow-up care begins.   
2.4.3.1 Fertility, premature menopause and stopping hormone replacement 
therapy   
Cancer treatment is gonodotoxic, particularly chemotherapy drugs. The regimen, 
the drug dose, duration of therapy and current menopausal status appear to 
influence the incidence and severity of symptoms, and the experiences of women 
with breast cancer across different age groups (Ganz et al. 2000; Walshe, 
Denduluri & Swain, 2006; Anderson et al. 2011; Pinto & de Azambuja, 2011; 
Cardoso et al. 2012). These symptoms post-treatment influence a woman’s 
recovery and quality of life (Thewes, 2003; Shultz, 2005; Stricker, 2007).   
 
UK age-specific breast cancer incidence rates rise sharply between the ages of 
35 and 39, with 48% of breast cancers occurring among women 50 - 65 years of 
age and around the time of the natural menopause (Cancer Research UK, 2012). 
Breast cancer therefore coincides with a time of natural aging, women who may 
be currently taking hormone replacement therapy (HRT) and those who are 
experiencing a premature therapy-induced menopause (Hickey et al. 2008; 
Cancer Research UK, 2012). Difficult symptoms are associated therefore with 
younger women, those experiencing a therapy-induced menopause, 
postmenopausal women and HRT users (Leining et al. 2006), a large number of 
the women diagnosed.  HRT is contra-indicated in breast cancer and 
recommended to be stopped once a diagnosis is confirmed (SIGN, 2013) with 
many of these women experiencing an exacerbation of their menopausal 
symptoms, the reason they began taking HRT. There is some promising evidence 
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emerging that supports non-pharmacological approaches to reducing 
menopausal symptoms  including homeopathic treatments, cognitive behavioural 
therapy (CBT) and relaxation (Hickey et al. 2008; Fenlon, Corner & Haviland, 
2009; Hunter et al. 2009; NICE, 2009; Mann et al. 2012). However, a full 
assessment is necessary if these interventions can be offered appropriately.  
2.4.4 Biological agents 
An over expression of human epidermal growth factor receptor 2 (HER2) is a 
poorer prognostic indicator in women with early breast cancer (Hicks & Kularni, 
2008).  However, this group, which constitutes approximately 12% of all breast 
cancer cases in Scotland, gain significantly from targeted therapy, trastuzumab, 
delivered for up to one year (SIGN, 2013). This drug is associated with 
cardiotoxicity and contraindicated in women receiving concurrent chemotherapy, 
particularly anthracyline agents (NICE, 2009). Short-term data suggests the risk 
of cardiac dysfunction may be as high as 16% after use of trastuzumab and 
minimising this risk is an on-going goal (Stegall Moss et al. 2009).   
2.4.5 Endocrine therapy  
Endocrine therapy is a key treatment in the management of ER positive breast 
cancer (Blowers & Foy, 2009). There are four major groups of endocrine agents: 
i) tamoxifen and other selective ER modulators, ii) progesterone (megestral 
acetate), iii) aromatase inhibitors (AIs) (anastrozole, letrozole and exemestane), 
iv) pure anti-oestrogens (fulvestrant),  Their role and function differ depending on 
the patients menopausal status, stage of disease and response.  All endocrine 
therapy aims to modulate or disrupt the process of oestrogen production. 
Tamoxifen blocks the ER, AIs inhibit the production of oestrogen and fulvestrat 
degrades ER. The most commonly used first line agents are tamoxifen and 
aromatase inhibitors. The EBCTCG (2005) concluded that 5 years of tamoxifen is 
better than 1-2 years. However, in a recent review of endocrine therapies by 
Palmieri et al. (2014), they concluded that there is sufficient data to support the 
extension of endocrine therapies beyond 5 years, including switching between 
groups of drugs up to 10 years. This change is being implemented in practices 
across the UK but has consequences for women who may experience an 
increased number of side effects and for a longer period of time.  Adverse events 
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associated with the two treatments differ quite significantly: tamoxifen is 
associated with hot flushes, endometrial disorders and thromboembolic events, 
while AIs are associated with arthralgia, muscoskeletal disorders, osteoporosis 
and vaginal dryness.    
 
However, any survival benefit can only be gained if they are taken as instructed, 
and many women struggle to cope with the side effects.  In a recent review of 
survival data by McCowan et al. (2013), those with low adherence to tamoxifen 
had a shorter time to recurrence, increased medical costs and worse quality of 
life. They propose interventions are required that encourage patients to continue 
taking their treatment daily and may in the long term prove highly cost-effective.   
2.5 Psychosocial consequences of diagnosis and treatment  
Maguire et al. (1978) were among the first to recognise the psychological 
morbidity associated with mastectomy. In their study, they compared women 
following mastectomy (n=75) with women with benign disease (n=50). Their 
findings indicated that women with breast cancer were significantly more likely to 
suffer from anxiety (19 - 25% compared to 5 - 10% control) and depression (16% 
- 33% compared to 3 - 8% control), with increased moderate to severe sexual 
difficulties. It drew attention to how HCP’s approached the emotional well-being of 
women with breast cancer and was instrumental in the introduction of SBCNs into 
clinical practice (Fallowfield & Baum, 1989). In a later study by Maguire et al. 
(1983), simple counseling by SBCN’s did not prevent depression, but they were 
able to recognise and refer women earlier for psychiatric support.  Findings 
suggested this action reduced psychological morbidity.   
 
Particular women at risk of psychological problems include: those with a previous 
psychiatric history; a lack of support from family and friends; an inability to accept 
the physical changes associated with the disease or its treatment; a lack of 
involvement in satisfying activities; prior adverse experiences of cancer in the 
family; low expectations regarding the effectiveness of treatment; pre-existing 
marital problems or being younger at diagnosis (Burton and Watson, 1998) 
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While many women psychologically adjust over time, some studies have shown 
that there are marked individual variations in the year following surgery and 
beyond, with a subgroup reporting no reduction in distress despite data 
suggesting average scores had reduced among the whole group (Millar et al. 
2005). Carver et al. (2005) also reported a significant correlation between the 
well-being and initial adjustment of women one year after surgery and their long-
term adjustment 5-13 years later, suggesting that both social and personality 
factors play a part in a woman’s recovery. Other authors, Deshields et al. (2006) 
have also described the psychological distress associated with the end of 
treatment. They found elevated scores of depression were reported at this time, 
and a relationship between high levels of depression and poorer quality of life.   
2.6 Transition between end of treatment and follow-up 
Cognitive changes in breast cancer survivors as they transition from completion 
of primary treatment to follow-up can result, “from the disease, the treatment, 
complications of treatment, co-morbid conditions, the adverse effects of drugs, 
other symptoms, aging, and psychological responses to the cancer diagnosis” 
(Nail, 2006, p.48). 
 
The unpredictability associated with breast cancer may contribute to the 
psychological and physical decline punctuated by periods of improvement and 
paradoxical decline that is seen among women as they complete treatment and 
recover. Knobf (2007) has described a woman’s feelings of uncertainty, 
vulnerability, ambivalence and mixed emotions as she completes treatment 
coupled with the physical aftermath of intensive treatment regimens; arm 
discomfort, fatigue, menopausal symptoms and lympoedema. While de Bock et 
al. (2004b) found information about side effects, hereditary changes, fear of 
recurrence and identifying changes in the untreated breast areas of greatest need 
during the follow-up period, Schmid-Buchi et al. (2008) found these issues were 
influenced by body image perception, role limitation, and relationships, Burton & 
Watson (1998) by previous psychological problems and Pelusi (2006) by 
sexuality and body image. Follow-up has been described by Ganz et al. (1996) as 
the transitional period from the end of primary treatment to survivorship.  
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One woman described this period: 
 
I have now finished surgery, chemotherapy, radiation, and 
reconstruction; I’m done, according to the medical profession. But 
I don’t really feel done. . . . We just move from the quantifiable, 
treatable disease to the immeasurable uncertainty of survivorship. . 
. . Being in the midst of active treatment means being seen 
regularly by a nurse or a physician—being cared for. (McKinley, 2000, 
p.479) 
 
Embarking on their follow-up and long-term monitoring is often when the 
psychosocial and physical implications of treatment are either only emerging or 
are on-going (Vivar & Mc Queen, 2005). 
 
A study by Ganz et al. (2004) investigating the quality of life of 558 breast cancer 
patients at the end of primary treatment found women reported increased stress, 
decreased energy, multiple treatment side effects and a greater need for 
interpersonal support.  Women post-mastectomy had poorer physical functioning, 
and sexual functioning was worse among women who received chemotherapy 
(p<0.001).  Similar findings have also been reported by Holzner et al. (2001).  
They measured quality of life differences among women who were 1 - 2 years 
post treatment, 2 - 5 years and more than 5 years.  Results indicated that women 
in the early phase (1 - 2 years) following treatment had a significantly reduced 
quality of life in relation to social and emotional aspects, fearing relapse and 
adapting to the illness and its treatment, with marked problems associated with 
body image, menopausal symptoms, and lack of self-esteem. Although the 
groups that were 2 - 5 years and > 5 years reported fewer difficulties, all groups 
reported fatigue, sleep disturbances and pain.   
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2.7 Follow-up care 
The pathway to long- term monitoring and follow-up is clearly individual.  NICE 
recommends that follow-up after treatment for primary breast cancer should 
include: 
 
clinical and radiological options for assessment of both the treated and the 
contralateral breast. It incorporates supervision of on-going adjuvant 
treatment and potential side effects, and review of patients who are in 
clinical trials. Follow-up should also include advice on general health, diet 
and exercise.  (NICE, 2009, p.97) 
 
2.7.1 Guidelines and recommendations  
While previous guidelines in the UK included substantial guidance about the 
provision of follow-up care (SIGN, 2005; NICE, 2004), updated versions have 
been less prescriptive (SIGN, 2013; NICE, 2009), and this is perhaps one of the 
reasons that variability is seen in follow-up care models used across the UK 
today. This is in contrast to the United States of America (USA) (National 
Comprehensive Cancer Network, NCCN 2014) and Canada (Grunfeld, Dhesy-
Thing & Levine, 2005); these countries continue to recommend who, when and 
how follow-up should be delivered. The 13th St Gallen International Breast Cancer 
Conference expert panel (Goldhirsch et al. 2013), a highly regarded expert body 
in collating and disseminating up to date evidence about breast cancer globally, 
believes that the provision of regular follow-up at the completion of primary 
treatment is appropriate and should continue. They support nurse specialists 
undertaking this care, but recommend it continues to be done in person rather 
than over the telephone. Telephone follow-up is an area which has yet to be 
widely adopted in the UK, but early results look promising when patients are 
carefully selected (Beaver, Williamson & Chalmers, 2009). 
 
Despite advances in the treatment of breast cancer, the optimum way in which 
patients should be followed-up remains elusive. Recommendations for the 
diagnosis and treatment of breast cancer are much clearer and guided by 
international evidence. However, follow-up differs between countries, with an 
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overview of some of these illustrated in Table 2.2. Only the Canadian (CMA), 
American (NCCN) and Australian guidelines (Cancer Australia, 2010) make any 
recommendation about the management of psychosocial issues, with the 
Canadian guideline specifically referring to the multiple needs which may arise 
following breast cancer treatment and the Australian one recommending an 
additional psycho-social assessment. While the UK guideline informs decision 
making, countries like the USA and Canada use them as a legal document of 
care which forms the basis for financial reimbursement of medical procedures 
(Senn, 2006).  
 
The success or otherwise of follow-up care is usually measured against numbers 
of recurrences identified in a clinic, rather than number of unmet needs 
addressed.  When compared against these criteria its success is questionable, 
with fewer recurrences identified in the clinic than outwith (Grunfeld et al. 2006; 
Rojas et al. 2009; Montgomery, Krupa & Cooke, 2007). However the more subtle 
benefits that women describe are less quantifiable: such as reassurance following 
clinical examination (Beaver & Luker, 2005; McGaughan & McSorley, 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
25 
 
 
Table 2.2: Comparison between clinical practice guidelines for breast cancer 
follow-up across the world 
 
Guidance 
S
IG
N
 
N
IC
E
 
B
A
S
O
 
E
S
M
O
 
N
C
C
N
 
C
M
A
 
D
F
 
N
H
M
R
C
 
Clinical history no no yes yes yes yes yes yes 
Physical exam no no yes yes yes yes no yes 
Mammography yes yes no yes yes yes yes yes 
Pelvic exam no no no no yes no no yes 
Patient education no yes no yes no yes no no 
Psychosocial 
support 
no no no no yes yes no yes 
Review new signs 
and symptoms 
no yes no yes yes yes yes yes 
Preferred method 
described 
no no no no yes yes no yes 
Frequency stated no no ^ risk no yes variable yes no 
Length 
no no 5 yrs no 
not 
clear 
no 10yr no 
Key: SIGN, Scottish Intercollegiate Guidelines Network, (2013); NICE, National Institute 
of Clinical Excellence (England and Wales) (2009); BASO, British Association of Surgical  
Oncology (UK) (2005); ESMO, European Society for Medical Oncology (2007); NCCN, 
National Comprehensive Cancer Network (USA) (2014); CMA, Canadian Medical 
Association (2005); DF, Dutch Breast Cancer Federation (2012); NHMRC, National 
Health and Medical Research Council of Australia (Cancer Australia, 2010) 
Kimman et al. (2007) reported a general feeling among clinicians in the 
Netherlands that limited time during the clinic visit prevents them adequately 
addressing the complex psychosocial issues which arise from a diagnosis of 
breast cancer. 
2.7.2 Policy, follow-up and survivorship 
The Scottish Government healthcare policy proposes quality, flexibility, 
responsiveness and putting the patient at the centre of care (Scottish 
Government, 2010a).  Follow-up care is not specifically referred to within cancer 
documents; rather the term used is “living with cancer” (Scottish Government, 
2010b), and more recently “survivors of cancer” (Scottish Government, 2013).  
Unlike diagnosis and treatment, follow-up care is not governed by targets or 
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legislation. The sense of urgency and timely treatment following diagnosis is 
welcome by women (Scottish Government, 2009) and can contribute to a feeling 
of security and support.  However, this sense of urgency stops as treatment 
finishes and may contribute to a sense of abandonment reported in the literature 
(Eccles et al. 2013). 
 
The measurement of a patients’ needs is increasingly seen as a means to 
understanding better the impact of a cancer diagnosis and treatment on an 
individual’s well-being (Sanson-Fisher et al. 2000; Sanson-Fisher, Carey & Paul, 
2009; Carlson, Waller & Mitchell, 2012). The term “needs” and indeed those 
perceived as unmet, is a conceptually complex term and by its very nature, 
subjective (Maslow, 1987; Tomey & Allgood, 2002).  Yet the term is widely 
integrated into cancer healthcare policy. While it is important that the cancer 
workforce “is responsive to the needs of patients…..and individuals are partners 
in their care” (Scottish Government, 2008, p.3), the achievement of this goal 
associated with follow-up care remains unclear. A report commissioned by the 
NCSI suggests five ‘key shifts’ are required to achieve change in how HCP’s 
meet cancer patient’s needs after treatment:  
 
“a cultural and attitudinal shift to focus on health and recovery; a shift 
towards improving information; a shift towards assessment and care 
planning; a shift towards providing tailored care pathways based on risk of 
future problems associated with the type of cancer, the type of treatment 
and the particular circumstances of the individual; and a shift towards 
improved measurement through patient reported outcome and experience 
measures”.   (Ipsos Mori, 2011, p. 6) 
 
Building on the work already undertaken in England, the launch of the 
transforming care after treatment initiative, a partnership between the Scottish 
Government and Macmillan Cancer Support has begun (Scottish Government, 
2013).  Early recommendations propose that cancer patients play an active role in 
their care, that services are tailored to the needs and preferences of people 
affected by cancer and that more support in dealing with the physical, emotional 
and financial consequences of cancer treatment is required.  While it may not be 
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clear as yet how this will be achieved within the current model of follow-up care 
some of the principles mirror work currently undertaken by SBCNs.  This includes 
tailoring consultations post-diagnosis with an overall aim of meeting the 
psychological, physical and practical needs of the women they meet. 
2.7.3 Models of delivering follow-up care  
Research into different models of delivering follow-up care has emerged over 
recent years. Primarily they have focused on reducing the number of face to face 
consultations within the hospital setting. The first group of studies compared 
providing follow-up support over the telephone without clinical examination. They 
found no increase in anxiety or a decrease in quality of life through this approach 
(Koinberg et al. 2004, 2009; Beaver, Williamson & Chalmers, 2009). The study by 
Beaver, Williamson & Chalmers (2009) indicated this approach was as effective 
as hospital-based follow-up care. The second group of studies compared hospital 
follow-up to no follow-up and encouraged women to self-refer as and when they 
felt they had a need. Neither study reported any decline in quality of life or 
increased incidence of recurrence using this approach (Brown, Payne & Royle, 
2002; Chapman et al. 2009; Sheppard et al. 2009). The third group of studies 
compared follow- up by hospital specialists (doctors) with GP’s and found no 
decline in quality of life or increased incidence of recurrence (Grunfeld et al. 
2006). A consistent finding among all the studies is that alternative delivery away 
from the hospital does not appear to impact on psychological morbidity, quality of 
life or recurrences seen. However none of them sought to review the way 
standard follow-up care meets the needs of women in the hospital  
 
Most follow-up in the first 2 - 3 years following completion of primary treatment is 
delivered in a hospital setting and increasingly by SBCNs or ANPs.  The report by 
the National Breast Cancer Centre defines the SBCN as:  
 
a registered nurse who applies advanced knowledge of the health needs, 
preferences and circumstances of women with breast cancer to optimise 
the individual’s health and well-being at various phases across the 
continuum of care, including diagnosis, treatment, rehabilitation, follow-up 
and palliative care. (National Breast Cancer Centre, NBCC, 2005, p. 4) 
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Studies to date report a high satisfaction level among patients when seeing 
nurses, and their clinical examination performance is equal to their medical 
colleagues after appropriate training (McIntosh & Fowler, 2011; Kimman et al. 
2011). However, studies that have focused on whether the introduction of nurses 
has improved health needs or overall well-being of women within this clinic are 
less visible.   
2.8 Conclusion 
This chapter has provided an overview of the development of breast cancer, 
diagnosis, the treatment modalities used and their corresponding side effects.  
Each part of this pathway has influenced the experiences and symptoms women 
report at follow-up.  While improvements in diagnosis, treatment and 
management have increased overall survival outcomes, the intensity of this 
approach has left many women experiencing cumulative physical, emotional and 
psychological side-effects. 
 
There is a consensus among clinicians that follow-up care is an important part in 
the monitoring of women post-treatment and increasingly recognition that on-
going side effects, changes to a woman’s body, provision of information and 
educating about what may constitute a recurrence, are integral to its success.  
However, they also accept that there is limited evidence to support this broader 
objective. It is important to acknowledge that follow-up is a continuation of care 
rather than a separate entity for most women. Therefore they cannot easily 
distinguish between symptoms that are related to normal recovery and those 
which are abnormal and a possible recurrence. Most women have little prior 
knowledge or experiences of breast cancer and cannot therefore compare 
themselves with others with the same condition, unlike specialists working in the 
area daily. 
 
If follow-up care is to be effective, it is important that an understanding of the 
perceived unmet needs of women attending is gained, otherwise HCP’s cannot 
offer appropriate interventions. The next chapter systematically reviews the 
evidence that reports the perceived unmet needs of women post-treatment and 
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whether the use of patient- reported outcomes measures which assess unmet 
needs within a clinical setting have been used to guide care. 
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Chapter 3: A systematic review of unmet needs 
and the use of needs assessment tools in follow-
up  
3.1 Introduction 
This chapter reviews the key literature which reports the perceived unmet needs 
of women with breast cancer post-treatment, the use of patient-reported needs 
assessment tools among this group in the follow-up setting and the effectiveness 
of this approach. In Chapter 2 the pathophysiology, treatment and follow-up of 
breast cancer was discussed from both a disease and policy perspective. It 
illustrated the complex nature of this heterogeneous disease, the increasing 
diversity of treatments a woman may receive, subsequent side effects and the 
role follow-up care plays in monitoring women as they recover. While follow-up 
care is not a new concept, there appears to be increasing evidence that the 
traditional hospital-based approach no longer addresses the diversity of needs 
women experience when primary treatment ends. The review is presented in two 
parts. This is to ensure the goals of the review are addressed in the broadest 
possible manner and aid the presentation of a wide range of literature.    
3.1.1 Part one: 
This part reports literature which addresses the perceived needs of women with 
breast cancer during follow-up and focused on the following questions: 
 
1. What is the evidence that women with breast cancer have unmet needs in 
the period known as “follow-up”?   
2. How and what are these reported perceived needs?  
3. Do socio-demographic and clinical factors affect the perceived needs 
women report? 
4. Do needs change for women from one follow-up consultation to another?  
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5. Is there any evidence of a relationship between unmet needs and quality of 
life?  
3.1.2 Part two:  
This part reports literature which reviewed the effectiveness of using needs 
assessment tools in a breast cancer clinic setting and focused on the following 
questions: 
 
1. Have patient reported needs assessment tools been used to guide care 
within a breast cancer follow-up setting? 
2. If so, how effective is this approach? 
 
The presentation of this chapter is informed by the Cochrane Collaboration 
Systematic Approach (Higgins & Green, 2011) and is presented in a way which 
includes reference to: an inclusion and exclusion criteria; a search strategy; the 
characteristics of studies; the methodological quality of studies; the results and a 
discussion. This approach was chosen to manage the considerable amount of 
literature pertaining to breast cancer and it provided a framework to allow this 
review to focus on a very specific area of the care of women with breast cancer; 
follow-up. The search strategy and methodological approach are described first. 
Similar approaches are used to address all the review questions.  Where these 
may differ, this is clearly described.  A conclusion is presented at the end of each 
part, an overall summary is presented at the end of the chapter and an outline of 
how these informed the research question is presented. 
3.2 Search strategy 
The systematic search strategy used to search for literature pertaining to both 
reviews was adapted from the Scottish Intercollegiate Guideline Network (SIGN) 
(2005), Management of Breast Cancer in Women (guideline 84), section 7: follow-
up. This strategy was developed to find literature that related particularly to breast 
cancer and follow-up, with the terms consistent with those required for this 
review. As an organisation, SIGN have extensive experience in systematic 
literature searching. Their search methods usually include methodological filters 
to increase specificity for RCTs and meta-analysis. However these were removed 
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for part one of the review as the purpose was to seek literature about perceived 
unmet needs and it was considered important to include both qualitative and 
quantitative literature. 
 
Additional search terms included “needs” and “nursing” and “needs assessment” 
included as a major concept for part two to ensure it was able to answer the 
specific review questions (Appendix 2).  The assistance of a librarian was 
invaluable in this process. 
3.2.1 Inclusion and exclusion criteria 
Both reviews sought to identify all published retrospective and prospective 
primary research in the English language from 1995 – 2009. The starting date 
was chosen to reflect the introduction of SBCNs into clinical practice and their 
emerging role in delivering follow-up care. The end date, 2009 was when this 
study commenced. Studies identified following this date are included in the 
discussion chapter (Chapter 6). 
 
The Medical Subject Headings (MeSH) term “breast neoplasm” is highly sensitive 
within all the electronic databases and breast cancer literature is the most 
frequently reported. To manage this and to increase sensitivity for this particular 
search strategy, clear inclusion and exclusion criteria were applied. Studies could 
include patients of any age but was restricted to female. Breast cancer is an 
infrequent event in men, with approximately 0.7% of all breast cancers diagnosed 
occurring in men (Nordman & Dalley, 2008). Clinicians have limited experience of 
male breast cancer due to its rarity and therefore the treatment and management 
follows a similar approach to females (Nordman & Dalley, 2008; Matterella, 
2010).   
 
No studies reporting investigative medical procedures used during follow-up to 
identify recurrence in asymptomatic women following completion of treatment 
were included: mammography, PET Scans, MRI or any other.   
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Studies could include women up to 5 years following diagnosis, but only beyond 
this point if relevant to the questions asked.  Studies that reported needs, unmet 
needs and a need for support post primary treatment, within a follow-up clinic or 
within primary care were included.  Studies which reported the experiences of 
receiving follow-up care or the context of follow-up care were excluded if they did 
not specifically address needs.   
 
Studies that reported a woman’s needs, unmet needs and a need for support 
while receiving surgery, chemotherapy, radiotherapy, and trastuzumab were 
excluded.  These treatments are known as primary treatments and are completed 
prior to a woman receiving follow-up care.  The review presented in this chapter 
was solely interested in studies which reported unmet needs post-primary 
treatment. 
 
Qualitative and quantitative primary research studies were included in part one, 
but in part two only RCTs and pilot RCTs were included.  The decision to do this 
was guided by the nature of the question in part two; to assess the effectiveness 
of using needs assessment tools during breast cancer follow-up clinics.  Studies 
could include other tools that measured quality of life, anxiety, depression or 
satisfaction with care, but must include a needs assessment tool.  Studies could 
include woman at any stage of the disease trajectory other than the terminal 
phase.   
 
The following search methods were used and judged as to provide the best 
possible coverage of the literature: 
 
1. Electronic searches: Medline 1995 - 2009; CINAHL 1996 - 2009; British 
Nursing index and archives 1994 - 2012; Psychinfo 1996 - 2009; Cochrane 
Library Central 2000-2009. 
 
2. Hand searching, was undertaken of Acta Oncologica (2006/2007), Psych-
Oncology; and Cancer Nursing to cover the years 2008/2009 and to 
assess sensitivity to search strategies. 
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3. Reference lists, from relevant studies were reviewed to identify any 
additional studies.   
3.3 Methodological quality 
To establish whether a paper should be included in a review, both its closeness to 
the inclusion/exclusion criteria and its methodological quality are assessed. The 
importance of this is reported by Cochrane as a critical part of any systematic 
review (Higgins & Green, 2011). Qualitative and quantitative research are derived 
from different research views and are often seen as competing paradigms, with 
no consensus on the criteria for appraising mixed methods research (O’Cathain, 
Murphy & Nicholl, 2008). There are a number of tools to assess quality in 
qualitative studies (Horsburgh, 2003), and quantitative studies (Greenhalgh & 
Peacock, 2005; Guyatt et al. 2011; SIGN, 2012) with fewer papers suggesting 
ways of reviewing qualitative, quantitative and mixed methods research 
concomitantly (Pluye et al. 2009). Early scoring systems which grade the quality 
of evidence have focused almost exclusively on study design.  Therefore the RCT 
provides stronger evidence than observational studies, and indeed qualitative 
studies are often not considered in the scoring systems. Dixon-Woods et al. 
(2005) acknowledge that it remains a challenge to review research with methods 
that vary in their strengths and abilities. Their suggestion that existing techniques 
are adapted rather than new approaches invented was considered the best 
approach for this review.  
 
During the review process, titles and abstracts identified in the searches were 
read for relevance. All relevant literature was then read in full. It was apparent 
that the criterion by Pluye et al. (2009) was too restrictive for the papers in this 
review. Therefore a data extraction tool was adapted from SIGN (2012) with an 
additional scoring system used for the RCTs and described in Table 3.1. 
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Table 3.1: Scoring framework of RCTs (Guyatt et al. 2011) 
Study 
design 
Quality of 
evidence 
Lower if Higher if 
Randomised 
trial→ 
 
 
 
High 
Risk of bias 
-1 serious 
-2 very serious  
Inconsistency 
-1 serious 
-2 very serious 
Indirectness 
-1 Serious 
-2 very serious 
 
Imprecision 
-1 serious 
-2 very serious 
 
Publication bias 
-1 likely 
-2 very likely 
 
Large effect 
+1 large 
+2 very large 
 
Dose response 
+1 evidence of 
a gradient 
 
All plausible 
confounding 
+ would reduce 
a demonstrated 
effect 
 
+1 would 
suggest a 
spurious effect 
when results 
show no effect 
Moderate 
Observational 
study→ 
Low 
Very low 
 
The characteristics and methodological quality of the studies extracted informed 
the specific aims of both reviews.  These are: 
 
Characteristics of the studies  
 Age of participants 
 Time since diagnosis 
 Type of follow up regimen of the participants 
 Origin of study 
 Stage of the breast cancer 
 Breast cancer specific details 
 Size of study 
 Were needs defined? (yes/no) 
 HCP involved 
 
 
 
Part 1 and 2 
Part 1 
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Methodological quality 
 Method 
 Inclusion criteria 
 Exclusion criteria 
 Description of intervention/interview 
 Needs assessment tools or other used 
 Outcome measures/aims stated 
 
 Randomisation process 
 Sample 
 Allocation concealment 
 Numbers followed up 
 Intention to treat analysis 
 
Factors that can decrease the quality of the evidence include: study limitations, 
inconsistency of results presented, indirectness of evidence and publication bias 
which may result in selective outcome reporting. Factors that may increase the 
quality include a large magnitude of effect and plausible outcomes. The 
characteristics of the studies are presented in Table 3.4 (part one) and Table 3.10 
(part two), the methodological quality are presented in Table 3.5 (part one) and 
Table 3.11 (part two) with factors which may have decreased or increased the 
quality discussed in Sections 3.4.4 and Section and 3.8.4 respectively. Finally, a 
results table was compiled to address the specific outcomes of this review and 
interpreted in Section 3.5 (Table 3.6) and Section 3.9 (Tables 3.12 and 3.13).   
3.3.1 Patient-reported outcome measures (PROMs) 
Data on the following PROMs were sought.  Data extracted for part one  included 
(Table 3.6): 
 
1. Patient reported levels of perceived unmet need during follow-up care to 
ascertain:  
 
Part 1 and 2 
Part 2 
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a)  The number of unmet needs reported; 
b)  The type of unmet needs reported; 
c)  Whether changes in needs are reported over time; 
d)  The effect of age on perceived needs; 
e)  Percentage of needs met; 
f)   Who meets these needs?    
g)  Predictors of reporting a need. 
 
2. Any patient reported data related to quality of life 
 
Data extracted for part two (Table 3.12 and 3.13) included: 
a. Patient reported changes of perceived needs.  
b. Patient reported changes in quality of life. 
3.4 Results of part one 
This part of the review reports literature that addresses the perceived needs of 
women with breast cancer during follow-up and focused on the following 
questions:  
1. What is the evidence that women with breast cancer have unmet needs in 
the period known as “follow-up”?   
2. How and what are these reported perceived needs?  
3. Do socio-demographic and clinical factors affect the perceived needs 
women report? 
4. Do needs change for women from one follow-up consultation to another?  
5. Is there any evidence of a relationship between unmet needs and quality of 
life? 
3.4.1      Outcome of search strategy 
The combined searches across all the databases, reference lists and hand-
searching identified 1,521 potential papers (Table 3.2). Once the abstracts were 
read it was apparent that the search strategy had identified many papers which 
were not relevant to this review. When the inclusion/exclusion criteria was applied 
only 22 (1.27%) papers were identified as potentially relevant and read in full. Of 
these, 16 papers were excluded and the reason for their exclusion is summarised 
in Table 3.3 with further discussion in Section 3.4.2.  
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Table 3.2 Record of searches up to 2009 (part one) 
Database 
Total 
no. of 
hits 
Included for 
full text 
review 
Included 
in review 
Excluded 
from 
review 
Medline 1066 18 5 13 
CINAHL 30 
1 duplicate 
from Medline 
0 0 
British Nursing 
Index 
400 
1 duplicate 
from Medline 
0 0 
PsycINFO 23 2 1 1 
Cochrane Library 0 
1 duplicate 
from Medline 
0 0 
Hand searching 2 2 0 2 
Total 1521 22 6 16 
 
3.4.2   Excluded studies 
Sixteen papers were excluded. Thirteen were primary research studies which 
reported different follow-up care practices, experiences of follow-up care and 
nursing involvement but failed to meet the inclusion criteria relating to needs, 
unmet needs and need for support during follow-up care (see Section 3.2.1) 
(Judkins, Peterson & Singletary, 1996; Earnshaw & Stephenson, 1997; Adewuyi- 
Dalton et al. 1998; Pennery & Mallet, 2000; Sanson-Fisher et al. 2000; Lindop & 
Cannon, 2001; Brown, Payne & Royle, 2002; Koinberg et al. 2004; Thompson et 
al. 2006; Kimman et al. 2007; Minstrell et al. 2008; Montgomery, Krupa & Cooke, 
2007; Sheppard et al. 2009). Three papers were excluded because they were 
literature reviews that considered types of follow-up care and frequency of 
delivery rather than the needs of the women attending (Collins, Bekker & 
Dodwell, 2004; Montgomery, Krupa & Cooke, 2007; Sheppard, 2007). Further 
details of the reasons for exclusion of all these papers is summarised in Table 
3.3. 
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Table 3.3 Summary of excluded studies (part one) 
Study 
Type of 
study 
Reason for exclusion 
Adewuyi- Dalton et al. 
(1998)  
Qualitative 
 
Explored the experience of women attending 
follow-up 
Brown, Payne & Royle, 
(2002) 
RCT 
Compared usual follow-up to no follow-up 
unless initiated by women 
Collins, Bekker & 
Dodwell (2004) 
Literature 
review 
Reviewed follow-up practices and nursing 
involvement not needs 
Earnshaw & 
Stephenson  
(1997)  
Audit 
Focused on nurse-led follow-up services, did 
not focus on needs 
Judkins, Peterson & 
Singletary (1996) 
Qualitative 
Compared non-doctor to doctor provider of 
follow-up 
Kimman et al. (2007) 
RCT 
protocol 
Insufficient data available, an abstract 
Koinberg et al. (2004) RCT 
Compared doctor led follow-up to nurse led 
telephone based follow-up 
Lindop & Cannon 
(2001)  
Qualitative 
Measured support needs across the breast 
cancer trajectory but data 
relating to follow-up period difficult to extract 
Minstrell et al. (2008) 
Longitudinal 
survey 
Needs of women with breast cancer 
following diagnosis over 3 months but did 
not consider  the follow-up period 
Montgomery, Krupa & 
Cooke (2007) 
Literature 
review 
Reviewed follow-up practices and nursing 
involvement 
Montgomery, Krupa & 
Cook (2008) 
Qualitative 
Explored experiences of women with breast 
cancer prior to receiving follow-up 
Pennery & Mallet 
(2000) 
Qualitative 
Did not specifically look at the needs of 
women during follow-up although it did 
consider their views of follow-up practices 
Sanson-Fisher et al. 
(2000) 
Survey 
Reviewed predictors and perceived needs 
during treatment rather than follow-up 
Sheppard (2007) 
Literature 
review 
Reviewed follow-up practices and nursing 
involvement but not needs 
Sheppard et al. (2009) RCT 
Compared usual follow-up to follow-up 
by request by women when they felt they 
needed to be seen but not needs 
Thompson et al. (2006) Qualitative 
Explored the experiences of women at 
follow-up, particularly motivators and barriers 
but not needs 
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3.4.3 Characteristics of included studies 
A summary of the characteristics of the six included studies is presented in Table 
3.4. None of the six included studies defined the term “needs” or “unmet needs”, 
however, following a review of the full papers they met most of the inclusion 
criteria: one study reviewed the needs assessment literature (Girgis et al. 2000) 
while the remaining five studies explicitly used the term “needs” in their overall 
aim or objectives (Raupach & Hiller 2002; Thewes et al. 2004; de Bock et al. 
2004b; Beaver et al. 2006; McCaughan & McSorley, 2007). 
 
A total of 712 (range 21 - 229) women with a mean age of 52 (range 30 - 89 
years) are included across the six studies; they are all diagnosed and treated for 
breast cancer, are disease free and have completed their primary treatment. The 
surveys constituted 645 of the participants. These data captured the range of 
perceived unmet needs women reported post-treatment and during follow-up care 
(Table 3.4). 
 
All the studies except Beaver et al. (2006) gave details of the time since diagnosis 
of the women (range 6 months to 21 years). The study by McCaughan & 
McSorley (2007) included some women who were over 5 years since diagnosis. 
The majority of the qualitative data presented in their paper referred specifically to 
women who were up to 5 years and in some areas of the results, it was difficult to 
identify the time since diagnosis. It was expected that the papers conclusions 
would add to this review.   
  
Only two studies described the follow-up regimen (de Bock et al. 2004b; Raupach 
& Hiller 2002) but all studies described the country of origin.  It is important to 
understand the origin of the study because differences occur in the frequency, 
intensity of regimens and length of follow-up between countries and access to 
support structures may be variable (see Table 2.2). In addition, cultural beliefs 
may differ between countries could impact on perceived unmet needs. Two 
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studies were undertaken in the UK (Beaver et al. 2006; McCaughan & McSorley, 
2007), three in Australia (Girgis et al. 2000; Raupach & Hiller, 2002; Thewes et al. 
2004) and one in Holland (de Bock et al. 2004b). 
   Table 3.4: Characteristics of included studies (part one) 
Study 
Needs 
defined 
Yes/no 
Type of 
follow-up 
a. timing 
b. Country  
Age 
a. C 
b. I 
Size 
C or/I 
 
Stage of 
breast 
cancer 
TSD 
 
HCP 
 
Beaver et al. 
(2006) 
no 
a. no 
b. UK 
a. mean 
age 55:  
(range 
32-79) 
b. mean 
age 59: 
range 38-
84 
135 
patients 
C. 67  
I. 68) 
2x SBCN 
interviewed 
n/a n/a 
SBCN 
Doctor  
De Bock et 
al. (2004) 
no 
a. 6 
Monthly 
b. Holland 
Med 56: 
range 33- 
90 
84 
DCIS: 11 
stage 1: 
36 (43%) 
stage 2a 
17 (20%) 
Stage 2b 
17 (20%) 
Stage3a 
14(4%) 
med 3 
years: 
range 2 - 
4.1 years 
n/a 
Girgis et al. 
(2000) 
no 
a. no 
b. Australia 
range 30-
89 
229 
rural - 129 
urban -100 
n/a 
6m – 5 
years 
n/a 
McCaughan 
& McSorley 
(2007) 
no 
a. no 
b. UK 
range 34-
89 
21 n/a 
2 - 21 
years 
Doctor  
Raupach & 
Hiller (2002) 
no 
a. 6 
monthly 
b. Australia 
mean 58 219 n/a 6 -30 m n/a 
Thewes et 
al. (2003) 
no 
a. no 
b. Australia 
mean 35 
(range 
26-45) 
24 
Early 
stage 
breast 
cancer 
12m – 5 
years 
n/a 
Note: C = Control; I = intervention; m = months; TSD = time since diagnosis; med = 
medium 
 
Two studies reported that a doctor undertook the follow-up consultation (Beaver 
et al. 2006; McCaughan & McSorley, 2007), although their level of seniority was 
not described. In one of these studies, the specialist breast care nurse (SBCN) 
undertook an additional intervention following a woman’s attendance at the clinic 
(Beaver et al. 2006). In the remaining four studies this information was 
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unavailable (Girgis et al. 2000; Raupach & Hiller, 2002; de Bock et al. 2004b; 
Thewes et al. 2004). 
 
Only one study (de Bock et al. 2004b) described the specific stage of breast 
cancer participants. These included women with ductal carcinoma insitu (DCI) 
and breast cancer, grades 1,2 and 3. Thewes et al. (2003) referred to participants 
in a generic manner as having early invasive breast cancer. This limits any 
comparisons between studies and is an important consideration.  The stage of 
breast cancer at presentation is an important indicator of treatment choice, 
regimen used, the risk of side effects and prognosis (see Chapter 2). 
3.4.3.1 Sample strategy and recruitment 
Thewes et al. (2003) recruited 24 participants and McCaughan & McSorley 
(2007) 21, with a single site location used by both studies. In the study by 
McCaughan & McSorley (2007), women were attending a UK breast cancer 
follow-up clinic but no details of how women were recruited into their study were 
provided. However, the purpose of this study, as exploratory, reflected the sample 
size used. 
 
The sample by Girgis et al. (2000) (n=229) was randomly selected from the New 
South Wales Central Cancer Registry and therefore had the highest potential to 
be representative. Strict ethical processes required permission from the GP prior 
to contacting the women by post, which according to the authors caused delays 
and barriers with recruitment. A significant number of women were considered 
ineligible to take part by the GP and this may have contributed to the non-
representativeness and low response rate (51% for urban v. 55% for rural). Up to 
8% (n =68) in both groups were considered emotionally or physically unstable 
according to the GP but the criteria by which this was arrived at is unclear.  These 
women may have had higher needs. Additionally, 80% (n=183/229) of women in 
the study were at least 3 years since diagnosis, and therefore was less 
representative of the range of women seen in breast cancer follow-up clinics.  In 
contrast, Raupach & Hiller (2002) and de Bock et al. (2004b) had good 
recruitment to their studies, with 82% (n=266) and 72% (n=116) taking part 
respectively. Both studies recruited participants from the current out- patient lists 
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but neither indicated how many patients overall were on these lists and so, 
representativeness of the sample is not clear.   
3.4.4 Methodological quality of included studies 
A summary of the methodological quality of the six studies is presented in Table 
3.5. 
Table: 3.5 Methodological qualities of included studies 
Beaver et al. 2006 
 
de Bock et al. 20004 Girgis et al. 2000 
Method: mixed 
Inclusion: access to phone 
Exclusion: n/a 
Needs assessment tool 
used: yes, INQ 
Other tools: STAI, GHQ-12 
QS: 58/100 
Method: Cross-sectional 
survey 
Inclusion: attending follow-up 
Exclusion: n/a 
Needs assessment tool 
used: yes, by authors 
Other tools: HADS, PSQ111 
QS: 33/100 
Method: Cross sectional 
survey 
Inclusion:6m - 6 years 
Exclusion: n/a 
Needs assessment tool 
used: yes, BR-CPNQ 
Other tools: n/a 
QS: 66/100 
Description of 
intervention/interview: 
Place: phone + hospital 
Timeframe: 3m and 8-12m 
No. interview x 1, 
questionnaires x 2 
 
Description of 
intervention/interview: 
Place: home 
Timeframe: n/a 
No. questionnaire x1 
Description of 
intervention/interview: 
Place: home 
Timeframe: n/a 
No. questionnaire x 1 
Aim: To examine the 
feasibility and acceptability 
of a nurse led telephone 
intervention to meet patient 
needs 
 
Aim: To analyse the needs of 
women at routine follow-up 
after treatment for primary 
breast cancer 
Aim: To assess prevalence of 
unmet needs among women 
diagnosed with breast cancer 
Identify predictors of 
expressing moderate – high 
needs 
McCaughan & McSorley 
(2007) 
 
Raupach & Hiller (2002) Thewes et al. (2004) 
Method: Non-participant 
observation and interviews 
Inclusion: n/a 
Exclusion: n/a 
Needs assessment used: 
n/r  
Other tools: n/r 
QS: 50/100 
Method: Cross-sectional 
survey 
Inclusion: attending cancer 
centre 
Exclusion: n/a 
Needs assessment used: 
yes, by authors 
Other tools: not used 
QS: 66/100 
Method: focus 
groups/interviews 
Inclusion: past 5 years, pre-
menopausal at diagnosis 
Exclusion: n/a 
Needs assessment used: n/r 
Other tools: n/r 
QS: 83/100 
Description of 
intervention/interview: 
Place: hospital 
Timeframe: not stated 
No. Interview x 1; 
observation x 7 clinics 
Description of 
intervention/interview: 
Place: home 
Timeframe: 6 – 30m 
No. questionnaire x 1 
Description of 
intervention/interview: 
Place: hospital 
Timeframe: not stated 
No. Interview x 1 
Aim: To explore healthcare 
needs of women attending 
follow up clinics, how they 
are met and HCP ways to 
improve services 
Aim: needs for, use of and 
satisfaction with information 
and support of woman 
Aim: To identify the fertility – 
and menopause – related 
information needs of younger 
women who have had early 
breast cancer 
Note: n/a = not available; n/r = not relevant; QS = quality score 
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Of the six studies included, two used a qualitative approach (Thewes et al. 2004; 
McCaughan & McSorley, 2007). Of these, neither reported any evidence of using 
a theoretical framework or a specific qualitative research methodology; a critical 
component in the assessment of quality in this methodological approach 
(Creswell & Plano Clark, 2007). The decision to include studies with different 
research designs in this review enabled a more in depth overview of the literature 
in this field; however the methodological quality of these studies was variable.  
Although considered low on the hierarchical scale of study types, in that they are 
qualitative studies (Thewes et al. 2004; McCaughan & McSorley, 2007), cross 
sectional surveys (Girgis et al. 2000; Raupach & Hiller, 2002; de Bock et al. 
2004b) or non-experimental studies (Beaver et al. 2006), Dixon-Woods et al. 
(2005) support the use of different types of evidence by practitioners and policy-
makers, particularly in the absence of any RCTs.   
 
Similarities in the overall aim or objectives across the four studies were seen 
(Girgis et al. 2000; Raupach & Hiller, 2002; de Bock et al. 2004b; McCaughan & 
McSorley, 2007). De Bock et al. (2004b) and McCaughan & McSorley (2007) 
aimed to explore and assess the perceived unmet needs of women attending 
follow-up care, while Girgis et al. (2000) wanted to understand unmet needs 
across different populations; rural and urban. Only one study (Thewes et al. 2004) 
focused specifically on the unmet needs associated with fertility and menopausal 
consequences of younger women (age 25 - 45 years), and Beaver et al. (2006) 
examined the feasibility of a nurse-led intervention to meet the information needs 
of women. In all the studies women received follow-up care in a clinic setting, but 
data which described the frequency of attendance was difficult to extract.  This 
meant there was uncertainty about the current support opportunities made 
available to women.  
 
Validation of quantitative and qualitative data is important as it reflects the ability 
to interpret and generalise findings. Two studies used a validated needs 
assessment tool although differently (Girgis et al. 2000; Beaver et al. 2006). 
Girgis et al. (2000) used the Supportive Care Needs Survey (SCNS) which 
measures both the unmet needs associated with psychological, health 
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information, physical/daily living, patient care/support and interpersonal 
communication as well as their requirement for help. Beaver et al. (2006) used an 
Information Needs Questionnaire (INQ) covering nine information needs. The 4 
point Likert scale asked questions about how much information they needed and 
whether they had received this information or not. It was originally developed and 
tested in Canada by Degner et al. (1998). Neither was specifically developed for 
use with breast cancer patients attending follow-up clinics. 
 
The Hospital Anxiety and Depression Scale (HADS) used by de Bock et al. 
(2004b) does not specifically measure unmet need. However psychiatric 
morbidity associated with mastectomy (Maguire et al. 1987) coupled with anxiety 
and depression scores among breast cancer patients have shown to be 
consistently high (Osborne et al. 2004), leading a number of authors to suggest 
that a high score on the HADS (HAD-A and HAD-B) indicate a high psychological 
need (Carroll, 1993; Karakoyun-Celik et al. 2010; McDowell et al. 2010). De Bock 
et al. (2004b) combined this information with a questionnaire they specifically 
designed for their study. Other validated questionnaires used measured quality of 
life (General Health Questionnaire, GHQ-12) (Beaver et al. 2006), levels of 
distress with the State- Trait Inventory (STAI) (Beaver et al. 2006) and a Patient 
Satisfaction Scale (PSQ 111) (de Bock et al. 2004b).   
 
Similar questions appeared about recurrence, side effects of treatment, spread of 
disease and impact on self and family in the questionnaires designed by Raupach 
& Hiller (2002) and de Bock et al. (2004b) and those used by Girgis et al. (2000) 
and Beaver et al. (2006). The distribution of all questionnaires following 
recruitment was clear. All participants were completed them at home (Girgis et al. 
2000; Raupach & Hiller, 2002; de Bock et al. 2004b; Beaver et al. 2006). In 
addition, Beaver et al. (2006) offered an interview to women at the hospital when 
attending their clinic appointment and two others interviewed women at the 
hospital (Thewes et al. 2004; McCaughan & McSorley, 2007). 
 
One limitation noted is the selective outcome reporting associated with a number 
of the publications. Two studies aimed to investigate and explore the perceived 
needs of women attending follow-up care (Raupach & Hiller, 2002; de Bock et al. 
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2004b), one aimed to understand perceived needs from different populations; 
rural and urban, post treatment (Girgis et al. 2000) or younger women (Thewes et 
al. 2004) or to understand the perceived needs through observation of the nature 
and context of the follow-up clinic (McCaughan & McSorley, 2007). One study 
aimed to examine the feasibility of a nurse-led intervention to meet the 
information needs of women (Beaver et al. 2006). While presenting aims rather 
than outcomes is consistent with non-experimental and qualitative designs, some 
inconsistencies in how the results were presented by Beaver et al. (2006), Girgis 
et al. (2000) and McCaughan & McSorley (2007) impacted on the interpretation of 
their studies.  
 
Thewes et al. (2003) did not provide detail of the qualitative approach used but 
did provide a clear explanation of the patients in their study, the interview, and the 
analytical approach that led to its findings. This strengthened the quality of data 
reported. 
3.5 Outcome results  
The six studies indicated that some level of unmet need persists for women post 
treatment and during a time they would receive follow-up care (Girgis et al. 2000; 
Raupach & Hiller, 2002; de Bock et al. 2004b; Beaver et al. 2006; McCaughan & 
McSorley, 2007). A summary of the results is presented in Table 3.6. 
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Table 3.6: Results of included studies in part one 
Study 
Unmet 
needs 
reported 
Change 
in needs 
over time 
Predictors 
of reporting 
a need 
Relationship 
between age 
and need  
% needs 
being met 
Beaver et 
al.(2006) 
Control: no 
data 
Intervention 
17-36%  
(time 1);  
3 - 40%  
(time 2) 
Cure,          
p <0.01  
Family 
impact,  
p 0.05 
Genetic risk, 
p <0.01 
(p=>0.05) 
n/a n/a 
Time 2 
Control   
27% - 57% 
Interventio
n  
60% - 91%  
De Bock et 
al.(2004) 
19 - 86% n/a 
Higher HADS 
scores 
Hormonal 
therapy 
Fear of 
recurrence 
General needs 
 -0.35** 
Specific needs  
-0.32** 
n/a 
Girgis et al. 
(2000) 
rural 28- 55%  
urban 28 - 
41% 
n/a 
Age 
Family income 
Chemo and 
radio in past 
month 
Younger 
women 
30 - 59 years 
70 - 89 years 
n/a 
McCaughan 
& McSorley 
(2007) 
n/a n/a n/a n/a 
n/a 
 
Raupach & 
Hiller (2002) 
36 - 90% n/a n/a 
Over 69 > 
needs 
compared to 
50-69 
Under 50 some 
<needs 
2 - 26%;  
(mean 16%)  
Thewes et 
al.(2003) 
n/a n/a  26 - 45 years  
Yes –  
narrative 
only 
 
The type and number of unmet needs reported across the studies varied 
depending on the specific aims of the study, its design and questions asked. It 
was clear though that irrespective of method used, common themes were 
emerging about the type of unmet needs reported by women at this time. These 
were categorised as: psychological, information and physical needs. Some of 
these categories were already pre-determined due to the nature of the 
questionnaires used (Girgis et al. 2000; Rauper & Hillier, 2002; de Bock et al. 
2004; Beaver et al. 2006). In other studies this was not as clear and a pragmatic 
decision was made according to the results described. A summary of the 
categories and particular needs is presented in Table 3.7  
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 Table 3.7: Range of unmet needs reported in the studies (part one) 
Study 
Psychological 
needs 
Information needs 
Physical and 
daily living 
Beaver et al. 
(2006) 
 
 Genetics, Spread, Side effects, 
Cure, Social Life, Sexual 
attractiveness, Treatment options, 
Self-care, Family impact  
 
Girgis et al. 
(2000) 
 
Fear of spread/ 
recurrence 
Anxiety/stress 
Feeling 
down/depressed  
Test results, knowledge of side 
effects, self-care, remission, 
treatment success, written 
information, support groups  
side effects  
Lack of energy 
and tiredness  
De bock et 
al. (2004) 
Fear of cancer 
returning  
Long term effects of treatment, 
prognosis, diagnosis information, 
side effects, hereditary factors,  
changes in untreated breast, 
reconstruction, family/friends, 
adaptation, additional 
investigations, prevention 
Fatigue, pain  
nutrition 
Rauper & 
Hiller, (2002) 
 Recurrence, cure, risk to family, 
Tamoxifen, effect on family, arm 
problems/Lymphoedema, 
appearance after surgery, 
menopause/HRT, prostheses  
sexuality and relationships, breast 
reconstruction, additional support 
 
Thewes et al. 
(2003) 
 Fertility, menopause, treatment, 
sexuality (narrative) 
 
McCaughan 
& McSorley 
(2007) 
Fear of 
recurrence 
Psychosocial 
needs (general) 
(narrative) 
  
 
All the studies are report unmet needs as a percentages except Thewes et al. 
(2003) and McCaughan & McSorley (2007) who described unmet needs through 
narrative. The most frequently reported unmet needs related to a fear of 
recurrence; managing side effects; and coping with the impact on self. Beaver et 
al. (2006) reported results relating to the 9 questions on the INQ, Raupach & 
Hiller (2002) only 13 and de Bock et al. (2004b), 15; Girgis et al. (2000) presented 
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data on the top 15 high to moderate needs expressed out of the 61 questions 
asked. 
 
The five highest unmet needs reported by de Bock et al. (2004b) was for 
information about long term side effects (84%, n=69/84), hereditary implications 
(68%, n=57), prognosis (85%, n= 69), identifying changes in the untreated breast 
(65%, n=55) and prevention of breast cancer (72%, n=60). These were similar to 
those reported by Rauper & Hiller (2002): recognising a recurrence (90% 
n=191/217), chances of cure (82%, n=167), risk to family (81%, n=167), side 
effects of endocrine therapy (72%, n=148) and effects on family (68%, n=142).  
 
Girgis et al (2000) reported similar results but these needs were lower among 
their sample; fears about cancer spreading (rural 55%, n=70 v. urban 41%, n= 
40), being fully informed of test results (45%, n=58v. 44%, n=43), benefits and 
side effects of treatment (44%, n=57 v. 42%, n-41), self-care (44%, n=56 v. 40%, 
n=39) and being informed about cancer remission (45%, n=58 v. 37%, n=36).  
Women continue to be fearful of a recurrence and anxious about their chances of 
cure and treatment success, despite regular engagement with HCPs during 
follow-up. Women described attending follow-up allayed their fears (McCaughan 
& McSorley, 2007) but in observations by the researcher, no evidence of specific 
conversations addressing this area of need was seen, rather a sense that if 
women left with no recurrence found, everything was alright. In contrast, women 
reported that needs associated with the side effects of treatment, body image, 
and sexuality were not addressed.  This suggests that once fears are allayed, 
women wish to focus on issues that affect their day to day lives. These areas 
though may require more active enquiry.  
 
Some authors suggest that any form of reassurance within a clinic will improve a 
woman’s ability to cope with the wider effects of treatment (de Bock et al. 2004b; 
Beaver et al. 2006), understanding the risk posed by breast cancer for their family 
members (Rauper & Hiller, 2002; Beaver et al. 2006;) and their general anxieties 
about the whole cancer experience (de Bock et al. 2004b; Beaver et al. 2006).  
Despite these conclusions, only one study (Beaver et al. 2006) gathered data 
from more than one time point to demonstrate changes over time.   
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The wish to receive information related to the consequences of breast cancer was 
more frequently reported than any other category (Table 3.7). Apart from 
information about the risk of recurrence, the other frequently reported information 
needs included: menopausal or fertility issues through narrative (Thewes et al. 
2003), genetics, 41% (n=27/67) and side effects of treatment, 35% (n=23) 
(Beaver et al. 2006) prevention, 72% (n=84/116) and hereditary factors, 68% 
(n=79) (de Bock et al. 2004), benefits and side effects of surgery prior to 
treatment, 44% (n=57) v 42% (n=41) (Girgis et al. 2000), and information about 
their prescribed hormone treatments (McCaughan & McSorley, 2007).  
 
Raupach & Hiller (2002) found that 205 out of 217 women reported the 
importance of receiving information. This included information about 
reconstruction (36%, n=74), sexuality and relationships (39%, n=81) and 
prostheses (41%, n=82). De Bock et al. (2004b) also found 26% (n=22) of women 
wanted information about reconstruction. In their study specific questions related 
to sexuality and prostheses were not included. Considering mastectomy and/or 
reconstruction is a common treatment questions of this nature are important to 
include. Girgis et al. (2000) did not ask women about any of these areas.  Lower 
needs were associated with lack of energy and tiredness (28% v. 28%) and 
feeling down or depressed (33% v. 29%).  
 
The wide range of information needs which are reported reflect the different types 
of breast cancer, the different treatments used and the individual reaction a 
woman may experience (Chapter 2). The participants in the study by Girgis et al. 
(2000) scored information about support groups and self- care approaches higher 
than participants in the study by Beaver et al. (2006). Why this may be the case is 
unclear from the results.   
 
None of the studies measured the unmet needs of women before and/or after the 
follow-up consultation, therefore it is difficult to know if some of these information 
needs were met during the follow-up consultation. Beaver et al. (2006) did offer 
their intervention following the follow-up consultation. They reported high levels of 
unmet needs in their sample following the consultation, measured using the INQ.    
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Five studies reported psychological needs or referred to it as psychological 
distress (Girgis et al. 2000; Thewes et al. 2003; de Bock et al. 2004; Beaver et al. 
2006; McCaughan & McSorley, 2007). Beaver et al. (2006) reported a significant 
difference between the mean STAI scores between the intervention (mean 31.1) 
and control (mean 34.9) post-intervention (t = - 2.02, p=0.05). The STAI scores 
between a range from 0 - 80. 
 
In contrast, de Bock et al. (2004b) reported that 18% (n=15) of their participants 
warranted further psychiatric evaluation after completion of the HADS. They 
applied a cut-off score of 8; a score considered the optimal balance between 
sensitivity and specificity (0.80) when the HADS is used as a screening tool 
(Bjelland et al. 2002). Satisfaction with care was measured using Ware’s tool 
(Hagedorrn et al. 2003). Multivariate analyses of the satisfaction with care results, 
in particular the interpersonal aspects, indicated that the score on the HADS was 
an independent predictor of needs and preferences (p<0001=0.52, anxiety; 
p<0.001=0.29, depression). These results suggest the HADS is a useful tool to 
measure psychological needs.   
3.5.1 Age-specific needs  
The age of women diagnosed with breast cancer includes those at a childbearing 
age, pre-, peri- and post-menopausal stage in their life cycle. This was apparent 
among the participants in the studies whose ages ranged from 26 – 90. Four 
studies considered how the age of a woman may predict her level of need (Girgis 
et al. 2000; Rauper & Hiller, 2002; Thewes et al. 2003; de Bock et al. 2004b). 
 
Rauper & Hiller (2002) (sample of 219) reported women over 69 (6%) were 
significantly less likely than women of 50-69 (27%) to receive information about 
physical appearance post-surgery (prevalence rate ratio (PRR) 0.24, 95% CI 
0.06-0.94) and where to go for information (6% v. 28%, PRR 0.23, 95% CI 0.06 – 
0.92). Women over 69 expressed lower needs with respect to information about 
sexuality and relationships (3% v. 41%, (PRR) 0.07, 95% CI 0.01-0.52), breast 
reconstruction (3% v.38%, PRR 0.08. 95% CI 0.01-0.56), menopause and HRT 
(10% v.50%, PRR 0.20, 95% CI 0.07-0.60), and physical appearance (20% v. 
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63%, PRR 0.32, 95% CI 16-0.63). Women under 50 reported higher needs for 
information compared to women 50-69 about: complementary and alternative 
therapies (71% v. 53%, PRR 1.34, 95% CI 1.12-1.83), menopause and HRT 
(72% v. 50%, PRR 1.43, 95% CI 1.12-1.83), sexuality and relationships (59% vs. 
41%, PRR 1.45, 95% CI 1.06-1.98), and breast reconstruction (54% v. 38%, PRR 
1.43, 95% CI 1.02-2.02).  
 
Two studies undertook multivariate analyses. They reported an association 
between different variables and reporting “some” need (Girgis et al. 2000; de 
Bock et al. 2004b). In the study by de Bock et al. (2004b) age (-0.35** -0.32**) 
having adjuvant hormonal treatment (0.24*), having chemotherapy (0.25*, 0.23*), 
anxiety (0.52***) and depression (0.29*) were predictors of reporting ‘some’ 
need.1  
 
Girgis et al. (2000) reported age as being associated with a psychological need 
(ages 30 - 49, p = 0.005), having radiotherapy or chemotherapy in the last month 
was associated with a patient care and physical need (p=0.023; p=0.033) and 
rural inhabitants were associated with having a physical and daily living need 
(p=0.014). 
 
The study by Thewes et al. (2003) particularly focused on the perceived unmet 
needs of younger women (age range 25 – 45) and who were attending follow-up 
(2 - 5 years since diagnosis). Through a series of focus groups facilitated by a 
psychologist, fertility-related, menopause related, treatment specific and sexuality 
issues were explored. Women described complex side effects associated with an 
iatrogenic menopause, loss of fertility and concerns about having further children. 
They felt their follow-up consultations had afforded them few opportunities to 
express a need for support in these areas.  
 
They described a process of “grieving” when faced with fertility issues and a 
premature menopause, placing increasing importance on it the further they were 
                                                          
1  *p<0.05, **p<0.001, ***p<0.0001 First result relates to general topics associated with need, the 
 second score relates to specific topics of need. 
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from treatment (Thewes et al. 2003). The menopause is diagnosed after 12 
months of amenorrhoea resulting from the permanent cessation of ovarian 
function regardless of whether the menopause was natural or induced 
(Greendale, Lee & Ariola,1999). Symptoms would therefore become more 
apparent during follow-up. The interviewed participants ranged in age, numbers 
of births, and status (single or married). Each participant expressed a highly 
individual situation associated with fertility and menopausal needs. Although 
some women sought formal support from HCPs there is no details reported about 
the nature of this. The authors recommend that fertility and menopause related 
issues should be revisited during follow-up.   
 
Menopausal issues are not exclusive to women under 50. The median age that 
menopause occurs in Europe ranges from 50.1 to 52.8 years (Palacios et al. 
2010). Rauper & Hiller (2002) also reported that menopausal issues were an 
unmet need. In their study, women aged 50-69 had high information needs 
relating to menopausal and HRT, rather than fertility needs. Many of these 
women would be receiving endocrine therapy, which can cause menopausal 
symptoms: therefore the result is perhaps not surprising.  Distinguishing between 
these needs is difficult and currently rests with the clinician who has the 
responsibility to provide opportunities for women to raise issues of a personal 
nature. Although the study by McCaughan & McSorley (2007) included women as 
young as 34, the data presented did not make reference to the age and need for 
support of individual participants. 
 
Girgis et al. (2000), using the Breast Cancer Patient Needs Questionnaire (BR-
CPNQ) reported that younger age was a predictor of psychological need (Odds 
Ratio 6.43, age 30-49 compared to 1.04, 60-69). The generalisability of these 
results is limited though as the study reports an under-representation of women 
aged 30 - 39 years. 
3.5.2 Changes in needs over time 
Beaver et al. (2006) was the only study included in this review which reported 
changes in needs over time, baseline (1 - 2 months) and time 2 (8-12 months) on 
a population of 135 (control, 67; intervention, 68). This study evaluated a 
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telephone intervention which aimed to meet the information needs of women with 
breast cancer. Although methodologically a RCT would have provided the most 
powerful rigor in establishing cause and effect, this pilot study aimed to test the 
feasibility and acceptability of this approach. The shortness of the questionnaire 
was appropriate when undertaking a telephone intervention. In addition, the STAI 
and the GHQ-12 were used.    
 
Beaver et al. (2006) reported needs associated with seroma formation, altered 
arm sensation and Lymphoedema, plus nine additional needs reported on the 
INQ. Changes were reported in both control and intervention groups between 
baseline and time 2. These included: seroma formation >16.7% (control) v. 59.3% 
(intervention); altered arm sensation > 11.1% v.  51.9%; Lymphoedema no 
change v. > 11.8%, however it is unclear from the data reported whether this was 
significantly different between the two groups. The participants were all post-
surgery (mean time since surgery 3-4 months).  However, it is unclear from the 
data reported whether some of the participants were also receiving additional 
treatments such as chemotherapy or radiotherapy.  
 
The STAI scores indicated a significant difference at time 2 between the 
intervention (M=31.1) and control (M=34.9, t= - 2.02, p=0.05). The ability of the 
nurse to meet the information needs through the intervention was high (73% - 
90%), though only 3 items were statistically different (information about cure: 
p=<0.01; family impact, p=0.05; genetic risk, p=<0.01). The intensity of the 
intervention by Beaver et al. (2006) may have contributed to these positive 
results.  However, the SBCN involved in the study found the intervention to be 
quite time consuming and the discussion of sensitive issues over the telephone, 
difficult at times. Despite this, the study indicated that using a structured approach 
to the assessment of need, nurses are able to respond to these in an effective 
way.  Effectiveness was measured by noting a significant reduction in anxiety and 
an increase in the perception of women that the nurses were able to meet their 
information needs over time.  
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3.5.3 Needs met and by whom  
Different HCPs are involved in the follow-up care of women. Both nurses and 
doctors were integral to the care of the women in the studies. Two studies 
specifically reported the input of the nurse or doctor (McCaughan & McSorley, 
2007; Beaver et al. 2006). In McCaughan & McSorley (2007) study, women 
described limited opportunities to have their information needs about hereditary 
implications, family issues or tiredness met by a HCP within the clinic setting. 
Despite the SBCN being viewed as an important source of support, women did 
not seek these nurses’ support when attending the clinic. A surprising finding was 
that women did not view the clinic nurses as someone who could meet their 
needs. It is concerning that women did not feel confident to access the SBCN 
when in the hospital. Rauper & Hiller (2002) and de Bock et al. (2004b) 
acknowledged that  there is a decline in the level of information and support 
women are offered the further they are from diagnosis, including access to a 
SBCN. 
 
Patients reported that they saw the nurses and doctors as integral to having their 
needs met (Rauper & Hiller, 2002; Beaver et al. 2006). Beaver et al. (2006) asked 
participants to indicate if they had received the information they needed. At time 2 
(8 - 12 months post-treatment) more participants in the intervention group than 
the control group had had their needs met across all nine questions on the INQ. 
These changes were statistically significant in relation to information about cure 
(p=<0.01), family impact (p=0.05) and genetic risk (p=<0.01). 
 
Raupach & Hiller (2002) asked women in their survey which HCP met their 
needs. The results were difficult to interpret and appeared conflicting. Women 
reported high levels of satisfaction with the cancer specialists (no detail given of 
who they are) (98%) and SBCNs (85%) they met but dissatisfaction about 
information to meet their needs. Information needs met in the previous 6 months 
ranged from 2% about sexuality and 32% about the chances of cure. There may 
have been some misunderstanding about the way questions were worded as they 
aimed to explore a need for help rather than how satisfied the women were with 
their care. This incidental finding is interesting and suggests that while 
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satisfaction with overall services may be good, there remain gaps in services at 
an individual patient level. Women also reported a decline in the level of 
information and support the further they were from diagnosis. Few women (<7%) 
used formal support services or the Internet to meet their needs and may reflect 
the timing of data collection in 2002.  
3.5.4 Quality of life  
Only two studies (de Bock et al. 2004b; Beaver et al. 2006) measured the impact 
of unmet needs on quality of life. One study (Beaver et al. 2006) reported the 
relationship between needs being met and changes in quality of life. No 
significant differences in the quality of life between control and intervention are 
reported at baseline and first measurement respectively but there is limited data 
to validate these findings.  De Bock et al. (2004b) measured quality of life using a 
simple 3-item scale to ascertain fear of recurrence. It was unclear how the three 
items were chosen and therefore their validity or reliability. 
 
3.6 Discussion 
Six studies specifically focused on the unmet needs of women post treatment and 
around the period of follow-up. This review showed that breast cancer survivors 
reported between 19 - 90% of unmet needs related to physical, psychological and 
information domains during the period when they would be receiving follow-up 
care. The studies were varied in design, with no RCTs identified. Therefore there 
are some limitations in this review due to the quality of evidence. Although all the 
participants had a diagnosis of breast cancer, inconsistencies in the way data 
were collected, selective outcome reporting, and results made it difficult to 
compare and contrast the studies. This led to an inability to determine the overall 
prevalence of unmet needs among this group.  
 
The three studies that were cross-sectional in design precluded any conclusions 
being made with regard to causality between women’s needs and psychological 
distress and /or quality of life (Girgis et al. 2000; Raupach & Hiller, 2002; de Bock 
et al. 2004b). However, there was evidence that higher scores on the HADS were 
predictors of “some” level of need (de Bock et al. 2004b). Based on this limited 
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data, further exploration of the relationship between perceived needs and 
psychological distress/quality of life would be warranted.  
 
It was not clear how studies viewed the concept of need; with only one study 
reviewing any literature about needs (Girgis et al. 2000), leading to differences in 
how studies interpreted and categorised need. Furthermore, the lack of 
longitudinal data in the majority of the studies meant unmet needs were identified 
but no action or input was initiated to reduce this need for support (Girgis et al. 
2000; Raupach & Hiller 2002; Thewes et al. 2003; de Bock et al. 2004b; 
McCaughan & McSorley, 2007). Therefore, the studies primarily informed this 
review about the type and nature of perceived unmet needs identified with women 
with breast cancer following treatment, and in some case the usefulness of using 
a tool to allow women to identify their priority needs, and what might be the 
potential predictors of reporting ‘some’ level of need (Girgis et al. 2000; Raupach 
& Hiller, 2002; de Bock et al. 2004b). 
 
The literature indicated that through a series of focused interviews and 
questionnaires, many needs of women can be understood. These included: fears 
about recurrence and a possible cure; managing side effects of treatment, 
understanding hereditary factors; menopausal and fertility issues; self - care 
strategies; adaptation to physical and psychological changes; and fatigue (Girgis 
et al. 2000; Raupach & Hiller, 2002; Thewes et al. 2003; de Bock et al. 2004; 
Beaver et al. 2006; McCaughan & McSorley, 2007). Although similarities were 
seen across the studies (Table 3.6), differences were acknowledged depending 
on the overall aims and design of the study.   
 
No conclusion could be reached about why some studies categorised the fear of 
recurrence/anxiety as an information need, while others viewed it as a 
psychological need. On-going psychological distress of women with breast cancer 
after their primary treatment finishes is estimated to be between 20 and 30 % 
(Carroll et al. 1993), a level which has remained consistent (McDowell et al. 
2010). Knowledge of this is important in the future design of studies. If not, this 
may affect how HCPs provide psychological support for these women. 
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The fear associated with the cancer returning, spreading or being cured is 
identified as important to women in all the studies. There is good reason for this 
concern, with the risk reaching a peak in the first two years after surgery of up to 
10-15%. While there is a decline in the incidence of recurrences after this point, 
risk continues between 3 - 5 years (4.3%), and 5 - 9 years (4.6%) (Gliogorov, 
Pritchard & Goss, 2007). Furthermore this risk continues throughout the second 
decade (EBCTCG, 2005). In the two qualitative studies (Thewes et al. 2003; 
McCaughan & McSorley, 2007), both reported that this fear is partially being met 
through attendance at a follow-up clinic and the act of the clinical examination. 
This reassurance, which is difficult to quantify has also been reported in other 
studies out- with this review (Pennery & Mallet, 2000; Beaver et al. 2005). The 
relatively small numbers involved in the studies and the subjective nature of fear 
makes conclusions difficult. However, it is clearly important that studies which 
seek to assess need in this population include questions about this area of 
concern. 
 
Studies using questionnaires allowed women to self-report their fears directly 
(Girgis et al. 2000; Raupach & Hiller, 2002; de Bock et al. 2004b; Beaver et al. 
2006). Only the study by Beaver et al. (2006) was able to report a reduction in 
needs following the introduction in an intervention over time. While this was not 
statistically significant, it could be argued this was clinically meaningful; 
representing an important shift in how SBCNs use self-reported tools to engage 
effectively with their patients. Although this intervention was undertaken following 
the clinic appointment with the doctor, it may be as beneficial if provided directly 
at the clinic, otherwise it may not be cost effective. 
 
Measuring data longitudinally may have been helpful in the studies by Girgis et al. 
(2000), Rauper & Hiller, (2002), and de Bock et al. (2004b). Their combined 
sample included 587 women reporting unmet needs during their follow-up period. 
The next stage is research into interventions to address these needs. 
 
In the study by Thewes et al. (2003) women described a range of needs including 
fatigue, breast and arm pain, late effects, and specific issues associated with 
early menopause; however they spoke about a need for support to understand 
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whether the multiple symptoms they experienced were normal or a sign of 
recurrence. This suggests that just focusing on recurrence is unhelpful for 
women, particularly when the symptomatology of breast cancer is primarily 
treatment related (Bloom et al. 1998). While follow-up clinics try to give women 
the opportunity to discuss their needs, education about distinguish effectively 
between what is normal or abnormal post-treatment requires a more focused 
approach. 
 
Most of the women in the study by Thewes et al. (2003) spoke about the 
importance of their treatment team at follow-up in providing emotional support 
and reassurance. Unfortunately, some of the younger patients felt physical 
aspects of care were viewed as more important than emotional needs. Similar 
issues were also reported by McCaughan & McSorley (2007). This affirms some 
of the criticism of the traditional model of follow-up care that little time is afforded 
to explore psychosocial needs (Chapter 2; Pennery & Mallet, 2000; Rojas et al. 
2008). 
 
While the risk associated with recurrence is important, menopausal changes, 
pain, side effects of treatment and adapting to the changes a diagnosis brings 
were also reported as important (Girgis et al. 2000; Raupach & Hiller, 2002; de 
Bock et al. 2004b; Beaver et al. 2006). The importance of women verbalising the 
wide range of unmet needs is clear in all the studies but this takes time. In the 
study by Thewes et al. (2003) women took part in a focus group lasting one and a 
half hours, a timeframe which would be difficult to match in the follow-up clinics, 
where appointments last approximately 10 - 15 minutes. The BR-CPNQ used in 
the study by Girgis et al. (2000) took approximately 20 minutes to complete at 
home. There may be merit in women completing questionnaires at home and 
bringing them to the clinic to share with their clinicians. This could save time, 
provide clinicians with an overview of a woman’s specific need for help and 
provide an opportunity to directly access and respond to patient-important 
outcomes. It would also address one of the limitations in the study by Girgis et al. 
(2000) not specifying the need for help to a specific time period. This makes 
interpretation more difficult. 
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Timing was also important in the qualitative studies. The retrospective design by 
Thewes et al. (2003) was a limitation and could have caused recollection bias. 
The women were recalling information that occurred 12 months (n=6), 12months 
to 2 years (n=11) and up to 5 years (n=8) since diagnosis. When interviewed, the 
women recalled receiving insufficient, inappropriate information. The nature in 
which this information was delivered at the time may have been a contributing 
factor, as many reported that it was “verbal”. 
 
Some studies used a breast cancer specific tool to assess need for support, while 
others did not. The tools used by de Bock et al. (2004b), Rauper & Hiller (2002) 
and Beaver et al. (2006) did appear to ask questions which were of importance to 
women with breast cancer, but further research is required to establish their 
validity and reliability in the follow-up setting. In contrast, the tool used by Girgis 
et al. (2000) was validated and specifically asked questions associated with 
breast cancer. However the results appear to underestimate levels of need 
compared to other studies and no explanation is given. The wording of questions 
and their relevance to women at different stages is important. This has 
implications for future studies. The solution is perhaps more studies which are 
prospective in design and explicitly indicate to participants the specific time period 
of interest in the study. In the case of studies associated with follow-up, this may 
be prior to a clinic appointment when women are preparing to attend the clinic 
and are reflecting on their current needs. 
 
The women did not report any difficulty completing the questionnaires. While the 
intention of the studies was not to incorporate into a clinic consultation, use of the 
INQ by Beaver et al. (2006) showed the SBCN can be effective in assessing and 
responding to women’s needs. Unfortunately, the practicality of providing patients 
with two consultations: a follow-up consultation with a doctor face to face plus a 
telephone consultation may not be cost effective. In fact, a later publication from 
this study suggested it was indeed more costly. Further involvement of nurses 
during follow-up consultations is important according to Rauper & Hillier (2002) 
and de Bock et al. (2004b) and practice has responded accordingly, specifically 
identifying SBCNs to provide services into the future. There is currently no 
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research evidence that these changes to follow-up practice have seen 
improvements in psychosocial needs reported or addressed.   
 
Women receive different treatment regimens depending on their disease, their 
age and their preference. This was reflected across the studies. The age of the 
women (range 26 - 89) appeared to determine where their emphasis lay in 
relation to needs.  Needs associated with hereditary factors, side effects of 
treatment, sexuality, impact on self and reconstruction. Acknowledging these 
differences is very important to an individual’s recovery and for the HCP, and 
encourages a more personalised approach to the follow-up consultation. Only 5-
10% of breast cancer cases (Clark & Domchek, 2011; Van der Groep, Van der 
Wall & Van Diest, 2011) are linked to hereditary factors and this area appeared 
as a disproportionately high area of need for information in relation to actual 
occurrence. None of the studies suggested why this may be the case. It is clearly 
an important area of dialogue to have with women as it may impact on how they 
discuss this aspect with their own daughters and friends. 
 
Only one study included data on the stage of the breast cancer participants (de 
Bock et al. 2004). Although breast cancer is a heterogeneous, highly variable 
disease (Reddy & Given-Wilson, 2006), there is a distinct correlation between the 
stage of disease, the treatment regimen used, the risk of complications and long-
term effects. Without knowledge of the stage, it was impossible to make 
comparisons between different groups. Although Girgis et al. (2000) and de Bock 
et al. (2004) reported that those receiving chemotherapy expressed a greater 
number of unmet needs than those who had not received this treatment, the data 
presented was difficult to interpret. 
 
The literature indicated that younger women (under 50) have different and often 
more needs to older women. This age group represents approximately 10,000 
cases annually in the UK (Cancer Research UK, 2012). They are a group who 
often receive multiple modalities of treatment and are more likely to be pre-
menopausal at diagnosis. Although the method used in the study by Thewes et 
al. (2003) was appropriate and a relatively new area of enquiry when data was 
collected in 1995, the timeframe could be considered a limitation to generalising 
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results to current practice in 2013. Since 1995, written information for younger 
women and menopausal issues has been produced in the UK by organisations 
such as Breast Cancer Care (2012), which have sought to address the deficit in 
information and may have some impact on these needs. However, in a qualitative 
study by Cruickshank & Hume (2014), there still appeared no clarity about how 
HCP’s assessed and managed women who reported significant distress 
associated with menopausal issues.  
 
Two studies reported their samples were under-representative of certain age 
groups, particularly younger women (Girgis et al. 2000; de Bock et al. 2004). As 
discussed above, these particular groups often report different unmet needs. The 
use of a needs assessment questionnaire may allow specific questions to 
encompass the range of needs across age groups.   
 
On the whole recruitment was very good in the studies, with no indication that 
women had any difficulty completing the questionnaires. Despite its name, the 
BR-CPNQ only asked 8 of the 61 questions specifically about breast cancer. This 
may have led to an under-estimation of the prevalence of unmet needs in the 
breast cancer population studied. Eighty per cent of the women were at least 3 
years since diagnosis and many of the questions were related to active treatment 
and irrelevant to this particular population. Asking the right questions at the right 
time is clearly important, and careful consideration needs to be given to the 
questionnaires used in any new study. One must also consider the value of each 
question asked, the length of the questionnaire and how clinicians can use the 
results effectively in practice. 
 
None of the studies had been undertaken in the past five years, prior to the 
introduction of new standardised treatments such as biological agents and 
aromatase inhibitors. An increased toxicity profile is associated with these newer 
agents (Moss et al. 2009) and may or may not alter the need for support of 
women currently; however, in the absence of any literature these remain 
anecdotal. It is important to include women who have received these treatments.   
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In conclusion, this review did find evidence that women with breast cancer report 
unmet needs post-treatment and during a period when they are receiving follow-
up care, but no studies were directly linked with women reporting these needs 
prior to their actual clinic appointment. 
3.7 Summary and implications for the thesis 
The findings from part one provide evidence that women with breast cancer have 
unmet needs post-treatment, a period when they would be receiving follow-up 
care. The literature describes a need for support which may be of a 
psychological, physical or informational nature. Despite using different methods of 
data collection a picture emerged that needs are very individual and different 
influences play a part, including the trajectory of care, response to treatment, age, 
menopausal, and psychological distress. Although women reported confidence in 
their treatment team, there is evidence that the way follow-up care meets their 
needs or improves their quality of life, could improve. Only one study considered 
changes in needs over time but the intervention was not delivered during the 
follow-up consultation, rather in addition. Indeed, none of the studies specifically 
focused on the follow-up consultation and interventions to address deficits in 
needs at this time. Before developing a new study, it was important to identify any 
research which reported the effectiveness of using patient reported needs 
assessment questionnaires to guide care within a follow-up setting.  A further 
search was undertaken to explore this and discussed in part two. 
3.8 Results of part two  
This part of the review addressed two specific questions; 
1. Have patient reported needs assessment questionnaires been used to 
guide care within a breast cancer follow-up setting? 
2. If so, how effective is this approach? 
3.8.1 Outcome of search strategy  
The combined searches across all the databases including hand-searching 
identified 1,378 papers (Table 3.8). Once the abstracts were reviewed it was 
apparent that the search strategy had identified many papers which were not 
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relevant to this review and already reviewed in part one. Initially a total of 11 were 
identified and thought to be relevant and read in full. However, none of the papers 
met the inclusion criteria.  It was decided to broaden the inclusion/exclusion 
criteria and include all RCTs which included breast cancer patients irrespective of 
the stage of care. When the changes were applied, nine of these papers were 
excluded and a rationale for their exclusion is summarised in Table 3.9. 
Table 3.8 Record of searches up to 2009 (part two) 
Database 
Total 
no. of 
hits 
Included for 
full text 
review 
Included 
in review 
Excluded 
from 
review 
Medline 334 7 1 6 
CINAHL 979 3 1 2 
British Nursing 
Index 
52    
PsycINFO 0    
Cochrane Library 0    
EMBASE 12    
Reference Lists 1 1  1 
Total 1378 22 2 9 
3.8.2. Excluded studies 
Nine papers were excluded according to the exclusion criteria and presented in 
Table 3.9. Seven studies reported the development, reliability and validation of a 
generic needs assessment tools (Cull, Stewart & Altman, 1995; Bonevski et al. 
2000; Sanson-Fisher et al. 2000; Fortner et al. 2003; National Comprehensive 
Cancer Network (NCCN), 2003; Zebrack et al. 2006). Two of these studies 
reported data from the same work (Sanson-Fisher et al. 2000; Bonevski et al. 
2000). Using a tool known as the Supportive Care needs Survey (SCNS), both 
Bonevski et al. (2000) and Sanson-Fisher et al. (2000) sought to identify the 
prevalence and predictors of need across a cancer population, including breast 
cancer.  Although it signified the ability of a tool to identify specific areas where 
patients required the most help when undergoing treatment, it did not use this to 
inform care delivery and subsequent interventions and was therefore excluded.   
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Table 3.9: Summary of excluded studies 
Study 
Type of 
study 
Reason for exclusion 
Bonevski et al. (2000) Survey Reported on the development of the 
supportive needs assessment tool 
Cull, Stewart & 
Altman, (1995) 
Audit Reported on the development of a needs 
assessment tool 
Fortner et al. (2003) Quantitative Reported on the development of a needs 
assessment tool 
NCCN (2003) Qualitative Reported on the development of a tool to 
measure distress not needs 
Sanson-Fisher et al. 
(2000) 
Survey Reviewed predictors and perceived 
needs during treatment rather than 
follow-up. Used same data as Bonevski 
et al. 2000 
Zebrack et al. (2006) Qualitative Reported on the development of a needs 
assessment tool 
McLachlan et al. 
(2001) 
RCT Did not include participants with breast 
cancer diagnosis at any stage of the 
disease trajectory 
Velikova et al. (2004) RCT Use a QOL tool rather than a needs 
assessment tool 
Thewes et al. (2004) Qualitative Reported on the development and 
validation of a breast cancer needs 
assessment tool (BCNQ) 
 
One study (McLachlan et al. 2001) used a needs assessment tool to guide care 
within a cancer clinic setting and measured the effectiveness of this approach to 
reduce cancer needs and improve quality of life over time. Despite this study 
excluding those with a breast cancer diagnosis and ineligible for inclusion in this 
review, it does warrant some further discussion. This trial did not record any 
meaningful difference in changes from baseline in cancer needs or quality of life 
between the intervention and control groups. A number of limitations in the study 
design was highlighted but overall this approach warrants further testing in 
everyday clinical practice among other disease specific groups. Another study 
(Velikova et al. 2004) was excluded as it used a quality of life questionnaire to 
guide care rather than a needs assessment tool. It is the only study which 
reported that using patient reported quality of life measurements, with feedback 
from the HCP, led to clinically meaningful improvements in overall quality of life 
and emotional well-being. Another excluded is the study by Thewes et al. (2004) 
which described the validity and reliability of a breast cancer questionnaire, 
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designed specifically for women who have completed treatment and are 
survivors.   
3.8.3 Characteristics of included studies  
A summary of the two included studies is presented in Table 3.10.   
Both studies were undertaken in Australia (Aranda et al. 2006; Boyes et al. 2006). 
Although neither of the studies defined needs, both referred to the literature which 
describes unmet needs of cancer patients (Boyes et al. 2006; Aranda et al. 2006).  
 
Both studies aimed to examine the effectiveness of patient self- reported needs 
questionnaires being made available to HCPs at the clinic to inform care delivery, 
although they differed in their design. Aranda et al. (2006) specifically examined 
the effectiveness of a nurse delivering interventions following presentation of the 
data to a doctor at the clinic, whereas Boyes et al. (2006) explored the use of a 
team approach to managing needs following presentation of the data to the 
oncologist within the clinic. 
 
Table 3.10: Characteristics of included studies (part two) 
Study 
 
Aranda et al. (2006 
 
Boyes et al. (2006) 
Needs defined yes/no no no 
Types of follow-up 
a. described 
b. country of origin 
a. no 
b. Australia 
a. no 
b. Australia 
Age 
a. Control 
b. Intervention 
 
a. 55 (range 36-82) 
b. 57 (range 34-85) 
a. 38 
b. 42 
Size of sample 105 80 
Breast cancer specific  
details 
All advanced breast cancer 
Breast cancer specific 
a. 34% 
b. 38% 
Stage of breast cancer Stage 4 Not stated 
Time since diagnosis  
(TSD) 
Time to metastases  
(TTM) 
TSD: 0-27 years (med 5 yrs.) 
TTM 
a. 0-14 yrs. (med 1) 
b. 0-7yrs (med 1) 
TSD: overall data presented 
Within last month: 21% v 29% 
1-6m: 68% v. 36% 
7-12m: 3% v. 10% 
>1 year: 8% v. 26% 
HCP involved Doctor , SBCN Doctor 
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In total 185 (range 80 - 105) cancer patients were involved in the studies: they 
were primarily patients on treatment and were all being reviewed within a clinic 
setting. A total of 127 (range 22 - 105) had breast cancer and of these 105 had 
confirmed metastases, 16 had primary disease, and the stage of the other four is 
unclear.   
 
Aranda et al. (2006) only included participants with advanced breast cancer 
(stage 4), while Boyes et al. (2006) included primary breast cancer patients 
among their sample. These included 34% (n =13) in the control group and 21%  
(n =9) in the intervention group, with the majority still receiving treatment. Aranda 
et al. (2006) reported no significant differences across most demographic, 
disease and treatment characteristics apart from the proportion receiving 
radiotherapy (intervention 93% v. control 73%, p = 0.001). The time since 
diagnosis differed between the studies.  In Aranda et al. (2006) both control and 
intervention were similar 0-26 years (median 5 years). Boyes et al. (2006) 
included participants: within last month, (control 21% v. intervention 29%); 1-6 
months (control 68% v intervention 36%); 7-12 months (control 3% v intervention 
10%); >1year (control 8% v. intervention 26%).   
 
Both studies reported participants meeting a doctor at the clinic but nurses were 
involved in the development of the strategies to meet the unmet needs (Aranda et 
al. 2006: Boyes et al. 2006). In the study by Aranda et al. (2006) the SBCN led 
and managed the intervention, which formed part of an additional 1 hour face to 
face session and follow-up telephone call. In contrast, strategies to meet the 
unmet needs were developed in consultation with the treatment team at the clinic 
with nurse’s part of this team alongside occupational therapists, nutritionists, 
social workers and medical staff, with no additional intervention out-with the clinic 
consultation reported (Boyes et al. 2006). 
3.8.4 Methodological quality of included studies 
A summary of the methodological quality is provided in Table 3.11. One study 
was a RCT (Aranda et al. 2006) and one a pilot RCT (Boyes et al. 2006). The 
randomisation process was described in both the studies however neither 
included details of a sample size calculation. In both studies the inclusion criteria 
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was clear. Boyes et al. (2006) included participants with cancer of the breast, 
colon, rectum, lung, lymphoma, and melanoma, attending the medical oncology 
clinic and receiving active treatment, whereas Aranda et al. (2006) included 
women with advanced breast cancer. In deciding to include studies which did not 
include women attending follow-up care and with a primary diagnosis, the quality 
of the studies to answer the initial objective of this review is recognised as being 
limited. Only Aranda et al. (2006) reported their primary outcome: quality of life. In 
Boyes et al. (2006) this is not explicit and they expressed an interest in improving 
a patient’s well-being.
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Table 3.11: Methodological qualities of included studies (part two) 
Study 
 
Aranda et al. (2006) 
 
Boyes et al. (2005) 
Method Inclusion: Newly diagnosed  
advanced stage breast cancer,  
recurred or progressed in preceding  
12 months; 18 or older; access to a 
telephone 
Exclusion: Not stated 
Randomisation: Sealed envelopes 
consecutively numbered 
Sample: No calculation reported 
Allocation concealment: Yes 
Follow-up: Overall response rates 71  
And  63% for the 1 and 3 month 
follow-ups respectively 
Intention to treat analysis: Yes 
 
Inclusion: Deemed eligible by  
clinic staff, 18 or older, first 
attendance at medical oncologists 
clinic, to receive treatment 
Exclusion: Not stated 
Randomisation: Computer  
Sample: No calculation reported; 
pilot study 
Allocation concealment: No 
Follow-up : Over response rates 
60% (both groups) at third 
follow-up 
Intention to treat analysis: Not 
stated 
Intervention/ 
Control  
groups 
Intervention (1 and 3 months) 
Two components: 
1. 1 hour face to face session  
within 10  days covering: orientation, 
tailored responses, coaching and 
practising self-care, concluding the 
session 
2. Telephone follow-up 1 week after 
first session 
Control 
Standard care (no specific details) 
referral to a SBCN or cancer support  
nurse out with study 
if appropriate 
Intervention  
(1,2,3 times at follow-up) 
Completed SCNS prior to clinic 
appointment, score generated 
and feedback sheet given to 
oncologist 
Control 
Usual consultation with  
oncologist, survey results not  
made available 
Needs  
assessment  
tool used 
 
SCNS  
(59 questions) 
 
SCNS  
(short form,  
34 questions) 
 
Other data 
tools used 
Demographics 
EORTC  
QLQ-C30 
 
Demographic and cancer 
characteristics 
Physical symptoms 
HADS 
Outcome Quality of life  
 
Not clear 
 
 
Aranda et al. (2006) used the Supportive Care Needs Survey full version (SCNS) 
and Boyes et al. (2006) used the Supportive Care Needs Survey truncated 
version (SCNS-SF34).  Both have high-level consistency and demonstrated 
construct and content validity (Bonevski et al. 2000). The full version contains 59 
questions: designed to measure patients perceived needs in five core domains: 
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psychological, health information, physical and daily living, patient care and 
support, and sexuality. The truncated version has 31 items across four domains:  
psychological (8 questions), health information (13 questions), physical and daily 
living (3 questions), and patient care and support (7 questions). There are five 
response options: 1 [no need: not applicable – This was not a problem for me as 
a result of having cancer]: 2 [no need: satisfied – I did need help with this, but my 
need for help was satisfied at this time], 3 [low need: This item caused me little 
concern or discomfort. I had little help for additional help], 4 [moderate need: This 
item caused me some concern or discomfort. I had some need for additional 
help], 5 [high need; this item caused me a lot of concern or discomfort.  I had a 
strong need for additional help].  A higher score indicates a higher perceived 
need. Additional tools were also used. These included: the European 
Organisation for the research and treatment of cancer (EORTC) QLQ-C30 
(Aranda et al. 2006) and HADS (Boyes et al. 2006). 
 
Aranda et al.’s (2006) intervention was facilitated by a breast cancer research 
nurse. The nurse focused responses and plan of care for the patient (intervention) 
on items which scored a 5 on the scale (a high need for help). The intervention 
was in addition to the consultation with the doctor. It lasted one hour for session 1 
and included a telephone follow-up call. A written summary was inserted in the 
medical notes.  Despite the uptake of the intervention being very high (100%), 
patients were more likely to accept physical symptom recommendations rather 
than counseling for emotional needs. The consistency in the number of 
interventions offered and accepted was variable. Overall 67% (n= 40) of 
participants were offered care to address unmet needs but only 38% (n = 15) 
accepted. This may have affected the statistical differences in the groups as the 
uptake of the self-care strategies was essential to the success of enhancing 
quality of life and reducing needs. Following the intervention, 56% (n = 20) of 
women reported their needs remained unmet and increased intensity may have 
allowed a greater number of needs to be addressed.  
 
Aranda et al. (2006) reported adequate allocation concealment despite the 
doctors seeing both control and intervention participants prior to randomisation. 
Boyes et al. (2006) reported difficulties in achieving an optimum experimental 
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design within a clinic where there were continuous complex interactions, and the 
doctors saw both the control and intervention patients over the study period.  
Patients lost to follow-up were reported in both studies. Attrition was 29% and 
37% respectively between 1 and 3 months (Aranda et al. 2006). This compared to 
40% (57/107) attrition at the third follow-up in the study by Boyes et al. (2006). 
 
Participants in the study by Boyes et al. (2006) were mainly one year since 
diagnosis. This included approximately 16/80 with a primary breast cancer.  
Because the results are not stratified to cancer groups, interpretation of the data 
is difficult. There were no significant statistical differences in changes over time 
for anxiety and depression (p =0.20) or between the groups in changes of 
moderate or high psychological needs over time (p = 0.83). This had been 
affected by three main reasons: sample size, eligibility criteria, and inability to 
blind sample effectively. This pilot RCT did not report and sample calculations. By 
not establishing an effect size at the beginning, ability to identify a change was 
more difficult. This was particularly important as participants reported high levels 
of psychological functioning and low levels of need for support at baseline.  When 
considering the overall quality of these studies and applying the scoring by Guyatt 
et al. (2011), both studies were of low quality. 
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3.9 Outcome results  
A summary of the results for the study by Aranda et al. (2006) and Boyes et al. 
(2006) is provided in Table 3.12 and 3.13 respectively.   
 
Table 3.12: Summary of results from Aranda et al. (2006) 
 
Difference in EORTC  
and SCNS domain 
scores post intervention 
baseline -1 month) 
mean (SD) 
Difference in EORTC and 
SCNS domain scores post 
intervention (1-3 months) 
mean (SD) 
EORTC 
Usual  
care 
Intervention Usual care Intervention 
Physical functioning 
(PF) 
19.6 (23.6) 21.7 (19.5) 17.9 (23.1) 21.6 (20.3) 
Role functioning (RF) -2.8 (34.8) -2.0 (29.9) 1.5 (33.9) 0.0 (32.9) 
Emotional 
functioning (EF) 
2.2 (24.3) 1.7 (18.3) 5.4 (25.6) 3.7 (20.6) 
Cognitive functioning 
(CF) 
1.9 (17.3) -2.9 (21.3) 2.0 (19.1) 0.8 (22.4) 
Social Functioning 
(SF) 
1.4 (29.4) 7.8  (26.7) 10.8 (29.3) 2.4 32,2) 
General quality of life -26.2 (42.7) -28.1(36.1) -33.6 (36.6) -22.6 (39.1) 
SCNS 
Usual  
care 
Intervention Usual care Intervention 
Psychological needs 2.3 (21.4) -6.1 (17.7) -6.5 (21.7) -2.8 (18.5) 
Health information -3.4 (21.9) -7.5 (27.6) -11.7(25.7) -9.4 (23.4) 
Physical and daily 
living  
2.2 (19.2) -1.7 (14.6) -3.6 (22.6) -3.6 (16.4) 
Patient care and 
support 
2.2 (11.3) 0.3 (16.7) -4.0 (9.4) -2.0 (16.2) 
Sexuality  1.3 (32.6) -6.5 (28.2) -6.8 (25.1) -9.8(28.5) 
When the sample is stratified to higher (score over 50) psychological needs, there was 
a significant difference (p=0.026) between intervention and usual care groups.  No 
other p values reported 
Notes: SCNS: Higher scores mean higher level of need (out of 100 and averaged), 
EORTC QLQ – C30: Higher scores mean better function (out of 100) 
HAD: Higher scores mean more distress (out of 20)  
 
The type of unmet needs reported offered parallels with those reported in part 
one, although categories were broadened to include psychological, health and 
information needs, physical and daily living, patient care and support needs and 
sexuality needs. Unfortunately despite similar questionnaires used by Girgis et al. 
(2000), Aranda et al. (2006) reported only three of the highest perceived unmet 
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needs among participants. These were concerns about family (31%, n=18), 
treatment related issues (31%, n=18) and fatigue and sleeping difficulties (29%, 
n=17). This varied to those reported in part one, reflecting the specific stage of 
these participants with advanced breast cancer, with fear and concerns about 
recurrence no longer an issue.   
 
Table 3.13 Summary of results from Boyes et al. (2006) 
Study: Boyes et al. 2005 
(HADS) Mean (SE) anxiety and depression scores at each visit 
 Visit Control Intervention p value 
Anxiety 1 6.1 (0.8) 6.8 (0.7) 
Baseline to 
4th visit 0.90 
 2 5.5 (0.8) 5.7 (0.8) 
 3 5.8 (0.8) 5.1 (1.0) 
 4 5.2 (0.7) 4.8 (1.1) 
Depression 1 3.8 (0.6) 5.0 (0.7) 
Baseline to 
4th visit 0.20 
 2 3.9 (0.7) 5.0 (0.8) 
 3 4.4 (0.7) 3.7 (0.8) 
 4 3.9 (0.7) 4.2 (0.9) 
SCNS mean % (Standard Error) numbers of items within each domain 
reported as moderate or high need 
Psychological 
1 0.24 (0.06) 0.26 (0.05) 
Baseline to 
4th visit 0.82 
2 0.16 (0.05 0.22 (0.06) 
3 0.17 (0.05) 0.13 (0.05) 
4 0.15 (0.05) 0.11 (0.05) 
Health 
system and 
information 
1 0.20 (0.05) 0.14 (0.04) 
Baseline to 
4th visit 0.44 
2 0.10 (0.04) 0.18 (0.06) 
3 0.11 (0.04) 0.08 (0.03) 
4 0.11 (0.04) 0.06 (0.03) 
Patient care 
and support 
1 0.10 (0.04) 0.07 (0.02) 
Baseline to 
4th visit 0.83 
2 0.07 (0.03) 0.11 (0.04) 
3 0.07 (0.03) 0.06 (0.02) 
4 0.06 (0.03) 0.01 (0.01) 
Physical and 
daily living 
1 0.20 (0.05) 0.19 (0.05) 
 Baseline to 
4th visit 0.38 
2 0.18 (0.04) 0.23 (0.06) 
3 0.11 (0.06) 0.11 (0.05) 
 4 0.17 (0.06) 0.08 (0.05)  
Notes: SCNS: Higher scores mean higher level of need (out of 100 and averaged) 
HAD: Higher scores mean more distress (out of 20)
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3.9.1 Patient reported changes in needs over time 
The presentation of the data precluded a meta-analysis of the results despite 
similar questionnaires being used. This was partly because of differences in how 
results were presented. Aranda et al. (2006) presented the difference between 
domain scores post intervention as a mean score adjusted for baseline whereas 
Boyes et al. (2006) presented the mean scores for each domain at each time 
point as a percentage and standard error. Neither study reported any significant 
statistical differences in changes in needs between baseline and end of the trial 
following the intervention.   
 
When data were stratified according to higher psychological needs (a score over 
50) or lower needs (a score 50 or below), Aranda et al. (2006) reported that those 
with higher baseline needs reported a 19point decrease in the intervention group 
compared to a 14point decrease in the control group.  Although this difference 
was statistically significant (p=0.026), it is unclear whether this was also clinically 
meaningful. 
 
In Table 3.13, the average proportion of items in each domain that were reported 
as a moderate or high need is presented by Boyes et al. (2006). Both the control 
and intervention groups saw a decrease in average number of moderate or high 
needs reported over time; time 1 - 4.  However there was no significant difference 
across any of the domains (psychological domain, p=0.82).  
 
It is difficult to draw any definitive conclusions about the fall in level of needs in 
both studies due to lack of statistical significance and limited explanation of how 
they have interpreted these in a clinically meaningful way. A further reason for a 
lack of significant differences in the studies may have been the expertise of the 
HCP to respond to the needs identified by the patients. In part one, Beaver et al. 
(2006) suggested this was extremely important in achieving a reduction in unmet 
needs for information between baseline and post-treatment in their study.  While 
neither commented on this, Aranda et al. (2006) offered a very short 2-day 
training for the SBCN while Boyes et al. (2006), offered no specific training.  Of 
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concern is the doctor’s reluctance to use the information provided to inform their 
decision. This led Boyes et al. (2006) to advocate that training in the use and 
significance of questionnaires should be included when introduced into clinical 
practice to optimise the effectiveness of them. They recommend that future 
studies provide the feedback reports to other members of the healthcare team 
including nurses. 
 
The intervention approaches used were not clearly represented in the data 
presented, limiting reproducibility of the study in other populations. Although 
management strategies were developed in response to different needs, Boyes et 
al. (2006) did not record this information and therefore it was unclear how the 
actions of the medical staff influenced any changes. Despite fears that repeated 
collection of questionnaire data could train patients and influence their scores, 
Aranda et al. (2006) and Boyes et al. (2006) found no evidence of this. This may 
have been the first opportunity for patients to express a need for support and 
reflect on how they viewed their health. 
3.9.2 Patient-reported changes in quality of life 
Aranda et al. (2006) was the only study which measured quality of life as their 
primary outcome, measured using the EORTC QLQ-C30. This scale has been 
widely used in the field of breast cancer (Fayer et al.1999). They reported no 
significant differences over time. However, they did report that physical 
functioning increased from baseline to 3 months (20 - 22 points on the scale). The 
reason for this is unclear, but the nurse recorded that patients accepted physical 
interventions more readily than emotional ones. Caution is required in 
interpretation of these results in relation to women attending follow-up care 
 
Psychological needs were measured using the HADS in the study by Boyes et al. 
(2006). Their interpretation is similar to the results reported by de Bock et al. 
(2004): with a score over 11 considered clinically significant for anxiety and 
depression. Boyes et al. (2006) reported mean anxiety scores decreased 
between baseline (control M=6.1; intervention M= 6.8) and time 4 (control M=5.2; 
intervention M =4.8).  This change was not significantly different (p=0.09). A 
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decrease in depression across both groups was also not statistically significant.  
An examination of the change scores between those classified as clinically 
depressed was also not significantly different.   
3.9.3 Acceptability of the intervention 
The acceptability of the intervention is described by both studies. Aranda et al. 
(2006) reported a high uptake of the intervention (100%), and perhaps these 
patients felt their needs were not being addressed currently in healthcare 
services. They did not though; specifically assess the views of the SBCN or 
doctors. However, the nurse did report that only allowing one week between the 
intervention and follow-up phone call was too short. It did not allow enough time 
for the strategies which involved referral to other HCP’s to be put in place. Boyes 
et al. (2006) posted an acceptability survey to both patients and medical 
oncologists at the end of the study. Of these, 48 out of 80 patients completed the 
survey. Most (n=34) reported the questionnaires were easy to complete and a 
good way of informing their doctors about their overall well-being and were happy 
to complete at each visit. Conversely, only 3 reported that their oncologist 
discussed feedback with them and all of them would have liked a summary to 
take home. The medical oncologists (n=4) completed the survey.  The majority 
(n=3) read the report prior to the consultation and found it helpful. However, it is 
unclear how many implemented the recommendations suggested as this was not 
recorded.   
3.10 Discussion 
Two studies were included in this part of the review. The initial objective of this 
review was to evaluate the effectiveness of using needs assessment 
questionnaires within a follow-up clinic among women with primary breast cancer. 
However no evidence was found in the literature that needs assessment 
questionnaires have been used in this particular setting and among this group of 
women. The studies in this review did include women with breast cancer, and 
illustrated that this approach is both feasible and practical within clinical practice. 
This review therefore concluded that there was further research required to fully 
explore the use of needs questionnaires in a breast cancer follow-up setting. 
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The quality of these studies was low. The reasons for this included: low sample 
sizes, limited generalisability due to inclusion of different cancer groups and 
blinding of participants. The quality reporting of RCTs-is sub-optimal according to 
Consolidated Standards of Reporting Trials (CONSORT), (2010) and the absence 
of details in the reporting of these studies contributed to some of the quality 
issues. These will now be discussed in more detail.  
 
Neither study was able to demonstrate any significant differences with any of the 
questionnaires used over time, in part due to a lack of power. Boyes et al. (2006) 
acknowledged that their study was not a large-scale RCT, rather a pilot study. 
They sought evidence that a feedback strategy which responds to a cancer 
patient’s self-reported needs could be an effective approach to improve cancer 
patients’ psychosocial outcomes. While the effects of this strategy on perceived 
needs was less evident, patients who had information about their well-being fed 
back to the medical oncologist reported fewer debilitating symptoms than patients 
for whom feedback was not provided. This suggests that research would be 
useful to explore this approach further. 
 
Aranda et al. (2006) recognised that their sample size may have been insufficient 
but question whether an increase in sample size and modest differences would 
represent a clinically significant change. A retrospective power calculation 
suggests that using the sample obtained, a standardised difference of 0.5 could 
be detected assuming p<0.05 and power of 70%. Projections using the new 
calculation suggest that there would continue to be no differences in quality of life 
between the two groups.  
 
Where possible a meta-analysis may have allowed pooling of data to quantify the 
benefits (or harms) of the interventions. Unfortunately this was not possible as 
significant differences in the participants, interventions and setting precluded this 
option. In addition the outcomes measured differed in each study, with neither 
paper containing the necessary information required to be extracted. Two of the 
studies that were excluded in this review also used the SCNS (Bonevski et al. 
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2000; Sanson-Fisher et al. 2000) and thought the possibility of pooling data would 
be worth exploring in the future.   
 
In addition to sample size, Boyes et al. (2006) reported difficulties in attrition. This 
may in part be due to the longitudinal nature of the study, measuring data at four 
time-points. However, the benefits of providing clinicians with information about 
specific issues that were important to individual patients at each visit outweighed 
the concerns of attrition. Attrition in the study by Aranda et al. (2006) reached 
35% (n = 37) of participants and impacted on overall results and indeed 
generalisability. Recruiting participants with advanced disease or experiencing 
acute treatment side effects can be difficult. It is unclear whether similar 
difficulties would occur with women during follow-up.   
 
One of the challenges with these two RCTs was blinding of participants to the 
intervention. In the study by Boyes et al. (2006), medical staff saw patients in both 
the intervention and control groups, presenting difficulties in achieving the optimal 
experimental design. A solution may have been to randomise medical staff, if 
sufficient doctors were available. The integration of the feedback into the 
consultation rather than patients having additional appointments was an 
interesting aspect of this study.  It may offer a more cost effective approach, 
although economic costing was not undertaken. In contrast, while the doctors saw 
both intervention and control, in the study by Aranda et al. (2006), the SBCN only 
saw the intervention group and out-with the clinic appointment. This is an 
important distinction and caution is required when interpreting results. Any new 
study should consider these issues carefully in their design: real time clinic 
environment or post clinic. 
 
The review indicated that patients could easily self-report their needs. The lack of 
breast cancer specific questions was a limitation for this review; type of treatment 
and outcomes differ widely between cancer groups. Part one indicated that 
women have very specific needs associated with menopause (iatrogenic or 
natural) and issues around self-image (prosthesis, reconstruction, fertility and 
sexuality), which would not be a focus for other cancers. The fear of recurrence 
which was a strong area of need for support in the studies reported in part one 
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would no longer be as relevant in an advanced breast cancer population. It 
remains unclear, then, how best to measure needs among breast cancer patients 
who are free of disease. One conclusion that can be made from these studies is 
that a needs assessment questionnaire should capture needs which are relevant 
to the population being studied. 
 
Although the study by Thewes et al. (2004) was excluded from this review as it 
did not meet the inclusion criteria, it did describe the development of a breast 
cancer specific questionnaire. As the use of a tool in breast cancer follow-up is an 
under researched area, this tool may offer an important contribution to this area. 
Choice of tool was an important consideration in this review. Quality of life 
instruments do differ in their purpose compared to needs assessment tools with 
Gustafson indicating that:   
 
“Satisfaction with care documents how well an organization satisfies 
patient and family needs, HRQOL captures how well the patient or family 
member is doing and the needs assessment provides the raw material for 
both these measures but primarily guides patient planning”. (Gustafson, 
2005, p. 306) 
 
Thus, needs assessment tools can measure patients’ own perceptions of their 
need for help on given issues but also directly measures the magnitude of the 
desire for help in dealing with unmet needs for themselves and their family. The 
importance of choosing the right tool to answer the research question is critical.  
Boyes et al. (2006) indicated they were interested in an individual’s psychosocial 
well-being, and it is clear from other literature in this field that this is broader than 
anxiety and depression. 
 
The studies did indicate that women with breast cancer (both primary and 
metastatic) can self-report their needs (Aranda et al. 2006; Boyes et al. 2006), 
and further research would confirm whether this approach is transferable to other 
groups. Although there were no significant changes, some improvements were 
seen in psychological needs which may have been clinically meaningful. This 
design would suit a follow-up setting as, there are many months between 
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appointments and women are seen over long periods of time. Offering HCP the 
opportunity to refer back to PROMs may be helpful to them and their patients 
when continuity of staff is difficult.  
 
When designing studies researchers must be mindful of the practicality of an 
intervention for a particular population. The intervention lasted a minimum of 90 
minutes in the study by Aranda et al. (2006). While cost-benefit analysis was not 
considered, the numbers of women who attend follow-up services would preclude 
its routine use in this population, other than perhaps those with complex needs. 
The integration of patient-reported questionnaires in a clinical setting as was done 
by Boyes et al. (2006) offers more promise. Offering all women attending follow-
up a separate intervention as well as a follow-up consultation would not be 
practical or financially viable. However, integrating patient -reported 
questionnaires at the clinic to guide care provides HCP’s the opportunity to 
identify patients who require additional support.    
3.10.1 Summary  
There is no evidence from the literature that the effectiveness of using a needs 
assessment tool or indeed another tool, to guide care within a breast cancer 
follow-up clinic, has been measured. However, there is some evidence that needs 
assessment tools have been successfully used to identify an individual’s need for 
help in clinical practice. Neither study was able to demonstrate any clinically 
significant change in quality of life and perceived needs over time. Without the 
use of a tool it is unclear how the HCP would have identified the wide range of 
needs identified within these studies. 
3.11 Overall summary and implications for thesis 
The diagnosis, treatment and management of breast cancer causes significant 
impact on a woman’s adaptation and recovery following primary treatment.  As 
they recover they continue to experience unpleasant side effects, altered body 
image and a future perspective which has been changed.  The literature in part 
one focused primarily on the many unmet needs women experienced months and 
indeed years following completion of primary treatment.  The range of unmet 
needs identified include: fears or recurrence; fertility or menopausal issues; 
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treatment side effects; the impact of hereditary factors; sexuality and 
relationships; Lymphoedema and the impact on self. While it is very important for 
HCP’s to know about these to inform their practice, no single study adequately 
addressed how these could be met by HCP’s when primary treatment is 
complete.  Indeed most of them suggested patient needs and individual 
preferences should be incorporated into current or new follow-up care, with 
strategies devised to address them. Currently, recovery post treatment includes 
regular visits to see a HCP at a follow-up clinic. The research in this part tended 
to focus on women’s unmet needs at different time points of recovery and it is 
unclear if these would persist if the follow-up consultation identified and 
addressed the unmet needs earlier in this period.  
 
The review presented in part two illustrated that measuring unmet needs in a 
consistent and systematic manner in a clinic setting is an infrequent event in the 
field of breast cancer, with few studies having used this approach. However, both 
studies were able to show that PROMs such as needs assessment tools can be 
integrated within a clinic setting; patients are comfortable completing these 
questionnaires, clinicians can use the information to guide care and the approach 
is equitable across patient groups. The question that arises, however, is whether 
this approach is feasible and practical to be used in breast cancer follow-up 
clinics. However, with large numbers of women attending follow-up clinics across 
the UK and numbers likely to rise further, it is clearly important for HCP’s to 
distinguish between women with low, moderate or high levels of need if they want 
to target support effectively. The research to date has mainly used generic needs 
assessment tools, although while this has provided useful evidence, it fails to take 
into account the very specific needs of women with breast cancer who are free of 
disease but may be experiencing a broad range of side effects due to their 
treatment.   
 
Breast cancer is not a single disease and the research to date has clearly 
illustrated the huge variability reported among women in relation to their unmet 
needs. The use of PROMs in many of the studies was useful in gauging the 
extent of unmet needs within the breast cancer population and most of them 
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concluded that patient needs and individual preferences should be incorporated 
into current or new follow-up care approaches. Using the existing literature 
explored in this chapter, the PICOT format was used to formulate the research 
question on the effectiveness of an intervention in a follow-up clinic.   PICOT 
refers to P = Patient population; I = Intervention; C = Comparison; O = Outcome; 
T = Time. The success or otherwise of follow-up care is ultimately based on how 
effectively it meets the needs of the women who attend. Irrespective of whether a 
doctor or a SBCN delivers the care, an understanding of what these needs are is 
critical. There are no adequately tested interventions which respond directly to 
patient-reported psychosocial needs attending follow-up clinics. Research in this 
area would move away from restricting interventions to those who meet criteria 
“cases” associated with risk of recurrence due to their breast cancer and towards 
those who want help.  To address this gap, the following question is used: 
 
What is the effectiveness of providing patient reported needs, quality of life 
and psychosocial information to the SBCN at the follow-up clinic in reducing 
cancer needs and improving quality of life compared to standard care? 
3.11.1 Primary research question 
This primary research question above is answered using the PICOT format. 
 
 (P) – Patient population: Women with primary breast cancer attending follow-up 
clinics  
 
(I) – Intervention:   
Definition: The patient completed self-reported questionnaires and this 
information was available to the SBCN at the clinic. In conjunction with the patient 
the nurse targets her consultation to address perceived needs which are 
identified as requiring support.  Pre-specified guidance was developed for the 
needs assessment tool from an expert group in the field of breast cancer. These 
were not prescriptive, rather a guide, and not a substitute for clinical assessment 
and judgment.  The local practice guidelines were used to inform management of 
anxiety/depression levels.  
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(C) – Comparison:  Standard follow-up  
Definition: a conventional clinical encounter  
The self-reported information was not available to the HCP in the clinic 
 
(O) – Outcome:  
 Change in identified needs over time; 
 Change in numbers of needs over time; 
 Change in anxiety and depression over time; 
 Change in quality of life over time. 
 
 (T) – Time: one year 
 
3.11.2 Secondary research questions 
What are the perceived needs of breast cancer patients attending follow-up 
clinics? 
 
Is there a relationship between the measures of perceived need and quality 
of life? 
3.11.3 Hypothesis  
Null hypothesis: Using interventions for women with breast cancer during follow-
up clinics will result in no differences in perceived need, or improvements in 
quality of life between the intervention and control groups. 
 
Alternative hypothesis: Using interventions for women with breast cancer during 
follow-up clinics will result in a decrease in need and a greater improvement in 
quality of life between the intervention and control groups.
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3.12 Conclusion 
In conclusion, from the findings of the literature review and what is known about 
follow-up care and breast cancer (Chapter 2), it is apparent that women with 
breast cancer post -treatment, have unmet needs and psychosocial distress 
which remains for many month or years. There is no consistent method to 
suggest the best way of identifying these unmet needs during this time. To date, 
no studies have used patient reported questionnaires in the hospital follow-up 
setting to identify and address need. Although some studies have indicated that 
this is both feasible and acceptable in other breast cancer settings or cancer 
groups, further research is required to meet the needs of women attending follow-
up clinics. This led the researcher to use the PICOT format to formulate the 
research questions, which seek to measure the effectiveness of an intervention 
which would respond to the patient reported needs and psychosocial information 
within a follow-up setting. In the next chapter the methodological approach taken 
to address the research question and hypothesis will be described.   
 
 Chapter 4: Methods 
4.1 Introduction 
This study was a single-centre randomised controlled trial (RCT) of an 
intervention by Specialist Breast Care nurses (SBCN) to address the perceived 
needs and quality of life of women with a diagnosis of breast cancer while 
attending their follow-up clinic in the hospital. To understand what a woman’s 
needs are, the Breast Cancer Needs Questionnaire (BCNQ) and the Hospital 
Anxiety and Depression Scale (HADS) was used, coupled with a person-centred 
conversation. The trial compared a study group (known throughout this thesis as 
the intervention group) and a control group. The SBCN intervention was delivered 
at a single follow-up clinic appointment and outcome measurements were taken 
at baseline and twelve months. The trial followed the Consolidated Standards of 
Reporting Trials (CONSORT) guidelines on the conduct and reporting of RCTs of 
non-pharmacologic treatments (Boutron et al. 2008). 
 
In this chapter the overall design of the study and the epistemological and 
ontological underpinnings of the thesis will be discussed.  In addition, the 
justification of tools used, the implementation of the methods and the analysis are 
described. 
4.2 Research question 
As described in Chapter 2, the number of women surviving breast cancer is 
increasing year on year. Studies revealed in Chapter 3 that there is a physical, 
psychological and social cost to this survival for a woman, with unmet needs 
continuing for many years despite regular monitoring at a follow-up clinic (Girgis 
et al. 2000; Raupach & Hiller, 2002; de Bock et al. 2004b; Beaver et al. 2006; 
McCaughan & McSorley, 2007). Although there are differences in the frequency 
that follow-up is delivered across the UK, it remains an important part of care, 
with many more nurses involved in this area of care. The researcher, informed by 
Chapter 2, the literature review in Chapter 3, and a personal interest in the 
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particular topic area, sought to measure the effectiveness of a new approach to 
delivering care to women at the follow-up clinic in the hospital. The method used 
was determined by the research question and discussed throughout this chapter; 
 
What is the effectiveness of making patient reported needs, quality of life and 
psychosocial information available to the SBCN at the follow-up clinic, in 
reducing cancer needs and improving quality of life compared to standard 
care? 
 
The null hypothesis for this study is: 
 
H0 Women with breast cancer attending follow-up receiving the intervention 
show no significant difference in level of need and quality of life than those 
receiving standard follow-up care 
 
The study's primary outcome measure was change in needs scored at baseline 
and 12 months using the BCNQ and HADS. The study also aimed to investigate a 
number of secondary outcomes namely changes in quality of life at baseline and 
12 months using the EORTC QLQ C30 and BR23, as well as looking at possible 
effects of the intervention on variables such as age, treatment severity and time 
since diagnosis. 
4.3 Ontological and epistemological direction 
Research paradigms are sets of beliefs and practices characterised by 
ontological, epistemological and methodological differences in their approaches 
to conducting research and contributing to knowledge (Weaver & Olson, 2006; 
Welford, Murphy & Casey, 2011). Parahoo (1997) suggests these are sometimes 
referred to as schools of thought; whereby different scientific communities share 
very clear but different beliefs, values and methods for determining how a 
question is answered. Paradigms are therefore mechanisms to bridge a 
disciplines requirement for knowledge, its systems and producing that knowledge 
(Weaver & Olsen, 2006). Furthermore, making explicit the conceptual framework 
in which the researcher is working determines the overall research approach.  
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This paradigmatic position or approach taken to data collection and analysis 
relates to the real world and what is known about it (ontological position), the 
relationship between the inquirer and that being studied (epistemological 
position), and the best way of finding out what can be known (methodology).  
These differences between what constitute knowledge and reality has been 
driven by opposing paradigms: positivism or interpretivism (see Table 4.1).   
Table 4.1: Comparisons between research paradigms (adapted from Polit & Beck 
(2004, p.14) and Welford, Murphy & Casey (2011, p.4) 
Assumption Positivism Interpretivism 
Ontology Reality exists in a ordered and 
regular world 
Reality is multiple and subjective 
Epistemology The inquirer is independent from 
those being researched and 
findings not influenced by them 
Interaction between inquirer and 
those being researched 
Methodology Deductive processes 
Emphasis on discrete, specific 
concepts 
Fixed design 
Emphasis on measured. 
quantitative information; 
Statistical analysis 
Seek generalisation 
Inductive processes 
Emphasis on entirety of some 
phenomenon, holistic 
Emerging interpretations grounded 
in participants experiences 
Flexible design 
Seeks patterns 
 
The evolution of these paradigms has created debate about which is best for 
nursing research. Polit & Beck (2004) contend that this is irrelevant when the 
ultimate goal of any discipline is to gain understanding of phenomena. Therefore 
irrespective of differences in philosophy and methodological approach, selection 
is determined principally by the nature of the research question and the 
researchers own position in respect to the question.   
4.4 Exploration of quantitative and qualitative approaches 
Healthcare purports to be based on evidence and has led to a hierarchy of 
research methods, with quantitative, namely the randomised controlled trial 
(RCT), placed at the top of the list (Shuldham & Hiley,1997). This view of the RCT 
as a “gold standard” approach reflects its robustness in design that can minimise 
certain systemic biases in the research.  Polit & Beck (2004) describe a hierarchy 
of evidence whereby meta -analysis of RCTs are the pinnacle and other studies 
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such as expert opinion are at the base.  Welford, Murphy & Casey (2011) dismiss 
the notion that there is a single paradigm superior to another, with Mantzoukas 
(2008) suggesting that the linearity and orderliness attributed to a hierarchy does 
not exist in the daily practice of HCPs, rather it is complex and uncertain. The 
RCT has been described by Cochrane “as a very beautiful technique, of wide 
applicability, but as with everything there are snags, in particular when humans 
have to make observations there is always the possibility of bias “(1972, p.2). 
 
Historically, the use of an experiment has contributed to the universal knowledge 
now acquired in healthcare, especially in the field of medicine (Maynard, 1999). 
Although this view point has been embraced worldwide, there remains a dearth of 
nursing studies which have used this approach (Watson, 2003; Cecil, Thompson 
& Parahoo, 2006). Certainly this conclusion was reached following the systematic 
review in Chapter 3 in relation to the topic area of this study. Qualitative 
approaches are invaluable for subjective experiences and can provide “rich 
insight into human behavior” (Guba & Lincoln, 1998, p.198). However, their value 
to nurses in practice has been questioned by Watson (2003) and Lipscomb 
(2012).  
 
The focus in nursing is to provide holistic care to our patients, and few would 
disagree that the interpersonal relationship between a nurse and a patient in the 
provision of care in health and illness, is a holistic art, recognising the multiplicity 
of factors that influence the psychosocial and physical environment (Hicks & 
Hennessy, 1997). This has sometimes been the reason that the quantitative 
approach and in particular the RCT, has been rejected in favor of a qualitative 
approach as a means of enquiry (Poole & Jones, 1996; Black, 1998).  
This study aimed to measure the effectiveness of making patient - reported needs 
and psychosocial information available to the SBCN at the follow-up clinic on its 
ability to reduce a woman’s needs over time and improve quality of life. The 
quantitative approach, and in particular the RCT was considered the best way of 
measuring the efficacy of an intervention, due to its ability to minimise bias and 
avoid wrong conclusions (Stephenson & Imrie, 1998). If interventions by SBCN’s 
hope to reduce needs and improve quality of life, measuring their effectiveness 
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through the use of a RCT would seem an appropriate approach. In designing the 
study it was recognised that interviews would have yielded a rich source of data 
about the needs of women during follow-up. However, the use of a needs 
assessment tool would also provide data about the needs of this population in a 
systematic way.  While one disadvantage of questionnaires is the inability to 
probe deeper and to allow the respondents to express in detail what matters to 
them and by using the information in conjunction with a consultation with the 
SBCN, opportunities for participants to engage in a meaningful way is provided.  
4.5 The criteria for a randomised controlled trial (RCT) 
A successful RCT is according to Sibbald & Martin (1998, p.201) and Altman 
(2001) dependent on a number of important features including: 
 
 Random assignment to intervention or control groups; 
 Patients and researchers remain unaware of which treatment is assigned 
which facilitates blinding and reduces bias; 
 All groups are treated identically except for the intervention given to the 
experimental group; 
 Patients are analysed within the group to which they are allocated; 
irrespective of whether they experienced the intended treatment (intention 
to treat analysis). 
The inherent challenges of evaluating the effectiveness of a nurse-initiated 
intervention with a RCT design was acknowledged by the researcher, indeed 
Thompson suggests the very nature of RCT’s ignore individual differences and as 
“nurses don’t treat, a RCT is inappropriate” (2004, p.11). However Jadad (1998) 
found that it is too easy to conceptualise interventions as only “treatment” when 
active treatment is a small element of the healthcare experience of the patient. 
Historically, women attending follow-up clinics only met a doctor but since the late 
1990s this has changed, with nurses across the UK involved with this part of care 
(Baildam et al. 2001).  SBCN’s have many opportunities to influence the 
outcomes of women with breast cancer through their provision of information, 
support and advice within their day to day practice.  It is reasonable to 
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hypothesise that their influence could extend further if they were able to identify 
and address more effectively the unmet needs of the women they see.   
 
As alluded to earlier, interventions in healthcare are frequently complex and this 
one, along with the majority of nursing interventions (Mohler et al. 2010), was of a 
complex nature. The UK Medical Research Council (MRC) (2000) has suggested 
a framework for the development and evaluation of complex interventions which 
has been updated by Craig et al. (2008). 
 
The  MRC (2000, p.2) describes complex interventions as;  
 
“built up from a number of components, which may act both independently 
and inter-dependently. The components usually include behaviour, 
parameters of behaviour (e.g. frequency, timing), and methods of 
organising and delivering those behaviour (e.g. type(s) of practitioner, 
setting and location). It is therefore not easy precisely to define the active 
ingredients of a complex intervention”.  
(MRC, 2000, p.2) 
 
Although the original framework (MRC, 2000) was presented as a discussion 
document, and clearly suggested that interventions can be influenced by theory, 
qualitative and quantitative evidence, proposing a stepwise approach along a 
continuum of increasing evidence (Figure 4.1), it became an authoritative 
guidance.  Critics of the framework suggest the definition of the complexity of 
interventions is perhaps a little narrow and the phases are more aligned to 
describing a commercial drug evaluation rather than a complex intervention 
between a patient and health professional (Hawe, Shiell & Riley, 2006; Corry et 
al. 2012) but there is wide evidence that the framework has provided a useful 
platform when undertaking evaluations of complex interventions.  Although the 
newer version by Craig et al. (2008) addressed the stages and simplified both the 
language and process, its impact, according to the authors is harder to gauge 
(Craig & Petticrew, 2013). However, with more emphasis given to the value of 
careful development work and the need to be mindful of the implementation 
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process throughout, more consideration about the context in which the complex 
intervention is delivered, has emerged as a key change.   
 
The flexibility of the model provided a useful process to guide the researcher’s 
decision making.  The authors of the original framework (MRC, 2000) 
acknowledge that in many areas of intervention development preliminary 
evidence already exists and this was the case in the present study.    
 
 
Figure 4.1: The MRC framework for the evaluation of complex interventions  
(MRC, 2000, p.695)  
4.6 Pre-clinical and modelling phases  
Using the original framework as guidance, the pre-clinical and modelling phase 
established the theoretical basis for the intervention and allowed the development 
and understanding of its component parts and how they inter-relate. 
The intervention was delivered in response to the perceived need for support 
reported by the individual woman. The core principles of the intervention were to 
target support to women in response to their self-reported needs, psychosocial 
and quality of life information. The overall aim of the intervention was to provide 
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supportive care through a person-centred approach by allowing the woman to 
engage in a meaningful way with the nurse in the follow-up clinic. 
 
As discussed in Chapter 3, the literature revealed that there was no precedence 
of using this approach in response to patient- reported needs and psychosocial 
information within a breast cancer follow-up setting.  Boyes et al. (2006) and 
Aranda et al. (2006) had used “targeted interventions” in other settings (women 
during treatment and with advanced breast cancer) however; there was no 
reproducible intervention guide to use in this study. From a theoretical level, the 
principles and aim of the intervention were influenced by the Supportive Care 
Framework for Cancer Care developed by Fitch.  She defines supportive care as 
“The provision of the necessary services for those living with or affected by 
cancer to meet their physical, emotional, social, psychological, 
informational, spiritual and practical needs during the diagnostic, treatment, 
and follow-up phases, encompassing issues of survivorship, palliative care 
and bereavement’ (Fitch, 1994, p.22).   
 
This framework draws upon the constructs of human needs, cognitive 
assessment, coping and adaptation as a basis for conceptualising how individuals 
experience the effects of cancer and deal with them.  Maslow (1987, p.25) 
believed that a human being is a “whole functioning, adjusting individual” who is 
best understood from a holistic approach. These needs are arranged in 
hierarchies of pre-potency, with the appearance of one dependent upon the 
satisfaction of a more pre-potent need, with an individual moving from 
physiological needs to those of safety, esteem and self-actualisation.  Maslow 
suggests the influence of knowledge and understanding, motivation and 
behaviour on the acquisition of basic needs, is fundamental to this process.    
The changing situation that women face creates new demands and anxieties in 
addition to their daily needs, therefore their usual way of meeting their daily needs 
may no longer be effective. They seek new information and support.  As 
discussed in Chapter 2, an individual woman’s pathway as she enters the 
healthcare system (Figure 2.1) can vary considerably, with no two individuals 
responding in the same way to a particular event. Fitch et al. (2009) suggests this 
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variation is attributed to an individual’s cognitive appraisal of the situation 
whereby they think about the circumstances they find themselves in and its effect 
on their own well-being. They are influenced by their individual experience or 
perceptions of breast cancer throughout the period from diagnosis, through 
treatment and beyond (Stanton, 2006), past experiences, self-concept, culture 
and socioeconomic status. If the woman can remove, minimise or counteract the 
perceived threat, emotional distress reduces.  However, if unable to do this, 
emotional distress escalates.   
Coping therefore becomes everything an individual does in order to deal with and 
manage a situation and its inherent distress. Predicting the specific combination 
of coping strategies a particular woman will use is difficult.  Fitch et al. (2009) 
contends that the key to understanding a specific person’s behaviour and 
emotional response is to understand the person’s interpretation and meaning of 
the situation. Hence, given the changing nature of needs, variation in human 
responses and the complexity of coping strategies, it can be challenging for HCPs 
to find a pathway to assist or intervene to help a person cope, adapt and recover. 
Although Fitch et al. (2009) acknowledge that outcomes may be defined or 
labelled in a common manner such as needs, quality of life and well-being; 
interventions should be matched or tailored according to the individual’s frame of 
reference. Based therefore on this approach, the intervention used careful 
assessment of an individual’s perceived needs across a range of domains 
coupled with a person-centred conversation. This conversation, often associated 
with the therapeutic relationship observed between the HCP and service user 
(Manley & McCormack, 2008), explored the options for the intervention, desire of 
the woman for assistance and best way to provide it. 
Supportive care supports the notion that a range of expertise is required to 
provide all the dimensions of care and is not the prerogative of a single 
profession. The researcher felt the SBCNs were the single most obvious group of 
HCPs to deliver the intervention. Hence, this study was developed to be delivered 
by an experienced SBCN who would refer women to other professionals as 
required.   
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4.6.1 Components of the intervention and control 
Table 4.2 illustrates the structure of the intervention and how it compares to 
standard care (control group). The timeline of the trial runs from top to bottom on 
the left hand side, with the times of randomisation and outcome measurement 
marked clearly. Each component of the intervention is represented separately. 
The components delivered concurrently are shown side by side, while those 
delivered sequentially are shown in a linear way.  Components are either objects 
or activities. Objects are indicated by a square (to represent a fixed nature) and 
activities by circles (to reflect their flexibility). Different components are labelled 
with different letters and the second section of Table 4.2 provides a brief 
description of each component including its content, function and details of who 
delivers it.  
  
Table 4.2: Illustration of the intervention and control process (adapted from 
Perera, Heneghan & Yudkin, 2007). 
 
Time Line 
Specialist Breast Care 
Nursing (Intervention) 
Standard Care 
(Control) 
   
Randomisation 
Baseline (time 1) 
Pre-follow up 
clinic 
  
Follow-up clinic 
   
1 - 4 weeks post 
clinic 
  
Time 2 (12 
months) 
Measurement of outcomes 
              
 
a 
Training the nurse about meeting the needs of women with breast cancer 
and providing clinical examination to women post breast cancer diagnosis 
(see protocol) 
b 
Questionnaires completed by patients prior to clinic at home to elicit whether 
they have a need for support on areas associated with breast cancer, their 
anxiety and depression level, and their quality of life 
c Demographic data collected 
d 
A clinical examination of the chest wall, ipsilateral nodes and axilla 
undertaken by the SBCN and the doctor plus an annual mammogram 
e 
The nurse scores the HADS and uses this and the information on the needs 
assessment questionnaire (score 3, 4 or 5) to structure and guide the 
consultation.  The nurse tailors the intervention to the woman’s individual 
needs and wishes. The nurse has extensive experience of advising and 
supporting women with breast cancer.   
Possible responses to the 40 items relating to a specific need for support was 
developed as a guide, based on best available evidence.  This guide is used 
in conjunction with the clinical judgement of the nurse and the patient’s 
wishes. The immediate concerns are discussed with the woman in the clinic 
environment.  Additional actions may be required out with the clinic and the 
nurse co-ordinates this   
f 
Researcher scores the HADS in the control group according to protocol and 
refers any patient with a score of 11 or above to the nurse not involved in the 
study   
g 
Phone call from nurse to any patient (5-10 minutes) who required additional 
information/therapeutic consultation organised alone or with family member 
a 
b c b c 
d e d 
g f 
b 
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4.6.2 Undertaking a RCT in a breast cancer follow-up setting 
The participating hospital formed part of a larger hospital group providing breast 
cancer services to over 700 patients a year. The participating hospital covered a 
geographical area 20 miles West of Edinburgh with approximately 100 new breast 
cancers diagnosed annually. Deprivation levels are recorded as higher in the 
participating hospital than the larger hospital site. There is an established breast 
cancer service. The study was co-ordinated by the researcher (SC). The follow-
up clinic was run by a Consultant Surgeon, an Associate Specialist and at the 
commencement of this study, a SBCN. The SBCN undertook a training 
programme to gain experience of clinical examination and meeting the needs of 
women with breast cancer post-treatment within the clinic setting. However she 
had extensive expertise in managing psycho-social areas of need. She provided 
care to all participants in the intervention group.   
4.6.3 Patient preferences and acceptability of intervention  
Changes in the delivery of follow-up care had not been initiated by patients with 
breast cancer in this participating hospital, moreover driven by service level 
requirements (Scottish Cancer Advisory Network, 2009). There was a strong 
possibility that some of the women attending the follow-up clinic would be 
attending for their first appointment following chemotherapy, radiotherapy or/and 
biological agents, and may wish to discuss the option of reconstructive surgery 
with the Consultant Surgeon. This raised the possibility that women would not 
want to be randomised into the group with the SBCN. Torgeson & Roland (1998) 
indicate that strong preferences could lead to compliance or the way a participant 
reports outcomes. Recognising patient preference in a RCT is favored by Coates 
(2010) in relation to complex interventions. She argues that taking no account of 
preference in complex trials which involve interventions that depend on patient 
involvement and co-operation, may be unwise. While this may or may not have 
influenced the decision of the participants to respond, the researcher considered 
this approach would have compromised the robustness of the randomised 
process.  
The purpose of this study was not to compare the doctor to the nurse; rather, 
participants in this study were being randomised to a different model of receiving 
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support within the hospital follow-up clinic. There was no reason, if the SBCN felt 
there was a clinical need or if the patient wished, for participants not to see the 
doctor.  
4.6.3.1 Inclusion criteria 
Breast cancer is an infrequent event in men, with approximately 0.7% of all breast 
cancers diagnosed occurring in men (Nordman & Dalley, 2008), therefore this 
group were not considered for this trial. 
 
The study enrolled women attending follow-up clinics at one single participating 
centre.  This centre discharged women from follow-up at 5 years or until a woman 
reached 50. Women were considered eligible if they had a primary breast cancer; 
were of any age; had no evidence of secondary spread; had completed their 
primary treatment; surgery, radiotherapy and chemotherapy; could be on 
continuous endocrine treatment; were not due to be discharged at 5 years; were 
able give informed consent. 
4.6.3.2 Exclusion criteria 
Women were considered ineligible if they were either participating in another trial 
requiring specialist follow-up care; had known mental health  difficulties; had a 
medical condition that required the expertise of the medical staff. 
4.7 The trial environment 
The context in which the trial was conducted was crucial. Some of the resistance 
to RCTs is that researchers make them so controlled however, Wilkinson (2011) 
suggests that in a post-positivist world the notion of practical effectiveness, rather 
than the ideal conditions of a RCT, should become a greater focus.  While the 
context of the healthcare environment may be complex, this is in fact the ordinary 
circumstances of a practice environment (Gotay, 2006), one in which RCT 
findings are implemented and used. It was important that the trial mirrored the 
realities of the follow-up clinic setting that women attended. While it was hoped 
the findings would reflect this it was more difficult to control all the confounding 
factors. 
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4.7.1 Consistency in delivery of the intervention  
On-going support was provided to the SBCN through regular meetings to discuss 
any problems which had arisen: the safety of the participants was paramount in 
this study. The usual practice of a SBCN is guided by standard 9 (follow-up) of 
the Clinical Standards for working in a breast speciality (Royal College of Nursing, 
(RCN), 2007). In addition, individual experiences of the nurse informs decision 
making.  As indicated in Chapter 3, the training of HCPs to undertake an 
intervention is extremely important to its success. Guidance is already available 
from a number of avenues which set out standards, knowledge and skills for 
SBCN working in follow-up care. Skills for Health (2006) have developed 
workforce generic competencies to monitor and assess individuals following 
treatment for breast cancer. Specifically, the Clinical Standards for working in 
Breast speciality (RCN, 2007) provides a guide to the essential knowledge and 
skills required to undertake follow-up care. This is supported by a European 
position paper by Cataliotti et al. on behalf of EUSOMA (2007). 
 
Despite these guidelines, the training of SBCNs to undertake follow-up is not 
uniform across the UK. This was addressed within this study by ensuring that the 
SBCN was fully trained before she began the clinic. The intervention required the 
SBCN to assess the BCNQ and HADS prior to seeing the participants so they 
could be used to guide the consultation. In addition she was undertaking clinical 
examination. Initially the intervention took longer than standard care 
(approximately 10 minutes), but very quickly the timing improved. Using only one 
individual to undertake the intervention ensured consistency. 
4.7.2 Control - standard care  
In order to understand the impact of the intervention it was necessary to collect 
the same data from a control group. Altman et al. (2001) criticises the literature 
when reporting RCTs for not providing sufficient information about “standard 
care”. Standard care in this study describes what is currently practiced in this 
breast cancer unit.  It involved an outpatient clinic appointment annually, whereby 
the woman was seen by a doctor. In other parts of the hospital group and indeed 
other hospitals nationally it is delivered by a SBCN or ANP.  
99 
 
 
This appointment is known as a “clinical consultation”. The patient is examined 
and undergoes a mammogram. History taking/problem seeking is unstructured 
and led by very broad open questions. There is little or no specific inquiry about 
any symptoms as it depends on the patient raising concerns themselves. It is not 
usual practice to systematically assess unmet needs, anxiety, depression or 
quality of life at this clinic and have this information available to the doctor.   
4.7.3 Objectives and hypotheses 
H0 Women with breast cancer attending follow-up receiving the intervention show 
no significant difference in level of need and quality of life than those receiving 
standard follow-up care 
 
H1 Women with breast cancer attending follow-up receiving the intervention show 
significant reduction in the level of need and improvement in quality of life than 
those receiving standard follow-up care.    
4.8 Outcome measurements 
The choice of measurement tools was a vital component of this study. Self-rated 
scales were chosen. All participants in the trial were asked to complete 
questionnaires prior to a follow-up clinic on two occasions, 12 months apart. It 
was difficult to ascertain the best time-point from reviewing the literature, leading 
to a pragmatic decision, aligning time point with clinic appointments.    
4.8.1 Primary outcome 
As described in Section 4.2, the primary outcome was a change in unmet needs 
at baseline and 12 months, between treatment groups.   
The 40-item breast cancer survivor-specific needs questionnaire was chosen 
(Thewes et al. 2004) to measure the primary outcome (Appendix 3). It is referred 
to in abbreviated form throughout this thesis as the BCNQ. This decision was 
guided by the literature, consideration of a number of needs assessment tools 
and the findings from the exploratory work and is discussed below (Section 4.9). 
Analysis suggested this was a valid instrument and internal consistency was high 
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with Cronbach alpha values ranging from 0.76 - 0.82 (mean=0.78). When 
compared to the generic Supportive Care Needs Survey (SCNS) - Short Form, 
this tool reported a greater proportion of high to moderate unmet needs 
expressed by women, suggesting that it assessed issues of greater relevance to 
women with breast cancer post-treatment (Thewes, 2000). It is a self-report 
measure asking the patient their level of need for help in a range of different 
areas using a 5-point Likert scale (where 1 = no needs: not applicable; 2 = no 
needs: satisfied; 3 = low need for help; 4 = moderate need for help; 5 = high need 
for help).  The score is gained by calculating a Likert summated scale by 
summing the individual items with a domain. There are five domains with possible 
values ranging from 0 to 5. 
4.8.1.1 Measuring level of need 
The assessment of patients’ needs is considered a vital step in achieving good 
patient centred care (Richardson, Medina & Brown, 2007). This recognition of 
need is a significant indicator to the HCP that the individual perceives a deficit or 
deficiency in their care or life situation (Davison et al. 2004).  However any form 
of patient-centred care is unachievable without a good understanding of what 
patient needs are and the influences that contribute to this state (Girgis et al. 
2006; Richardson, Medina & Brown 2007). Despite Davidson et al. (2004) 
intimating that similarities arise between different conditions, particularly chronic 
ones; Gustafson (2005) maintains that an effective needs assessment instrument 
pursues detail and captures information that enables the clinician to understand 
what it is like for the person in the particular context. Indeed although Fitch, Porter 
& Page (2009) identified types of unmet needs which may arise as a result of 
cancer, she recognised the benefits of a questionnaire which could identify those 
patients who might need help.     
As described in Chapter 2, an individual woman’s pathway of treatment can vary 
considerably. In addition the variety of needs in relation to physical, psychological 
or social issues also had the potential to differ considerably. By contextualising 
the situation for an individual the decision was made to only consider instruments 
that reflected a cancer experience.  While Richardson, Medina & Brown (2007) 
are strong advocates of the benefits of considering individual needs, the 
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measurement of these constructs has not been widely explored in a practice 
setting within the field of breast cancer.   
 
In Chapter 3, the literature indicated that women post-treatment expressed many 
unmet needs relating to emotional, physical, social and psychological areas. This 
aligns with the beliefs espoused by Maslow (1987, p.25) that a human being is a 
“whole functioning, adjusting individual” and their needs are best understood 
through a holistic approach. Therefore the needs assessment tools considered for 
use in this study required to reflect this.  Few studies to date had used validated 
tools to gather data in a holistic manner. Of the studies which did, Beaver et al. 
(2006) used the INQ.  Although it was relatively short (11 items) and easy to use, 
with validity and reliability confirmed by Degner et al. (1998), it was not suitable 
for this study as it only enquired about information needs rather than view a 
woman holistically and include aspects related to physical, emotional, 
psychological and practical needs. Although Girgis et al. (2000) used the BR-
CPNQ which was breast-cancer specific, it was not available for this study.  
Aranda et al. (2006) and Boyes et al. (2006) described using the SCNS 
questionnaire developed by Bonevski et al. (2000) in Australia. Although the 
validity and reliability is established (Bonevski et al. 2000), and the tool was 
specifically designed to be used in a cancer setting, it was a generic instrument 
rather than specific for breast cancer.   
 
In 2004, Thewes et al. reported a pilot study following the development and 
validation of a breast cancer survivor-specific needs assessment instrument.  
Ninety-five participants were recruited through radiation and oncology clinics and 
completed the questionnaire at two time points (14 days apart). Results 
suggested good reliability and validity.  Initially it had been designed to be used in 
conjunction with the 59-item SCNS instrument described above (Bonevski et al. 
(2000), although the authors did report it had the potential to be used alone. 
Following a small pilot of this instrument and recognition that it could capture 
information to enable the clinician to understand what it is like for a woman in the 
post-treatment, in a holistic way, it was considered the most suitable tool to use in 
this study.  Alternative tools did not offer this specificity. 
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4.8.1.2 Measuring anxiety and depression  
The HADS was chosen (Appendix 4). It is a 14-item self-administered 
questionnaire used to measure the anxiety and depression of medically ill 
patients (Carroll et al.1993). There are 14 questions to answer: seven associated 
with depression (HAD-D), seven with anxiety (HAD-A). Scores with a cut off of 8 
for both HAD-A and HAD-D has been established as providing the optimum 
indication of anxiety/depression in cancer patients (Bjelland et al. 2002) and these 
parameters are used in the clinical area where the study was undertaken (see 
Table 4.3). The literature also suggests that this instrument it is a good predictor 
of need and is used regularly within clinical practice, in particular breast cancer 
(Watson, Greer & Rowden, 1991; Hall, A’Hern & Fallowfield, 1999). Recognising 
the relationship between needs, anxiety and depression, this instruments 
sensitivity and specificity has been established (Osborne et al. 2004). The HADS 
is routinely used within the breast services where the study is undertaken as a 
screening tool at diagnosis. Both the women and the SBCN were familiar with it. 
The HADS scores were collected at baseline (time1) and 12 months (time 2) to 
measure changes over time. This tool has been tested for validity and reliability 
(Zigmond & Snaith, 1983).  Each item on the questionnaire is scored from 0 - 3.  
A person can score 0 - 21 for either anxiety or depression.  
Table 4.3: HADS scoring protocol 
Abnormal scoring 
The anxiety and depression subscale scores were categorised as: 
0 – 7  normal 
8 – 10  borderline anxious/depressed 
> 11  probably case of anxiety/depression 
 
Participants were asked to complete the HADS at baseline (time 1) and 12 
months (time 2) to measure how these had changed over time. The patients in 
the SBCN group were scored and assessed by the SBCN who would initiate care 
as appropriate. 
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The participants in the control group were scored by the researcher. If they 
scored 11 or over, the researcher referred to a SBCN not involved in the study for 
further assessment. All the participants were informed of this possibility in the 
information sheet and again when the researcher discussed the study. 
4.8.2 Secondary outcome 
As described in Section 4.2, the secondary outcome was a change in quality of 
life between baseline and 12 months, between the groups 
The quality of life domains were measured using the European Organisation for 
Research and Treatment of cancer (EORTC) QLQ-C30 and a breast cancer 
specific domain EORTC BR23 (Appendix 5).  The justification of this choice is 
discussed below. The EORTC QLQ-C30 is a reliable and validated self -report 
measure of quality of life domains including physical, personal, cognitive, 
emotional and social domains with the EORTC QLQ-BR23 breast cancer-specific 
(Aaronson et al. 1993; Nagel et al. 2001). These are 30 and 23 - item 
questionnaires which combine self -reported generic and breast-cancer specific 
questions.   
 
In this study the EORTC QLQ C30 and the QLQ BR23 was not used as a 
screening tool, as recommended by the authors. The individual patient scale 
score has large standard deviations and therefore the confidence intervals are 
wide, making the scores unreliable for decision making.   
4.8.2.1 Measuring quality of life  
Health-related quality of life is considered a multidimensional construct which at a 
minimum encompasses physical, mental and social domains (Ferrans, 2005) and 
in a broader sense evolves to refer to well-being, quality of survival, human 
values and the satisfaction of needs (Ferrell et al. 1996; World Health 
Organisation, 1995). 
The literature reported a relationship between a diagnosis of breast cancer, 
subsequent treatments and a change in a woman’s quality of life (Ferrell et al. 
1997; Ferrell et al. 1998; Holzner et al. 2001; Ganz et al. 2004; Schultz et al. 
2005).  Research has suggested that assessing the effectiveness of an 
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intervention on a woman’s quality of life is a valuable indicator of care 
(Montazeria, Gillies & McEwen, 1996). The concept of assessing quality of life in 
routine practice has not been uniformly embraced (Schwartz, Mirjam & Spranger, 
2002), the length and complexity of many tools making them difficult to use in a 
clinical environment. The secondary outcome of this study was overall quality of 
life and changes over time of quality of life. The challenge and focus was 
identifying a suitable instrument for the population of interest under study; women 
with breast cancer, free of disease and attending follow-up care. Despite the 
multidimensional nature of quality of life experienced by women with breast 
cancer, caution was needed to ensure the dimensions measured were ones that 
could reasonably be expected to be affected by this disease, its treatment 
regimens and toxicity profile. To guide this process the quality of life instruments 
were mapped to gain a clearer overview of the constructs they measured and 
how they aligned with the multidimensional constructs broadly covered in the 
breast cancer literature (Appendix 6). 
 
A questionnaire which measured overall quality of life rather than single 
constructs of quality of life was favoured. Sloan et al. (2002) recommend that the 
choice of a quality of life assessment should include a combination of generic, 
supplemented with disease specific questionnaires. A number of generic 
instruments were identified which have been validated in a breast cancer 
population and included; the functional living index- cancer (FLIC) (Schipper et al. 
1984), the European Organisation for Research and Treatment of Cancer quality 
of life (EORTC QOL C30) (Aaronson et al. 1993), the Cancer Rehabilitation 
Evaluation System – (CARES) (Ganz et al. 1992), the Medical Outcomes Study – 
short form health status survey (MOS SF-36), the Profile of Mood States (POMS) 
(Curran, Andrykowski & Studts, 1995), and the Short Form health survey (SF-36) 
(Grov et al. 2005).  
 
Some instruments were immediately excluded for practical purposes: this 
included POMS because a charge was required to use this questionnaire; 
CARES because it was considered too onerous for women to complete with 139 
items assessed including many that were deemed irrelevant to the study 
population. Others such as the SF-36, and FLIC were excluded because they did 
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not include items of importance to primary breast cancer patients such as 
menopausal symptoms, body image and sexual function, distress/adjustment. 
 
The EORTC QOL-C30 version 3.0 alongside the supplementary module for 
breast cancer QLQ-BR23, were chosen. These are 30 -  and 25 - item 
respectively, self-reported generic and breast cancer specific questionnaires. The 
EORTC C30 instrument assesses the functional, cognitive, emotional and social 
aspects of life and has been widely used in clinical trials globally (Aaronson et al. 
1993), but like so many quality of life instruments, has not been used much in 
day-to day clinical practice. The different domains including functional, 
psychological and physical were consistent with those identified within the quality 
of life breast cancer literature (Ferrell et al. 1997; Ferrell et al. 1998; Holzner et al. 
2001; Ganz et al. 2004; Schultz et al. 2005). It has been shown to be sensitive to 
change and can distinguish between performance status levels, with internal 
consistency 0.65-0.92 (Aaronson et al. 1993).  
 
The breast cancer module (BR23) is also sensitive to different stages of disease 
and treatment modalities. It addresses body image, sexual functioning, systemic 
therapy side effects, arm symptoms and future perspective. Its validity and 
reliability with this group has been established (Spranger et al.1996).   
 
Permission was granted for its use from the European Organisation for Research 
and Treatment of Cancer Quality of Life Study Group. This permission includes a 
caveat that the EORTC QLC-C30 and QLQ BR 23 data are made available to the 
group for validation purposes. Information is provided on the consent form for the 
participants and also disclosed to the Ethics Committee. 
4.8.3 Demographic and clinical information 
Data were collected from medical notes by the researcher on the following: age, 
type of surgery, type of axillary surgery, time since diagnosis, side of primary, 
pathological tumour size, tumour grade, histological type, node status, HER2 
status, ER status, and adjuvant treatment (Appendix 7).  Socioeconomic status is 
defined by The Scottish Index of Multiple Deprivation (SIMD) (Scottish 
Government, 2012) whereby an individual’s postcode serves as a proxy for their 
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socioeconomic status. The SIMD defines relative deprivation by combining 
information from across seven domains: employment; income; health; education, 
skills and training; geographic access to services; crime; housing. 
4.9 Pre-study exploratory work 
4.9.1 Introduction 
The aim of the exploratory work was to: 
  
 test the recruitment process; 
 test the questionnaires to be used and 
 Assess the intervention procedures. 
 
This is an important stage and recommended as good practice by Lancaster, 
Dodd & Williamson (2004) and Craig et al. (2008) when using the MRC 
framework as guidance. Although this process allowed assessment of the validity 
and reliability of the instruments within the clinical setting, Gerrish & Lacey (2006) 
acknowledge that this is not as necessary when instruments used are already 
validated.  All three instruments: BCNQ, the EORTC C30 and QLQ BR23 were 
validated. Permission to undertake the exploratory work was included in the 
original ethics application. 
4.9.2 Method 
Women with a diagnosis of breast cancer were approached during an end of 
treatment meeting, facilitated by the SBCN at the Cancer Centre which formed 
part of the overall group of hospitals within the NHS Trust in April 2008. Women 
attended this “end of treatment meeting” voluntarily following an invitation from 
the SBCN. As the title suggests, all women had completed their primary 
treatment.   
The literature clearly indicates that a woman’s needs while receiving follow-up 
care are shaped by life experiences and their treatment pathway. The women 
were asked to complete the 40-item BCNQ and the EORTC C30 and BR23 and 
return these to the researcher to ensure the efficiency of the process. In addition, 
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they were sent the short-form (SCNS-SF34: 34 items), the long-form (SCNS- 
SF59: 59 items) (Bonevski et al. 2000) and the 8-item BCNQ instrument to review 
and return in a stamped addressed envelope. The HADS questionnaire was not 
included. This instrument is currently used within the breast cancer service and 
as a screening tool at diagnosis. It was decided this would not be further 
reviewed.   
4.8.3 Results 
Eight women attended the “end of treatment meeting’” and were invited to 
participate: 65% (n=5) agreed to be contacted and this occurred within a week of 
the clinic.  Following contact, four gave verbal consent. The questionnaires, a 
consent form and the information sheet about the main study were sent to the 
participants. All four women returned their questionnaires, the BCNQ, the EORTC 
QLQ C30 and QLQ BR23.    
4.9.3.1 Quantitative data 
The women were aged 52 – 67 (mean age 58.5 years). Two had undergone a 
mastectomy, one a bilateral mastectomy and one a wide local excision. Two had 
received chemotherapy, three had received radiotherapy, and all were receiving 
on-going endocrine therapy. 
 
Within this small sample, women reported some need for help across 24 out of 
the 40 items. This was not particularly surprising. Numerous studies have 
reported that the impact of a diagnosis of breast cancer and side effects 
associated with treatment continue for many years after curative treatment is 
completed (McPhail, 1999; Ganz et al. 2000; Knobf, 2001; Harris et al. 2002; 
Biglia, 2003; Thewes et al. 2003; Shultz, 2005; Walsh, Denduluri & Swain, 2006; 
Stricker, 2007; Neal & Hoskins, 2009). This questionnaire had clearly provided 
women the opportunity to voice their needs as well as have them subsequently 
met.  
 
The 10 most frequently expressed low to high unmet needs (3 or more women 
identified need for support) on the BCNQ are reported in Table 4.4  
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Table 4.4 Top 10 needs expressed using the BCNQ. 
Type of need for support 
1 Pain or discomfort in the area of your affected breast 
2 Dealing with fears of the cancer returning 
3 Trying to find meaning in this experience 
4 Coping with changes with others attitudes and behaviour toward you 
5 Finding a support group which addresses their particular needs 
6 Meeting other breast cancer survivors who are your age 
7 Being informed about the possible effects of the cancer on the length of your life 
8 Being informed about the causes, preventions and treatment of Lymphoedema 
9 Being informed about the causes and possible triggers of breast cancer 
10 Receiving information which is specific to women of your age 
 
Of the 10 highest needs expressed, seven items related to information and 
medical communication, one to the impact of pain and two to coping. Table 
4.5.reports the top five expressed moderate to high unmet needs on the BCNQ 
reported by the four women. Again, information and medical communication were 
the most prevalent items identified among this group. 
 
Table 4.5: Top 5 needs expressed as a moderate to high need. 
Type of need for support 
% sample reporting of a 
moderate (score 4) or high 
(score 5) need 
(n=4) 
Dealing with fears of the cancer returning  75 
Being informed about the causes, 
preventions and treatment of 
Lymphoedema  
50 
Being informed about the causes and 
possible triggers of breast cancer  
50 
Having one doctor who knows all about 
your condition, treatment and follow-up  
50 
Being able to negotiate with your 
specialists about the frequency or length of 
follow-up appointments  
50 
 
The quality of life data indicated that the overall quality of life of the participants 
ranged from 4 - 6 (0=poor to 7=excellent). However, the sample was too small to 
do any inferential statistics. 
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4.8.3.2 Qualitative data 
Each of the women who returned questionnaires were contacted individually and 
the following questions were explored over the telephone and unmet needs 
identified were explored further:  
 How long each questionnaire took to complete? 
 How clear were the instructions? 
 Did they have a preferred option? 
 Did they have further comments about the information sheet, consent, 
study? 
The time spent on the phone ranged from 30 - 90 minutes. The interview was not 
recorded and in hindsight this may have been useful to aid my recall at a later 
date. However, notes were taken. As well as determining the reliability and 
content validity of the questionnaires, the researcher explored with the women 
some of the needs they had identified as requiring help with, within the 
questionnaire. As mentioned earlier, the researcher was previously a SBCN and 
had worked in the area of breast cancer for many years. This experience allowed 
the researcher to understand the needs identified by the women and, if able to, 
the necessary support was provided. One question relating to “finding a support 
group” registered as a low need for support (score=3) and was simply managed 
by sending out information and contact details of the local support group. 
However, two women scored more than five areas of need (score =4 or 5). They 
were offered a referral to a SBCN to further discuss these issues, and both 
accepted.   
 
An overview of the feedback is presented in Table 4.6. Some women included 
written comments on their questionnaires and these are presented among the 
more generic comments made on the telephone.   
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Table 4.6:  Summary of comments about the questionnaire 
Instrument 
Time to 
complete 
Additional written comments from 
participants (4) 
The supportive 
care needs 
Survey SCNS 
(SF-59) 
20 - 30 
minutes 
No.1: “Some questions were very broad”  
commented on Q37 specifically as she felt there 
was a lack of continuity experienced  
No.2: “It was at times puzzling and I found myself 
changing my answers again and again, seeing the 
questions from a different angle.  I think it all stems 
from the clarity of the instructions on the front page” 
No.3: “Instructions unclear” 
No.4: no comment 
The short form 
SCNS (SF-34) 20 minutes Similar comments to above 
Breast cancer 
survivor-specific 
needs 
assessment (40 
items) (BCNQ) 
10 minutes 
All the women commented on the telephone that 
the questions captured many of their current needs 
No. 2 Found the questionnaire an opportunity to 
reflect with her daughters about how well she was 
coping/recovering 
Breast Cancer 
Module (8 items) 
3 minutes 
All the women commented on the telephone that 
this questionnaire was too short to capture all their 
needs 
EORTC QLQ-
C30 
10 - 15 
minutes 
No.1: no comment 
No.2: “I did not feel comfortable about questions 
44-46 related to sexual activity.  If questions were 
framed differently they may be more acceptable”. 
No.3: no comment 
No.4: no comment 
 
All the women expressed a preference for the BCNQ. They felt it closely reflected 
the context of their stage at this time and was quick and easy to complete. The 
women raised concerns that any further questions (adding in the SCNS –SF59) 
would make it too cumbersome to be reviewed in a clinic environment. They 
viewed the use of questionnaires as of personal benefit to them, especially as 
some questions were quite sensitive to raise within the clinic. 
 
Two SBCNs from a different hospital reviewed the questionnaires. They could 
identify similarities between the individual items on the questionnaire and the 
clinical consultations they had with women at the end of treatment. They provided 
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additional expertise and validation about the type and range of approaches they 
currently use to address areas of need highlighted in the questionnaire. This was 
collated and used as part of the training for the SBCN undertaking the 
intervention.  
4.10 Conclusion 
This pre-study exploratory work was able to gather data from 50% (n=4) of the 
sample approached. Dellson et al. (2011) suggests that worldwide only 5 - 10% of 
cancer patients are treated in clinical trials.  Although this data refers primarily to 
pharmacological trials, 50% recruitment in this trial seemed a reasonable target. 
Although the numbers were small, the researcher concluded that the self-rated 
40-item BCNQ met content and face validity within a follow-up setting. It picked 
up needs which were common to this group of women such as “fear of the cancer 
returning” but was specific to capture needs associated with different age groups.  
Further areas that were informed through this pilot work included: 
 
 The information about the study and consent form was reported as easy to 
understand. No further amendments were made.  
 
 The recruitment process seemed overly cumbersome, in particular 
identifying patients who were receiving follow-up care and accessing their 
information in a timely manner. This was refined for the main study and a 
clinical protocol developed (available as a separate document).  
  
The feedback from the women confirmed my decision to use the BCNQ alone. 
From a practical perspective asking women to identify more than 40 items would 
be excessive.  Equally, from a practical perspective, having more than 40 items 
on the BCNQ and 14 items on the HADS were felt to be too difficult for the SBCN 
to review in a short clinical consultation.   
 
The BCNQ identified areas of need that were important to the four women on a 
personal level. Through the telephone interview, the researcher was able to offer 
specific support in response to some, but not all, of these needs. It indicated that 
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the intervention was feasible, acceptable to the women and manageable within 
the context of a follow-up clinic.  
  
4.10.1 Reliability and validity of using self-reported questionnaires in clinics 
The lack of research to support the use of self-reported needs assessment 
questionnaires within a breast cancer follow-up setting raised potential reliability 
and validity issues:    
 There was a risk that women would express unmet needs which did not 
appear on the BCNQ. If this happened, the SBCN would document 
accordingly, respecting the wishes of the patient and use her clinical 
judgment to initiate care as required;   
 There was a concern that the use of patient-reported questionnaires would 
impact on the time patients spent in the clinic, prolonging the consultation.  
This was monitored and when it occurred, discussed by the researcher 
with the SBCN about the reasons;   
 There was a risk that women would tick multiple unmet needs. This could 
reflect the complexity of a diagnosis of breast cancer or the first time these 
women had been given the opportunity to identify some of their need for 
help. In this situation, the SBCN in consultation with the patient identified 
the three most important needs. The SBCN used their clinical expertise 
and determined if a longer consultation out-with the follow-up clinic was 
required and this intervention was recorded. 
4.10.2 Recurrence/mortality 
Any patients presenting with a recurrence/mortality during the study will be 
documented as per policy.  A recurrence changes the status of an individual 
participant.
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4.11 Introduction to the main study 
The results from the previous phases informed the central aspects of the complex 
intervention and the main randomised controlled trial.  The importance of the 
power, randomisation, blinding, outcome measures and informed consent and 
other features are considered to ensure a well-designed trial. 
4.11.1 Sample size calculation 
An important aspect of this study and indeed quantitative studies in general, is the 
number of participants required to test the research hypotheses.  An approach to 
sample size estimation is known as “power analysis” (Ingram, 1998) and was 
calculated for the purpose of this study.  The researcher acknowledged the 
complex nature of undertaking power analysis and took advice from the 
statistician involved with the study.  Altman et al. (2001, p.670) suggest the 
sample size should be large enough  
 
“to have a high probability (power) of detecting as statistically significant a 
clinically important difference of a given size if such a size exists.” (Altman 
et al. 2001, p.670). 
          
A power analysis is based on four factors:  
 sample size (N): determined by the study population and purpose of the 
study;  
 significance level (α): criterion used in hypothesis testing such as  rejecting 
the null hypothesis; 
 effect size (ES): a measure of the strength of the relationship between 
variables; 
 the statistical power expressed as a probability.  
       (Polit & Sherman, 1990)   
 
There were no studies found that examined the effectiveness of the intervention 
described in the present study, therefore an initial calculation was performed 
based on the original primary outcome, quality of life, and the instrument to be 
used, EORTC QLQ-C30. Ingram (1998) suggests there are three ways of 
determining the effect size; using data from pilot studies, to consider previous 
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research where similar instruments have been used or to make a personal 
assessment. The researcher chose to use previous research by Cheung et al. 
(2005), who had considered the variability and sample size requirements of the 
quality of life instruments; EORTC C-30, FACT-G and FLIC. They found the effect 
size in relation to the Eastern Cooperative Oncology Group was 0.5 although 
other studies had placed 0.07 to 0.73.  The figure of 0.5 was used and considered 
an arbitrary level (medium effect size) which could be adopted if using indices set 
out by Cohen (1992) when no specific data is available. The two most frequently 
used significance levels are 0.05 and 0.01. Polit & Beck (2004) maintain that with 
a significance level of 0.5 we are accepting the risk that a true null hypothesis will 
be rejected 5 times in every 100. If we had taken the significance level to 0.1 this 
would have lowered the risk of a type 1 error but in turn potentially increased the 
risk of type ǁ errors.   
 
It was therefore concluded that based on a power of 80% to detect a significance 
level (p=0.05) between the groups, the study required a sample size of 64 in each 
arm. To allow for attrition of 15%, 74 patients would need to be randomised in 
each arm. The researcher recognised that as this is a new area of enquiry and 
the effect size may have been set too high.  Black et al. (1998) suggest that in 
new areas of enquiry estimates of sample size should not be considered as 
precise because of uncertainty about the underlying assumptions.   
4.12 Patient identification, recruitment and informed consent 
4.12.1 Identification 
Patients were identified by the SBCN from the follow-up clinic lists available 
through a computerised system. Unfortunately, this system was cumbersome to 
use and a patients stage of follow-up difficult to extract, therefore the researcher 
decided to invite all patients on the follow-up clinics.  A patient known to have 
underlying mental health problems, complications/special circumstances which 
required monitoring by the doctor or were known to have dementia was excluded 
at this stage. 
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4.12.2 Recruitment  
Following ethical approval, all patients who were eligible for inclusion were sent a 
letter of invitation to take part in the study (Appendix 8) and an information sheet 
about the study (Appendix 9) from the SBCN.  An administrator helped with this 
process. Those women interested in participating sent a reply slip back to the 
researcher or emailed. The researcher contacted the women by phone to confirm 
trial eligibility and offer an opportunity to ask further questions. The reason for a 
women being ineligible at this stage was documented. The women gave verbal 
consent to be randomised during the phone call and provided the researcher with 
their full name and address to send out questionnaires and consent forms. Once 
randomisation was done (detailed below), the study questionnaires and consent 
form were posted to the women. Those allocated to the intervention were 
provided with new appointment details which were organised through the 
outpatient clinic by the researcher. This was a challenging process as this 
frequently occurred within a day or two of the clinic and required the researcher to 
telephone the participant to indicate which arm of the trial they had been allocated 
to.    
4.12.3 Informed consent 
The women received information about the study through the post. Women could 
contact the researcher by post, email or phone. The researcher telephoned all the 
participants to answer any questions they may have and sent the forms at least 
48 hours prior to the women attending the clinic. It was the responsibility of the 
researcher to obtain written informed consent from the participants prior to 
entering the study (Appendix 10). The SBCN checked that a consent form was 
completed prior to the first consultation (baseline), while the control group 
returned their forms to the researcher.   
4.12.4 Randomisation and blinding 
An individually-randomised parallel group design was used for randomisation and 
considered a robust approach (Craig et al. 2008), and conducted independently 
by a statistician. Participants were assigned a unique number and this number 
remained with them throughout the study. A computer-generated block design 
randomisation was used to keep the numbers of subjects in the different groups 
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closely balanced at all times. Subjects were allocated on a consecutive basis to 
the next group within the block.  
 
The researcher recognised that the trial was small and that baseline 
characteristics risked being imbalanced. It would have been useful to have 
achieved certain baseline characteristics between the groups at the end of 
recruitment. The literature has suggested that characteristics such as 
psychological status, age and type of treatment were associated with a moderate 
to high expressed need for help. However, randomisation by minimisation was 
not possible in this study. Access to the notes by the researcher was only 
possible once randomisation had occurred and was part of the requirement set 
out by the ethics committee. Coupled with the short timeframe to consent, 
randomise and ensure the questionnaires were completed prior to the clinical 
consultation (minimum 1 week, maximum 3 weeks) further prevented this 
occurring.    
 
Blinding is the ability to keep the study participants, those providing the 
healthcare and those collecting and analysing the data unaware of the assigned 
groups (Noseworthy et al.1994). All opportunities to blind aspects of the study 
and minimise these effects was maximised. The SBCN sent out the initial 
information but replies were returned to the researcher. This guaranteed that the 
SBCN was unaware of who had agreed to participate and could not influence the 
randomisation process. The randomisation process was discussed with a 
statistician prior to commencing the study and undertaken externally and off site: 
the researcher was unaware of any medical details of the patients until after 
randomisation, when documentation could be sent and the consent form was 
received.   
 
The researcher was responsible for contacting and informing the participant about 
which study arm they were in. Participants were allocated to either the 
intervention or control groups: however, blinding of specific group allocation was 
impossible as both the SBCN and the doctor undertook the clinic in the same 
clinic area.  Care was taken to maintain blinding of patients seen by the doctor 
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and if they required a referral to a nurse, they were seen by one of the other 
nurses in the department not involved in the study.  
4.12.5 Monitoring of completers and non-completers 
If a woman failed to attend her second follow-up appointment or complete the 
questionnaires the reason was ascertained and further questionnaires were sent. 
If they failed to respond they were considered a non-completer. All participants 
were intended to be analysed within the groups to which they were randomly 
allocated on, an “intention to treat “basis. 
4.12.6 Withdrawal of patients 
Participants could decide to withdraw from the study at any time. The researcher 
could also withdraw a patient from the study if it was felt to be in the best interest 
of the participant, for example a recurrence. If a patient withdrew, this was 
documented as a loss to follow-up. All analyses were to be done on an intention 
to treat basis. 
4.12.7 Managing adverse events 
Breast cancer is an unpredictable disease (Gligorov, Pritchard & Goss, 2007).  
Although this study was a non-drug intervention, the patients were attending 
routine follow-up care and had primary breast cancer. This meant that any 
incidence of recurrence and a change in management altered their primary status 
and care requirements. They were treated as lost to follow-up and the reason 
given. 
 
The following was reported and documented in the patients’ notes to ensure that 
clinical characteristics were updated and interventions undertaken were reported: 
 
 Any confirmed local recurrence; 
 Any confirmed metastatic recurrence; 
 Any change to their psychological status; 
 Death due to breast cancer; 
 Death due to other causes.  
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4.12.8 Follow-up of participants 
Patients were seen in the clinic by either a doctor (Control group) or the SBCN 
(Nurse group) at two time points, 12 months apart. The intervention group 
returned the questionnaires to the SBCN and therefore she was aware 
immediately if a patient had not received the questionnaires through the post. 
This happened on a number of occasions and the nurse was able to allow the 
participant time prior to the clinic to complete the questionnaires. Because the 
control group posted their questionnaires back to the researcher in a stamped 
addressed envelope provided, there was a time lag to knowing if the patients had 
received them. The researcher had intended to phone the patients if no 
questionnaires were returned but this proved difficult since many of the women 
were working and it was not always easy to contact them. As a solution, a 
different SBCN in the department, not associated with the study, was contacted 
who knew the patients to ensure that the participant’s attended when planned, 
was still eligible and to check their current survival status. Further questionnaires 
were then sent as soon as the researcher could confirm this. Prior to the second 
questionnaires being sent out, all the participants’ survival status were checked 
before any forms were sent. For non-responders, a reason was obtained if 
possible and recorded. 
4.13 Analysis  
The data were analysed using SPSS version 20 software (IBM, 2011). All 
analyses were to be based on intention to treat, meaning that all study 
participants are retained in their groups to which they were originally allocated 
and no participants are removed from the analysis by the researcher. It was 
agreed that participants, who chose to withdraw following randomisation, were 
removed from the analyses. Descriptive statistics were to be used to summarise 
the demographic and clinical characteristics of the data, including subgroups 
based on age, stage of disease and treatment received.   
 
A score was calculated to compute severity of treatment (women who had 
multiple treatments). This may or may not be an important variable when 
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predicting unmet needs. The types of perceived needs will be presented as: 
domain, number of items, minimum, maximum and mean (standard deviation).  
Differences between completers and non-completers on demographic 
characteristics will be assessed through t-test and chi-square tests. Comparison 
of baseline characteristics between the control and intervention group uses 
inferential statistics such as t-tests for means and    for proportions.  A p-value of 
p=<0.05 would be considered statistically significant. 
Initial review of the BCNQ using factor analysis includes examining the adequacy 
of sample size and the factorability of the correlation matrix. The Kaiser Meyer-
Olkin measure of sampling adequacy (0.64) indicates satisfactory factorability of 
the correlation matrix (values above 0.5 are acceptable; between 0.8 and 1 are 
viewed as very good) (Field, 2012).  In conjunction with the high significance (p = 
< .001) of Bartlett’s test of sphericity, the data were considered suitable for factor 
analysis. Exploratory factor analysis using an extraction method is undertaken to 
examine the factor structure of the items of the BCNQ. 
 
Linear and multiple regression analysis is used to investigate the relationship 
between measures of perceived needs, anxiety, depression  and quality of life.  
4.14 Ethical approval 
Ethical approval was gained from Napier University Ethics Committee, Lothian 
Research Ethics Committee (LREC) on 30th August 2007 and the Lothian NHS 
management approval was granted on 15th September 2007.  In accordance with 
research governance principles which decree that honorary contracts should be 
issued to researchers to ensure access to NHS data and premises. One was 
issued to the researcher on the 24th July 2007 for the duration of the study period.  
 
There were a number of points raised from the ethics submission.  These 
primarily related to the indemnity and indeed competence of the SBCN to 
undertake the clinical examination as part of standard care.  Confirmation was 
provided by the senior management that SBCN currently delivered follow-up care 
in the Trust, indemnity concerns were covered within the Trust and guidance is 
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provided to nurses to ensure that any risk to patients and clients are minimised 
through the Nursing and Midwifery Council (NMC).  
 
‘ if an aspect of practice is beyond your level of competence or outside 
your area of registration, you must obtain help and supervision from a 
competent practitioner until you and your employer consider that you have 
acquired the required knowledge and skill’ (NMC,2008, p.9). 
 
However, despite precedence in the service of nurses undertaking clinical 
examination and indeed a willingness from both the clinician and the SBCN to 
ensure competent practice prior to delivery, no formal protocol for training was in 
place. In discussion with the SBCN, a training package was developed by the 
researcher and the SBCN and included guidance on managing unmet needs 
identified (see protocol). The competencies required were aligned to a number of 
key documents including the NHS Knowledge and Skills Framework which 
“defines and describes the knowledge and skills which NHS staff need to apply in 
their work in order to deliver quality services” (Scottish Executive, 2004, p.3). 
 
The Royal College of Nursing Clinical Standards for working in a Breast specialty 
states that nurses should: 
 
“Articulate dimensions of breast care nursing to promote uniform and high 
quality care.  They provide guidance for nursing performance, and define 
what it means to provide skilled nursing care within a breast 
specialty”.(RCN, 2007, p.2).  
 
And as mentioned earlier, the guidance provided by NMC, the nursing 
professional body includes:  Code of Professional Conduct: Standards for 
Conduct, Performance and Ethics, Record Keeping (2007), Confidentiality 
(2006a) and Consent (NMC, 2006b).  
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4.15 Qualitative data  
As part of the intervention, the SBCN kept a narrative of the person-centred 
conversation she had, and the actions she undertook to address unmet needs.  
These are presented in Chapter 5 and discussed in Chapter 6.   
4.16 Summary 
If time, manpower and resources had been available, it may have been useful to 
have combined a qualitative and quantitative approach. However throughout the 
development of this study, it was evident that much of the research to date has 
focused on describing the unmet needs of women post-treatment rather than 
measuring the effectiveness of interventions to address them. Drawing on these 
data, the intervention and subsequent methodology has been derived. Changes 
in follow-up care are evolving and there is no clear approach, particularly when 
addressing unmet needs.     
  
The researcher recognised the methodological challenges posed when evaluating 
a complex intervention in a clinical setting, but to answer the research question, 
the RCT was the appropriate approach. From a clinical perspective, knowing the 
effectiveness of two follow-up care practices and how they differ in meeting the 
unmet needs of women with breast cancer will provide information that is valuable 
to those working in the field of breast cancer.  
 
On a theoretical level, this study integrated factors within the complex intervention 
which recognised the individual nature of cancer recovery, morbidity associated 
with treatment, fear of recurrence, and adaptation to survival.  The next chapter 
reports the results of the study.
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Chapter 5: Results 
5.1 Introduction 
In this chapter the descriptive and inferential results are presented. As discussed 
in Section 4.2, the primary outcome for the study was a change in needs scored 
at baseline (time 1) and at the end of the trial (12 months, time 2). The study also 
aimed to investigate a number of secondary outcomes namely changes in quality 
of life at baseline and 12 months, as well as looking at possible effects of the 
intervention on variables such as age, treatment severity of treatment and time 
since diagnosis. The following hypothesis was tested: 
 
H0 Women with breast cancer attending follow-up receiving the intervention 
show no significant difference in level of need and quality of life than those 
receiving standard follow-up care 
 
H1 Women with breast cancer attending follow-up receiving the intervention 
show significant reduction in the level of need and improvement in quality of 
life than those receiving standard follow-up care.    
 
Data were analysed using SPSS version 20 software (IBM, 2011).  Statistical 
significance was accepted at the 5% level (p<=0.05). This chapter presents 
details of the numbers of participants, non-completers and completers, and 
statistical analyses used.  This is followed by the descriptive demographic, clinical 
and deprivation characteristics of the participants. Descriptive statistics relating to 
the primary outcome are presented first followed by the inferential statistics.  This 
includes data related to the BCNQ, HADS-A and HADS-D.  This is followed by 
the secondary outcome; descriptive statistics are presented first followed by 
inferential statistics.  This includes data related to the EORTC QLQ C30 and 
BR23.  The regression analyses will then be presented.  Following each section a 
short synopsis of the results is given and the chapter concludes with an overall 
summary of the whole chapter. 
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5.2 Participants 
The participants were identified from the clinic lists available from the online 
patient record system. According to these records, 360 women were due to 
attend clinics over a 1 year period. It was impossible at this stage to apply the 
exclusion criteria (see Section 4.6.3.2) due to limited access to individual cases. 
A pragmatic decision was therefore made to invite all 360 women to participate in 
the present study, knowing that the number may not fully reflect all eligible 
participants. In total 47 were excluded, 22 did not meet the inclusion criteria, 18 
were not contactable prior to the clinic to screen for eligibility, and there was no 
reason documented for 7. Ninety-three were randomised to the present study but 
11 of these withdrew following randomisation. Therefore 37 participants were 
randomised to the standard care group (CG) and 45 to the nurse group (NG). Of 
the 82 entered at baseline, at 12 months there were 24 participants in the CG and 
37 participants in the NG. The expected attrition drop in the original power 
calculation was 15% at 12 months; excluding deaths, the actual drop-out was 
20% overall; 22% in the CG and 16% in the NG.  Figure 5.1 in Section 5.7 
presents a flow diagram of the participants through the study. 
5.3 Completers and non-completers 
There were 82 participants randomised into the study of which 61 completed. In 
both arms of the study if a woman failed to attend her appointment or complete 
the questionnaires, the reason was ascertained. Further questionnaires were sent 
and if they failed to respond they were considered a non-completer. All 
participants were analysed within the groups to which they were randomly 
allocated. The numbers completing were proportionally higher in the NG: 82.2% 
compared to the CG: 64.9%, however this was not found to be a significant 
statistical difference (Pearson’s chi-square, p=0.073). The proportion of 
completers having a mastectomy was 75% or a wide local excision 73.8%, with 
no significant statistical difference between the two groups (Pearson’s chi-square, 
p=0.902). 
 
Comparisons between the completers and non-completers using t-tests was 
undertaken to determine if there was a difference in demographic variables such 
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as age, time since diagnosis and socio economic status between the groups.  
The results, as shown in Table 5.1 indicate no significant differences were found 
for age (two sample t-test, t=0.28, df=80, p=0.978), time since diagnosis (two 
sample t-test, t=-0.365, df=80, p=0.716) or SIMD (two sample t-test, t=-0.555, 
df=77, p=0.580). Therefore, demographic variables did not seem to influence 
whether or not a participant completed the study. 
 
Table 5.1: Comparison of demographic data between the completers and non-
completers 
 Completers (61) 
 
Mean (SD) 
Non-completers 
(21) 
Mean (SD) 
p-value 
Age   53.26 (10.41) 53.33 (9.01) 0.978 
Time since 
diagnosis  
33.74 (18.63) 32.00 (19.33) 0.716 
SIMD 3592.31 (1841.41) 3335.95 (1803.26) 0.580 
 
5.4 Statistical analyses 
Univariate analyses were used to describe the demographic characteristics of the 
sample and the HADS, BCNQ, EORTC QLQ C30 and QLQ-BR23 measures.   
 
In preparation to measure the primary outcome, change in need scores, an initial 
review of the BCNQ was undertaken that included the examination of item 
frequency distributions to identify items with skewed response distribution or low 
variability. Sample size and factorability of the correlation matrix were examined 
using the Kaiser Meyer-Olkin sampling adequacy measure and Bartlett’s test of 
sphericity. Exploratory factor analysis using Maximum Likelihood extraction was 
conducted to examine the underlying factor structure of the items of the BCNQ 
(Appendix 11). The scales internal consistency were analysed through Cronbach 
alpha and item-scale correlations were assessed to decide if any item should be 
removed.   
 
The alpha level for all the scales is presented in Table 5.2. Alpha levels above 0.7 
are considered good and levels above 0.8 are very good (Field, 2005). The alpha 
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levels for all except sexuality indicated good to very good reliability. Although the 
sexuality scale was low in meeting adequate levels of internal consistency, it was 
retained because there was no significant improvement overall if this factor was 
deleted. The result may also reflect that the measures are not specific enough to 
measure sexuality, particularly in an older population, as many of the population 
in this study were. 
 
Table 5.2: Cronbach alpha levels for each subscale of the BCNQ 
Scale  
Cronbach alpha levels 
Baseline 
Post 
intervention 
Psychological 0.910 0.906 
Health system and 
information 
0.882 0.919 
Physical and daily living 0.831 0.754 
Patient care and support 0.746 0.774 
Sexuality 0.534 0.482 
 
Pearson’s chi-square was used to compare frequencies between the groups and 
t-tests were used to compare continuous variables between the groups. These 
included the independent t-test to compare the means of the NG and CG for the 
BCNQ, HADS, EORTC QLQ C30 and QLQ-BR23 and the paired t-test to analyse 
data before and after the intervention. 
 
A series of models were constructed using multiple regression analysis to assess 
the contribution of patient and clinical characteristics to reporting “some need”, 
anxiety or depression.  The following were examined: age, severity of treatment 
(severity), time since diagnosis (TSD): treatment group (TG) and postcode on 
developing a need for support, anxiety and depression levels at baseline and time 
2.  Initially, a series of tests were carried out to examine the suitability of the 
present data for regression analysis – a stepwise method was used and retained 
based on statistic criteria (probability of F to enter<.05, and to remove >.10.  No 
multicollinearity was suggested, as tolerance values were all above 0.4 (0.1 is the 
minimum; Field 2005, p.175) 
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The whole EORTC QLQ C30 and QLQ BR23 have been fully analysed; however, 
only selected scales were used in the linear regression models. This decision was 
informed by previous research. The scales used as dependent variables from the 
EORTC QLQ C30 included: physical functioning, role functioning, emotional 
functioning, cognitive functioning, social functioning, fatigue and pain.  All scales 
were used as dependent variables in the QLQ-BR23. 
5.5 Participant characteristics 
The baseline demographic and disease characteristics of the two groups were 
similar and these are presented in Table 5.3. The baseline treatment 
characteristics are presented in Table 5.4. Statistical comparison tests were 
carried out in two ways depending on whether the demographic variables were 
considered: categorical or continuous. The results, as shown in Table 5.3 indicate 
no significant differences between the age of the NG: M = 53.48, SD 9.25 
compared to the CG: M = 53.11, SD 10.70 (two sample t-test, t (168) = 80, 
p=0.867.  They also indicate that there are no significant differences between the 
time since diagnosis of the NG: M = 34.48 months, SD 20.79 compared to the 
CG: M = 32.31, SD = 16.97 (two sample t-test, t (522) = 80, p=0.865).
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Table 5.3: Baseline demographic and disease characteristics of the study 
participants  
Variable   Nurse group (44) Control group (37) p-value 
Age in years 
mean(range) 
 
52 (range 38 - 72) 53 (range 21 - 76) 0.86
a
 
Months since 
diagnosis 
mean(range) 
 
25 (range 6 - 84) 26 (range 5 - 64) 0.86
a
 
    N % N %  
Tumour 
grade 
1 8 22 7 16 
0.10
a
 
2 8 22 20 44 
3 18 48 15 33 
unknown 0 0 2 4 
DCIS 3 6 1 2 
Histological 
type 
ductal 33 75 38 78 
0.61 lobular 4 11 6 13 
not reported 0 0 1 2 
Node status 
positive 15 41 16 36 
0.65
b
 
negative 22 59 29 64 
HER2 status 
positive 5 13 6 13 
0.74
b
 negative 22 60 30 67 
unknown 10 27 9 20 
Pathological 
tumour size 
0-0.9 1 2 0 0 
0.49
a
 
1.0-1.9 16 36 11 28 
2.0-2.9 16 36 11 30 
>3.0 12 26 15 41 
  Notes: SD=standard deviation a t-test b    test 
 
5.6 Participant treatment characteristics 
In Chapter 2 the type of treatments a woman would be offered were outlined.  
Many of these treatments cause short-term but also long-term side effects. 
Although all treatments have their unique set of side effects there is a cumulative 
effect seen the more treatments received.  Breast cancer is unique because most 
women receive more than one treatment and for some, up to five.  The 
researcher made an assumption that the more treatments a woman receives, the 
greater the likelihood of a cumulative risk of side-effects. To adjust the analyses 
for this occurring, an additional variable was calculated based on the number of, 
and anticipated impact of a different treatment for each individual participant; 
scoring range 0 (surgery alone) → 8 (surgery plus endocrine, herceptin, 
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chemotherapy and radiotherapy, with more toxic treatments like chemotherapy 
scoring higher). This variable is referred to throughout this thesis as “severity of 
treatment”. There are no significant statistical differences observed between the 
mean values of the severity of treatment of the NG (M = 4.27, SD = 2.10) 
compared to the CG (M = 4.37, SD = 2.05), (two-sample t-test, t (183) = 80, 
p=0.855).  All other variables are found not to be significantly different.  
 
Table 5.4: Baseline treatment characteristics of the study participants 
Variable   Nurse group Control group p-value 
  N % N %  
Mastectomy  20 54 20 44 
0.50
b
 
Wide local 
excision 
 17 46 25 56 
Reconstruction  
yes 12 32 10 22 
0.33
b
 
no 25 68 35 78 
Axillary surgery 
sample 18 49 18 40 
0.56
a
 clearance 17 46 22 49 
SLNB 2 5 5 5 
Endocrine 
yes 26 70 34 76 
0.63
b
 
no 11 30 11 24 
Chemotherapy 
yes 25 67 28 62 
0.65
b
 
no 12 32 17 38 
Herceptin  
yes 4 11 4 9 
1.00
b
 
no 41 89 33 91 
Radiotherapy 
yes 11 30 12 27 
0.81
b
 
no 26 70 33 73 
     Notes:  a t-test     b    test 
 
5.6.1 Deprivation levels 
The Scottish index of Multiple Depression (SIMD) (Scottish Government, 2012) 
was used to determine the overall deprivation of the population being studied. 
The SIMD is based on seven domains: employment; income; health; education, 
skills and training; geographic access to services; crime and housing.  The scores 
categorise deprivation levels according to an individual’s location using the 
postcode (1 = most deprived to 6,505 = least deprived). The mean SIMD score 
for the sample was 3524.16 (range 599 to 6474); with 25% of participants falling 
within the most deprived ranked 30% of the Scottish population (1-1952). There 
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was no significant difference between the groups (Pearson    0.574, df 69). The 
scores indicated there were more participants classified as living in a deprived as 
non-deprived area in both groups compared to the Scottish breast cancer 
average (Information Services Division, 2013). However, these results are similar 
to the UK overall average of 23% (National Cancer Intelligence Network, 2011). 
This was anticipated as the location of the study is in an area categorised, 
according to SIMD, as being an area of higher deprivation. 
5.6.2 Summary of demographic and clinical findings 
 Demographic, disease and treatment characteristics were similar between 
the two groups at the onset of the trial 
 Completers and non-completers did not differ on demographic variables 
and therefore did not appear to influence whether a participant completed 
the study or not. 
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5.7 Flow of patients through the trial 
The progress of patient through the trial is shown in Figure 5.1, which is based on 
that recommended in the CONSORT statement on the reporting of trials (2010) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Flow of participants through the trial
Assessed for eligibility (n= 360) 
Excluded (n= 47) 
 Not meeting inclusion criteria (n= 22) 
 No reason documented (n= 7) 
Other reasons (n= 18) 
Non-responders (n= 220) 
Analysed (n= 24) 
 
Lost to follow-up (give reasons) (n=13) 
Transferred to different clinic (n=2); died 
prior to 2
nd
 clinic (n=2); recurrence prior 
to 2
nd
 clinic (n=2); psychological reasons 
(n=1); non-returns (n=6) 
 
Allocated to intervention (n=37) 
 Received allocated intervention  
(n= 37) 
 
Lost to follow-up (give reasons) (n=8) 
Transferred to different clinic and withdrew 
from study (n-4); died prior to 2
nd
 clinic (n-1); 
recurrence prior to 2
nd
 clinic (n=3) 
 
Allocated to intervention (n=45) 
 Received allocated intervention (n=44) 
 
Analysed (n=37) 
 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n=93) 
Enrolment 
Declined following 
randomisation (n = 11) 
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5.8 Primary outcome 
The descriptive statistics associated with the primary outcome are reported first.  
This includes the means, standard deviation (SD), minimum and maximum 
scores for all the measures used. All testing was two-tailed and statistical 
significance was accepted at the 5% level (p=<0.05). Participants completed 
measures for level of need using the BCNQ and levels of depression and anxiety 
using the HADS.  Although depression and anxiety scores are collected together 
on one questionnaire they are analysed separately; HAD-A, anxiety and HAD-D, 
depression and is consistent with the reporting of this in the literature. 
5.8.1 Descriptive data of overall needs  
Participants completed a 40 item BCNQ questionnaire. For each item, 
participants are asked to indicate their level of need for help over the last month 
as a result of having breast cancer, using the following responses:  
   
 
 
 
 
 
 
Scored 1-5, a higher domain score represents a higher level of need for help. 
The distribution of the summated scales, which form part of the BCNQ, at 
baseline for the nurse group (NG) and control group (CG) are presented in Table 
5.5.  
 
 
 
 
 
 
 
 
No need Some need 
Not applicable 
1 
Satisfied 
2 
Low Need 
3 
Moderate 
need 
4 
High need 
5 
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Table 5.5:  Descriptive baseline data for the BCNQ divided into the five subscales 
  Baseline – nurse Baseline – control 
Scale 
No.  of 
items 
M SD Min Max M SD Min Max 
Psychological 14 1.92 0.70 1 3.57 1.84 0.80 1 3.93 
Health system and 
information 
16 1.92 0.76 1 4.90 1.94 0.76 1 3.5 
Physical and daily 
living 
4 2.35 1.09 1 4.67 2.23 1.04 1 5 
Patient care and 
support 
3 1.97 0.97 1 5 2.09 0.95 1 4 
Sexuality 3 2.02 0.94 1 4.50 1.7 1.09 1 5 
M= mean, SD = standard deviation 
 
Scores were normally distributed. The responses of both groups to individual 
items were compared. There was a significant difference between mean values 
for item 7 “Coping with lymphoedema” on the psychological scale between the 
NG (M=1.92, SD=0.70) compared to the CG (M=1.84, SD=0.80), (two-sample t-
test, t (2.126) = 76, p=0.037). 
Some questions would be more relevant to women of a certain age, particularly 
item 30 “Being informed about the impact of cancer treatment on your fertility” on 
the health system sub-scale. In the analysis of this question all women over 45 
were excluded, leaving nine participants. The results indicate there are no 
significant statistical differences between the NG (M=1.22, SD=0.44) and the CG 
(M=1.40, SD=0.55), (two sample t-test, t (-0.665) =12, p=0.519). 
No other responses for items on the scales are statistically significant.  
 
The distribution of the summated scales at the end of the trial for the NG and CG 
are presented in Table 5.6. An independent t-test indicated there are no 
significant differences in unmet needs expressed across all the subscales 
between the two groups at the end of the trial. 
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Table 5.6: Descriptive post-intervention data for the BCNQ divided into the five 
subscales 
  
Post intervention – 
nurse 
Post intervention – 
control 
Scale 
No.  of 
items 
M SD Min Max M SD Min Max 
Psychological 14 1.54 0.49 1 2.5 1.68 0.59 1 2.93 
Health system and 
information 
16 1.58 0.50 1 2.81 1.71 0.61 1 3.25 
Physical and daily 
living 
4 1.86 0.8 1 3.73 1.9 0.72 1 3.75 
Patient care and 
support 
3 1.72 0.66 1 3.33 1.76 0.74 1 3.67 
Sexuality 3 1.55 0.59 1 3 1.52 0.76 0.5 3.5 
Notes: M= mean 
SD = standard deviation 
The individual questions informed the direction the intervention took.  The 20 
most frequently reported unmet needs expressed on the BCNQ are presented in 
Table 5.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
134 
 
Table 5.7: Top 20 needs expressed across both groups on the BCNQ 
Ranked Item no. 
 
Needs 
1 15 Dealing with fears about the cancer spreading or returning 
2 10 Dealing with a lack of energy or tiredness 
3 31 Being informed about the causes and possible triggers of 
breast cancer 
4 28 Being informed about the latest developments in treatment 
and prevention of breast cancer 
5 12 Pain or discomfort in the area of the affected breast 
6 11 Pain of discomfort in the arm near your surgery 
7 26 Being informed about the possible effects of the cancer on the 
length of your life 
8 37 Having one doctor who knows all about your condition, 
treatment and follow-up 
9 19 Accepting changes in your appearance 
10 27 Being informed about the causes, preventions and treatment 
of lymphoedema 
11 40 Having access to HCP (eg. GPs,dieticians, physiotherapists) 
who specialise in dealing with people who are cancer 
survivors (or people who are recovering from cancer) 
12 17 Coping with changes to your usual routine and lifestyle 
13 20 Coping with changes in your sexuality or to your sexual 
relationships 
14 8 Coping with what having breast cancer might mean for your 
daughters and sisters 
15 9 Being informed about your daughters and/or sister’s risk of 
developing breast cancer 
16 25 Meeting other breast cancer survivors who are your age 
17 35 Receiving information which is specific to your age 
18 22 Coping with the impact your cancer is having on your 
relationship (both to you and/or your partner) 
19 29 Being informed about insurance issues 
20 36 Feeling able to ask your cancer specialist specialists for 
information about a range of issues not just medical issues 
5.8.2 Changes in needs over time 
The primary outcome of interest was testing the effect of the intervention between 
baseline (time 1) and the single post-intervention (time 2). The sub-scores that 
make up the total BCNQ scores were analysed separately first.  Presented in 
Figure 5.2 is a graphical representation of results across all the five subscales: 
psychological, health system and information, physical and daily living, support 
and sexuality at baseline (time 1) and post intervention (time 2). The error bars for 
each mean are the 95% confidence intervals for that mean based on each means 
standard error.   
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Figure 5.2: Error bar graph comparing the mean differences with 95% confidence 
intervals for baseline and post intervention groups for BCNQ subscale scores 
The first analysis undertaken compared the mean response scores before and 
after the intervention on the five subscales of the BCNQ in each group to 
understand the changes that occurred in each of the groups.  This was conducted 
on 55 participants to test the following hypothesis:   
 
H0: There is no significant difference in mean values of unmet needs 
(subscales) between beginning and end of the trial for control group 
v 
H1: There is a significant difference in mean values of unmet needs 
(subscales) between beginning and end of the trial for control group 
 
H0: There is no significant difference in mean values of unmet needs 
(subscales) between beginning and end of the trial for intervention group 
v 
H1: There is a significant difference in mean values of unmet needs 
(subscales) between beginning and end of the trial for intervention group 
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Using a paired t-test, the results, as shown in Table 5.8 indicate that four 
subscales (psychological, health system and information, physical and daily living 
and sexuality) showed a significant difference in mean value responses before 
and after treatment compared to one subscale in the control group (health system 
and information).    
 
Table 5.8: Mean differences over time for BCNQ subscale scores by treatment 
group 
 
 
 
 
 
Group     Pair 
Paired Differences  
 
 
t 
 
 
 
df 
 
 
 
Sig. (2-
tailed) 
       
 
M 
 
      
  
SD 
 
 
SE Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Nurse 
P1 Psychological  .34 .66 .11 .11 .56 3.025 34 .005* 
P2  Information  .24 .60 .10 .03 .44 2.370 34 .024* 
P3 Physical .37 .92 .16 .05 .69 2.368 34 .024* 
P4 Support  .21 .90 .15 -.10 .52 1.376 34 .178 
P5  Sexuality  .47 .82 .14 .19 .75 3.393 34 .002* 
Control 
P1 Psychological  .20 .52 .12 -.04 .45 1.711 19 .103 
P2 Information  .32 .60 .13 .04 .61 2.428 19 .025* 
P3  Physical  .40 .99 .22 -.06 .86 1.804 19 .087 
P4 Support  .30 .92 .21 -.13 .73 1.453 19 .163 
P5 Sexuality .22 .75 .17 -.13 .58 1.339 19 .197 
* Denotes significance 
 
Nurse Group: Results indicate that there is a significant difference between the 
mean value psychological responses before (M=1.89, SD=0.72) and after 
(M=1.56, SD= 0.83) (paired t-test, t = 3.025, df = 34. p=0.005).    
Nurse group: There is a significant difference between the mean value health 
system and information responses before (M=1.84, SD=0.63) and after (M=1.60, 
SD=0.50) (paired t-test, t = 2.370, df = 34, p=0.024)  
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Nurse Group: There is a significant difference between the mean value physical 
responses before (M=2.25, SD=1.11) and after (M=1.88, SD=0.82). (paired t-test, 
t = 2.368, df = 34, p=0.025 (CG). 
Nurse Group: There is a significant difference between the mean value sexuality 
responses before (M=2.01, SD=0.90) and after (M=1.54, SD=0.60).  (paired t-
test, t = 3.393, df = 34, p=0.02)  
Control Group: There is a significant difference between the mean value health 
system and information responses before (M=1.86, SD=0.68) and after (M=1.53, 
SD=0.44) (paired t-test, t = 2.428, df =19, p=0.025)  
These results reject the hypothesis in four out of five subscales for the nurse 
group and one subscale for the control group. It appears that participants 
exposed to the nurse group saw more improvements compared to the control 
group.  
To understand the extent of this improvement and whether there was a significant 
difference between the control and intervention groups, a regression approach 
was used. This approach adjusted for any chance imbalance between the groups 
in any of the outcome variables at baseline. 
This approach tested the following hypothesis:  
H0: There is no significant difference in mean values in unmet needs 
(subscales) between the control and treatment groups at end of the trial   
v 
H1: There is a significant difference in mean values in unmet needs 
(subscales) between the control and treatment groups at end of the trial   
 
The results, as shown in Table 5.9 indicate there is no significant difference 
between any of the subscales between the two groups at the end of the trial. The 
results fail to reject the null hypothesis. 
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Table 5.9: Linear regression: The association between BCNQ subscale scores 
and the treatment groups 
 
 
Score at time 1 
Co-efficient of 
group indicator 
BCNQ 
Subscales β 
p 
value β 
p 
value 
Psychological 0.377 <0.001 0.124 0.311 
Information 0.353 <0.001 0.009 0.94 
Physical 0.373 <0.001 0.007 0.971 
Support 0.245 <0.016 0.054 0.739 
Sexuality 0.387 <0.001 0.054 0.739 
 
*Group indicator=0 if control group; 1 if nurse group 
 
5.8.3 BCNQ: Dichotomous outcome 
To test the effect of the intervention and determine if it was successful or not in 
achieving changes in unmet needs over time, a dichotomous outcome measure 
was established. The criteria to classify the outcome was having a need for any 
one of the items in a subscale and therefore an item was scored 3, 4 or 5 
compared to those who had no need and therefore scored an item 1 or 2. The 
analysis indicated that the proportion of participants expressing a need across the 
whole BCNQ score at baseline was 77.8% (n=34) (NG) and 78.9% (CG). 
Following the intervention, this level decreased to 58.3% and 66.7% respectively. 
The overall dichotomised score was added together (range 0–34) and this gave a 
continuous score whose summary mean at baseline and post-intervention are 
presented in Table 5.10.   
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Table 5.10: Summary mean BCNQ scores at baseline and post intervention 
BCNQ Nurse  Control  p value 
Participants 
 
44 
 
 
37 
  
Time 1: Baseline  
Need for 
support 
 
40 items 11.11 M 8.99 SD 9.23 M 8.64 SD p 0.35 
Time 2: Post Intervention  
Participants  36 24  
Need for 
support 
40 items 4.19 M 6.09 SD 7.75 M 6.63 SD p 0.35 
Notes: M=mean, SD = standard deviation  
 
In Figure 5.3, the error bars for each mean are the 95% confidence intervals for 
that mean based on each mean’s standard error.  
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Figure 5.3: Error bar graph comparing the mean differences with 95% confidence 
intervals for baseline and post intervention group for BCNQ scores  
 
The graph shows the differences between the groups at baseline and post 
intervention in regard to overall needs. There was an improvement in both 
groups. The first analysis compared the mean response scores before and after 
the intervention using the dichotomous outcome variable.  
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This was conducted on 57 participants to test the following hypotheses:  
 
H0: There is no significant difference in unmet needs between beginning 
and end of trial for the control group (paired).  
v 
H1 There is a significant difference in unmet needs between beginning 
and end of trial for the control group (paired).  
 
H0: There is no significant difference in unmet needs between beginning 
and end of trial for the intervention group (paired).  
v 
H1 There is a significant difference in unmet needs between beginning 
and end of trial for the intervention group (paired).  
 
It can be seen from the data that the mean response scores for the BCNQ at time 
1 was 10.9 (NG) compared to 8.1 (CG), whilst the mean response scores at time 
2 was 4.26 (NG) compared to 4.41 (CG) (95% confidence interval for the 
difference 3.5–9.8, NG, compared to 0.7–6.8, CG).  The results, as shown in 
Table 5.11 indicate that there is a significant difference between the mean 
response scores for the BCNQ before and after the intervention (paired t-test, 
NG: t = 4.282, df = 34, p =< 0.001; CG: t = 2.627, p=0.016.  This result rejects the 
null hypothesis for control and intervention. 
 
Table 5.11: Mean differences over time for BCNQ dichotomous outcome scores 
by treatment group 
 
 
 
 
 
Group  Pair 
Paired Differences  
 
t 
 
 
df 
 
 
Sig. (2-
tailed) 
 
M 
 
SD 
 
SE 
Mean 
95% Confidence Interval 
of the Difference 
         Lower Upper 
Nurse P1 BCNQ 6.63 9.16 1.55 3.48 9.77 4.282 34 .000* 
Control P1 BCNQ 3.73 6.66 1.42 .78 6.68 2.627 21 .016* 
* Denotes significance 
 
To understand the extent of this improvement and whether there was a significant 
difference between the control and intervention groups, a regression approach 
was used which adjusted for any chance imbalance between groups in any of the 
outcome variables at baseline.  
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The regression analysis tested the following hypothesis: 
 
H0: There is no significant difference in unmet needs between control and 
intervention groups at the end of the trial  
v 
H1: There is a significant difference in unmet needs between the control 
and treatment group at the end of the trial 
 
The results, as shown in Table 5.12 indicate that although the intervention 
improved unmet needs in the expected direction, this change is not statistically 
significant between the groups (p=0.518). This result rejects the alternative 
hypothesis. 
 
Table 5.12: Linear regression: The association between BCNQ scores and the 
treatment groups 
  
  Score at time 1 
coefficient of 
group indicator  
 
β p value β p value 
BCNQ 
dichotomous 0.279 <0.001 0.918 0.518 
 
* Group indicator=0 if control group; 1 if nurse group 
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5.8.3 Summary of findings: Unmet needs 
 
 Levels of unmet needs as measured by the BCNQ  are not significantly 
different across both groups.  
 The overall proportion of participants expressing an unmet need was high 
in both groups.  
 Both groups saw a reduction in overall unmet needs between the 
beginning and end of the trial.  
 Changes before and after the intervention are significantly different in four 
out of five subscales in the NG compared to one in the CG. However, this 
is not a statistically significant difference between the groups. 
 The intervention improved unmet needs in the right direction but this 
change is not statistically significantly and no differences between the 
groups. 
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5.8.4 Descriptive data of overall anxiety and depression  
Participants completed a 14 item HADS questionnaire: 7 items associated with 
levels of anxiety, 7 items associated with levels of depression. The distribution of 
the summated scales that form the HADS are presented in Table 5.13.  Although 
the baseline mean scores are higher for anxiety among the CG (M=8.24) 
compared to the NG (M=7.07) and depression among the CG (M=4.88) 
compared to the NG (M=3.36), there is no statistical difference between the 
groups’ mean anxiety scores t (- 1.002) = 75, p= 0.319 or mean depression 
scores (two-tailed, t (- 1.682) = 75, p= 0.97). 
 
Table 5.13: Summary mean scores of anxiety and depression of the HADS at 
baseline and post-intervention 
HAD Nurse  Control  
  Baseline (44) Baseline (37) 
Scale No.  of items M SD Min Max M SD Min Max 
Anxiety  7 7.07 4.75 0 18 8.24 5.51 0 20 
Depression  7 3.36 3.59 0 17 4.88 4.31 0 17 
    Post intervention (37) Post intervention (23) 
Anxiety  7 5.81 4.86 0 21 6.04 4.01 0 13 
Depression  7 3.14 3.65 0 17 3.08 2.57 0 9 
Notes: M = Mean, SD = standard deviation 
 
5.8.5 Clinical abnormal levels of anxiety and depression 
Each scale for anxiety and depression is scored from 0 – 21. Clinical indicators of 
psychological distress are determined by the overall score: a score of 0 -7 is 
considered normal; a score of 8-10 is borderline anxious/depressed; a score >11 
is probably a case of anxiety/depression (Zigmond & Snaith, 1983; Bjelland et al. 
2002). To distinguish between the mean scores and the presence of anxiety and 
depression scores of the individual participants, the results, shown in Table 5.14 
(baseline) and Table 5.15 (post-intervention) are categorised according to the 
abnormal scoring protocol (see Table 4.3).  The single most striking observation 
is the high number of women in both groups who appear to have clinically 
significant levels of anxiety at baseline (NG=43%; CG=60%) and which appear to 
decline but not resolve at the end of the trial (NG=35%; CG = 48%). Pearson’s    
145 
 
chi-square was performed on the data at the onset of the trial and the end to 
determine if there was a significant difference in the frequency of these scores 
reported between the two groups. Results, as shown in Table 5.14 and 5.15 
indicate there is no statistical difference between the start and end of the trial. 
 
Table 5.14: Presence of anxiety and depression symptoms among participants as 
per HADS at baseline 
HADS 
Score 
Baseline anxiety Baseline depression 
Nurse 
(44) 
Control (33) 
Nurse 
(44) 
Control (33) 
 n % n  % n % n % 
0 - 7 24 54.55 13 39.39 40 90.91 27 81.82 
8 - 10 11 25.00 12 36.36 1 2.27 4 12.12 
>11 8 18.19 8 24.24 3 6.82 2 6.07 
   .369   .458 
     
 
Table 5.15: Presence of anxiety and depression symptoms among participants as 
per HAD scale at post intervention 
HADS 
Score 
Post-intervention anxiety Post-intervention depression 
Nurse 
(37) 
Control (23) 
Nurse 
(37) 
Control (23) 
 n % n % n % n % 
0 - 7 24 64.86 13 56.52 34 91.89 22 95.65 
8 - 10 6 16.22 7 30.43 2 5.41 1 4.54 
>11 7 18.92 4 17.39 1 2.70 0 0 
   .326   .563 
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5.8.5 Changes in anxiety over time 
The following section presents data associated with changes in anxiety over time. 
 
 
Figure 5.4: Error bar graph comparing the mean differences with 95% confidence 
intervals for baseline and post intervention group for anxiety scores  
 
In Figure 5.4, the error bar for each mean are the 95% confidence intervals for 
that mean based on each mean’s standard error. From the graph above a fall in 
anxiety occurs in both the nurse and the control group. The first analysis 
compared the mean value of the anxiety response scores on the HADS before 
and after the intervention. This was conducted on 57 participants to test the 
following hypothesis:  
 
H0 There is no significant difference in anxiety between beginning and end 
of trial for the intervention group 
v 
H1 There is a significant difference in anxiety between beginning and end 
of trial for the intervention group 
147 
 
H0 There is no significant difference in anxiety between beginning and end 
of trial for the control group 
v 
H1 There is a significant difference in anxiety between beginning and end 
of trial for the control group 
The mean anxiety score at time 1 was 1.03 (NG) compared to 1.04 (CG), whilst 
the mean anxiety score at time 2 was 0.83 (NG) compared to 0.80 (CG) (95% 
confidence interval for the difference 0.07–0.33, NG, compared to 0.04 – 0.45, 
CG).  It can be seen from the data in Table 5.16 that there is a significant 
difference between the mean value responses before and after the intervention in 
both groups (paired t-test, NG: t = 3.043, df =35, p = 0.004; CG: t = 2.457, df = 
20, p = 0.023). This result means that a significant difference in anxiety in both 
groups has been shown and supports the alternative hypothesis. 
 
Table 5.16: Mean differences over time for HADS scores by treatment group 
 
 
 
 
 
Group 
 
 
 
 
Pairs 
Paired Differences  
 
 
 
t 
 
 
 
 
df 
 
 
 
 
Sig. 
(2-
tailed) 
 
 
 
M 
 
 
 
SD 
 
 
 
SE 
mean 
95% 
Confidence 
Interval of the 
Difference 
Lower Upp
er 
Nurse 
P1 Dep .05 .39 .07 -.08 .18 .785 35 .437 
P2 Anx .20 .39 .07 .07 .33 3.043 35 .004 
control 
P1 Dep .19 .19 .04 .10 .28 4.513 20 .000 
P2 Anx .24 .45 .10 .04 .45 2.457 20 .023 
 
To understand the extent of this improvement and whether there was a significant 
difference between the control and intervention groups, a regression approach 
was used.  This adjusted for any chance imbalance between groups in any of the 
outcome variables at baseline.  
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This approach tested the following hypothesis: 
 
H0: There is no significant difference in anxiety between control and 
treatment groups at end of the trial; 
v 
H1: There is a significant difference in anxiety between control and 
treatment groups at end of the trial. 
 
Table 5.17: Linear regression: Association between HAD-A scores and treatment 
groups 
  Score at time 1 
coefficient of  
group indicator 
HAD A β p value β p value 
anxiety 0.764 <0.001 0.366 0.632 
 
* Group indicator=0 if control group; 1 if nurse group 
 
 
The results, as shown in Table 5.17 indicate that although the intervention 
improved anxiety levels in the expected direction, this change is not statistically 
significant between the groups (p=0.632). The results fail to reject the null 
hypothesis. 
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5.8.6 Changes in depression over time 
There is a higher proportion of participants with depression in the control group 
compared to the nurse group at baseline (CG: 68%) compared to NG: 48%).   
 
 
Figure 5.5: Error bar graph comparing the mean differences with 95% confidence 
intervals for baseline and post intervention group for depression  
 
In Figure 5.5, the error bars for each mean are the 95% confidence intervals for 
that mean based on each mean’s standard error. A fall occurs in the control group 
between baseline and the end of the trial. The first analysis compared the mean 
value of the depression response scores on the HADS before and after the 
intervention.  
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This was conducted on 57 participants to test the following hypothesis:  
 
H0 There is no significant difference in depression between beginning and 
end of trial for the intervention group 
v 
H1 There is a significant difference in depression between beginning and 
end of trial for the intervention group 
H0 There is no significant difference in depression between beginning and 
end of trial for the control group 
v 
H1 There is a significant difference in depression between beginning and 
end of trial for the control group. 
The mean response scores for the depression values at time 1 is 0.50 (NG) 
compared to 0.56 (CG), whilst the mean response values at time 2 was 0.44 (NG) 
compared to 0.37 (CG) (95% confidence interval for the difference 0.10– 0.28, 
NG, compared to -0.82 – 0.18, CG). It can be seen from the data in Table 5.16 
that there is a significant difference between the mean response scores for 
depression before and after the intervention in the control group (paired t-test, t = 
4.513, df=20, p=< 0.001) but not the nurse group (t=0.785, df=35, p=0.437.   
 
To understand the extent of this improvement and whether there was a significant 
difference between the control and intervention groups, a regression approach 
was used.  This adjusted for any chance imbalance between groups in any of the 
outcome variables at baseline. This approach tested the following hypothesis: 
 
H0: There is no significant mean difference in depression values between 
the nurse and control group at the end of the trial; 
v 
H1: There is a significant mean difference in depression values between 
the nurse and control group at the end of the trial. 
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Table 5.18: Linear regression: Association between HAD-D scores and treatment 
groups 
 
  Score at time 1 
coefficient of 
group indicator 
HAD-D β p value β p value 
depression 0.71 <0.001 -0.833 0.163 
 
* Group indicator=0 if control group; 1 if nurse group 
 
The results, as shown in Table 5.18 indicate that although the intervention 
improved depression levels in the expected direction, this change is not 
statistically significant between the groups (p=0.163). The results fail to reject the 
null hypothesis 
5.8.8 Summary of findings: Anxiety and depression 
 Anxiety levels are high in both groups at the onset of the trial.  
 Anxiety and depression levels are not significantly different between the 
groups at the onset and end of the trial.   
 Anxiety and depression responses fell in both groups between baseline 
and the end of the trial. 
 There is a significant statistical difference in anxiety and depression 
between the beginning and end of the trial in both groups. 
 There are no significant differences between the control and treatment 
groups at the end of the trial. 
 
152 
 
5.9 Secondary outcome 
5.9.1 Descriptive data of quality of life  
The whole quality of life questionnaires: the QLQ C30 and the QLQ BR23 were 
administered to participants at baseline and 12 months. The QLQ C30ver3.0 was 
a 30-item generic cancer questionnaire. For items 1 - 28, participants are asked 
to answer questions relating to their health, using the following responses: not at 
all (1); a little (2); quite a bit (3); very much (4).  Item 29 and 30 ask participants to 
rate their health and quality of life on a scale of 1 (very poor) to 7 (excellent). The 
questionnaire is divided into functional scales (5), symptom scales/item (8) and 
global health status/quality of life (1). All the measures range in score from 0 - 
100.  Interpretation of high scores is as below:   
 
A high score for a functional scale represents a high/healthy level of 
functioning 
A high score for the global health status/quality of life represents a 
high quality of life 
A high score for a symptom scale/item represents a high level of 
symptomatology/problems     
(Fayers et al.1999, p.7) 
 
The distribution of all the summated scales, which form part of the EORTC QLQ 
C30, at baseline for the nurse group (NG) and control group (CG), are shown in 
Table 5.19. The summated scales for post intervention scales are shown in Table 
5.20. The cognitive functioning scale (CF) at baseline is the only scale in which 
one could not assume equality of variances. 
 
Independent t-tests are used to determine if there is a significant difference in 
quality of life scores (EORTC QLQ C30) between the two groups at baseline. The 
results, as shown in Table 5.19 indicate that in the CG four symptom scales are 
higher compared to the NG.  These scores are for appetite loss (CG, M=14.20) 
compared to the NG (M=5.30), constipation, (CG, M=22.78) compared to NG (M 
= 12.12), diarrhoea (CG, M=25.49) compared to the NG (M=11.63), and financial 
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difficulties (CG, M=28.44) compared to the NG (M=13.18). However, none of 
these are statistically different between the groups’, appetite loss scores (two-
sample t-test, t (- 0.236) = 77, p= 0.48, constipation scores t (0.130) = 77, p = 
0.90, diarrhoea t (0.663) = 76, p=0.97, financial difficulties scores t (0.069) = 75, p 
= 0.95).   
 
Independent t-tests are used to determine if there is  a significant difference in 
quality of life between the two groups at the end of the trial, measured using the 
EORTC QLQ C30.  The results, as shown in Table 5.20 indicate that there are no 
significant differences in quality of life between the NG and CG at the end of the 
trial. The results however do indicate that there have been some changes in the 
scores either upwards (functional scales) or downwards (symptom scales).  
 
The distribution of the summated scales, which form part of the QLQ BR23, at 
baseline and post intervention for the nurse group (NG) and control group (CG), 
are shown in Table 5.21 and Table 5.22 respectively. BRB1 (body image) was the 
only scale on the QLQ BR23 one could not assume equality of variance at 
baseline. The results, as shown in Table 5.21 indicate that body image scores in 
the CG (M=69.76) are lower compared to the NG (M=81.35).  However, this is not 
a statistically significant difference between the groups at the end of the trial (two-
tailed t-test, t (- 1.755)=58.7, p=0.08).   
 
The results also indicate that breast symptom scores in the NG (breast 
symptoms, M=18.94) are higher compared to the CG (M = 14.05), as are arm 
symptom scores in the NG (arm symptoms, M= 23.48) compared to the CG 
(M=16.19).  However, this is not a statistical difference between the groups (two-
tailed t-test, t (1.394.) = 77, p=0.17, and arm symptoms scores t (1.471) = 77, 
p=0.15. 
 
Post intervention, independent t-tests were carried out across all the scales and 
presented in Table 5.22.  There is no significant difference in quality of life (BR 
23) between the CG and NG at the end of the trial.    
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Table 5.19: Summary means scores for the EORTC QLQ C30 at baseline 
 
 Scale 
No. of 
items 
Baseline – Nurse Baseline – Control p-value 
Global health status/QoL 
  
M SD Min Max M SD Min Max 
 
Global health status/QoL Ql2 2 70.70 19.87 16.67 100 69.3 25.06 0 100 0.78 
Functional scales            
Physical functioning PF2 5 79.55 16.79 33.33 100 81.71 19.02 6.67 100 0.59 
Role functioning RF2 2 82.95 26.53 0 100 80.00 26.13 0 100 0.62 
Emotional functioning EF 4 76.16 25.24 8.33 100 69.52 28.44 8.33 100 0.28 
Cognitive functioning CF 2 79.46 19.87 16.67 100 68.57 34.00 0 100 0.10 
Social functioning SF 2 84.11 21.81 33.33 100 80.88 25.99 0 100 0.57 
Symptom scales            
Fatigue FA 3 32.30 25.75 0 88.89 33.33 24.40 0 100 0.86 
Nausea and vomiting NV 2 3.79 8.70 0 33.33 11.83 11.83 0 50.00 0.68 
Pain PA 2 31.40 28.69 0 100 24.03 24.03 0 83.33 0.09 
Dyspnoea DY 1 18.94 25.31 0 66.67 21.91 21.91 0 66.67 0.50 
Insomnia SL 1 32.58 34.09 0 100 36.28 36.28 0 100 0.49 
Appetite loss AP 1 5.30 14.28 0 66.67 14.20 14.20 0 33.33 0.48 
Constipation CO 1 12.12 23.94 0 100 22.78 22.78 0 66.67 0.90 
Diarrhoea DI 1 11.63 19.08 0 66.67 25.49 25.49 0 100 0.97 
Financial difficulties FI 1 13.18 26.37 0 100 28.44 26.44 0 100 0.95 
* Denotes significance 
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Table 5.20: Summary mean scores for EORTC QLQ C30 post-intervention  
 
 Scale 
No. of 
items 
 Post-intervention – Nurse Post-intervention – Control p-value 
Global health 
status/QoL 
  M 
Change 
scores 
SD Min Max M 
Change 
scores 
SD Min Max  
Global health status/QoL Ql2 2 73.20 2.5 22.06 8.33 100 79.17 9.37 19.50 33.33 100 0.29 
Functional scales              
Physical functioning PF2 5 85.77 6.22 16.57 33.33 100 84.44 2.73 13.28 46.67 100 0.74 
Role functioning RF2 2 87.39 4.44 27.33 0 100 90.97 10.97 13.88 66.67 100 0.56 
Emotional functioning EF 4 77.03 0.87 22.77 0 100 80.43 10.91 19.88 16.67 100 0.56 
Cognitive functioning CF 2 83.33 3.87 20.41 0 100 80.56 11.99 20.67 33.33 100 0.61 
Social functioning SF 2 89.64 5.53 20.54 16.67 100 87.50 6.62 25.18 0 100 0.72 
Symptom scales              
Fatigue FA 3 21.32 -10.98 26.50 0 88.89 20.83 -12.50 17.43 0 55.56 0.94 
Nausea and vomiting NV 2 4.05 0.26 9.94 0 50 3.47 -8.36 8.48 0 33.33 0.81 
Pain PA 2 18.10 -13.3 21.53 0 83.33 24.60 +0.57 26.68 0 100 0.32 
Dyspnoea DY 1 9.91 -9.03 15.45 0 33.33 16.67 -5.24 26.00 0 100 0.21 
Insomnia SL 1 30.63 -1.95 29.79 0 100 27.78 -8.50 34.98 0 100 0.73 
Appetite loss AP 1 8.10 +2.8 19.88 0 100 8.33 -5.87 17.72 0 66.67 0.96 
Constipation CO 1 12.61 0.49 26.47 0 100 8.33 -14.45 17.72 0 66.67 0.49 
Diarrhoea DI 1 8.33 -3.3 18.47 0 66.67 5.56 -19.93 21.23 0 100 0.69 
Financial difficulties FI 1 9.00 -4.18 20.26 0 100 11.11 -17.33 25.38 0 100 0.72 
* Denotes significance 
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Table 5.21: Summary mean scores for the QLQ – BR23 at baseline  
 
 Scale 
No. of 
items 
Baseline – Nurse Baseline – Control p-value 
   M SD Min Max M SD Min Max  
Functional scales            
Body image BRBI 4 81.35 22.83 16.67 100 69.76 33.03 0 100 0.84 
Sexual functioning BRSEF 2 19.76 20.97 0 83.33 18.57 24.18 0 100 0.82 
Sexual enjoyment BRSEE 1 53.03 24.47 0 100 57.78 32.04 0 100 0.61 
Future perspective BRFU 1 56.81 30.14 0 100 55.24 34.25 0 100 0.83 
Symptom scales            
Systemic therapy 
side effects 
BRST 7 16.56 11.22 0 38.10 19.73 16.26 0 80.95 0.31 
Breast symptoms BRBS 4 18.94 15.08 0 66.67 14.05 16.01 0 75 0.17 
Arm symptoms BRAS 3 23.48 21.99 0 88.89 16.19 21.78 0 77.78 0.15 
Upset by hair loss BRHL 1 35.71 38.04 0 100 27.78 34.33 0 100 0.58 
Notes: * Denotes significance 
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Table 5.22: Summary mean scores for QLQ – BR23 post-intervention  
 
 
Scale 
No. of 
items 
Post intervention – Nurse Post intervention – Control 
p-
value 
   
n M 
Change 
in 
score 
SD Min Max n M 
Change 
in 
score 
SD Min Max 
 
Functional 
scales 
               
Body image BRBI 4 37 87.16 5.81 20.66 25.00 100 24 82.84 13.05 24.44 16.67 100 0.44 
Sexual 
functioning 
BRSEF 2 37 77.48 57.24 22.64 33.33 100 24 79.55 60.98 30.83 0 100 0.77 
Sexual enjoyment BRSEE 1 23 44.93 -8.1 29.49 0 100 10 53.78 -4.00 35.83 0 100 0.49 
Future 
perspective 
BRFU 1 37 63.06 1.7 29.17 0 100 24 55.56 0.32 30.56 0 100 0.34 
Symptom scales                
Systemic therapy 
side effects 
BRST 7 37 14.80 -1.76 12.74 0 47.62 24 13.10 -6.99 12.74 0 42.86 0.61 
Breast symptoms BRBS 4 37 11.81 -7.13 16.23 0 66.67 24 10.76 -3.29 13.57 0 50.00 0.80 
Arm symptoms BRAS 3 37 14.81 -8.67 18.01 0 88.89 24 17.13 -0.15 16.04 0 55.56 0.61 
Upset by hair loss BRHL 1 11 24.24 -11.47 39.70 0 100 8 41.67 +13.89 49.60 0 100 0.41 
Note: *Denotes significance 
 
Change scores for functional scales: a negative result indicates a lower level of functioning over time and a positive result an improvement 
Change scores for symptom scales: a negative result indicates a lower level of problems and a positive result a worsening of 
symptoms/problems 
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5.9.2 Changes in quality of life over time 
To aid the interpretation of quality of life scores, Fayers et al. (1999) recommend 
that comparisons are made with reference data. Although this was made 
available to the researcher, this data excluded participants who were “off 
treatment”:  those who had completed chemotherapy and radiotherapy.  As the 
present study specifically recruited women with breast cancer who had completed 
primary treatment, datasets were not comparable.  
 
Analyses were undertaken to determine if there was a significant difference 
between the mean value responses to the EORTC QLQ C30 and QLQ BR23 
before and after treatment (paired sample t-test) and then the differences 
between the groups compared. In addition, an alternative to interpreting whether 
the change in mean scores were clinically meaningful across any of the scales, a 
method described by Osaba et al. (2005), was used. They suggest that on a 
scale of 1-100 the mean changes required to constitute a clinically meaningful 
difference are: 5-10 equals little change; 10-20 moderate change; >20 a large 
change. The score at time 2 was subtracted from those at time 1 to give the mean 
change score.  
 
Using the scoring process above, the results, as shown in Table 5.20, indicate 
that all scores changed in the desired direction apart from appetite in the NG and 
pain in the CG.  Although most recorded little change, fatigue registered a 
moderate change in both the NG (-10.98) and the CG (-12.50), as did 
constipation (CG, -14.45), diarrhoea (CG, -19.93), financial difficulties (CG, -
17.33), and pain (NG, -13.3).  
 
The results, as shown in Table 5.20 indicate that there are some mixed results. 
There was a moderate improvement in body image in the CG (13.05) and a large 
improvement in sexual functioning across both groups. While a moderate 
improvement in symptoms associated with hair loss was noted in the NG (-11.47), 
a moderate worsening of symptoms was seen in the CG (+13.89). Further 
statistical tests were undertaken. 
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To assess if there is a statistically different change in the mean value responses 
across the EORTC QLQ C30 and QLQ BR23, analysis was conducted on 57 
participants to test the following hypothesis:  
 
H0 There is no significant difference in quality of life between beginning 
and end of trial for the control group. 
v 
H1 There is a significant difference in quality of life between beginning and 
end of trial for the intervention group. 
H0 There is a significant difference in quality of life between beginning and 
end of trial for the control group. 
v 
H1 There is a significant difference in quality of life between beginning and 
end of trial for the intervention group. 
 
The results, as shown in Tables 5.23 and Table 5.25 indicate that a number of 
sub scales on both the EORTC QLQ C30 and BR23 showed a significant 
difference in mean value responses over treatment period.  Results indicate that 
there was a significant difference between the mean value fatigue responses in 
both groups before (NG: M=31.43, SD=27.15; CG: M=32.32, SD=21.11) and after 
(NG: M=22.54, SD= 26.74, CG: M=20.71, SD=17.91) (paired t-test, NG, t = 
2.198, df = 34. p=0.035; CG, t = 3.352, df = 21. p=0.003). This was the only scale 
where both groups saw a significant change.  
The results, as shown in Table 5.23 indicate that a further three subscales 
(physical functioning, pain and social functioning) showed a significant difference 
in mean value responses before and after treatment in the NG compared to two 
subscales in the CG (role functioning and insomnia). An improvement in 
functional scales is an increase towards 100; an improvement in symptom scales 
is a decrease towards 0. 
Nurse Group: Results indicate that there is a significant difference between 
the mean value physical functioning responses before (M=80.19, SD=17.49) 
and after (M=85.37, SD=16.62) (paired t-test, t = -2.129, df = 34. p=0.040).    
Nurse Group: Results indicate that there is a significant difference between 
the mean value pain (symptom) responses before (M=28.79, SD=27.72) and 
after (M=18.18, SD=21.80) (paired t-test, t = 2.514, df = 34. p=0.017).    
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Nurse Group: Results indicate that there is a significant difference between 
the mean value social functioning responses before (M=81.90, SD = 22.28) 
and after (M= 89.05, SD=20.98) (paired t-test, t = -2.001, df = 34. p=0.053).    
Control Group: Results indicate that there is a significant difference between 
the mean value role functioning responses before (M = 81.06, SD = 23.73) 
and after (M= 91.67, SD = 13.36) (paired t-test, t = -2.388, df = 21. p=0.027).    
Control Group: Results indicate that there is a significant difference between 
the mean value insomnia (symptom) responses before (M = 37.88, SD = 
38.89) and after (M= 25.76, SD = 32.42) (paired t-test, t = 2.347, df = 21, 
p=0.029).    
These results both support and reject the null hypothesis. 
 
For the QLQ BR23, the results, as shown in Table 5.25  indicate that there is a 
significant difference between the mean value sexual functioning responses in 
both groups before (NG: M =17.59, SD = 19.08; CG: M = 17.50, SD = 25.06) and 
after (NG: 77.78, SD= 22.89, CG: 78.33, SD = 32.04) (paired t-test, NG, t = -
9.992, df = 35. p = <0.001; CG, t = -5.075, df = 19. p = <0.001). This is the only 
scale where both groups saw a significant change.  
They also indicate that there is a significant difference between the mean value 
breast symptom (symptom) responses in both groups before (NG: M = 18.10, SD 
= 14.07; CG: M = 16.67, SD = 17.06) and after (NG: 11.67, SD= 16.44, CG: 9.47, 
SD = 11.00) (paired t-test, NG, t = 1.961, df = 34. p = <0.058; CG, t = 2.610, df = 
21. p = <0.016). 
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Table 5.23: Mean differences over time for QLQ C30 scores by treatment group  
 
Paired Samples Test 
 
 
 
 
Group  Pairs 
Paired Differences  
 
t 
 
 
df 
 
 
Sig. 
(2-tail) 
 
 
 
M 
 
 
     
 
SD 
 
Std. Error  
 
Mean 
95% Confidence 
 Interval of the Difference 
Lower Upper 
Nurse 
P1 FI 5.71 28.57 4.83 -4.10 15.53 1.183 34 .245 
P2 PF -5.19 14.62 2.44 -10.13 -.24 -2.129 35 .040* 
P3 RF -4.17 29.65 4.94 -14.20 5.86 -.843 35 .405 
P 4 FA 8.89 23.92 4.04 .67 17.11 2.198 34 .035* 
P 5 NV -1.39 11.53 1.92 -5.29 2.51 -.723 35 .475 
P 6 PA 10.61 24.23 4.22 2.01 19.20 2.514 32 .017* 
P7 DY 6.48 23.66 3.94 -1.53 14.49 1.643 35 .109 
P 8 SL 2.78 31.24 5.21 -7.79 13.35 .533 35 .597 
P 9 AP -4.63 19.76 3.29 -11.32 2.06 -1.405 35 .169 
P10 CO -.93 25.80 4.30 -9.66 7.80 -.215 35 .831 
P 11 DI 1.96 21.62 3.71 -5.58 9.50 .529 33 .600 
P12 EF -.95 13.52 2.29 -5.60 3.69 -.417 34 .680 
P13 CF -4.76 17.42 2.94 -10.75 1.22 -1.617 34 .115 
P 14 SF -7.14 21.11 3.57 -14.40 .11 -2.001 34 .053* 
Control 
P1 FI 3.17 25.61 5.59 -8.48 14.83 .568 20 .576 
P 2 PF -2.73 9.12 1.94 -6.77 1.32 -1.402 21 .175 
P 3 RF -10.61 20.92 4.46 -19.88 -1.33 -2.378 21 .027* 
P 4 FA 11.62 16.26 3.47 4.41 18.82 3.352 21 .003* 
P 5 NV .76 14.06 3.00 -5.48 6.99 .253 21 .803 
P 6 PA -2.63 36.54 8.38 -20.24 14.98 -.314 18 .757 
P 7 DY -3.03 9.81 2.09 -7.38 1.32 -1.449 21 .162 
P 8 SL 12.12 24.22 5.16 1.38 22.86 2.347 21 .029* 
P 9 AP -1.52 7.11 1.52 -4.67 1.64 -1.000 21 .329 
P 10 CO 3.03 14.21 3.03 -3.27 9.33 1.000 21 .329 
P 11 DI -3.03 14.21 3.03 -9.33 3.27 -1.000 21 .329 
P12 EF -8.33 23.27 5.08 -18.93 2.26 -1.641 20 .116 
P13 CF -6.82 26.05 5.55 -18.37 4.73 -1.227 21 .233 
P14 SF -6.35 17.85 3.90 -14.48 1.78 -1.630 20 .119 
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To understand the extent of this improvement and whether there was a significant 
difference between the control and intervention groups, a regression approach 
was used.  This adjusted for any chance imbalance between groups in any of the 
outcome variables at baseline. This approach tested the following hypothesis:  
 
H0: There is no significant mean difference in EORTC subscale values 
between the nurse and control group at the end of the trial; 
v 
H1: There is a significant mean difference in EORTC subscale values 
between the nurse and control group at the end of the trial. 
 
Table 5.24: Linear regression: Association between EORTC QLQ-C30 subscale 
scores and treatment groups 
 
 
Score at time 1 
coefficient of 
group indicator 
EORTC  Scale β p value β p value 
Global health 
status/QoL 
Ql2 
 
0.723 <0.001 8.366 0.048* 
Functional scales   
 
   Physical functioning PF2 0.647 <0.001 -1.774 0.574 
Role functioning RF2 0.374 <0.001 5.307 0.364 
Emotional functioning EF 0.615 <0.001 6.494 0.109 
Cognitive functioning CF 0.503 <0.001 -0.470 0.922 
Social functioning SF 0.498 <0.001 0.721 0.88 
Symptom scales   
 
   Fatigue FA 0.588 <0.001 -2.359 0.647 
Nausea and vomiting NV 0.094 0.500 -1.232 0.634 
Pain PA 0.280 0.035 7.033 0.302 
Dyspnoea DY 0.530 <0.001 8.087 0.073 
Insomnia SL 0.551 <0.001 -7.302 0.266 
Appetite loss AP 0.892 <0.001 -2.86 0.522 
Constipation CO 0.570 <0.001 -3.920 0.467 
Diarrhoea DI 0.563  0.006 1.368 0.797 
Financial difficulties FI 0.261  0.006 -0.509 0.921 
 
*significant p=0.05 
** Group indicator=0 if control group; 1 if nurse group 
 
The results, as shown in Table 5.24 indicate that although the intervention 
improved EORTC subscale levels in the expected direction; this change is only 
statistically significant between the groups for global health status/QoL at the end 
of the trial.  This result indicates that there was an improvement in global health 
status for those participants in the nurse group (p=0.048)..  
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The results in Table 5.25 also indicate two further significant differences in the 
nurse group.    
Table 5.25: Mean differences over time for QLQ BR23 scores by treatment group 
Paired Samples Test 
 Paired Differences  
 
 
t 
 
 
 
    df 
 
 
 
Sig. 2-
tailed 
 
 
M 
 
 
SD 
 
 
SE Mean 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Nurse 
P1 BRBI -8.33 15.39 2.60 -13.62 -3.05 -3.203 34 .003* 
P2 BRSEF -60.19 36.14 6.02 -72.41 -47.96 -9.992 35 .000* 
P3 BRSEE -2.78 17.16 4.95 -13.68 8.13 -.561 11 .586 
P4 BRFU -7.41 32.96 5.49 -18.56 3.74 -1.348 35 .186 
P5 BRST .66 13.57 2.26 -3.93 5.25 .292 35 .772 
P6 BRBS 6.43 19.40 3.28 -.23 13.09 1.961 34 .058* 
P7 BRAS 7.62 25.10 4.24 -1.00 16.24 1.796 34 .081* 
P8 BRHL 26.67 64.12 28.67 -52.95 106.28 .930 4 .405 
Control 
P1 BRBI -8.71 24.05 5.13 -19.38 1.95 -1.699 21 .104 
P2 BRSEF -60.83 53.61 11.99 -85.92 -35.75 -5.075 19 .000* 
P3 BRSEE 13.33 18.26 8.16 -9.34 36.00 1.633 4 .178 
P4 BRFU -7.58 20.40 4.35 -16.62 1.47 -1.742 21 .096 
P5 BRST .87 8.77 1.87 -3.02 4.76 .463 21 .648 
P6 BRBS 7.20 12.93 2.76 1.46 12.93 2.610 21 .016* 
P7 BRAS 5.56 17.73 3.78 -2.31 13.42 1.469 21 .157 
P8 BRHL -11.11 17.21 7.03 -29.18 6.95 -1.581 5 .175 
*Denotes significance 
 
Results indicate that there is a significant difference between the mean value 
body image (function) responses before (M = 79.29, SD = 23.60) and after (M= 
87.62, SD=21.14) (paired t-test, t = -3.203, df = 34. p=0.003).  Results also 
indicate that the difference between the mean value arm symptoms responses 
before (M = 22.85, SD = 19.42) and after (M= 15.24, SD=18.09) (paired t-test, t = 
1.796, df = 34. p=0.081) failed to meet significance.  These support the 
alternative hypothesis. 
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To understand the extent of this improvement and whether there was a significant 
different between the control and intervention groups, a regression approach was 
used.  This adjusted for any chance imbalance between groups in any of the 
outcome variables at baseline. This approach tested the following hypothesis 
H0: There is no significant mean difference in quality of life values 
between the nurse and control group at the end of the trial; 
v 
H1: There is a significant mean difference in quality of values between the 
nurse and control group at the end of the trial. 
 
Table 5.26: Linear regression: Association between BR23 subscale scores and 
treatment groups 
 
 
Score at time 1 
coefficient of group indicator 
group 
EORTC BR23 Scale β p value β p value 
Functional scales   
 
   Body image BRBI 0.583 <0.001 -0.780 0.858 
Sexual functioning BRSEF 0.766 <0.001 0.485 0.934 
Sexual enjoyment BRSEF 1.266 <0.001 23.649 0.051 
Future perspective BRFU 0.487 <0.001 -1.126 0.864 
Symptom scales   
 
   Systemic therapy 
side effects 
BRST 
 
0.608 <0.001 -0.893 0.772 
Breast symptoms BRBS 0.322 0.011 -1.737 0.648 
Arm symptoms BRAS 0.258 0.017 0.843 0.851 
Upset by hair loss BRHL 0.630 0.092 32.432 0.265 
 
* Group indicator=0 if control group; 1 if nurse group 
 
The results, as shown in Table 5.26 indicate that although the intervention 
improved BR23 subscale levels in the expected direction; this change is not 
statistically significant between the groups at the end of the trial. 
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5.9.3 Summary of findings: Quality of life 
 The overall quality of life of the women was good at baseline 
 There is no significant differences in quality of life subscales between the 
groups at the onset or at the end of the trial   
 Clinically meaningful changes in quality of life, using Osaba’s approach,  are 
seen for fatigue (NG and CG), pain (NG), constipation, diarrhoea and 
financial difficulties (CG). 
 A number of quality-of-life scales significantly improved when measured at 
the beginning and end of the trial for both group: fatigue, sexual functioning 
and breast symptoms; the nurse group alone, physical functioning, pain, 
social functioning, body image and arm symptoms; control group alone, role 
functioning and insomnia.   
 There is a statistically significant difference between the groups for global 
health status/QoL at the end of the trial.   
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5.10 Regression analysis   
5.10.1 Introduction 
Previous research has indicated that anxiety and depression may predict some 
level of unmet need among cancer patients (McDowell et al. 2010), fatigue and 
pain post treatment predicts anxiety and depression (Vahdaninia, Omidvan & 
Montazeria, 2009), and quality of life variables such as body appearance, 
emotional status and fatigue predict anxiety and depression (Karakoyun-Celik et 
al. 2010).  In studies reporting all cancers together, demographic variables such 
as age, treatment received and time since diagnosis have also been suggested 
as predictors of unmet need (Sanson-Fisher et al. 2000).  However although 
these findings informed a series of regression analyses, these analyses were to 
determine if an association between the independent and dependent variables 
was evident.   
 
The following section reports of the procedure of which, if any, of the independent 
variables: age, treatment group, anxiety at time 1, severity of treatment, time 
since diagnosis, postcode, depression at time 1, needs at time 1 are associated 
with the dependent variable of needs, anxiety, depression, QLQ BR 23 (overall 
score and individual scales) and a number of EORTC QLQ C30 scales.  The 
procedure sought to test the following hypothesis:  
 
H0 There is no relationship between unmet needs and treatment group, or 
anxiety at time 1, or severity of treatment, or time since diagnosis, or 
postcode, or depression at time 1, or quality of life variables; 
v 
H1There is a relationship between unmet needs and treatment group, or 
anxiety at time 1, and severity of treatment, or time since diagnosis, or 
postcode, or depression at time 1 or quality of life variables. 
 
Prior to beginning the regression analysis, the SIMD (postcode) variable, was 
recoded into a dichotomised outcome: either, a participant fell within the most 
deprived ranked 30% of the Scottish population (score=1) or not (score=0).  The 
rationale for doing this is based on previous research which has suggested breast 
cancer patients in the most deprived group have poorer survival outcomes than 
those less deprived.  Understanding if there is an association between unmet 
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need, anxiety, depression, quality of life and being in the deprived ranked 30% is 
useful to clinicians in providing appropriate support to this group of women. 
 
A backward stepwise approach was used for all regression models.  It was 
chosen because unlike forward selection, it was less likely to exclude variables 
involved in suppressor effects and thus reduce the risk of making a type 11 error 
(missing a variable that is associated with the outcome). 
 
5.10.2 Unmet needs outcomes 
Standard multiple ordinary least squares regression was conducted to determine 
the accuracy of the independent variables (treatment group, age, SIMD, time 
since diagnosis, anxiety at time 1, severity of treatment, , depression at time 1 
and needs at time 1 in their association with the dependent variable, needs at 
time 2. In the first model, the independent variables were entered simultaneously 
as a block and a summary of regression coefficients is presented in Table 5.27.  
The overall model (model 1) accounts for 39% of overall variance in needs 
scores, (adjusted R2 = 0.386; F 5,48 = p <0.001).  Once all the variables are 
excluded only depression at time 1 significantly contributed to the model 
(p=0.005) and anxiety at time 1 just failed to meet significance (p=0.074). This 
result indicates that having depression at time 1 is associated with having unmet 
needs among women attending breast cancer follow-up.   
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Table 5.27: Summary of regression coefficients for variables associated with 
BCNQ (n=55) 
    
Model 1:BCNQ 
      
Model 2:BCNQ 
    
Independent 
variable 
B SE B β p value B SE B β p value 
Constant 2.900 4.104 
 
0.483 -0.852 1.043 
 
0.418 
Age 0.047 0.059 .087 0.433 
    
Severity  -0.64 0.288 .024 0.825 
    
SIMD  0.998 1.454 .077 0.496 
    
Anxiety t1 0.298 0.209 .25 0.16 0.328 0.180 .276 0.074 
Depression 
t1 
0.724 0.277 .464 0.009 0.728 0.246 .448 0.005 
TSD 0.012 0.035 .039 0.732 
    
Treatment 
group 
0.379 1.278 .033 0.768 
    
Need t1 0.033 0.087 .054 0.702 
    
R2 0.474 0.461 
Notes: * p < 0.05, ** p< 0.01, *** p<0.001 
5.10.3 Anxiety outcome  
Following the outcome in Section 5.10.2, a further model was developed.  It was 
conducted to assess the association of the independent variables: age, severity, 
SIMD, anxiety (time 1), depression (time1), time since diagnosis, treatment group, 
needs (time 1) and their association with anxiety at time 2 (dependent variable).  
In the first model, the independent variables were entered simultaneously as a 
block and a summary of regression co-efficient is presented in Table 5.28.  The 
overall model (model 1) accounts for 61% of overall variance in anxiety scores, 
adjusted R2 = 0.614; F 8,47 = p <0.001.   When severity was removed, R
2 = 0.396; 
F 7,48, =  p 0.825, when treatment group was removed,  R
2
 = 0.409; F6,49 =  p 
0.757, when time since diagnosis was removed, adjusted R2 = 0.420; F 5,50 , = p 
0.745, when needs t1 was removed, R2 = 0.429; F4,51, = p 0.688), and when 
SIMD was removed, R2 = 0.435; F3,52 = p 0. 471) and when age was removed, R
2 
= 0.441; F2,53 = p 0.506.   A summary of regression coefficients is presented in 
Table 5.28. Once all the variables are excluded only anxiety at time 1 significantly 
contributed to the model (p=<0.001).  The results indicate that higher anxiety at 
time 1 is associated with higher anxiety at later date. 
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Table 5.28: Summary of regression coefficients for variables associated with 
anxiety (n=57) 
  
  
Model 1: Anxiety t2 
  
  
Model 2: Anxiety t2 
  
Independent 
variable 
B SE B β p value B SE B β p value 
Constant -0.344 2.702 
 
0.899 0.184 0.662 
 
0.782 
Age 0.020 0.039 .045 0.61 
    
Severity -0.007 0.182 -.003 0.971 
    
SIMD -0.360 0.934 -.035 0.701 
    
Anxiety t1 0.62 0.133 .652 <0.001* 0.764 0.077 .804 <0.001* 
Depression 
t1 
0.192 0.179 .147 0.289 
    
TSD -0.005 0.023 -.021 0.819 
    
Treatment 
group 
-0.288 0.815 -.029 0.744 
    
Need t1 0.047 0.054 .095 0.395 
    
R2 0.671 0.647 
Notes: * p < 0.05, ** p< 0.01, *** p<0.001 
5.10.4 Depression outcome 
Based on results in Section 5.10.2 whereby depression was significant in the 
model, the depression score at time 2 became the dependent variable  
 
This regression model was constructed to assess the association of the 
independent variables anxiety at time 1, treatment group, and severity of 
treatment, age, and time since diagnosis, SIMD and needs at time 1 and their 
association with having depression at time 2. All variables were entered into the 
model and removed one at a time based upon a level of significance for removal 
(p>0.10). When all variables were entered, the R2 value account for a variance of 
57% (adjusted R2 = 0.569; F8,48 =  p <0.001 ).  When SIMD was removed, R
2 = 
0.578; F 7, 49, = p 0.948, when severity was removed, R
2
 = 0.587; F6,50 =  p 0.941, 
when needs t1 was removed, adjusted R2 = 0.593; F 5,51 , = p 0.688, when age 
was removed, R2 = 0.596; F4,52, = p 0.434), and when time since diagnosis was 
removed, R2 = 0.592; F3,53 = p 0. 212) and when treatment group was removed, 
R2 = 0.586; F2,54 = p 0.194.  A summary of regression coefficients is presented in 
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Table 5.29.  The results indicate that depression and anxiety at time 1 are 
associated with changes in depression scores at time 2.  However, having 
depression is twice as likely as anxiety to affect depression scores.   
 
Table 5.29: Summary of regression coefficients for variables associated with 
depression (n=57) 
    
Model 1 
Depression t2 
      
Model 2 
Depression t2 
    
Independent 
variable 
B SE B β p value B SE B β p value 
Constant 0.668 1.972 
 
0.729 0.341 0.509 
 
0.506 
Age 0.021 0.028 .067 0.471 
    
Severity 0.010 0.137 .006 0.943 
    
Dichotomous 
SIMD 
0.046 0.697 .006 0.948 
    
Anxiety t1 0.177 0.100 .258 0.084 0.202 0.089 .283 0.027 
Depression 
t1 
0.568 0.133 .607 <0.001 0.496 0.121 .530 <0.001 
TSD 0.019 0.017 .105 0.269 
    
Treatment 
group 
0.984 0.612 -.148 0.114 
    
Need t1 0.016 0.041 -.046 0.692 
    
R2 0.631 0.601 
Notes: * p < 0.05, ** p< 0.01, *** p<0.001 
5.10.5 Summary of findings: Unmet needs, anxiety and depression 
 Being in the intervention group was not associated with unmet need, 
anxiety or depression. 
 A higher level of depression at baseline was found to be associated with 
being anxious at baseline; the more depressed a woman was, the more 
anxiety they had at baseline. 
 Age, time since diagnosis, SIMD, and severity of treatment are not 
associated with changes in unmet needs, anxiety or depression.
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5.10.6 Quality of life outcomes 
The secondary outcome was changes in quality of life.  Based on data in the 
previous sections and studies suggesting fatigue and pain may be associated 
strongly with quality of life variables, a regression model was constructed using a 
backward stepwise approach to assess the association of the independent 
variables anxiety at time 1, depression at time 1, fatigue, and pain and treatment 
group, age, needs at time 1, time since diagnosis, SIMD, severity of treatment 
and BR23 total scores at time 2 (dependent variable).  The regression analysis 
sought to test the following hypothesis:  
 
 
H0There is no relationship between quality of life variables and level of 
unmet needs, or treatment group, or anxiety at time 1, or severity of 
treatment, or time since diagnosis, or postcode, or depression at time 1; 
v 
H1There is a relationship between level of unmet needs and treatment 
group, or anxiety at time 1, and severity of treatment, or time since 
diagnosis, or postcode, or depression at time 1. 
 
Regression results indicated that the overall model was found to be associated 
with changes in BR23 total scores.  When all variables were entered, the R2 value 
accounted for a variance of 41%, adjusted R2 = 0.424; F9,47  = p<0.001, when 
anxiety at time 1 was removed,  R2 = 0.436; F8,48 = p 0.997, when SIMD was  
removed, R2 = 0.447; F7,49  = p 0.849, when time since diagnosis was removed, 
R2 = 0.458; F6,50 = 0.834, when needs at time 1 was removed, R
2 = 0.465; F5,51 = 
p 0.603, when severity was removed, R2= 0.470; F4,52 = p 0.450, when treatment 
group was removed R2= 0.466; F3,53 = p0.253. A summary of regression 
coefficients is presented in Table 5.30 and indicates that only depression 
(p=<0.001) and age (p=0.012) significantly contributed to the model. The result 
suggests that having depression at time 1 and being younger is associated with 
changes in overall BR23 scores. 
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Table 5.30: Summary of regression coefficients for variables associated with 
BR23 (n=57) 
 
 
Model 1: BR23 Model 2: BR23 
Independent 
variable B SE B β p value B SE B β 
p 
value 
Constant 2.903 1.668 
 
0.88 2.768 1.274 
 
0.034 
SIMD -0.111 0.594 -.02 0.853 
    Severity 0.085 0.116 .737 0.465 
    
Treatment 
group -0.634 0.519 -.131 0.227 
    Age -0.041 0.024 -.182 0.092 -0.046 0.022 .206 0.040 
TSD 0.003 0.015 .022 0.849 
    Anxiety t1 0.000 0.086 -.001 0.997 
    
depression t1 0.357 0.112 .524 0.002 0.329 0.073 .483 <0.001 
needs t1 -0.017 0.037 -.067 0.646 
    BR23 t1 0.257 0.111 .307 0.026 0.234 0.090 .280 0.012 
         R2 0.517 0.495 
 
Notes: * p < 0.05, ** p< 0.01, *** p<0.001 
Further multiple separate regression models were constructed to assess the 
association of the independent variables anxiety at time 1, treatment group, 
severity of treatment, age, time since diagnosis, SIMD and needs at time 1, and 
their association with changes in the scores on the QLQ BR23 (total scores) and 
individual subscales (body image, sexual functioning, sexual enjoyment, future 
perspectives, systemic therapy side effects, breast symptoms, arm symptoms 
and hair loss), and some of the EORTC QLQ C30 subscales (physical, role, 
emotional, cognitive and social functioning; fatigue and pain). A summary of 
regression coefficients that were significant is presented in Table 5.31. 
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Table 5.31: Summary of regression coefficients for variables associated with emotional functioning, fatigue and sexual 
functioning (n=57) 
  
Model 1 
Emotional Functioning (n=55) 
Model 2 
Fatigue (n=56) 
Model 3 
Sexual Functioning (n=55) 
Predictor  B SE B β p value B SE B β p value B SE B β p value 
Constant 52.768 11.471 
 
<0.001 -25.093 12.252 
 
0.039 89.119 6.048 
 
<0.001 
SIMD 
   
 
       
 
Age 
    
0.475 0.210 .215 0.028 
   
 
Needs t1 
   
     
-0.889 0.363 -.312 0.018 
Treatment group 8.996 3.626 .213 0.016 
       
 
Depression t1 -2.519 0.830 -.419 0.004 2.983 0.819 .442 0.001 
   
 
Anxiety t1 
   
     
1.551 0.715 .275 0.035 
TSD 
   
 
    
    
Severity 
   
 
       
 
EF t1 0.309 0.108 .394 0.006 
       
 
Fatigue t1 
   
  0.346 0.114 .371 0.004 
   
 
BRSEF t1                 -0.767 0.131 -.622 <0.001 
R2 0.628 0.543 0.451 
 
Notes: * p < 0.05, ** p< 0.01, *** p<0.001 
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Model 1: Emotional Functioning 
The first model examined the association of the independent variables EF at time 
1, anxiety at time 1, treatment group, severity of treatment, age, time since 
diagnosis, SIMD, needs at time 1 and EF at time 2.  Regression results, indicate 
that the overall model is able to explain emotional functioning scores, R2 = 0.628; 
F 3,51 = 28.653, p <0.001.  This model accounts for 56% of variance in emotional 
functioning scores.  A summary of regression coefficients is presented in Table 
5.31 and indicates that the most important independent variable contributing to 
the model is depression (p=0.004), followed by emotional functioning scores at 
baseline (p=0.006) and then treatment group (p=0.016). The results indicate all 
three are associated with changes in emotional functioning scores.  In addition 
being in the nurse group is positively associated with changes in emotional 
functioning scores.  
 
Model 2: Fatigue 
The second model examined the association of the independent variables anxiety 
at time 1, treatment group, severity of treatment, age, and time since diagnosis, 
SIMD, fatigue at time 1, needs at time 1 and fatigue scores at time 2.  Regression 
results indicate that the overall model is able to explain changes in fatigue scores, 
R2 = 0.543 F 3,52  = 20.572, p <0.001.  This model accounts for 54% of the 
variance in fatigue scores.  A summary of regression coefficients is presented in 
table 5.31 and indicates two of the seven variables significantly contributed to the 
model (depression p=0.001, age p= <0.001, time since diagnosis p=0.027).  
Depression, age and time since diagnosis are associated with change in fatigue 
scores. 
 
Model 3: Sexual Functioning 
The third model examined the association of the independent variables anxiety at 
time 1, treatment group, severity of treatment, age, time since diagnosis; 
postcode, sexual functioning at time 1 and needs at time 1 and sexual functioning 
at time 2.  Regression results indicate that the overall model predicts sexual 
functioning, R2 = 0.451. F 3,51 = 13.967; p= <0.001.  This model accounts for 45% 
of the variance in sexual functioning.  A summary of regression coefficients is 
presented in Table 5.31 and indicates that the most important independent 
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variable contributing to the model is sexual functioning score at baseline 
(p=<0.001), needs at baseline (p=0.018 and anxiety (p=0.035). The results 
indicate that having a higher score of sexual functioning was associated with 
higher baseline scores.   
 
5.10.7 Summary of findings: Quality of life 
 A depression score at baseline is associated with changes in QLQ BR23  
scores 
 The age of a woman, depression scores at baseline and the time since 
diagnosis are associated with changes in fatigue scores. 
 Emotional functioning scores at baseline, depression and treatment group 
are associated with changes in emotional functioning. 
 Sexual functioning scores at baseline, needs and anxiety are associated 
with changes in sexual functioning. 
 The intervention was associated with changes in emotional functioning. 
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5.11 Summary of quantitative findings 
This chapter has presented the findings of both descriptive and inferential 
statistics to investigate the primary outcome, changes in unmet need between 
baseline and the end of the trial, the secondary outcome, changes in quality of life 
baseline and the end of the trial, and the relationship of a number of variables in 
predicting changes in unmet need, anxiety, depression and quality of life 
domains.   
 
The demographic and clinical characteristics of the breast cancer participants in 
the present study were similar at baseline, with no significant differences between 
the two groups. The diversity of participants’ age, breast cancer characteristics 
and treatment are reflective of the spectrum of breast cancers seen and managed 
within breast cancer services, and illustrated in Chapter 2. Although the groups 
did not differ, there were higher deprivation scores among the overall sample 
compared to the Scottish average. This can partly be explained by the 
geographical area the study was in, but this will be discussed further in the 
following chapter. 
 
The participants reported unmet needs, anxiety and depression which were high 
in both groups at baseline. Although there are no significant differences between 
the groups for changes in any of the measurements over time, there is a 
statistically significant decrease in the mean needs, anxiety and depression 
scores within both groups, between baseline and the end of the trial. These 
significant decreases within groups could be seen as a positive outcome, 
although caution with this interpretation is required.   
 
The quality of life of participants is high at baseline and therefore any changes 
that occurred at the end of the trial are small. There are significant differences 
when measured at the beginning and end of the trial for both groups in relation to: 
fatigue, sexual functioning and breast symptoms; the nurse group alone for, 
physical functioning, pain, social functioning, body image and arm symptoms; and 
the control group alone for role functioning and insomnia. These differed to the 
clinically meaningful changes in quality of life, using Osaba’s approach: fatigue 
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(NG and CG), pain (NG), constipation, diarrhoea and financial difficulties (CG).  
The overall quality of life score showed a statistically significant difference at the 
end of the trial but no other scores on the EORTC QLQ BR23 and QLQ BR23 
showed a significant different between groups at the end of the trial. 
 
Finally, a series of regression analyses sought to determine which, if any, of the 
independent variables anxiety at time 1, treatment group, severity of treatment, 
age, time since diagnosis, postcode and needs at time 1 could explain unmet 
need, anxiety or depression, QLQ BR23 (subscales: body image, sexual 
functioning, sexual enjoyment, future perspectives, systemic therapy side effects, 
breast symptoms, arm symptoms and hair loss), and some of the EORTC QLQ 
C30 subscales (physical, role, emotional, cognitive and social functioning, fatigue 
and pain). 
 
Regression results indicate that depression and anxiety are significantly 
associated with unmet needs; having depression at baseline was strongly 
associated with anxiety, depression at baseline was significantly associated with 
poorer levels on the QLQ BR23, younger age. Time since diagnosis was 
significantly associated with higher levels of fatigue, unmet needs at baseline are 
associated with poorer emotional functioning, and lower socioeconomic status 
and younger age are significantly associated with poorer sexual functioning. 
 
In summary, these findings suggest that the intervention was as effective as 
standard follow-up care in reducing cancer needs, anxiety and depression, and 
improving quality of life between baseline and post intervention.  Regression 
analysis revealed that having anxiety and depression are independently 
associated with unmet needs, and a number of quality of life independent 
variables.    
5.12 Qualitative data  
The primary outcome of this study was a change in needs from baseline to time 
2.  The key components of the intervention required the SBCN to interpret the 
needs; anxiety and depression scores self-reported by the women and use these 
and the wishes of the women to guide the consultation. The initial guide 
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developed following the pilot work about responding to the BCNQ was used as 
part of the training plus the protocol for scoring and managing the HADS.  
However, the flexibility of the intervention was a key factor, placing a greater 
emphasis on the woman’s perspective of their well-being rather than the 
professional perspective.  It also required the SBCN to use her clinical judgement 
and the patient to follow through recommendations. 
 
The SBCN kept a record of the needs she discussed with the participants in the 
intervention group.  Although the provision of this data is perhaps not usual, in 
this thesis it is entirely appropriate as this conversation provided the context in 
which actions were agreed and the complex intervention delivered.  Many of 
these needs were raised by multiple participants and from the nurse’s records, 
some areas associated with mood, self-esteem, body image and menopausal 
symptoms continued to require support at time 2. The Wordle™ below illustrates 
the issues discussed between the patients and the SCBN at the clinic.  The size 
of the Wordle denotes the frequency that the word was used with the SBCN’s 
notes. 
 
 
  
Figure 5.6: Key areas addressed through the person-centred conversation 
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It was unclear from the nurses notes if there was a relationship between the 
symptoms discussed and her actions in response to the needs identified.  Corter 
et al. (2013) have suggested that an association exists between illness 
perceptions, side effects and fear of recurrence.  It may explain why symptoms 
appeared so prominently in the Wordle when fear of recurrence was expressed 
as a high need among the participants. 
 
In conclusion, the results of this present study have shown that using patient 
reported needs and psychological information by the SBCN in the follow-up clinic 
to inform an intervention proved to be no better, rather equally effective as 
standard follow-up care. The next chapter will explain and interpret these findings 
further, how they inform clinical practice in this area, and situate and compare 
these results with other work in this field. 
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Chapter 6: Discussion and interpretation of 
results 
6.1 Introduction 
The present study was designed to determine the effectiveness of a different way 
of delivering follow up care by the SBCN, which sought to target support to 
women in response to their self-reported needs and psychosocial information 
compared to follow-up care delivered by medical staff in the NHS. This chapter 
will begin with a brief summary of the research and the main findings. The design 
and sample characteristics will then be reviewed and the hypotheses considered 
in more detail. The ethical and clinical implications of the study will be discussed 
and finally, the main strengths and weaknesses of the present study will be 
discussed and recommendations for future work. 
6.2 Summary of contextual background to the study 
Results from an extensive review of the literature demonstrated that there had 
been few RCTs which had used PROMs such as needs assessment and 
psychological information to guide care.  Follow-up is an integral part of the 
pathway of care for women diagnosed with breast cancer.  While the literature 
indicated that unmet needs post-treatment were expressed in relation to fears of 
recurrence, fertility or menopausal issues, treatment side effects, the impact of 
hereditary factors, sexuality and relationships, lymphoedema and the impact on 
self, the assessment of these, and interventions to address them within a follow-
up setting is underpinned by limited evidence. Evidence from studies in the field 
of breast cancer illustrated that measuring unmet needs in a consistent and 
systematic manner in a clinic setting is an infrequent event, with few studies 
having used this approach.  
Whilst no studies to date have examined the effectiveness of this approach 
specifically in a breast cancer follow-up clinic in the hospital, some have reported 
findings among other breast cancer populations that indicate the feasibility of this 
approach (Boyes et al. 2006; Aranda et al. 2006). Indeed, patients appeared at 
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ease completing these questionnaires and the results provided the HCP an 
opportunity to use the information to guide care.  If, by using PROMs by SBCNs 
in the follow-up setting reduces cancer needs and improves quality of life, it may 
be considered an effective intervention in the management of these women in this 
setting. In order to investigate the effectiveness of introducing this new model, a 
RCT was chosen as the most appropriate method.   
6.3 Summary of the results from the current study 
The study results showed that the effectiveness of using patient-reported data to 
inform the SBCN’s provision of supportive care at follow-up to reduce needs, 
anxiety and depression was not proved to be better than standard care, nor was 
there sufficient evidence to suggest it was any worse. Global health status/QoL 
showed significant differences between groups.  However, all the other outcome 
measurements, showed no significant differences between the groups in the 
present study.  Although there were no significant differences between the 
groups, there were statistically significant changes over time within groups for 
needs, anxiety, depression and quality of life, and some clinically meaningful 
changes observed. Regression analysis revealed that having higher levels of 
depression at baseline was found to be associated with anxiety at baseline; the 
more depressed a woman was, the more anxiety she had at baseline. 
In addition, depression at baseline is associated with poorer scores on the QLQ 
BR23: the age of a woman and the time since diagnosis is associated with 
changes in levels of fatigue; unmet needs at baseline are associated with 
changes in sexual functioning and the intervention was associated with changes 
in emotional functioning. 
The present study confirms previous findings that women breast cancer treatment 
experience unmet needs months and indeed years following their diagnosis.  It 
contributes additional evidence about how unmet needs can be assessed within a 
follow-up clinic and the information used to guide the consultation. Although the 
current study is based on a small sample of participants, the findings suggest that 
PROMs can be integrated successfully into a follow-up clinic and the evidence 
emerging of associations between needs, anxiety and depression will serve as 
the basis for future studies in this area.  The study will also inform the National 
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Survivorship Initiative (2014) and go some way to addressing the gaps in breast 
cancer research identified by Eccles et al. (2013). 
6.4 Hypothesis 
Returning to the hypothesis posed at the beginning of this study:  
H0 Women with breast cancer attending follow-up receiving the intervention 
show no significant difference unmet needs and quality of life than those 
receiving standard follow-up care 
 
H1 Women with breast cancer attending follow-up receiving the intervention 
show significant difference in unmet needs and improvement in quality of 
life than those receiving standard follow-up care. 
 
It is now possible to state that the intervention improved global health status but it 
was as effective, and certainly no worse than standard follow-up care, in reducing 
unmet needs, anxiety and depression, and improving quality of life. The results do 
not support the null hypothesis.  Anthony (1999) suggests that in all areas of 
scientific enquiry equivalent results are as important as positive ones. The 
interpretation therefore of the results will consider possible explanations for the 
results presented in Chapter 5 incorporating its main strengths and limitations. 
6.5 Discussion of key results 
One of the first aspects in the design of this study concerned the measurement of 
unmet need and psychological status in this particular population. As discussed in 
Section 4.6.1, this provided the basis from which the person-centred conversation 
occurred and the intervention delivered.   
 
The BCNQ was used as it specifically asked questions of relevance to women 
with breast cancer (Chapters 2 and 3) and initial factor analysis indicated good 
validity and reliability (Thewes, 2000). Due to the limited use of the BCNQ in 
previous research, exploratory factor analysis was undertaken again in the 
preliminary analysis stage. The results indicated very good reliability across all 
scales except sexuality, which was good. Overall the data suggested the BCNQ 
183 
 
can be used as a reliable and valid measure to assess unmet needs in woman 
post-treatment attending follow-up clinics. In addition, the tool was able to 
distinguish between women with unmet needs and those with no need for 
support. This is crucial in the applicability to everyday practice as the detection of 
problems is the first step towards a positive outcome and the benefits of 
introducing them routinely. 
 
The present study included participants across a wide range of ages (21-76), 
disease and treatment characteristics (Tables 5.3 and 5.4). This reflects the age 
range seen among breast cancer generally. The non- completers were not 
statistically different to those who completed, and therefore the researcher 
concluded that age, deprivation level or time since diagnosis did not appear to 
adversely affect attrition although may have affected recruitment. Overall 
deprivation scores were higher than the Scottish average in breast cancer, but 
only slightly above the UK average. Women with lower socio-economic factors 
are known to be under-represented in cancer trials (Dellson et al. 2011), however 
there is no evidence this affected attrition or indeed recruitment in this trial.   
 
Initial analyses of the mean needs scores of participants in both groups included 
all scores (1 - 5), and all subscales. Differences between groups in mean scores 
of needs were not significant at the start or end of the trial, and scores were 
normally distributed across each subscale and between each group.  The mean 
scores ranged from 1.7 - 2.35 (range 1-5) and suggested that needs were not 
particularly high in both groups, which did not concur with previous studies that 
had measured unmet need among this population  (Beaver et al. 2006; de Bock 
et al. 2004; Raupach & Hiller, 2002; Girgis et al. 2000). However, when overall 
scores were analysed further; either having a need or having no need, the data 
revealed a different picture. The results indicated that the proportion of women 
expressing a need for support was 77.8% (n=34) (NG) and 78.9 (n=29) (CG) at 
baseline and at the end of the trial 58.3% (n=21) (NG) and 66.7% (n=15) (CG).  
 
Although participants were at different time points since diagnosis, the results 
indicate that many women still require support across many areas as they attend 
follow-up care.  The fall in the proportion of needs reported in both groups 
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represented a significant improvement and suggested the BCNQ was sufficiently 
sensitive to capture changes over time. However, in the absence of published 
clinical guidelines regarding the clinical significance of the improvements seen, or 
indeed the magnitude of change required to be clinically meaningful, one can only 
speculate on the causes of these improvements based on statistical significance. 
 
The same pattern of improvements in both groups was observed for anxiety and 
depression using the HADS.  However, again there was no statistical difference 
between the groups at the end of the trial. A number of studies have suggested 
that a high score on the HADS indicates high psychological need among breast 
cancer survivors (Carroll et al. 1993; Karakoyun-Celik et al. 2010; McDowell et al. 
2010).  The results showed that using this scale, psychological needs, and 
specifically anxiety levels was more prevalent than depression among the sample 
and clinically high at baseline. These are in line with other studies that have used 
the HADS among breast cancer survivors (Osborne et al. 2004; Boyes et al. 
2006), although levels in the study by de Bock et al. (2004b) were lower. One 
possible explanation for the high levels of anxiety at baseline may be due to the 
timing of the questionnaires, close to the clinic appointment and a time, known to 
be when women feel anxious in anticipation of the outcomes of the clinic. 
(Montgomery et al. 2007).   
 
The improvements over time in both groups were clinically significant and this 
pattern of improvement does not reflect other RCTs which have measured 
psychological morbidity in this population over time. Sheppard et al. (2009) 
reported no benefit following clinical review for women two years or more post 
diagnosis and Beaver et al. (2009) reported mean scores in their groups did not 
improve over time in either the hospital or telephone based follow-up groups. One 
explanation for the results is that the HADS is more sensitive to change in this 
population than the tools used in the other studies: general health questionnaire 
and the STAI. It may also suggest the skills of the practitioner may be critical in 
their ability to influence psychological morbidity. 
 
Overall, the findings did not support the primary hypotheses that there would be a 
significant difference between the groups in unmet needs from baseline. There 
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are a number of possible explanations for this.  First, the sample size was not 
sufficiently large to detect differences between the two groups and discussion 
related to this will be explored in more depth within methodological limitations. 
Second, it may be that the intervention was not sufficiently different or intense 
compared to standard care to achieve a greater change. 
 
The results indicated that needs were similar and changed over time in both 
groups. Systematically assessing needs revealed the most important ones 
expressed in both groups using the BCNQ as being: fears about the cancer 
spreading or returning; lack of energy; pain in the breast and surrounding area; 
receiving information on causes; triggers and latest developments in breast 
cancer; sexuality and sexual relationships; appearance; hereditary risks and the 
requirement to receive age specific information. These findings extend knowledge 
gained from previous studies.  Interestingly, the top 10 needs expressed in this 
study were the same apart from one question to those reported by Thewes (2000) 
during the development of the questionnaire, some 14 years earlier. The 
question, dealing with menopausal symptoms, was not ranked highly as an 
expressed need in this study in either group. This is perhaps a little surprising 
considering previous research in this area which suggests women are 
experiencing menopausal symptoms which impact on their quality of life (Fenlon, 
Corner & Haviland, 2009; Cruickshank & Hume, 2014). 
 
One explanation may be that in recent years there is an increased awareness 
among HCPs of the high possibility of symptoms occurring post chemotherapy or 
while taking endocrine therapies, and this has led to better information and 
support. Another explanation is that there is more detailed guidance available 
about interventions to reduce symptoms, the overall management has improved. 
Alternatively, when faced with 40 different questions, women ranked other areas 
as more important than dealing with menopausal symptoms at this time, reflecting 
the broader context of supportive care described by Fitch, Porter & Page (2009). 
From a clinical perspective, these results are important as they help services 
understand about where future intervention strategies may be required. These 
results suggest an increased focus may be required on strategies to manage fear, 
anxiety, fatigue; pain and sexuality post-treatment. 
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Using the information of participant’s specific needs, the SBCN tailored the 
intervention, providing a person-centred approach to care. However, the results 
imply that the intervention was as effective as, and certainly no worse than 
standard follow-up care.  Although previous research about hospital-based follow-
up has suggested that its primary focus is detecting recurrence rather than the 
psycho-social needs of women (Raupach & Hiller, 2002; de Bock et al. 2004a; 
Beaver et al. 2006), the results do not support this conclusion when using the 
current measures in this study. It is possible that the current standard care, in this 
study delivered by senior doctors, shares common goals in achieving a person-
centred approach to care and already adequately addresses patients’ needs and 
psychological distress. Person-centred care is care which is responsive to 
individual preferences, needs and values and assures that patient values guide 
all clinical decisions (NHS Education for Scotland, 2014).  It is unlikely that the 
doctors undertaking standard care did not address some, if not all, of the  
needs expressed by women in their clinic, minimising the effect of the    
intervention. It is important to recognise that not all follow-up care in the hospital is 
delivered by senior doctors; indeed junior doctors frequently undertake this care.  
Therefore changes between the groups may have differed if the doctors were less 
experienced in the field.   
 
However it is also possible that the completion of the questionnaires by women in 
the control group immediately prior to the clinic acted as a reminder for women to 
raise concerns with the doctor. One cannot also preclude that women 
spontaneously volunteered information about their unmet needs and 
psychological state because they felt comfortable seeing the senior doctor. 
 
Although average anxiety and depression scores improved over time, the 
analysis revealed that a subgroup of patients maintained high levels of anxiety at 
the end of the trial. This finding corroborates with other studies that have 
measured anxiety and depression levels using the HADS among breast cancer 
survivors (Millar et al. 2005; Vahdaninia, Omidvari & Montazeria, 2010). On the 
BCNQ women expressed high needs associated with the fear of recurrence 
which may cause an element of anxiety  Without previous knowledge of an 
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individual’s psychological state it is difficult to draw any definitive conclusions. 
However, one explanation may be that the uncertainty and fear that is associated 
with a breast cancer diagnosis is expressed as an unmet need through the BCNQ 
or HADS, and it is possible that no intervention would be able to adequately 
address this fear. Reassurance may be effective at the time of the clinic but may 
not be sustained over time for some women. It is also possible that high levels of 
anxiety are an obstacle to women responding to the information and interventions 
offered, requiring perhaps a different approach to providing support or a further 
consultation to clarify the nature of this need. The results together support a role 
for the use of screening tools which measure psychological needs in follow-up 
services in conjunction with clinical judgement.  
 
While data were recorded by the SBCN in relation to the interventions she 
initiated, any additional referrals in the control group were not recorded. Of 
particular interest would have been the number of times women attending the 
clinic in the control arm also met a SBCN from the team during the same visit to 
address psychosocial areas of care. The SBCN delivering the intervention 
referred to other professionals but not to other SBCNs in the team during the 
consultation. This additional support which may have been sought by the doctors 
in the control group may or may not have impacted on the overall result.   
 
The secondary outcome, changes in quality of life, was measured using the 
EORTC QLQ C30 and QLQ BR23.  The results show that for most women, their 
overall quality of life was high at the beginning of the trial and improved in a 
positive direction at the end of the trial. Comparisons with reference data to aid 
interpretation were not possible as they differed to the sample in this study.  
 
Improvements were seen within both groups across symptom and functional 
subscales, although these differed between the groups, at the end of the trial 
changes between groups were not statistically significant. There are similar topics 
covered in both  the BCNQ, EORTC CLC C30 and BR23 and include among 
them: pain, fatigue, body image, sexual functioning but the quality of life data was 
not used by the SBCN to guide care within the clinic. In this study the BCNQ 
encouraged women to express the needs they wished help with while the quality 
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of life measures captured how well they felt they were doing in relation to their 
overall well-being.    
 
Some interesting findings emerged from the data that saw statistically different 
and clinically meaningful changes in both groups over time. In the nurse group 
more improvements were seen across symptom and functional domains than in 
the control group, but none were statistically significant between the groups at the 
end of the trial.  In the nurse group improvements over time occurred in relation to 
physical functioning, social functioning, pain, body image and arm symptoms.  In 
the control group, these improvements occurred in relation to role functioning and 
insomnia. In both groups’ improvements over time occurred in relation to fatigue, 
sexual functioning and breast symptoms. The areas identified by the women 
concur with previous research studies reporting the short and long-term effects of 
treatment on a woman’s quality of life (Bower et al. 2000; Holzner et al. 2001; 
Ganz et al. 2004; Lee et al. 2008) and those reported as requiring  help when 
using the BCNQ. 
 
Taken together, these results suggest that the SBCN using PROMs has not been 
proven to be any better than standard care in improving a woman’s overall quality 
of life as she recovers from a diagnosis and treatment. The improvements seen in 
the nurse group and not in the control group may be explained by the very nature 
of the SBCN’s role, which provides information and support daily to address pain, 
body image, and breast symptoms, social and physical functioning aspects of a 
woman’s recovery. Some symptoms may also have improved over time due to 
the healing process, but for some of these women it had taken 3 - 5 years since 
diagnosis to achieve improvements.  
 
Much of the research in breast cancer focuses on prognostic characteristics of 
breast cancer and their ability to predict survival outcomes (Goldhirsh et al. 2013; 
Dinh, Sotiriou & Piccart, 2007). The findings from this study undertook a series of 
regression analysis and provide a new understanding about the association 
between levels of anxiety, depression, unmet needs, quality of life, demographic 
and treatment characteristics. The results of this study could not corroborate the 
findings by Sanson-Fisher et al. (2000) that age, time since diagnosis or the 
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combinations of treatment are predictors of unmet needs. However, the present 
study did suggest that age is associated with higher levels of fatigue, poorer 
sexual functioning and poorer emotional functioning. 
 
Of particular importance is the association of depression in explaining changes to 
the BR23 overall scores and unmet needs. Although the number of participants 
who were depressed at baseline was small, identification of these women earlier 
may allow more timely interventions to be offered. The present study suggests 
that both depression and indeed anxiety, when identified in this post-treatment 
population can be improved by HCPs. 
 
Early studies supporting the wide introduction of SBCNs focused on their role 
supporting women post-mastectomy (Maguire et al. 1983), the first line treatment 
at that time, rather than on survivorship, a term used today.  With more and more 
SBCN and ANP involved in the delivery of follow-up services in the hospital 
setting, there is now evidence that their actions in conjunction with assessment 
tools can reduce women’s needs and intervene early to manage anxiety and 
depression.  It is not simply that a nurse can provide follow-up but rather how the 
SBCN interprets the information provided to her by the patient which will be 
effective.   
 
The overarching purpose of any research study is that there is no harm to the 
participant (Watson, 2012). Although the present study did not show any 
significant differences between the nurse and control group in terms of changes 
in need, the study adhered to the ethical recommendations set out by the NHS 
Research Ethics Committee and showed no evidence of causing any harm. 
 
The enquiry of participants about their psychological needs raised ethical issues 
about the management of the control group. In the planning stage it was accepted  
that screening the participants for anxiety and depression was outside the normal 
or usual practice for the participant; a recognition that this may impact on the 
individual guided the decision-making to score the control group and initiate 
referral to a SBCN not involved in the study based on their scores on the HADS 
(<11). There were ten participants referred for further assessment. This may have 
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contributed to the statistically significant changes over time within both groups for 
anxiety and depression at the end of the trial.  
 
6.6 Informing policy about needs of women with breast cancer 
The momentum to improve and change the way cancer patients receive care 
once their primary treatment is completed has seen the National Cancer 
Survivorship Initiative (England), and the Transforming Care after Treatment 
programme (Scottish Government, 2013) gain prominence. Their common goal is 
to consider how best aftercare could be tailored to meet individual cancer 
patient’s needs by providing an assessment of the full range of cancer survivors 
needs, encouraging professionals to work in partnership, and develop post 
treatment strategies to encourage patients to self-manage their recovery. The 
language is inclusive and ambitious with the suggestion that assessment of need 
is already an integral part of cancer care. However, the literature reviewed at the 
outset and end of this study clearly indicated that measuring needs in a 
systematic manner which then informs evidence-based interventions is very 
limited, certainly in the field of breast cancer. There is no ‘gold standard’ needs 
assessment tool identified to date. This study goes some way to extending the 
knowledge in this area by indicating how current systems can be adapted to 
deliver on these goals.  
 
Using tools to screen for unmet needs, psychological information and quality of 
life is insufficient to facilitate any change in patient outcomes alone.  The clinical 
skills of the practitioner are vital to interpret findings. The results of this study 
provide evidence that the BCNQ and HADS can be used successfully within a 
planned follow-up clinic setting. However when faced with these questionnaires, 
the SBCN took time adapting to their use in the beginning. This was especially so 
among those women who expressed a high number of unmet needs. The SBCN 
adopted a triage approach: dealing with those needs requiring urgent 
management and then putting a plan in place with the woman to address other 
less urgent areas. However some needs such as making sure the woman always 
saw the same HCP were not easy to achieve within the current system. Therefore 
the suggestion that HCPs can meet all needs must be tempered with caution. The 
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SBCN was very experienced, as were the doctors in the control group so it is 
unclear if the same results would be seen in other groups. However, despite the 
experience of the SBCN, some form of training in how to interpret the information 
provided by patients using needs assessment tools or HADS was required. In 
essence, the introduction of an assessment instrument needs guidance for HCPs, 
otherwise the information is collected and the HCPs don’t know what to do with it. 
 
This study did not stratify patients to their individual risk of recurrence at baseline; 
rather all women were invited to participate. The BCNQ and the HADS 
successfully identified those with unmet needs and those without. This is an 
important result, especially if services wish to use resources efficiently and 
effectively. Breast cancer affects many thousands of women and identifying those 
women with the highest needs, and therefore requiring help, from those who may 
have no needs and are recovering well, is very important.  It links to the quality 
ambitions that aim to be person-centred, safe, effective, efficient, equitable and 
timely (Scottish Government, 2010; NHS Quality Improvement, England, 2014), 
recognising that resources are finite and HCPs must consider how best to use 
them in practice. In addition, not all women have the confidence to raise concerns 
verbally within clinics or directly to HCPs. The questionnaires gave the 
opportunity to women who may be less confident in articulating their needs to 
identify areas of importance to them.  Following the study, the SBCN stated she 
found issues about sexuality, relationships, body image and other sensitive 
issues difficult to raise spontaneously in a clinic environment. When identified by 
the woman on the questionnaire, the subsequent conversation was easier.   
 
The potential use of the tool for those who might benefit from specific 
interventions to address these areas, and others, offers real potential.  If those 
who require no need for support are discharged from follow-up with clear 
mechanisms to re-establish relationships, there is scope to focus on those 
requiring help.  This would change the landscape of follow-up care from a service 
which offers all women the same follow-up care, to one that is needs driven.  This 
may require additional training of the SBCN’s to address more and perhaps 
different complex needs than they currently address.  Considering fear of 
recurrence is identified as the most important expressed need in this study, a 
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stronger focus on teaching women to recognise signs and symptoms of 
recurrence, and adjusting to changes after cancer would appear timely.   
 
Stratifying follow-up care according to a woman’s risk of recurrence, individual 
needs or both is currently being debated (Watson et al. 2012). The NCSI (2014) 
is soon to report on models of aftercare which have evaluated risk stratifying 
cancer patients according to their needs, disease and co-morbidities. The results 
in this study indicated that disease and treatment characteristics were not 
associated with changes in unmet needs or improvements in quality of life. 
Rather, specific treatment side effects and emotions appear to influence this 
change. Being younger is associated with higher levels of fatigue, poorer sexual 
functioning and body image; higher levels of depression at baseline was found to 
be associated with being more anxious at baseline; expressing a need at baseline 
is associated with changes in emotional functioning over time and lower 
deprivation scores and a younger age are associated with changes in sexual 
functioning over time. If treatments are delivered to minimise the risk of 
recurrence but the uncertainty of predicting recurrence remains, this outcome 
may not be a good indicator of whether follow-up care effectively meets the 
psychosocial needs of a woman and therefore may not be a good determinant of 
who is offered support and who is not.  Conversely, the results indicate that the 
nurse group that used PROMs to inform care did not do better than standard 
care; assessment of needs alone may not be a good indicator in isolation of other 
information.   
6.7 Methodological limitations 
It is important to review the internal and external validity of the study to 
understand the limitations associated with the interpretation of the conclusions 
made. The potential threats to internal validity can compromise the confidence 
that a relationship exists.  Threats to statistical conclusion validity include low 
statistical power resulting from inadequate sample size and this will be addressed 
first.  Other aspects that will be discussed are: blinding, method of analysis and 
attrition.   
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6.7.1 Sample size  
Sample size calculations are beneficial as they have a high chance of detecting a 
significant effect if it occurs and provides confidence that if the effect is not 
detected it is because it does not exist (Field, 2013).  In the development of this 
study, there had been no previous research to use as a reference point.  This was 
particularly relevant when predicting the effect size, the power and sample size 
required to detect the effect.  Initial calculations at the outset of this study were 
calculated based on the EORTC QLQ C30.  In the absence of previous data, an 
effect size of 0.5 was used and informed by Cheung et al. (2005) and Cohen 
(1992).  Therefore a power of 80% to detect a significance level (p=0.05) between 
the groups required a sample size of 64 in each arm.  Allowing for attrition of 
15%, 74 patients in each arm was needed. After the study started the primary 
outcome changed to changes in unmet needs.  However, following advice from 
the statistician the original power calculation was not altered as recruitment had 
started.  Therefore the calculation based on the EORTC QLQ C30 data, this 
raised the possibility of the study being under or over powered to detect the 
primary outcome. The results possibly reflect some of the uncertainty of 
estimating effect size in the absence of previous studies. In addition, an 
estimation of a moderate effect following the intervention, particularly when this 
affect has been achieved in few nursing studies, was possibly optimistic when this 
was a new area of enquiry.  
 
In this study the results were unable to reject the null hypothesis.  However not 
being able to reject it does not mean that it is true; rather, the low numbers made 
the study underpowered and there was not enough precision to allow the null 
hypothesis to be rejected.   
6.7.2 Blinding 
Randomisation is one of the strengths of the RCT and avoids bias in allocating 
interventions to the trial.  It was well organised in this study.  Subjects were 
allocated on a consecutive basis to the next group within the block.  Statistical 
tests were used to compare the baseline variables of the two groups and no 
differences were found.  Blinding the participants however to the group they were 
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allocated was impossible in this study.  It was necessary to inform the participant 
who they would see at the clinic; the doctor or the nurse.  However, the allocation 
sequence was concealed but was compromised by lack of blinding. 
6.7.3 Intention to treat analysis  
“Intention to treat” analysis was the intended strategy for this study at the outset. 
The strength of this approach is that all randomised participants are included in 
the analysis and retained in the group to which they were allocated (Gupta, 
2011).  One of the challenges using “intention to treat” is the need for complete 
data and missing data is a known problem in many trials, occurring in this study. 
The CONSORT Group (2010) recognise that strict intention to treat analysis is 
difficult to achieve due to the practical clinical scenario whereby non-compliance 
and protocol violations will occur.  They therefore no longer include this in their 
checklist and instead favour a clear description of who is included in the analysis.   
 
It was decided, due to missing outcomes data from some participants, to use a 
complete case analysis approach rather than imputation of missing data.  While, 
the disadvantage may be that the sample size reduced further, there was no clear 
justification for imputation.  It was important to understand the type of missing 
data and how this could relate to bias in the subsequent analysis. Analysis of 
completers and non-completers across demographic variables indicated that they 
did not differ and it is likely the data was missing randomly.   
6.7.4 Attrition  
“Attrition” refers to the dropout of participants in a study and is not uncommon in 
longitudinal studies and a source of potential bias. Attrition was 20% overall in 
this study, 22% in control group and 16% in the nurse group.  Although it was 
considerably better than the studies by Boyes et al. (2006), Aranda et al. (2006) 
and Velikova et al. (2004) who had used PROMs to guide care and reported 
attrition levels of 40%, 50% and 46% respectively, it was recognised that this was 
not ideal. Studies that are longitudinal are particularly vulnerable to attrition and 
the timing of the questionnaires, one year apart in this study, probably contributed 
to this.  
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An additional problem in this study was that dropout rates differed between 
treatment arms, known as “differential dropout”.  While this can bias results, a 
recent paper by Bell et al. suggests that “unequal bias rates do not mean the 
results are biased and conversely equal dropout rates do not imply that results 
will not be biased” (2013, p.1). The critical factor is the missingness of the data 
and the statistical analyses, with both areas considered and discussed above.  
 
6.8 Comparisons with other research 
As discussed in Chapter 1, this study was conceived through the personal 
experiences of the researcher and a systematic review in Chapter 3. There were 
no RCTs which sought to measure the effectiveness of using PROMSs to guide 
care by the SBCN on needs over time of women attending breast cancer follow-
up in a hospital. Surprisingly, the paucity of evidence continues up to the writing 
of this thesis. However three studies, one in the UK and two out with the UK  
have contributed to the body of evidence about a woman’s unmet needs, anxiety 
and depression levels post-treatment since this study began and will be 
discussed.   
 
Study 1: Beaver et al. (2009) “Comparing hospital and telephone follow-up after 
treatment for breast cancer: randomised equivalence trial”. 
 
This study was not solely undertaken in the hospital environment like the present 
study but was an extended full RCT of the study reviewed in Chapter 3. The 
SBCN delivered a structured intervention over the telephone that aimed to meet 
the need for information and support of women receiving follow-up care 
compared to hospital-based standard care. This was an equivalent trial and found 
that telephone follow-up by SBCNs using a needs assessment questionnaire 
were as effective as hospital-based follow-up in its ability to meet the information 
needs of women.  The results illustrate the difficulties comparing studies in this 
area: standard hospital follow-up in the study was offered more frequently than in 
the present study, participants with a high risk of recurrence were excluded and 
women no longer received a clinical examination in the telephone follow-up 
group.  Despite this, the results are consistent with the present study, by 
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incorporating PROMs such as needs assessment questionnaires into follow-up 
consultations, women with breast cancer are afforded an opportunity to raise 
issues of importance to them rather than those of importance to the HCP. 
 
Study 2: Vahdaninia, Omidvari & Montazeria (2010), “What do predict anxiety 
and depression in breast cancer patients? A follow - up study. 
This study, undertaken in Iran, measured the possible predictors of having 
anxiety and depression among breast cancer patients post treatment (n=167) (3 
and 18 months). The measures used were the HADS and EORTC C30, similar to 
the present study.  The results indicated that at 18 months the percentage of 
participants with anxiety was 38.4% and depression was 22.2%.  Regression 
analysis indicated that a significant risk factor for developing depression was 
fatigue and pain; and for anxiety, it was pain.  Caution is needed in the 
interpretation of these results in relation to the present study for a number of 
reasons.  First, 37% of the sample had metastatic disease and second, the 
context of the healthcare setting in Iran is very different from the Scottish NHS 
and it is unclear what impact that may have on individual’s anxiety and 
depression levels post-treatment. 
 
Study 3: Akechi et al. (2011) “Patient’s perceived need and psychological 
distress and/or quality of life in ambulatory breast cancer patients in Japan” 
 
This study investigated the association between patients’ perceived needs and 
psychological distress, and or quality of life among Japanese breast cancer 
patients with a high level of unmet needs. The women were ambulatory and the 
majority had primary breast cancer (338 out of 408), which is consistent with the 
women in the present study. However it was unclear from the data presented by 
Akechi et al (2011) whether woman had completed primary treatments or whether 
women they were still receiving them.  Women were invited to complete three 
questionnaires at one time point: the SCNS-SF34, the HADS, and the EORTC 
QLQ-C30. The SCNS-SF34 was the short version of the SCNS used by Girgis et 
al. (2000).  The 10 most frequent unmet needs were reported, using a cut off of 
three or above to classify as unmet. The results are consistent with previous 
studies that reported the fear of cancer spreading as the most important unmet 
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need (63%) (Raupach & Hillier, 2002; de Bock et al. 2004b; Girgis et al. 2000; 
Thewes et al. 2004; McCaughan & McSorley, 2007; Beaver et al. 2006).  In fact 
similarities were seen in the top 10 unmet needs between this study and the 
previous ones reviewed, reaffirming earlier findings that unmet needs are 
multifactorial.   
 
An association between the unmet needs (score on SCNS-SF34) and 
psychological distress (HADS) and quality of life is reported.  When 
psychologically distressed patients (HADS > 11) were compared to those without 
distress (HADS < 10), the distressed patients reported a higher number of unmet 
needs (18.9 v. 8.3).  Similarly, when seriously psychologically distressed patients 
(HADS >20) were compared to those without distress (HADS<19), these patients 
experienced a much higher number of unmet needs (26.7 v. 11)  while the cross- 
sectional design prevents any causal relationship between needs, psychological 
distress and quality of life being made. The findings are consistent with the 
present study that women with breast cancer report unmet needs but also the 
association between anxiety, depression, unmet needs and quality of life.   
 
These studies provide an important addition to the literature reviewed in Chapter 
3 and re-affirm that women attending follow-up continue to have high anxiety, 
depression and unmet needs.  While the study by Beaver et al. (2009) indicated 
that needs can be assessed and met through telephone consultations by SBCNs 
compared to hospital follow-up, they were unable to demonstrate changes over 
time in these groups. There remains a dearth of studies that have measured the 
effectiveness of interventions to address needs and psychosocial issues at follow-
up in the hospital setting. The present study incorporated the previous literature to 
inform the development of the study and the effectiveness of the intervention to 
achieve change. 
6.9 Main strengths of the study 
The main strength of this study was the method used, a RCT.  It is considered the 
most appropriate method to measure cause and effect which is not achieved in 
other designs. To determine the effectiveness of the intervention used in this 
study, the RCT was deemed the most appropriate approach. The randomisation 
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approach was well set up and strategies used to maximise recruitment and 
retention were undertaken. The data should therefore be taken as useful 
preliminary data to inform future studies. Considering this research is a new area 
of enquiry, it may have been beneficial to have considered undertaking this study 
as an equivalence trial. An equivalence trial would have hypothesised that the 
intervention demonstrated equivalence with standard care.   
 
A key strength of this study was that pilot work was undertaken. This informed the 
choice of questionnaires used, the acceptability of completing questionnaires in 
the particular population studied, the intervention and training of the SBCN. 
 
Another key strength of this study was the choice of measurement tools used.  
The BCNQ was specifically designed to be used with survivors (post-primary 
treatment) rather than women immediately post-diagnosis or during treatment. It 
was able to distinguish between those expressing unmet needs and those who 
have none which is very important if healthcare resources can be focused 
towards those people who require help. The results have therefore provided a 
better understanding. 
 
Another key strength was that the study was undertaken in the real clinic 
environment where follow-up care is delivered. Most of the evidence about using 
PROMs such as needs assessment tools and HADS, including some of the 
information provided by the NCSI, have not used them within a busy clinic and 
within a short appointment time.  
6.9.1 Generalisability of results 
The target population of this study was women with breast cancer attending 
follow-up clinics in a hospital.  Although the sample size was not reached, the 
participants were representative of the breast cancer population in the UK.  As 
the timing and purpose of follow-up care are influenced by the cultural 
background and medical system in each country, the findings may not be 
applicable to other populations in other countries.  In addition, the use of multiple 
tests risked a chance significant finding being reported. 
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6.10 Main limitations of the study 
All studies have limitations and these will be discussed further including strategies 
that were undertaken to minimise them. Reflecting on the learning the researcher 
gained throughout the research training and experience of undertaking the study, 
possible ways the researcher would strengthen the study for the future if 
repeated. 
 
6.10.1 The intervention 
The use of the BCNQ provided structure to the consultation; however this could 
be viewed as limiting opportunities to provide person-centred care. By combining 
a structured questionnaire with a person-centred conversation there was an 
opportunity for the woman to raise issues which may not have been captured 
within the BCNQ alone.  The SBCN and the woman could then explore the 
options for the intervention, desire of the woman for assistance and the best way 
to provide it. 
A deeper understanding of this person-centred conversation between the SBCN 
and the woman within the clinic may have been useful.  Although the SBCN 
documented areas discussed and referrals made, the documentation of this did 
not align well with the BCNQ responses. In particular the notes appeared to focus 
primarily around symptom management and body image (see Section 5.12) 
rather than fears of recurrence, one of the top five needs expressed. Corter et al. 
(2013) suggests that there is an association between illness perceptions, side 
effects and fear of recurrence.  The SBCN had to assess and use the information 
she received within a short time frame and may have combined areas where she 
saw natural associations. A more in-depth understanding of the relationship 
between the words documented and the needs expressed on the BCNQ and 
HADS would have been useful to understand whether the intervention was 
appropriate or whether further refinement of it was necessary to achieve 
differences compared to standard care.    
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6.10.2 The pilot work  
The pilot work was undertaken to determine the best possible needs assessment 
tool to use, review the recruitment process and inform the development of the 
intervention. Despite eight women agreeing to participate, only four did.  It may 
have been useful to have approached the non-responders at this stage to 
ascertain the reasons for non-response.  It may have further informed the 
recruitment process.  In addition, reviewing the BCNQ in the clinic rather than 
over the phone would have provided a better indication of how long it would take 
the nurse to review and deliver the intervention. This would have informed the 
training. 
 
6.10.3 Recruitment 
The recruitment of women into the trial was influenced by practical, logistical and 
ethical reasons. The participants in this study were regarded as ‘vulnerable’ and 
ethical approval was conditional on accessing participants by post to invite into 
the study. While this approach negated gatekeeping by HCPs involved in the 
women’s’ care, a process which occurs according to Patterson et al. whenever 
“access to someone or something is allowed or denied by a third party.”(2011, 
p.2), it may have affected the timing and numbers of participants responding. The 
recruitment process depended on participants responding to recruitment 
materials by phone, post or email rather than within the clinical setting.   
 
The researcher maximised the clarity of the process by providing comprehensive 
information, a clear statement that potential participants can refuse to participate 
or withdraw at any time and an explicit offer to answer questions or provide 
further information. The timing of the intervention was critical to its success.  
Because the study sought to undertake the intervention within the follow-up clinic, 
it was important that women were recruited prior to this clinic. The clarity of the 
information provided to women was reviewed by patients, HCP and the Ethics 
Committee and deemed appropriate. However, during the development of this 
thesis it became apparent that explaining a complex intervention can in itself be 
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complex.  It may have been more effective to present the intervention 
diagrammatically rather than just in words or recruit face to face within the clinic.  
By providing recruitment details in writing an assumption is made that all the 
participants are literate and can clearly understand the concept under study. This 
may have improved recruitment. 
 
A number responded after their follow-up consultation. This could have been self-
selection; however Dellson et al. (2010) has suggested that recruitment can be 
impeded by feelings of context evoking insecurities, a sense of fear associated 
with words used and individual preferences.  Studies, such as the one by 
Montgomery et al. (2008), report that the period leading up to the follow-up 
appointment is full of emotion, anticipation and expectation and may offer some 
explanation. This may be an area which warrants further exploration if PROMs 
are to be used widely in follow-up.  Another limitation was the decision to stop 
recruitment before the required sample size had been reached.  As the study was 
part of a doctoral thesis, a pragmatic decision was made to stop and ensure 
completion of the studies within the timeframe.  
 
6.10.4 Outcome measurements 
The BCNQ (Thewes, 2000) was used in the present study and had been used 
once before in this population.  While it was an advantage, one disadvantage of 
this measure was that there is no comparative reference data of women with 
similar characteristics to compare against that of the general population.  The 
review of alternative assessment tools was restricted to those previously used in 
the post-treatment breast cancer literature described in Chapter 3.  It may have 
been useful to have also considered other cancer needs assessment tools 
although the integration of theory and choice of tool was directly linked to the 
individual requirements of the population under study. This was also true of the 
EORTC QLQ C30 and QLQ BR23, whereby the reference data available included 
women with breast cancer receiving treatment rather than having completed 
primary treatment.   The reduction of perceived needs and improvement in quality 
of life is a core goal of policies that direct breast cancer services.  As more 
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women survive it will become increasingly necessary to understand how these 
goals can be effectively achieved.    
 
This study formed part of a part-time doctoral thesis and a pragmatic decision 
was made to gather data on two occasions, 12 months apart.  However, the 
complexity of some of the unmet needs expressed which relate to sexuality, 
appearance and body image may follow a much longer recovery path. Some 
women were referred for further discussion about reconstructive surgery, and this 
takes time.  Equally, the one year follow-up measurement point may have limited 
evidence of a short-lived effect seen at 3, 6 or 9 months.   
6.10.5 Health economics 
Health economic data was not routinely collected as part of this study.  Economic 
analyses of nursing interventions are not widely undertaken. However, the 
researcher recognises the importance of ensuring that healthcare interventions 
introduced into practice are cost-effective as well as being based on evidence. In 
undertaking follow-up care in this study, this was a transformation of the scope of 
the SBCN’s role. While she focused on providing supportive care to women from 
diagnosis of breast cancer within the context of the multi-disciplinary team, she 
had not undertaken clinical examination and follow-up prior to the study 
commencing. The demands on follow-up services coupled with finite resources 
indicate that cost analysis of the intervention would have been beneficial. The 
cost of paper-based questionnaires, an experienced SBCN, training and lengthier 
appointments at the outset would all need to be factored into the costs compared 
to standard care. However, a balance is required between standardisation in the 
absence of individual context, professional autonomy and judgement.   
 
6.11 The strengths and limitations of using the MRC framework 
The use of the MRC framework to guide the study design and execution was 
extremely useful, particularly as a novice researcher. The MRC are a respected 
organisation and it challenged the researchers thinking to look beyond just 
defining the components of the intervention as standard towards considering how 
it was possible to define the standard steps in the process and describe the 
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context. In their discussion document, the MRC refer to constant and variable 
components in an intervention but they failed to define them, leaving this open to 
interpretation.  However, the emergence of published examples of how it can, and 
could be applied to complex interventions aided the interpretation (Campbell et al. 
2000; Byrne et al. 2006; Higginson et al. 2006).  Hawes et al. (2004) referred to 
“constants” as functions that could be standardised and the variable aspects 
adapted to different contexts.  The emergence of a graphical method for depicting 
the RCT of complex interventions provided further assistance (Perera et al. 
2007). The use of the framework was coupled with the extension to the 
CONSORT statement (Boutron et al.2008) about the reporting of non-
pharmacologic randomised trials.  Again, the importance of describing context 
and process is highlighted.   
One limitation of using the framework was that gaining a good understanding of it 
and adhering to the phases was time consuming and difficult at times. Craig et al. 
(2008) suggested in their updated version that more attention should be given to 
the exploratory/pilot work. The researcher used a systematic approach to develop 
an intervention informed by empirical evidence and established theory.  The 
feasibility and acceptability as delivered by the SBCN was tested and led to a 
definitive RCT. This aimed to mitigate against results that showed no effect.  
However it is clear that other influences play a part and extensive learning was 
gained from this experience. 
6.12 Conclusion 
This chapter sought to analyse and interpret the findings and set them within the 
context of relevant literature and current work in the field of breast cancer follow-
up. The clinical application of using the BCNQ and HADS has shown them to be 
a rapid and simple method of identifying women who required help with particular 
aspects related to their breast cancer diagnosis and treatment effects. This could 
be valuable in distinguishing those requiring help and those not, and initiate early 
interventions for those expressing high depressive, anxiety and psychosocial 
needs. The findings extend the knowledge of the perceived unmet needs of 
women attending follow-up care and unlike previous studies, and importantly, 
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sought to address these needs within a clinic environment. The intervention by 
the SBCN indicated that it was as effective as current standard care. 
 
The findings resonate the direction of healthcare to offer person-centred services 
which meet the needs of patients; importantly, this study represents a model 
whereby an individual’s needs can be assessed alongside a clinical examination 
within the context of a hospital setting. It illustrates that some of the tensions 
between the medical model and the provision of a person-centred holistic 
approach, can be allayed and need not be mutually exclusive. By offering all 
patients an equal opportunity to identify their need for help, services naturally 
become more equitable and place more responsibility on the individual. Further 
work is required to apply this approach across larger numbers of women. The 
women expressed significant anxiety and unmet needs. Perhaps the high use of 
healthcare services identified in this group reflects on-going needs and anxiety 
among them. Earlier psychosocial interventions in this group after primary 
treatment is completed may help further. 
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Chapter 7: Conclusion and recommendations 
7.1 Introduction 
The present study set out to measure the effectiveness of delivering follow-up 
care in a hospital setting to address the perceived needs, psychological state and 
quality of life of women with breast cancer. Follow-up care is an integral part of 
breast cancer services that are provided to women once primary treatment 
(chemotherapy, radiotherapy, surgery) is complete. Criticism about the benefits, 
or otherwise of follow-up has largely focused on gains associated with the 
identification of recurrences. However, the intensity of treatments used, and the 
range of side effects seen, have left many women unsure about what these 
symptoms are and how best to manage them moving forward.  Attendance at the 
follow-up clinic provides an opportunity for women to gain psychosocial support 
from healthcare professional’s familiar with breast cancer. Evidence suggests that 
while many women wish these clinics to continue, some are leaving these clinics 
with unmet needs. This juxtaposition between the goals of follow-up and the 
outcomes women report led the researcher to argue that an approach to follow-up 
care is required that should assess the perceived needs and psychological state 
of the woman in partnership with the HCP to improve outcomes. This gap 
identified in the field of study led to the following research question: 
 
 What is the effectiveness of providing patient-reported needs, quality of life 
and psychosocial information to the SBCN at the follow-up clinic in 
reducing cancer needs and improving quality of life compared to standard 
care? 
 
This final chapter draws conclusions from the preceding analysis and 
discussions, identifies the specific contribution to knowledge and identifies areas 
for future research.  It also makes some recommendations for policy, education 
and clinical practice emerging from the research.   
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7.2 Conclusion 
To answer the primary research question in this study, a randomised controlled 
trial was used.  By measuring the primary outcome, changes in needs over time 
at baseline and 12 months using the breast cancer needs questionnaire (BCNQ), 
the hospital anxiety and depression scale (HADS), and quality of life 
questionnaires, QLQ C30 and BR23, the researcher was able to conclude that 
the intervention by the specialist breast care nurse was as effective as, and 
certainly no worse, than standard follow-up care. in reducing unmet needs, 
anxiety and depression, and improving quality of life among breast cancer 
participants. 
 
The results indicated that patient-reported outcome measures (PROMs) such as 
the BCNQ and HADS can be used effectively and in a timely manner within a 
busy breast cancer follow-up clinic, to inform and guide interventions by the 
SBCN.  The SBCN did not require an additional consultation; rather the use of 
these tools was integrated into the planned clinical appointment.  The participants 
included in the study reflected the range of women seen within this clinic. 
Throughout Chapter 2, 3 and the exploratory work, the specific areas of 
importance to a women recovering from a diagnosis of breast cancer was 
reported.  Although generic instruments are widely used, they fail to capture the 
unique psychological and physical needs associated with a mastectomy, 
reconstruction, arm/shoulder pain, menopausal symptoms and body, to name a 
few, that differ to other cancer groups.  
 
The BCNQ demonstrated good validity and reliability.  It identified both the 
women with unmet needs but also those who had no need for support.  Although 
the SBCN found it easy to use and quick to scan for high expressed needs, the 
flexibility of the tool combined with a person centred conversation accommodated 
women with a higher need for help than others.  The needs of women decreased 
over time in both groups but were not statistically significant at the end of the trial.  
Although the study was underpowered, the decrease was proportionally similar in 
both groups, suggesting a higher sample may not have achieved different results.  
The improvement in both groups suggests follow-up in the hospital setting 
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provides more benefit in relation to psychosocial support, rehabilitation and 
monitoring of side effects than previously reported.   
 
Previous literature (Chapter 3) clearly indicated anxiety and depression continues 
to be high in a significant number of breast cancer survivors (McDowell, 2010) 
and high scores indicate psychological need.  The HADS is not routinely used 
among women attending follow-up care but demonstrated good validity and 
reliability in this study.  The data indicated that anxiety levels were high in both 
groups at the start of the trial but did decrease over time. Although there was no 
significant differences between the groups at the end of the trial, there was a sub-
group of women who when assessed against the HADS scoring protocol, 
continued to record high scores. By combining this screening measure with the 
person centred conversation, a better understanding of what the score 
represented, was gained.  This is particularly important as risk factors associated 
with anxiety and depression (see Section 2.5) is broad. 
 
Depression scores across both groups were low at the start of the trial and did 
improve over time. Again, using the HADS score combined with the person 
centred conversation allowed the small group of women with high scores to be 
identified and assessed further.  However, high scores were also reported in the 
control group for further evaluation. Depression emerged as being associated 
with changes in anxiety and need for support at time 1.  It is therefore important 
these women are identified and supported appropriately. 
 
The quality of life of participants in both groups was good to high.  The 
interpretation of these scores quickly is often challenging for practitioners and 
therefore in this study, these questionnaires were not used to inform the person-
centred conversation. All the results changed in the right direction, suggesting 
over time, quality of life improves in this group of women.   
 
7.3 New knowledge from the findings 
This research addressed a specific group of participants, women with breast 
cancer attending a hospital follow-up clinic. As discussed in Chapter 3 research 
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existed which reported multiple unmet needs of women with breast cancer post-
treatment but not directly at the time when they would be receiving follow-up care, 
or, capturing this information in a systematic manner.  There was also no 
evidence of nursing interventions used to address these unmet needs at follow-up 
and seek to improve patient outcomes.  This study has contributed to the existing 
knowledge of women attending follow-up. In particular, the use of a specific 
breast cancer needs questionnaire that captured areas relevant to a women 
recovering from breast cancer and provided a broader overview of this 
population’s psychosocial needs, than previously reported.  It also provided 
further evidence of the utility of HADS to screen breast cancer survivors for 
psychological needs. 
 
Follow-up care is offered uniformly to every woman irrespective of needs, age, 
disease and treatment plan, and the results indicated that although there were 
unmet needs across both groups at the start and end of the trial, a proportion of  
these women report no need for support across any of the areas assessed. This 
is an important aspect that has emerged from this study and provides the platform 
to make changes in follow-up services. It indicates that support from HCPs may 
no longer be required within a hospital clinic setting for some women and 
empowering them to move on in their lives is a positive rather than a negative 
outcome. To date, either all women are discharged at a set time point or all 
women continue indefinitely.  This study’s findings indicate that it is possible to 
use tools in practice to identify those with the greatest need for support and those 
who are coping well and no longer require specialist interventions, thus providing 
effective use of resources using a person-centred approach to follow-up care.  
These women may be suitable for discharge from follow-up care irrespective of 
time since diagnosis if clear mechanisms are in place to allow rapid access back 
to specialist services when concerns arise about a possible recurrence.  
7.4 Specific contribution to knowledge 
This study has provided a major contribution to the methodological evidence base 
about complex interventions in nursing practice.  The findings showed that to 
measure the effectiveness of a nursing intervention during follow-up that focused 
on addressing unmet needs and encompassing a person centred approach, can 
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be studied using the RCT approach. The use of a RCT has benefits for the 
effective accumulation of knowledge within healthcare but its use to measure 
interventions by nurses is not widely used. It is certainly a new approach when 
combined with a person-centred conversation, as was the case with this study.     
 
By using the MRC framework to guide the development and testing of the 
complex intervention in the follow-up setting, the research has been able to 
highlight both the diversity of needs among breast cancer survivors, but, also the 
means to address these needs in an individualised manner. The function and 
process of the intervention was standardised, however not the individual 
components. This enabled the intervention to be tailored to a woman’s individual 
needs. In the pre-clinical (theoretical) phase, the intervention was based on the 
supportive care framework which drew on constructs such as human needs, 
coping, adaptation, personal experience and expectations.   
 
There was no intervention guide prior to commencing this study.  By drawing on 
qualitative and quantitative research, and theory within the context in which the 
intervention was implemented, the probability of success was maximised and a 
reproducible intervention was devised, one which can be used in future studies.  
In addition, there is now preliminary data, including standard deviations of a 
breast cancer survivor population’s psychosocial needs which will serve as the 
basis for future studies, and offer a more precise sample size calculation in the 
future.  The priori sample calculation for this study was based on the secondary 
outcome, quality of life, as there was no previous research that had measured 
changes in needs in this setting.   
 
Policy, in particular the National Cancer Survivorship Initiative and the 
Transforming Care after Cancer, suggests interventions to meet the perceived 
needs of breast cancer survivors will increase and drive forward service re-design 
in follow-up care.  It is important that theoretical and methodological aspects are 
considered in the development of interventions, but, also how the effectiveness of 
these interventions can be measured. This study adds considerably to this area of 
work. Of particular significance is the development within this study of an 
approach to assessing and addressing psychosocial needs within the context of a 
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“real life” clinic environment.  By combining the use of PROMs, the clinical 
expertise of a SBCN and clinical examination, services can aid the recovery, 
support and adaptation of women as they survive breast cancer.  While this 
approach was developed with the SBCN as the key professional, it may also be 
helpful, following adaptation, for use in primary care by GP’s and other HCPs 
involved in the care of women post-treatment.  While this work contributes to the 
existing knowledge of follow-up care in breast cancer, transferability of this 
approach to other cancer groups it also a possibility, where similar goals exist to 
address psychosocial needs, monitor for signs of recurrence and long-term 
morbidity.  However, further research would be recommended. 
7.5 Recommendations  
The following recommendations were identified following the study which 
encompasses policy, practice, education and research. 
 
7.5.1 Recommendations for policy 
 
 The findings suggest using PROMs such as the BCNQ and the HADS 
offers promise in identifying unmet needs among those with breast cancer.  
At present no systematic approach is used and therefore patients may be 
under-reporting needs at clinics.  With the identification of needs arguably 
comes the requirement to meet those needs: without the resources that 
are identified to meet the needs of cancer survivors, we could be raising 
expectations which cannot be met.  These choices will be difficult, 
particularly in the field of breast cancer where there are high levels of need 
reported and large numbers of survivors.   
 
 This study included training for the SBCN and suggested interventions to 
meet the needs of women were discussed.  If widespread use of a needs 
assessment tool is integrated into practice, evidence of effective 
interventions, to meet needs, are required, so the HCPs can clearly 
signpost their patients towards them.  There may also be a training 
requirement for HCPs to effectively use a needs assessment tool and its 
associated interventions. 
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 Women immediately post-treatment can expect to be seen by specialists in 
breast cancer for at least a couple of years. The findings suggest there is a 
requirement to consider the right time to introduce the BCNQ and HADS in 
a follow-up setting to understand the needs of these women as they 
recover and offer timely, appropriate interventions.  A number of women 
beyond 3 years expressed high levels of need and may have benefited 
from an earlier opportunity to express their need for support.    
7.5.2 Recommendations for practice 
 If PROMS are to be used routinely in clinical practice, consideration is 
required about how this will be achieved to avoid high additional costs.  
Paper-based approaches are an option but assessment of psychosocial 
outcomes using electronic means may be the most cost effective approach 
to moving forward.  
 
 If PROMs are to be used, there is a need to consider the cognitive ability of 
patients and how this may affect response rates. 
 
 It would be premature to recommend the intervention for general clinical 
practice. The evidence is only preliminary and it is likely that some work 
would be required to translate it fully into clinical practice. The skill of the 
practitioner is likely to have an impact on the patient’s reduction in needs, 
anxiety and depression, and therefore recognition of this is required or 
otherwise a dilution of effect may occur. 
 
 The study has highlighted that the recording of psychosocial information 
within a follow-clinic, including interventions offered, is very limited.  In 
particular linking the specific need reported by the woman and the actions 
or intervention initiated by the SBCN.  If a stronger focus on these areas 
emerges, a standardised assessment and reporting mechanism is 
required. This would improve continuity between HCPs and directly link 
outputs to outcomes. 
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 If PROMS, such as the BCNQ and HADS are used regularly within follow-
up clinics, reporting of this information, through formal gathering of 
datasets would be valuable. These data could inform future planning of 
services to support breast cancer survivors.   
7.5.3 Recommendations for education 
 In the development of this study it was apparent that there are 
inconsistencies in how SBCN are assessed for competence to undertake 
clinical examination within the whole context of “standard care”.  A 
consistent approach is required to assess the initial and on-going 
competence of nurses undertaking clinical examination and assessment 
within a follow-up clinic.   
 
 This study identified the SBCN to undertake the intervention.  However if 
different approaches are used in the delivery of follow-up care, multi-
professional training and education will be required.   
 
 The women in this study identified areas such as fear of recurrence, 
fatigue, pain and sexuality as areas of high need for support.  There is a 
requirement to review education and support strategies used by SBCN’s in 
relation to these areas on a regular basis. 
 
 The findings suggested that women require information and support to 
understand recurrence of breast cancer, genetics and new treatment 
developments alongside issues related to sexuality, body image and 
appearance.  It is unclear if current educational models provide 
opportunities to consider patho-physiology of breast cancer and holistic 
aspects together.  This study indicates that SBCNs undertaking follow-up 
require broad educational preparation.    
 
7.5.4 Recommendations for future research 
 The approach used in this study offers a promising way of meeting the needs 
of women in a person-centred way, in a breast cancer follow-up setting.  The 
trial was undertaken in one cancer centre and future research should consider 
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a multi-centre trial.  Although this study focused on the intervention delivered 
by the SBCN, it would be useful for future studies to capture more detail about 
standard care, delivered by doctors or SBCN.   
 
 There is no data to date about the clinical interpretation of needs 
assessment data; when a score represents a problem, either in absolute 
terms or changes in an individual patients score over time.  Further 
research is required in this area. 
 
 The literature reviewed about the use of needs assessment tools to guide 
care within a follow-up clinic did not undertake any cost-benefit analysis.  A 
study examining the costs over time of the intervention used in this study 
would be beneficial.  It may also inform future strategies to meet the needs 
of breast cancer survivors.   
 
 Although the results indicate the BCNQ is sensitive in identifying changes 
in unmet needs among breast cancer survivors, further psychometric 
testing is required on larger samples, over more geographical locations 
and over longer time periods. 
 
7.6 Dissemination of Findings 
The findings of this study will be disseminated through presentations and peer 
reviewed journals. Two opportunities arose to present some early discussion 
about the study and generated interest from SBCNs working in follow-up clinics in 
a hospital setting.  Details of these can be found in at the beginning of this thesis.  
The importance of sharing the results with practitioners and policy makers is vital 
as the results have the potential to shift thinking and influence the planning of 
future follow-up services. 
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7.7 Final Summary 
This chapter has provided a conclusion of the findings, a synopsis of the new 
knowledge gained and the specific contribution of this study.  Follow-up care is a 
service which has continued to be delivered in the hospital setting in the same 
way, irrespective of whether a doctor or SBCN delivers the service. Diagnostic 
knowledge and treatment modalities have seen huge changes but this has not 
been translated to follow-up care. This study highlighted that an intervention by 
SBCN, guided by PROMs and a person centred conversation could be delivered 
in a follow-up clinic and within a short timeframe.  The results imply that the 
intervention was as effective as, and certainly no worse than standard follow-up 
care. However the learning gained about the perceived needs and quality of life of 
this population has provided evidence that many of these women are recovering 
well and do not seek support while others are struggling.  Prior to this study, little 
was known about the perceived needs and quality of life of women attending a 
follow-up care and the data can inform services in the future.  Although these 
findings are preliminary, they suggest that future studies in follow-up care may 
benefit from this intervention approach. 
215 
 
References 
Aaronson, N., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N.J., 
Filiberti, A., Flechtner, H., Fleishman, S.B., de Haes, J.C. et al., 1993. The 
European Organisation for Research and Treatment of Cancer QLQ-C30: 
a quality of life instrument for use in international clinical trials in oncology. 
Journal of National Cancer Institute, 85 (5) pp.365-376. 
 
Aapro, M., 2006. Breast Cancer: not a single disease. European International 
Cancer Supplement, 4 (4) pp. 1-3. 
 
Adewuyi-Dalton, R., Ziebland, S., Grunfeld, E. & Hall, A., 1998. Patients’ views of 
routine hospital follow-up: a qualitative study of women with breast cancer 
in remission. Psycho-oncology, 7 (5) pp.436-439. 
 
Akechi, T., Okuyama, T., Endo, C., Sagawa, R., Uchida, M., Nakaguchi, T., 
Akazawa, T., Yamashita, H., Toyama, T. & Furukawa, T.A., 2011. Patient’s 
perceived need and psychological distress and/or quality of life in 
ambulatory breast cancer patients in Japan. Psycho-oncology, 20 (5) 
pp.497-505. 
 
Altman, D.G., Schulz, K.F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., 
Gotzsche, P.C. & Lang, T. for the Consort Group, 2001. The revised 
CONSORT statement for reporting randomized trials: explanation and 
elaboration. Annals of internal medicine, 134 (8) pp.663-694. 
 
Andersson, M., Awada, A., Barrett-Lee, P., Ellis, P., Hupperets,P., Jackish, C., 
Kubista, E., Luck, H-J., Monnerat, C., Nitz, U., 2008. European 
oncologists’ preferences for the management of breast cancer: case 
presentations and expert commentary.  The Breast, 17 (52) pp. s1-s11. 
 
 
 
216 
 
Anderson,D,J., Yates, P., McCarthy, A., Lang, C,P., Hargreaves, M., McCarthy, 
N., Porter-Steele, J., 2011. Younger and older women’s concerns about 
menopause after breast cancer. European Journal of Cancer Care, 20 pp. 
785-794. 
 
Anthony, D., 1999. Understanding Advanced Statistics A guide for Nurses and 
Healthcare Researchers. London: Churchill Livingstone. 
 
Aranda, S., Schofield, P., Weih, L., Milne, D., Yates, P. & Faulkner, R., 2006. 
Meeting the support and information needs of women with advanced 
breast cancer: a randomized controlled trial. British journal of cancer, 95 
(6) pp.667-673. 
 
Armer, J.M., Henggler, M.H., Brooks, C.W., Zagar, E.A., Homan, S. & Stewart, 
B.R., 2008. The health deviation of post-breast cancer lymphedema: 
symptom assessment and impact on self-care agency. Self-care, 
dependent-care & nursing, 16 (1) pp.14-21. 
 
Baildam, A., Keeling, F., Noble, M., Thompson, L., Bundred, N. & Hopwood, P., 
2001. Nurse led follow-up for women treated for breast cancer: a 
randomised controlled trial. European journal of of surgical oncology, 27 
(8) p.792. 
 
Baum, M., 2002. The changing face of breast cancer – past, present and future 
perspectives. Breast Cancer Research and Treatment, 75 s1-s5. 
 
Beaver, K. & Luker, K., 2005. Follow-up breast cancer clinics: reassuring for 
patients rather than detecting recurrence. Psycho-oncology, 14 (2) pp.94-
101. 
 
Beaver, K., Twomey, M., Witham, G., Foy, S. & Luker, K., 2006. Meeting the 
information needs of women with breast cancer: piloting a nurse-led 
intervention. European journal of oncology nursing, 10 (5) pp.378-390. 
 
217 
 
Beaver, K., Williamson, S. & Chalmers, K., 2009. Telephone follow-up after 
breast cancer treatment for breast cancer: views and experiences of 
patients and specialist breast cancer nurses. Journal of clinical nursing, 19 
(19-20) pp.2916-2924. 
 
Bell, M., Kenward, M,G., Fairclough, d, l., Horton, N,J., 2013. Differential dropout 
and bias in randomised controlled trials: when it matters and when it may 
not. British Medical Journal, 346 pp. 1-7. 
 
Biglia, N., Cozzarello, M., Cacciari, F., Ponzone, R., Roagna, R., Maggiorotto, F. 
& Sismondi, P., 2003. Menopause after breast cancer: a survey on breast 
cancer survivors. Maturitas, 45 (1) pp.29-38. 
 
Bjelland, I., Dahl, A.A., Haug, T. & Neckelmann, D. 2002. The validity of the 
hospital anxiety and depression scale. Journal of psychosomatic research, 
52 (2) pp.69-77. 
 
Black, S., 1998. Editorial. Nurse researcher, 6 (1) pp.3-4. 
 
Bloom, J.R., Stewart, S.L., Johnston, M. & Banks, P., 1998. Intrusiveness of 
illness and quality of life in young women with breast cancer. Psycho-
oncology, 7 (2) pp.89-100. 
 
Blowers, E. & Foy, S., 2009. Breast cancer overview: current treatments. Practice 
nursing, 20 (6) pp.282-286. 
 
Boehhmke, M.M. & Dickerson, S.S., 2006. The diagnosis of breast cancer: 
transition from health to illness. Oncology nursing forum, 33 (6) pp.1121-
1127. 
 
Bonevski, B., Sanson-Fisher, R., Girgis, A., Burton, L., Cook, P. & Boyes, A., 
2000. Evaluation of an instrument to assess the needs of patients with 
cancer. Cancer, 88 (1) pp.217-225. 
 
218 
 
Boutron, I., Moher, D., Altman, D.G., Schulz, K.F. & Ravaud, P. for the 
CONSORT Group, 2008. Extending the CONSORT statement to 
randomised trials of non-pharmacologic treatment: explanation and 
elaboration. Annals of internal medicine, 148 (4) pp.295-309. 
 
Bower, J,E., Ganz, P,A., Desmond, K,A., Rowland, J,H., Meyerowitz, B,E., Belin, 
T,R.,2000. Fatigue in breast cancer survivors: Occurrence, Correlates, and 
Impact on quality of life. American Society of Clinical Oncology, 18 (4) pp. 
743-53. 
 
Boyes, A., Newel, S., Girgis, A., McElduff, P. & Sanson-Fisher, R., 2006. Does 
routine assessment and real-time feedback improve cancer patients’ 
psychosocial well-being? European journal of cancer care, 15 (2) pp.163-
171. 
 
Breast Cancer Care., 2012. Accessed from http://www.breastcancercare.co.uk on 
22nd January 2014. 
 
British Association of Surgical Oncology (BASO), 2005. Guidelines for the 
management of symptomatic breast disease. European journal of cancer 
care, 31 pp.S1-S21. 
 
Brooks, J.J., 2006. A patient’s journey: living with breast cancer. British medical 
journal, 333 (7557) pp.31-33. 
 
Brown, L., Payne, S. & Royle, G., 2002. Patient initiated follow-up of breast 
cancer. Psycho-oncology, 11 (4) pp.346-355. 
 
Burton, M., & Watson, M., 1998.Counselling people with cancer. Chichester: John 
Wiley. 
 
Budin, W,C., Cartwright-Alcarase, F., Hoskins, C, N., 2008. The breast cancer 
treatment response inventory: development, psychometric testing, and 
219 
 
refinement for use in practice. Oncology Nursing Forum, 35 (2) pp. 209-
215. 
 
Byrne, M., Cupples, M,E., Smith, S,M., Leathem, C., Corrigen, M., Byrne, M,C., 
Murphy, A,W., 2006. Development of a complex intervention for secondary 
prevention of coronary heart disease in primary care using the UK medical 
research council framework. The American Journal of Managed Care, 12 
(5) pp. 261-266. 
 
Campbell, M.,Fitzpatrick, R., Haines, A., Kinmonth, A,L., Sandercock, P., 
Spiegalhalter, D., Tyrer, P., 2000. Framework for design and evaluation of 
complex interventions to improve health. BMJ, 321 pp. 694-696. 
 
Canadian Medical association, The steering Committee on Clinical Practice 
Guidelines for the Care and Treatment of Breast Cancer., 1998. Clinical 
practice guidelines for the care and treatment of breast cancer. CMA,158 
(suppl. 3), pp.1-83. 
 
Cancer Australia., 2010. Clinical practice guidelines for management of early 
breast cancer: recommendations for follow-up of women with early breast 
cancer. Accessed from 
http://guidelines.canceraustralia.gov.au/guidelines/early_breast_cancer/ch
01.php#Ch1053Se228454 on 9th February 2014. 
 
Cancer Research UK, 2012. Breast cancer survival statistics. Accessed from 
http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/breast/survival/ on 18th January 2014. 
 
Cardoso, F., Loibl, S., Pagani, O., Graziottin, A., Panizza, P., Martincich, L., 
Gentilini, O., Peccatori, F., Fourquet, A., Delaloge, S., Marott, L., Penault-
Llorca, A,M., Rodger, A., Harbeck, N., 2012. The European Society of 
breast cancer specialists’ recommendations for the management of young 
220 
 
women with breast cancer. European Journal of Cancer, 48 pp. 3355-
3377. 
 
Carey, M., Lambert, S., Smits, R., Paul, C., Sanson-Fisher, R. & Clinton-McHarg, 
T., 2012. The unfulfilled promise: a systematic review of interventions to 
reduce the unmet supportive care needs of cancer patients. Support care 
cancer, 20 (2) pp.207-219. 
 
Carlson,L,E., & Bultz,B,D., 2004. Efficacy and medical cost offset of psychosocial 
interventions in cancer care: making the case for economic analyses. 
Psycho-Oncology, 13 (12) pp. 837-849. 
 
Carlson, L.E., Waller, A. & Mitchell, A.J., 2012. Screening for distress and unmet 
needs in patients with cancer: review and recommendations. Journal of 
clinical oncology, 30 (11) pp.1160-1177. 
 
Carroll, B.T., Kathol, R.G., Noyes, R. Jr, R., Wald, T.G. & Clamon, G.H., 1993. 
Screening for depression and anxiety in cancer patients using the hospital 
and anxiety depression scale. General Hospital Psychiatry, 15 (2) pp.69-
74. 
 
Carver, C,S., Smith, R,G., Petronis, V,M., Antoni, M,H., 2005. Quality of life 
among long-term survivors of breast cancer: different types of antecedents 
predict different classes of outcomes. Psych-Oncology, 15, pp.749-758. 
 
Cataliotti, L., et al on behalf of EUSOMA., 2007. Position paper, Guidelines on the 
standards for the training of specialized health professionals dealing with 
breast cancer. European Journal of Cancer, 43 pp. 660-675. 
 
Cecil, R., Thompson, K. & Parahoo, K., 2006. The research assessment exercise 
in nursing: learning from the past, looking to the future. Journal of clinical 
nursing, 15 (4) pp.395–402. 
 
221 
 
Chapman, D., Cox, E., Britton, P.D. & Wishart, G.C., 2009. Patient-led breast 
cancer follow-up. The breast, 18 (2) pp.100-101. 
 
Cheung, Y-B., Goh, C., Thumboo, J., Khoo, K-S. & Wee, J., 2005. Variability and 
sample size requirements of quality of life measures: a randomized study 
of three major questionnaires. Journal of clinical oncology, 23 (22) 
pp.4936-4944. 
 
Clark, A.S. & Domchet, S.M., 2011. Clinical management of hereditary breast 
cancer syndromes. Journal of mammary biology neoplasia, 16 (1) pp.17-
25. 
 
Coates, V., 2010. The RCT: a very beautiful technique.  The 2009 Janet Kinson 
lecture. Practical Diabetes, 27 (1) pp. 27-31. 
 
Cochrane, A.L., 1972. Effectiveness and efficiency: random reflections on health 
services. Abington: The Nuffield Provincial Hospitals Trust. p.2. 
 
Cohen, J.,1992. A power primer. Psychological bulletin, 112 (1) pp.155-159. 
 
Collins, R.F., Bekker, H.L. & Dodwell, D.J., 2004. Follow-up care of patient’s 
treatment for breast cancer: a structured review. Cancer treatment 
reviews, 30 (1) pp.19-35. 
 
Consolidated Standards of Reporting Trials (CONSORT)., 2010. Accessed from 
http://www.consort-statement.org/consort-statement/further-
explanations/box6_intention-to-treat-analysis/ on 9th February 2014. 
 
 
Corter, A.L., Findlay, M., Broom, R., Porter, D. & Petrie, K.J., 2013. Beliefs about 
medicine and illness are associated with fear of recurrence in women 
taking adjuvant endocrine therapy with breast cancer. British journal of 
health psychology, 18 (1) pp.168-181. 
 
222 
 
Coyne, J.C., Palmer, S.P., Shapiro, P.J., Thompson, R. & De Michele, A., 2004. 
Distress, psychiatric morbidity, and prescriptions for psychotropic 
medication in a breast cancer waiting room sample. General hospital 
psychiatry, 26 (2) pp.121-128. 
 
Craig, P., Dieppe, P., Macintyre, S., Michie, S., Nazareth, I. & Petticrew, M., 
2008. Developing and evaluating complex interventions: new guidance. 
Accessed from http://www.mrc.ac.uk/complexinterventionsguidance in July 
2013. 
 
Creswell, J, W., & Plano Clark., 2007. Designing and conducting mixed methods 
research. CA, USA: Sage Publications. 
 
Cruickshank, S., Kennedy, C., Lockhart, K., Dosser, I. & Dallas, L., 2008. 
Specialist breast care nurses for supportive care of women with breast 
cancer. Cochrane Database of Systematic Reviews. Accessed from 
http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD0056
34/frame.html  on 20th January 2014. 
 
Cruickshank, S., & Hume, A., 2014. The experience of providing support about 
menopausal symptoms to women with breast cancer. European Journal of 
Oncology Nursing, 18 (1) pp. 110-117. 
 
Cull, A., Stewart, M. & Altman, D.G., 1995. Assessment of and intervention for 
psychosocial problems in routine oncology practice. British journal of 
cancer 72 (1) pp.229-35. 
 
Curran, S.L., Andrykowski, M.A. & Studts, J.L., 1995. Short form of the profile of 
mood states (POMS-SF): psychometric information. Psychological 
assessment, 7 (1) 80-83. 
 
Davidson, P., Cockburn, J., Daly, J. & Fisher, R.S., 2004. Patient-centred needs 
assessment: rationale for a psychometric measure for assessing needs in 
heart failure. Journal of cardiovascular nursing, 19 (3) pp.164-171. 
223 
 
 
Davies, N.J. & Batechup, L., 2009. Cancer follow-up: towards a personalised 
approach to aftercare services. A review of current practice and selected 
initiatives. London: Macmillan Cancer Support. Accessed from 
http://www.ncsi.org.uk/wp-content/uploads/Follow-Up-Towards-a-
Personalised-Approach-to-Aftercare.pdf on 3rd February 2014. 
 
De Bock, G.H., Bonnema, J., van der Hage, J., Kievit, J. & van de Velde, C.J., 
2004a. Effectiveness of routine visits and routine tests in detecting isolated 
locoregional recurrences after treatment for early stage invasive breast 
cancer: a meta-analysis and systematic review. Journal of clinical 
oncology, 22 (19) pp.4010-4018. 
 
De Bock, G.H., Bonnema, J., Zwaan, R.E., van de Velde, C.J.H., Kievit, J. & 
Stiggelbout, A.M., 2004b. Patient’s needs and preferences in routine 
follow-up after treatment for breast cancer. British journal of cancer, 90 (6) 
pp.1144-1150. 
 
Degner, L.F., Davison, B.J., Sloan, J.A. & Mueller, B., 1998. Development of a 
scale to measure information needs in cancer care. Journal of nursing 
measurement, 6 (2) pp.137-153. 
 
Delon, M., Wade Evans, A., Cooper, S., Walls, C., McGillycuddy, B., Martlew, B., 
2008. Early post-op swelling and its association with lymphoedema. 
Journal of Lymphoedema, 3 (1) pp.26-30. 
 
Dellson, P., Nilbert, M., Bendahl, P-O., Malmstrom, P. & Carlsson, C., 2011. 
Towards optimised information about clinical trials, identification and 
validation of key issues in the collaboration with cancer patient advocates. 
European journal of cancer care, 20 (4) pp.445-454. 
 
Department of Health., 2011. Improving outcomes: a strategy for cancer. London: 
Department of Health. 
 
224 
 
Deshields, T., Tibbs, T., Fan, M-Y. & Yaylor, M., 2006. Differences in patterns of 
depression after treatment for breast cancer. Psycho-oncology, 15 (5) 
pp.398-406. 
 
Dinh, P., Sotiriou, C., & Piccart, M., 2007. The evolution of treatment strategies: 
aiming at the target. The Breast, 18 pp. s10-s16. 
 
Dixon, J.M. & Montgomery, D., 2008. Follow-up after breast cancer. British 
medical journal, 19 (336) pp.107-108. 
 
Dixon-Woods, M., Agarwal, S., Jones, D., Young, B. & Sutton, A., 2005. 
Synthesising qualitative and quantitative evidence: a review of possible 
methods. Journal of health services research and policy, 10 (1) pp.45-53. 
Dutch Breast Cancer Federation., 2012 The Dutch breast cancer guideline, 
available from http://www.oncoline.nl/breastcancer   on 16th February 
2014. 
 
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), 2005. Effects of 
chemotherapy and hormonal therapy on recurrence and 15-year survival: 
an overview of the randomized trials. Lancet, 365 (9472) pp.1687-1717. 
 
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).,2011. Effect of 
radiotherapy after breast conserving on 10 year recurrence and 15 year 
breast cancer death: meta-analysis of individual patient data for 10,801 
women in 17 randomised trials, Lancet 378 pp. 1707-1716. 
 
Earnshaw, J.J. & Stephenson, Y., 1997. First two years of a follow-up breast 
clinic led by a nurse practitioner. Journal of the Royal Society of Medicine, 
90 (5) pp.258-259. 
 
Eccles, S.A., Thompson, M. et al., 2013. Critical research gaps and translational 
priorities for the successful prevention and treatment of breast cancer. 
Breast Cancer Research, 15 (5) R92 pp.1-37. Accessed from http://breast-
cancer-research.com/content/15/5/R92 on 25th January 2014. 
225 
 
 
Emens, L.A. & Davidson, N.E., 2003. The follow-up of breast cancer. Seminars in 
oncology, 30 (3) pp.338-348. 
 
European Society for Medical Oncology., 2007. Primary breast cancer: ESMO 
clinical recommendations for diagnosis, treatment and follow-up. Annals of 
oncology, 18 (suppl. 2), pp.i5-i8. 
 
Ewert, M., Jensen, A, B., 2011. Late effects of breast cancer treatment and 
potentials for rehabilitation. Acta Oncologica, 50 pp.187-193. 
 
Fallowfield, L.J. & Baum, M., 1989. Psychological welfare of patients with breast 
cancer. Journal of Royal Society of Medicine, 82 (1) pp.4-5. 
 
Fallowfield, L. & George, D., 2008. Introduction to the session on “Debate: 
extended follow-up of breast cancer patients in clinic wastes time for both 
patients and doctors”. Breast cancer research, 10 (suppl. 4) pp.1-2. 
 
Farrell, G.A., 1991. How accurately do nurses perceive patients’ needs? A 
comparison of general and psychiatric setting. Journal of advanced 
nursing, 16 (9) pp.1062-1070. 
 
Fayers, P., Aaronson, N., Bjordal, K., Curran, D., Groenvold, M., 1999. EORTC 
QLQC30 Scoring manual plus supplementary modules. EORTC Data 
Center, Brussels. 
 
Ferrans, C.E., 2005. Definitions and conceptual models of quality of life. In 
Lipscomb, J., Gotay, C.C. & Snyder, C., 2005. Outcomes assessment in 
cancer: measures, methods and applications. Cambridge: Cambridge 
University Press. pp.14-30. 
 
Fenlon, D,R., Corner, J,L., Haviland, J.,2009. Menopausal hot flushes after breast 
cancer. European Journal of Cancer Care, 18 pp.140–148. 
 
226 
 
Ferrell, B.R., Grant, M., Funk, B., Otis-Green, S. & Garcia, N., 1997. Quality of life 
in breast cancer. Part 1: physical and social well-being. Cancer nursing, 20 
(6) pp.398-408 
 
Ferrell, B.R., Grant, M., Funk, B., Otis-Green S. & Garcia, N., 1998. Quality of life 
in breast cancer. Part II: psychological and spiritual well-being. Cancer 
nursing, 21 (1) pp.1-9. 
 
Ferrell, B.R., Grant, M., Garcia, N., Otis-Green, S. & Schaffner, M.L.J., 1996. 
Quality of life in breast cancer. Cancer practice, 4 (6) pp.331-340. 
 
Field, A., 2005. Discovering statistics using SPSS. 2nd ed. London: Sage. 
 
Field, A., 2013. Discovering statistics using IBM SPSS statistics. 4th ed. London: 
Sage publications. 
 
Filippakis, G, M., Zografos, G.,2007. Contraindications of sentinel lymph node 
biopsy: Are there any really? World Journal of Surgical Oncology, 5 pp.1-
11. 
 
Fitch, M.I., 1994. Providing supportive care for individuals living with cancer. 
Taskforce report. Toronto: Ontario Cancer Treatment and Research 
Foundation. 
 
Fitch, M,I., Porter, H, B., & Page, B,D., 2002. Pathway of care for cancer, p.15 IN 
Fitch, M.I., Porter, H.B. & Page, B.D., 2009. Supportive care framework: a 
foundation for person-centred care. Ontario: Pappin Communication. 
 
Fitch, M.I., 2008. Supportive care framework. Canadian oncology nursing journal, 
18 (1) pp.6-24. 
 
Fitch, M.I., Porter, H.B. & Page, B.D., 2009. Supportive care framework: a 
foundation for person-centred care. Ontario: Pappin Communication. 
 
227 
 
Folkman, S., & Greer,S., 2000. Promoting psychological well-being in the face of 
serious illness: When theory, research and practice inform each other. 
Psycho-Oncology, 9  pp.11-19. 
 
Franks, P., Williams, A & Moffatt, C., 2006. A review of the epidemiology of 
BCRL. Journal of Lymphoedema, 1 (1) pp. 66-70. 
 
Fortner, B., Okon,T., Schwartzberg, L., Tauer, K. & Houts, A.C., 2003. The 
cancer care monitor: psychometric content evaluation and pilot testing of a 
computer administered system for symptom screening and quality of life in 
adult cancer patients. Journal of pain and symptom management, 26 (6) 
pp.1077-1092. 
 
Ganz, P.A., Coscarelli, A., Fred, C., Kahn, B. & Polinsky, M.L., 1996. Breast 
cancer survivors: psychosocial concerns and quality of life. Breast cancer 
research and treatment, 38 (2) pp.183-199. 
 
Ganz, P.A., Greendale, G.A., Peterson, L., Zibecchi, L., Kahn, B. & Berlin, T.R., 
2000. Managing menopausal symptoms in breast cancer survivors: results 
of a randiomised controlled trial. Journal of National Cancer Institute, 92 
(13) pp.1054-1064. 
 
Ganz, P.A., Kwan, L., Stanton, A.L., Krupnick, J.L., Rowland, J.H., Meyerowitz, 
B.E., Bower, J.E. & Belin, T.R., 2004. Quality of life at the end of primary 
treatment of breast cancer: first results from the moving beyond cancer 
randomised trial. Journal of National Cancer Institute, 96 (5) pp.376-387. 
 
Ganz, P.A., Schag, C.A.C., Lee, J.J. & Sim, M.S., 1992. The CARES: a generic 
measure of health related quality of life for patients with cancer. Quality of 
life research, 1 (1) pp.19-29. 
 
Gerrish, K., & Lacey, A., 2006. The research process in Nursing. London: 
Blackwell. 
 
228 
 
Girgis, A., Boyes, A., Sanson-Fisher, R. & Burrows, S., 2000. Perceived needs 
of women diagnosed with breast cancer: rural versus urban location. 
Australian and New Zealand journal of public health, 24 (2) pp.166-173. 
 
Gligorov, J., Pritchard, K. & Goss, P., 2007. Adjuvant and extended adjuvant 
used of aromatase inhibitors: reducing the risk of recurrence and distant 
metastasis. The breast, 16 (3) pp.S1-S9. 
 
Goldhirsch, A., Glick, J,H., Coates,A,S., Thulmann,B., Senn, H-J., and panel 
members., 2005. Meeting highlights: International expert consensus on the 
primary therapy of early breast cancer. Annals of Oncology, 16 pp. 1569-
1583. 
 
Goldhirsch, A., Winer, E.P., Coates, A.S., Gelber, R.D., Piccart-Gebhart, M., 
Thurliman, B., Senn, H. & Panel Members, 2013. Personalising the 
treatment of women with early breast cancer: highlights of the St Gallen 
international expert consensus on the primary therapy of early breast 
cancer 2013. Annals of oncology, 24 (9) pp.2206-2013. 
 
Gotay,C., 2006. Increasing trial generalizability. Journal of clinical oncology, 24 
(6) pp.846-847. 
 
Greendale, G.A., Lee, N.P. & Arriola, E.R., 1999. The menopause. Lancet, 353 
(9152) pp.571-580. 
 
Greenhalgh, T. & Peacock, R., 2005. Effectiveness and efficiency of search 
methods in systematic reviews of complex evidence: audit of primary 
sources. British medical journal, 331 (7524) pp.1064-1065. 
 
Grov, E.K., Dahl, A.A., Moum, T. & Fosså, A., 2005. Anxiety, depression, and 
quality of life in caregivers of patients with cancer in late palliative phase. 
Annals of oncology, 16 (7) pp.1185-1191. 
 
229 
 
Grunfeld, E., Dhesy-Thind, S. & Levine, M., 2005. Clinical practice guidelines for 
the care and treatment of breast cancer (summary of the 2005 update). 
Canadian medical association guidelines, 172 (10) pp.1319-1320. 
 
Grunfeld, E., Levine, M.N., Julian, J.A., Coyle, D., Szechtman, B., Mirsky, D., 
Verma, S., Dent, S., Sawka, C., Pritchard, K., Wood, M. & Whelan, T., 
2006. Randomized trial of long-term follow-up for early stage breast 
cancer: a comparison of family physician versus specialist care. Journal of 
clinical oncology, 24 (6) pp.848-855. 
 
Guba, E.G. & Lincoln, Y.S., 1998. Competing paradigms in qualitative research. 
In: Denzin, N.K. & Lincoln, Y.S., eds., 1998. The landscape of qualitative 
research. London: Sage. pp.195-220. 
 
Gupta, S,K., 2011. Intention to treat concept: A review.  Perspectives in Clinical 
Research, 2 (3) pp. 109-112. 
 
Gustafson, D.H., 2005. Needs Assessment in Cancer. In: Lipscomb, J., Gotay, 
C.C. & Snyder, C., 2005. Outcomes assessment in cancer: measures, 
methods and applications. Cambridge: Cambridge University Press. 
pp.305-328. 
 
Guyatt, G., Oxman, A., Akl, E.I., Kunz, R., Vist, R., Brozek, J., Norris, S., Falck-
Ytter, Y., Glasziou, P., de Beer, H., Jaeschke, R., Rind, D., Meerpohl, J., 
Dahm, P. & Schunemann, H.J., 2011. GRADE guidelines: 1. Introduction - 
GRADE evidence profiles and summary of findings tables. Journal of 
clinical epidemiology, 64 (4) pp.383-394. 
 
Hagedorm, M., Uijl, S.G., Van Somderen, E., Ranchor, A.V., Grol, B.M., Otter, R., 
Krol, B., Van den H.W., Sanderman, R., 2003. Structure and reliability of 
Ware’s satisfaction questionnaire  111 (should be roman numerals but 
can’t find it): patients satisfaction with oncological care in the Netherlands. 
Medical Care, 41 pp. 254-263.  
 
230 
 
Hall, A., A’Hern, R. & Fallowfield, l., 1999. Are we using appropriate self-report 
questionnaires for detecting anxiety and depression in women with early 
breast cancer? European journal of cancer, 35 (1) pp.79-85. 
 
Halkett, G, K, B., 2007.The phenomenon of making decisions during the 
experience of early breast cancer. European Journal of Cancer Care, 16 
pp. 322-330. 
 
Harris, P., Remington P., Trentham-Dietz, A., Allen, C. & Newcomb, P., 2002. 
Prevalence and treatment of menopausal symptoms among breast cancer 
survivors. Journal of pain and symptom management, 23 (6) pp.501-509. 
 
Hawe, P., Shiell, A., Riley, T., 2004. Complex interventions: how “out of control” 
can a randomised controlled trial be? BMJ, 328 pp.1561-1563. 
 
Hicks C. & Hennessay, D., 1997. Mixed messages in nursing research: their 
contribution to the persisting hiatus between evidence and practice. 
Journal of advanced nursing, 25 (3) pp.595-601. 
 
Hicks, D,G., Kulkarni, S.,2008. Trastuzumab as adjuvant therapy for early breast 
cancer. Arch Pathology Laboratory Medicine, 132  pp.1008-1015. 
 
Hickey, A., Saunder, C., Partridge, A., Santoro, N., Joffee, h., Stearns, V., 2008. 
Practical clinical guidelines for assessing and managing menopausal 
symptoms after breast cancer.  Annals of Oncology, 19 pp. 1669-1680. 
 
Higgins, J.P.T. & Green, S,M., eds., 2011. Cochrane handbook for systematic 
reviews of interventions, version 5.1.0. London: The Cochrane 
Collaboration. Accessed from www.cochrane-handbook.org on 10th July 
2012. 
 
Higginson, I,J., Vivat, B., Silber, E., Saleem, T., Burman, R., Hart, S., Edmonds, 
P., 2006. Study protocol: delayed intervention randomised controlled trial 
within medical research council (MRC) Framework to assess the 
231 
 
effectiveness of a new palliative care service. BMC Palliative Care,  5 (7) 
pp.1-11. 
 
Holmes, C.A. & Warelow, P.J., 1997. Culture, needs and nursing: a critical theory 
approach. Journal of advanced nursing, 25 (3) pp.463-470. 
 
Holzner B., Kemmler, G., Kopp, M., Moschen, R., Schweigkofler, H., Dunser, M., 
Margreiter, R., Fleishhacker, W. & Sperner-Unterweger, B., 2001. Quality 
of life in breast cancer patients – not enough attention for long-term 
survivors. Psychosomatics, 42 (2) pp.117-123. 
 
Horsburgh, D., 2003. Evaluation of qualitative research. Journal of clinical 
nursing, 12 (2) pp.307-312. 
 
Houssami, N., Cuzick, J., Dixon, J,M., 2006. The prevention, detection and 
management of breast cancer. Medical Journal of Australia, 184 (5) pp. 
230-234. 
 
Hunter, M.S., Coverntry, S., Hamed, H., Fentiman, I., Grunfeld, E.A., 2009. 
Evaluation of a group cognitive behavioural intervention for women 
suffering from menopausal symptoms following breast cancer treatment. 
Psych-Oncology. 18 pp. 560-563 
 
Ipsos Mori., 2011. National Cancer Survivorship Initiative Evaluation of adult 
cancer aftercare services – Wave 1 Report.  Accessed from 
http://www.ipsos-
mori.com/researchpublications/publications/1608/National-Cancer-
Survivorship-Initiative-Wave-1-Evaluation.aspx on 9th February 2014. 
 
IBM Corp, release., 2011. IBM SPSS statistics for windows, ver 20.0, NY: IBM 
Corp. 
 
Information Services Division, Scotland., 2010. Breast cancer statistics. 
Edinburgh: NHS National Services Scotland. Accessed from 
232 
 
http://www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/Breast/ 
on 25th January 2014. 
 
Ingram, R., 1998. Power analysis and sample size estimation. NT Research, 3 (2) 
pp.132-138. 
 
Isasi, C, R., Moadel, R,M., Donald Blaufox, M., 2005. A meta-analysis of FDG-
PET for the evaluation of breast cancer recurrence and metastases. Breast 
Cancer Research and Treatment, 90  pp.105-112. 
 
Jadad, A., 1998. Randomised controlled trials: a user’s guide. London: British 
Medical Journal. 
 
Judkins, A.F., Peterson, S.K. & Singletary, E.S., 1996. Satisfaction of breast 
cancer patients with a nonphysician-provider model of long term follow-up 
care. Breast disease, 9 (3) pp.139-144. 
 
 
 
Karakoyun-Celik, O., Gorken, I., Sahin, S., Orcin, E., Alanyali, H. & Kinnay, M., 
2010. Depression and anxiety levels in woman under follow-up for breast 
cancer: relationship to coping with cancer and quality of life. Medicine 
oncology, 27 (1) pp.108-113. 
 
Kimman, M.L., Benedict, G.C., Boersma, L.J., Lambin, P. & Dirksen, C.D., 2010. 
Follow-up after treatment for breast cancer: one strategy fits all? An 
investigation of patient preferences using a discrete choice experiment. 
Acta oncologica, 49 (3) pp.328-337. 
 
Kimman, M.L., Voogd, A.C., Dirksen, C.D., Falger, P., Hupperets, P., Keymeulen, 
K., Hebly, M., Dehing, C., Lambin, P. & Boersma, L.J., 2007. Improving the 
quality and efficiency of follow-up after curative treatment for breast cancer 
– rationale and study design of the MaCare trial. Accessed from 
http://www.biomedcentral.com/1471-2407/7/1 on 25th January 2014. 
233 
 
 
Kimman, M,L., Dirken, C,D., Voogd, A, C., Falger, P., Gijsen, B,C,M., Thuring,M., 
Lenssen, A., van der Ent, F., Verkeyn, J., Haekens, P., Hupperets, P., 
Nuytinck, J,K,S., van Riet, Y., Brenninkmeijer, S,J., Scheijmans, L,J,E,E., 
Kessels, A., Lambin, Ph., Boersma,L,J., 2011. Nurse-led telephone follow-
up and an educational group programme after breast cancer treatment: 
Results of a 2x2 randomised controlled trial. European Journal of Cancer, 
47 pp.1027-1036. 
 
Knobf, M.T., 2001. The menopausal symptom experience in young mid-life 
women with breast cancer. Cancer nursing, 24 (3) pp.201-211. 
 
Knobf, M,T., 2007. Psychosocial responses in breast cancer survivors. Seminars 
in Oncology Nursing, 23 (1) pp.71-83. 
 
Koinberg, I.L., Engholm, G.B., Genell, A. & Holmberg, L., 2009. A health 
economic evaluation of follow-up after breast cancer surgery: results of an 
RCT study. Acta oncologica, 48 (1) pp.99-104. 
 
Koinberg, I.L., Fridlund, B., Engholm, G.B. & Holmberg, L., 2004. Nurse-led 
follow-up on demand or by a physician after breast cancer surgery: a 
randomized study. European journal of oncology nursing, 8 (2) pp.109-
117. 
 
Lancaster, G.A., Dodd, S. & Williamson, P.R., 2004. Design and analysis of pilot 
studies: recommendations for good practice. Journal of evaluation in 
clinical practice, 10 (2) pp.307-312. 
 
Lee, T,S., Kilbreath, S,L., Refshauge, K, M., Herbert, R,D., Beith, J,M., 2008. 
Prognosis of the upper limb following surgery and radiation for breast 
cancer.  Breast Cancer Research Treatment, 110 pp. 19-37. 
 
Leining, M.G,. Gelber, S., Rosenberg, R., Przypyszny, M., Winer, E.P., Partridge 
A.H, (2006) Menopausal-type symptoms in young breast cancer survivors. 
Annals Oncology. 17 (12) pp.1777-82. 
 
234 
 
Lindop, E. & Cannon, S., 2001. Evaluating the self-assessed support needs of 
women with breast cancer. Journal of advanced nursing, 34 (6) pp.760-
771. 
 
Lipscomb, M., 2012. Questioning the use value of qualitative research findings. 
Nursing philosophy, 13 (2) pp.112–125. 
 
Loftus, L.A. & Weston, V., 2001. The development of nurse-led clinics in cancer 
care, Journal of clinical nursing, 10 (2) pp.215-220. 
 
Maddams, J., Brewster, D., Gavin, A., Stewart, J., Elliott, J., Utley, M. & Moller, 
H., 2009. Cancer prevalence in the United Kingdom: estimates 2008. 
British Journal of Cancer, 101 (3) pp.541-547. 
 
Maguire,G,P., Lee, E,G., Bevington, D,J.,Kuchemann, C,S., Crabtree, R,J., 
Cornell, C,E., 1978. Psychiatric problems in the first year after 
mastectomy. British Medical Journal, 1 pp. 963-965. 
 
Maguire, P., Brooke, M., Tait, A., Thomas, C. & Sellwood, R., 1983. The effect of 
counselling on physical disability and social recovery after mastectomy. 
Clinical oncology, 9 (4) pp.319-324. 
 
Mann, E., Smith, M,J., Hellier, J., Balabanovic, J,A., Hamed, H., Grunfeld, E., 
Hunter, S., 2012. Cognitive behavioural treatment for women who have 
menopausal symptoms and breast cancer treatment, MENO1: a 
randomised controlled trial., 2012. Lancet Oncology, 13 pp. 309-318. 
 
Manley, K. & McCormack, P., 2008. Person-centred care. Nursing management, 
15 (8) pp.12-13. 
 
Mansel, R,E., Fallowfield, L., Kissin, M., Goyal, A., Newcombe, R, G., Dixon, M, 
J., Yiangou, C., Horgan, K., Bundred, N.,Monypenny, I., England, D., 
Sibbering, M., Abdullah, T, L., Barr, L., Chetty, U., Sinnett, D, H., fleisig, A., 
Clark, D., Ell, P,J., 2006. Randomized multicenter Trial of Sentinel node 
biopsy versus standard axillary treatment in operable breast cancer: The 
235 
 
ALMANAC TRIAL. Journal of the National Cancer Institute 98 (2) pp.599-
609. 
 
Mantzoukas, S., 2008. A review of evidence-based practice, nursing research 
and reflection: leveling the hierarchy. Journal of clinical nursing, 17 (2) 
pp.214-223. 
 
Marx, K., 1964. Precapitalist economic formations….Translated….by Jack Cohen. 
London: Lawrence & Wishart. 
 
Maslow, A., 1943. A theory of human motivation. Psychology review, 50 (1943) 
pp.370-396. 
 
Maslow, A,H., 1987. The theory of human motivation. In: Maslow, A,H., 
Motivation and personality 3rd ed. London: Harper & Row. Chapter 2 pp. 
15-31 
 
Matterella, A., 2010. Breast cancer in men. Radiologic technology, 8 (4) pp.361-
378. 
 
Maynard, A., 1999. Commentary: clinical governance: the unavoidable economic 
challenges. Nursing times research, 4 (3) pp.189-191. 
 
McArdle, J,M., Hughson, A,V,M., McArdle, C,S.,Smith, C., 1990. Reduced 
psychological morbidity after breast conservation. British Journal of 
Surgery, 77 pp. 1221-1223. 
 
McCaughan, E. & McSorley, O., 2007. Consumers’ and professionals’ 
perceptions of a breast cancer review clinic. Journal of advanced nursing, 
60 (4) pp.419-426. 
 
McCowan, C., Wang, S., Thompson, A, M., Makubate, B., Petrie, D, J., 2013. The 
value of high adherence to Tamoxifen in women with breast cancer: a 
community based cohort study. British Journal of Cancer, 109 pp.1172-
1180. 
236 
 
 
McDowell, M.E., Occhipinto, S., Ferguson, M., Dunn, J. & Chambers, S.K., 2010. 
Predictors of change in unmet supportive care needs in cancer. Psycho-
oncology, 19 (5) pp.508-516. 
 
McIntosh, J., Fowler, C.A., 2011. Patient satisfaction with nurse-led follow-up for 
breast cancer: A questionnaire study. The Breast Journal, 17 (2) pp.213-
214. 
 
McKinley, E.D., 2000. Under toad days: surviving the uncertainty of cancer 
recurrence. Annals of internal medicine, 133 (60) pp.479-480. 
 
McLachlan, S-A., Allenby, A., Mathews, J., Wirth, A., Kisane, D., Bishop, M., 
Beresford, J. & Zalcberg, J., 2001. Randomized trial of coordinated 
psychosocial interventions based on patient self-assessments versus 
standard care to improve the psychosocial functioning of patients with 
cancer. Journal of clinical oncology, 19 (21) pp.4117-4125. 
 
McPhail, G., 1999. Menopause as an issue for women with breast cancer. Cancer 
nursing, 22 (2) pp.164-171. 
 
Medical Research Council, 2000. A framework for the development and 
evaluation of RCT’s for complex interventions to improve health. London: 
Medical Research Council. 
 
Millar, K., Purushotham, A.D., McLatchie, E., George, W.D. & Murray, G.D., 2005. 
A 1-year prospective study of individual variation in distress, and illness 
perceptions, after treatment for breast cancer. Journal of psychosomatic 
research, 58 (4) pp.335-342. 
 
Minstrel, M., Winzenberg, T., Rankin, N., Hughes, C. & Walker, J., 2008. 
Supportive care of rural women with breast cancer in Tasmania, Australia: 
needs over time. Psycho-oncology, 17 (1) pp.58-65. 
 
237 
 
Mitchell, A, J., Kaar, S., Coggan,C., Herdman, J., 2008. Acceptability of common 
screening methods used to detect distress & related mood disorders – 
preferences of cancer specialists and non-specialists, Psycho-Oncology, 
17 pp. 226-236. 
 
Mohler, R., Bartoszek, G., Kopke, S. & Meyer, G., 2010. Proposed criteria for 
reporting the development and evaluation of complex interventions in 
healthcare (CReDECI): guideline development. International journal of 
nursing studies, 49 (1) pp.40–46. 
 
Molino, A., 2008. What is the best follow-up methodology in early breast cancer? 
The breast, 17 (1) pp.1-2. 
 
Montazeria, A., Gillies, R., McEwen, J., 1996. Measuring quality of life in 
oncology: is it worthwhile? 1. Meaning, purpose and controversies, 
European. Journal of Cancer, 5 pp.159-67. 
 
Montgomery, D.A., Krupa, K. & Cooke, T.G., 2007. Follow-up in breast cancer: 
does routine clinical examination improve outcome? A systematic review of 
the literature. British journal of cancer, 97 (12) pp.1632-1641. 
 
Montgomery, D.A., Krupa, K., Wilson, C. & Cooke, T.G., 2008. Patients’ 
expectations for follow-up in breast cancer – a preliminary, questionnaire-
based study. The breast, 17 (4) pp.347-352. 
 
Moss, L.S., Starbuck, M.F., Mayer, D.K., Harwood, E.B. & Glotzer, J., 2009. 
Trastuzumab-induced cardiotoxicity. Oncology nursing forum, 36 (6) 
pp.676-685. 
 
Nagel, G.C., Schmidt, S., Strauss, B.M. & Katenkamp, D., 2001. Quality of life in 
breast cancer patients: a cluster analytic approach. Empirically derived 
subgroups of the EORTC-QLQ BR 23: a clinically oriented assessment. 
Breast cancer research and treatment, 68 (1) pp.75–87. 
 
238 
 
Nail, L, M., 2006. Cognitive changes in cancer survivors. American Journal of 
Nursing, 106 (3) (suppl) pp. 48-54. 
 
National Breast Cancer Centre., 2005. Specialist breast care nurse competency 
standards and educational requirements.  Australia: National Breast 
Cancer Centre.  
 
National Cancer Intelligence Network., NCIN., 2011. The Second  All Breast 
Cancer Report. NCSI. 
 
National Cancer Comprehensive Network., NCCN, 2003. Distress Management 
Guidelines. Journal National Comprehensive Cancer Network, 1 (3) pp. 
344-74. 
 
National Comprehensive Cancer Network., 2014. Practice guidelines in oncology 
(NCCN Guidelines Breast Cancer v1.2014). Accessed from 
http://www.nccn.org/professionals/physician_gls/f_guidelines_nojava.asp#
site on 25th January 2014. 
 
National Cancer and Survivorship Initiative., 2014. Accessed from 
http://www.ncsi.org.uk/  on 18th February. 
 
National Institute for Clinical Excellence (NICE), 2004. Guidance on cancer 
services – improving outcomes in breast cancer. Accessed from 
http://www.nice.org.uk/pdf/Improving_outcomes_breastcancer_manual.pdf 
on 25th January 2014. 
 
National Institute for Clinical Excellence (NICE), 2009. Early and locally advanced 
breast cancer: diagnosis and treatment (NICE Guideline: CG80). Cardiff: 
National Collaborating Centre for Cancer. Accessed from 
http://www.nice.org.uk/CG80 on 25th January 2014. 
 
239 
 
Neal, A.J. & Hoskins, P.J., 2009. Breast cancer. In: Neal, A.J. & Hoskins, P.J., 
2003. Clinical oncology: basic principles and practice. 4th  ed. London: 
Hodder Arnold. pp. 89-115. 
 
NHS Education for Scotland., 2014.Person centred care accessed from 
http://www.nes.scot.nhs.uk/education-and-training/by-theme-
initiative/public-health/health-improvement/current-health-improvement-
work/person-centredness.aspx on 18th February 2014. 
 
NHS Information Centre for health and social care. 2011. National Mastectomy 
and breast reconstruction audit. Leeds: The NHS Information Centre. 
 
NHS Improving Quality., 2014. Accessed from http://www.nhsiq.nhs.uk/ 
 on 20th February 2014. 
 
Nordman, I.C., Dalley, D.N., 2008. Breast cancer in men - should aromatase 
inhibitors become first line hormonal treatment? The breast, 14 (6) pp.562-
569. 
 
Noseworthy, J, H., Ebers, G, C., Vandervoort, M, K., Farquhar, R, E., Yetisir, E., 
Roberts, R., 1994. The impact of blinding on the results of a randomised, 
placebo-controlled multiple sclerosis clinical trial. Neurology, 44, pp.16-20. 
 
Nursing and Midwifery Council.,2008. NMC code of professional conduct: 
standards for conduct, performance and ethics. Accessed from 
http://www.nmc-uk.org/Publications/Standards/The-code/Introduction/  on 
7th February 2014. 
 
Nursing and Midwifery Council.,2007. NMC Record Keeping guidance. Available 
from http://www.nmc-uk.org/Publications/Guidance/ on 7th February 2014.  
 
Nursing and Midwifery Council., 2006a. Confidentiality.  Available from 
http://www.nmc-uk.org/Nurses-and-midwives/Regulation-in-
240 
 
practice/Regulation-in-Practice-Topics/Confidentiality/ on 7th February 
2014. 
 
Nursing and Midwifery Council., 2006b. Consent.  Available from: 
http://www.nmc-uk.org/Nurses-and-midwives/Regulation-in-
practice/Regulation-in-Practice-Topics/consent/ on 7th February 2014. 
 
O’Cathain, A., Murphy, E. & Nicholl, J., 2008. The quality of mixed methods 
studies in health services research. Journal of health services research & 
policy, 13 (2) pp.92-98. 
 
Office for National Statistics., 2008. Cancer statistics registrations: registrations of 
cancer diagnosed in 2005, England (Series MB1 number 36). London: 
Office for National Statistics. 
 
Osaba, D., Bezak, A., Brundage, M., Zee, B., Dongsheng, T., Pater, J., for the 
quality of life committee of the NCIC CTG., 2005. Analysis and 
interpretation of health-related quality of life data from clinical trials: basic 
approach of the National Cancer Institute of Canada Clinical Trials Group. 
European Journal of Cancer, 41 pp. 280-287. 
 
Osborne, R,H., Elsworth, G,R., Sprangers, M,A,G., Oort, F,J., Hopper, J,L., 2004. 
The value of the Hospital Anxiety and Depression Scale (HADS) for 
comparing women with early onset breast cancer with population-based 
reference women.  Quality of Life Research, 13 pp.191-206. 
 
Oxlad, M., Wade, T.D., Hallsworth, L.B. & Koczwara, B., 2008. “I’m living with a 
chronic illness, not . . . dying with cancer”: a qualitative study of Australian 
women’s self-identified concerns and needs following primary treatment for 
breast cancer. European journal of cancer care, 17 (2) pp.157-166. 
 
Palacios, S., Henderson, V., Siseles, N., Tan, D. & Vilaseca, P., 2010. Age of 
menopause and impact of climacteric symptoms by geographical region. 
241 
 
Climateric: The Journal of the International Menopause Society, 13 (5) 
pp.419-428. 
 
Parahoo, K., 1997. Nursing research, principles, process and issues. London: 
Macmillan. 
 
Palmieri, C., Patten, D, K., Januszewski, A., Zucchini, G., Howell, S.J., 2014. 
Breast cancer: current and future endocrine therapies. Mollecular and 
Cellular Endocrinology, 381 (1) pp.695-723. 
 
Patterson, S., Mairs, H., Borschmann, R., 2011. Successful recruitment to trials: a 
phased approach to opening gates and building bridges. BMC Medical 
Research Methodology, 11 pp.. 1-6. 
 
Pelusi, J., 2006. Sexuality and Body Image: Research on breast cancer survivors 
documents altered body image and sexuality. Cancer Nursing, 
Supplement: 29 (2) pp. 32-38. 
 
Pennery, E. & Mallet, J., 2000. A preliminary study of patients’ perceptions of 
routine follow-up after treatment for breast cancer. European journal of 
oncology nursing, 4 (3) pp.138-47. 
 
Perera, R., Heneghan, C. & Yudkin, P., 2007. Graphical method for depicting 
randomised trials of complex interventions. British medical journal,  334 
(7585) pp.127-129. 
 
Perreault, A., & Fothergill Bourbonnais, F., 2005. The experience of suffering as 
lived by women with breast cancer. International Journal of Palliative 
Nursing, 11 (10) pp. 510-519. 
 
Pestalozzi, B.C., Luporsi-Gely, E., Jost, L.M. & Bergh, J., 2005. ESMO minimum 
clinical recommendations for diagnosis, adjuvant treatment and follow-up 
of primary breast cancer. Annals of oncology, 16 (suppl. 1) pp.i7-i9. 
 
242 
 
Pinto, A,C., de Azambuja E., 2011. Improving quality of life after breast cancer: 
Dealing with symptoms. Maturitas, 70 pp. 343-348 
 
Plant, R., Lesser, H., Taylor-Gooby, P., 1980. Political philosophy and social 
welfare: essays on the basis of welfare provision. London: Routledge & 
Kegan Paul. 
 
Pluye, P., Gagnon, M-P., Griffiths, F. & Johnson-Lafleur, J., 2009. A scoring 
system for appraising mixed methods research, and concomitantly 
appraising qualitative, quantitative and mixed methods primary studies in 
mixed review studies. International journal of nursing studies, 46 (4) 
pp.529-546. 
 
Polit, D.E. & Beck, C.T., 2004. Nursing research principles and methods. 7th ed. 
Philadelphia: Lippincott Williams and Wilkins. 
 
Polit, D.F. & Sherman, R.E., 1990. Statistical power in nursing research. Nursing 
research, 39 (6) pp.365-369. 
 
Poole, K. & Jones, A., 1996. A re-examination of the experimental design for 
nursing research. Journal of advanced nursing, 24 (1) pp.108-114. 
 
Raupach, J. & Hiller, J.E., 2002. Information and support for women following the 
primary treatment of breast cancer. Health expectations, 5 (4) pp.289-301. 
 
Reddy, M. & Given-Wilson, R., 2006. Screening for breast cancer. Women’s 
health medicine, 3 (1) pp.22-27. 
 
Richardson, A., Medina, J. & Brown, V., 2007. Patients’ needs assessment in 
cancer care: a review of assessment tools. Cancer, 15 (10) pp.1125-1144. 
 
Roche, N., 2006. Follow-up after treatment for breast cancer in young women 
with breast cancer. The breast, 15 (suppl. 2) pp.S71-S75. 
 
243 
 
Rojas, M.P., Telaro, E., Russo, A., Moschetti, I., Coe, L., Fossati, R., Palli, D., 
Roselli del Turco, M. & Liberati, A., 2009. Follow-up strategies for women 
treated for early breast cancer. Cochrane Database of Systematic Reviews 
(4). Accessed from http://dx.doi:10.1002/14651858.CD001768.pub2  on 
10th July 2013. 
 
Roger, A., Stebbing, J., Thompson, M., 2006. Breast Cancer (non-metastatic). 
Clinical Evidence, 15, pp.1-34. 
 
Rose, P,W., & Watson,E., 2009. What is the value of routine follow-up after 
diagnosis and treatment of cancer? British Journal of General Practice, 59 
(564) pp. 482-483. 
 
Royal College of Nursing, 2007. Clinical standards for working in a breast 
specialty: RCN guidance for nursing staff. Accessed from 
http://www.rcn.org.uk/publications on 9th February 2014. 
 
Rutgers, E.J., 2004. Follow-up in breast cancer. Expert review of anti-cancer 
therapy, 4 (2) pp.212-218. 
 
Ryan, L., Golden, A., 2006. ‘Tick the box please’: A reflexive approach to doing 
quantitative social research. Sociology, 40 (6) pp.1191-1200. 
 
Sakorafas, G.H., Tsiotou, A.G. & Pavlakis, G., 2000. Follow-up after primary 
treatment for breast cancer. Acta oncologica, 39 (8) pp.935-940. 
 
Sanson-Fisher, R.W., Carey, M. & Paul, C., 2009. Measuring unmet needs of 
those with cancer: a critical overview. Cancer forum, 33 (3) pp.198-201. 
 
Sanson-Fisher, R., Girgis, A., Boyes, A., Bonevski, B., Burton, L., Cook, P. and 
the Supportive Care Review Group, 2000. The unmet supportive care 
needs of patients with cancer. Cancer, 88 (1) pp.226–237. 
 
244 
 
Schipper, H., Clinch, J., McMurray, A. & Levitt, M., 1984. Measuring the quality of 
life of cancer patients: the functional living index – Cancer: development 
and validation. Journal of clinical oncology, 2 (5) pp.472-483. 
 
Schmid-Buchi, S., Halfens, R.J.G., Dassen, T. & van den Borne, B., 2008. A 
review of psychosocial needs of breast cancer patients and their relatives. 
Journal of clinical nursing, 17 (21) pp.2895-2909. 
 
Schwartz, C.E., Mirjam, S. & Spranger, A.J., 2002. An introduction to QOL 
instruments in oncology: the value of measuring patient-reported 
outcomes. The American journal of managed care, 8 (18) pp.S550-S559. 
 
Scottish Cancer Advisory Network, 2009. Accessed from 
http://www.scan.scot.nhs.uk/HealthProfessionals/Pages/default.aspx  on 
25th January 2014. 
 
Scottish Executive., 2004. Knowledge and Skills Framework. Edinburgh, 
Department of Health. 
 
Scottish Executive., 2006.Radiotherapy activity planning for Scotland 2011-2015. 
Edinburgh: NHS Scotland. 
 
Scottish Government., 2008. Better Cancer Care, An action plan. Edinburgh: 
Scottish Government. 
 
Scottish Government., 2009. Cancer waiting times. Accessed from 
http://www.scotland.gov.uk/News/Releases/2012/03/cancer-waiting-times-
27032012 on 25th January 2014. 
 
Scottish Government.,2010a. The Healthcare Quality Strategy for NHSScotland, 
Edinburgh: Scottish Government. 
 
245 
 
Scottish Government.,2010b. Better Cancer Care Progress report. Edinburgh: 
Scottish Government. Accesed from 
http://www.scotland.gov.uk/Topics/Health/Services/Cancer/Progress-
Report-2010 on 22nd January 2014. 
 
Scottish Government, 2012. Scottish index of multiple deprivation. Accessed from 
http://simd.scotland.gov.uk/publication-2012/ 9th  February 2014. 
 
Scottish Government, 2013.  Transforming care after treatment. Accessed from 
http://www.scotland.gov.uk/Topics/Health/Services/Cancer/TCAT on 9th 
February 2014. 
 
Scottish Intercollegiate Guideline Network., 2005. Management of breast cancer 
in women: a national guideline. (Guideline 84).  
 
Scottish Intercollegiate Guideline Network, 2013. Management of primary breast 
cancer. Edinburgh: SIGN [SIGN Guideline: 134]. Accessed from 
http://www.sign.ac.uk/pdf/SIGN134.pdf on 25th January 2014. 
 
Senn, H-J., 2006. Significance and usefulness of guidelines. Breast care, 1 (4) 
pp.220-222. 
 
Shapiro,C,L., Recht, A., 2001.Side effects of adjuvant treatment of breast cancer. 
The New England Journal of Medicine, 344 (26) pp.1997-2009. 
 
Sheppard, C., 2007. Breast cancer follow up: literature review and discussion. 
European journal of oncology nursing, 11 (4) pp.340-347. 
 
Sheppard, C., Higgins, B., Wise, M., Yiangou, D., Dubois, D. & Kilburn, S., 2009. 
Breast cancer follow-up: a randomised controlled trial comparing point of 
need access versus routine 6-monthly clinical review. European journal of 
oncology nursing, 13 (1) pp.2-8. 
 
246 
 
Shuldham, C. & Hiley, C., 1997. Randomized controlled trials in clinical practice: 
the continuing debate. NT research, 2 (2) pp.128-135. 
 
Shultz, P.N., Klein, M.J., Beck, M.L., Stava, C. & Sellin, R.V., 2005. Breast 
cancer: relationship between menopausal symptoms, physiologic health 
effects of cancer treatment and physical constraints on quality of life in 
long-term survivors. Journal of clinical nursing, 14 (2) pp.204-211. 
 
Sibbald, B. & Martin, R., 1998. Understanding controlled trials: why are 
randomised controlled trials important? British medical journal, 316 (7126) 
p.201. 
 
Skills for Health., 2006. Accessed from  http://www.skillsforhealth.org.uk/ on 4th 
March 2014. 
 
Slamon, DJ., Clark, GM.,Wong, SA.,1987. Human breast cancer: Correlation of 
relapse and survival with amplification of HER-2/neu proto-oncogene. 
Science, 235 pp.177. 
 
Sloan, J.A., Aaronson, N., Cappelleri, J.C., Fairclough, D.L. & Varricchio, C., 
2002. Clinical significance consensus meeting group: assessing the clinical 
significance of single items relative to summated scores. Mayo clinic 
proceedings, 77 (5) pp.479-87. 
 
Sprangers, M.A., Groenvold, M. & Arraras, J.I., Franklin, J., te Velde, A., Muller, 
M., Franzini, L., Williams, A., de Haes, H.C., Hopwood, P., Cull, A. & 
Aaronson, N.K., 1996. The European Organisation for Research and 
Treatment of Cancer breast cancer-specific quality-of-life questionnaire 
module: first results from a three country field study. Journal of clinical 
oncology, 14 (10) pp.2756-2768. 
 
Stanton, A.L., 2006. Psychosocial concerns and interventions for cancer 
survivors. Journal of clinical oncology, 24 (32) pp.5132-5137. 
 
247 
 
Stegall Moss, L., Fields Starbuck, M., Mayer, D,K., Brooks Harwood, E., Glotzer, 
J., 2009. Trastuzumab-Induced Cardiotoxicity. Oncology Nursing Forum, 
36 (96) pp. 676-685.  
 
Stephenson, J. & Imrie, J., 1998. Why do we need randomised controlled trials to 
assess behavioural interventions? British medical journal, 316 (7131) 
pp.611-613. 
 
Stricker, C.T., 2007. Endocrine effects of breast cancer treatment. Seminars in 
oncology, 23 (1) pp.55-70. 
 
Thewes, B., 2000. Development of a breast cancer survivor’s module. 
Unpublished MPsych thesis: University of Sydney, Australia. 
 
Thewes, B., Butow, P., Girgis, A. & Pendlebury, S., 2004. The psychosocial 
needs of breast cancer survivors: a qualitative study of the shared and 
unique needs of younger versus older survivors. Psycho-oncology, 13 (5) 
pp.177-189. 
 
Thewes, B., Meiser, B., Rickard, J. & Friedlander, M., 2003. The fertility- and 
menopause-related information needs of younger women with a diagnosis 
of breast cancer: a qualitative study. Psycho-oncology, 12 (5) pp. 500-511. 
 
Thompson, C., 2004. Fortuitous phenomena: On complexity, pragmatic 
randomised controlled trials, and knowledge for evidence-based practice. 
Worldviews on Evidence-based Nursing, 1 pp.9-17. 
 
Thompson, H.S., Littles, M., Jacobs, S. & Coker, C., 2006. Post-treatment breast 
cancer surveillance and follow-up care experiences of breast cancer 
survivors of African descent: an exploratory qualitative study. Cancer 
nursing, 29 (6) pp.478-486. 
 
248 
 
Thompson, A,M., Wells, M., 2006. Surgery IN Kearney, N., Richardson, A., 
Nursing patients with cancer principles and practice. Edinburgh: Elsevier 
Churchill Livingstone. 
 
Tolaney, S. & Winer, P.E., 2007. Follow-up care of patients with breast cancer. 
The breast, 16 (3) pp.S45-S50. 
 
Tomey, A.M. & Alligood, M.R., 2002. Nursing theorists and their work. St Louis, 
NO: Mosby. 
 
Torgeson, D. & Roland, M.,1998. Understanding controlled trials: what is Zelen’s 
design? British medical journal, 316 (7131) p.606. 
 
Van der Groep, P., van der Wall, E. & van Diest, P., 2011. Pathology of hereditary 
breast cancer. Cell biology, 34 (2) pp.71-88. 
 
van Hezewijk, M., van den Akker, M., van der Helde, C.J.H., Scholten, A.N. & 
Hille, E.T.M., 2012. Costs of difference follow-up strategies in early breast 
cancer: a review of the literature. The breast, 21 (6) pp. 693-700. 
 
Vahdaninia, M., Omidvan,S., & Montazeri, A., 2009. What do predict anxiety and 
depression in breast cancer patients? A follow-up study. Social psychiatry 
and psychiatric epidemiology, 45 pp. 355-361. 
 
Veronesi, U., Cascinelli, N,M., Bufalino, R.,1983. Risk of internal mammary lymph 
node metastases and its relevance on prognosis in breast cancer, Annals 
of Surgery,198 pp.681-84. 
Veronesi U., Viale, G., Rotmensz, N., Goldhirsh, A., 2006. Rethinking TNM : 
breast cancer TNM classification for treatment decision-making and 
research. Breast, 15 (1) pp. 3-8. 
 
Velikova, G., Booth, L., Smith, A.B., Brown, P.M., Lynch, P., Brown, J.M. & Selby, 
P.J., 2004. Measuring quality of life in routine oncology practice improves 
249 
 
communication and well-being: a randomised controlled trial. Journal of 
clinical oncology, 22 (4) pp.714-724. 
 
Vivar, C.G. & McQueen, A., 2005. Informational and emotional needs of long-
term survivors of breast cancer. Journal of advanced nursing, 51 (5) 
pp.520-528. 
 
Walshe, J.M., Dendulur,i N. & Swain, S.M., 2006. Amenorrhea in premenopausal 
women after adjuvant chemotherapy for breast cancer. Journal of clinical 
oncology, 24 (36) pp.1-11. 
 
Watson, E.K., Rose, P.W., Neal, R.D., Hubert-Williams, N., Donnelly, P., 
Hubbard, G., Elliott, J., Campbell, C., Weller, D. & Wilkinson, C., 2012. 
Personalised cancer follow-up: risk stratification, needs assessment or 
both? British journal of cancer, 106 (9) pp.1-5. 
 
Watson, M., Greer, S. & Rowden, L., 1991. Relationships between emotional 
control, adjustment to cancer and depression and anxiety in breast cancer 
patients. Psychological medicine, 21 (1) pp.51-57. 
 
Watson, R., 2003. Scientific methods are the only credible way forward for 
nursing research. Journal of advanced nursing, 43 (3) pp.219–220. 
 
Watson, R., 2012. Editorial: NHS Research Ethics Committees: for those 
protection? Journal of clinical nursing, 21 (15-16) pp.2097-2098. 
 
Weaver, K. & Olson, J.K., 2006. Understanding paradigms used for nursing 
research. Journal of advanced nursing, 53 (4) pp.459-469. 
 
Weigelt, B., Peterse, J.L. & van ’t Veer, L.J., 2005. Breast cancer mets: markers 
and models. Cancer, 5 (8) pp.591-602. 
 
Welford, C., Murphy, K. & Casey, D., 2011. Demystifying nursing research 
terminology. Part 1. Nurse researcher, 18 (4) pp.38-43. 
250 
 
 
Wells, M., Williams, b., Treweek, S., Coyle, J., Taylor, J., 2012. Intervention 
description is not enough: evidence from an in-depth multiple case study 
on the untold role and impact of context in randomised controlled trials of 
seven complex interventions. Trials, 13 95.  Accessed from 
http://www.trialsjournal.com/content/13/1/95 on 9th February 2014. 
 
Welsh Cancer Intelligence and Surveillance Unit, 2008. Cancer incidence in 
Wales. Cardiff: Welsh Cancer Intelligence and Surveillance Unit. 
 
Wen, K.Y. and Gustafson, D.H., 2004. Needs assessment for cancer patients and 
their families. Health quality of life outcomes, 2 (11) pp.1-12. 
 
Wilkinson, J.E., 2011. Using qualitative methodologies to evaluate randomized 
controlled trials: an ontological and epistemological paradox or a pragmatic 
recognition that context matters? Worldviews on evidence-based nursing, 
8 (2) pp.63-65. 
 
World Health Organization Quality of Life Group., 1995. The World Health 
Organisation quality of life assessment (WHOQOL): Position paper from 
the World Health Organization. Social Science & Medicine, 42 (10) 
pp.1403-1409. 
 
Zabora, J., 2001. The prevalence of psychological distress by cancer site. Psych-
oncology, 10 (1) pp.19-28. 
 
Zebrack, B.J., Ganz, P.A., Bernaards, C.A., Peterson, L. and Abraham, L., 2006. 
Assessing the impact of cancer: development of a new instrument for long-
term survivors. Psycho-oncology, 15 (5) pp.407-421. 
 
Zigmond, A.S. & Snaith, R.P., 1983. The hospital anxiety and depression scale. 
Acta psychiatrica scandinavica, 67 (6) pp.361-370. 
 
 
251 
 
Appendix 1: Researchers reflections of the research process 
The researcher’s experience of the field of breast cancer gave her a unique 
understanding of how the service operated and of the different staff members 
who may interact with the study participants. It also challenged her to develop 
objectivity as a researcher, so necessary in the research field. Wells et al. (2012) 
supports reflexivity within RCTs, suggesting it allows a greater understanding of 
the complexity and background activity which contextualises real-life situations. 
The researcher shares this view and that of Ryan & Golden, that “reflexivity adds 
a necessary insight into the complex dynamics that do exist between researchers 
and participants in quantitative research’ (2006, p.1194). While some may 
suggest the use of reflexivity may challenge the validity of quantitative research, 
the researcher would contend it does the opposite: it provides openness about 
how, where and by whom the data were collected, firmly locating the researcher 
as a participant in the dynamic inter-relationship of the research process. 
 
The researcher embarked on this research with a passion for the subject area 
following many years working in the field of breast cancer, surgical and 
chemotherapy services. This has kept her going. Balancing the demands of a full-
time job as a lecturer, her part-time PhD study and family commitments were a 
constant challenge throughout the period, balancing tensions and difficulties in 
equal measure. The researcher once read that patience, flexibility and humility 
are important characteristics to a successful PhD: she would add perseverance. 
 
Patience was required at the outset, balancing the needs of the clinical area 
where the study was to be undertaken and the time pressures of the PhD. 
Systems for identifying the participants for the study, the recruitment process and 
the intervention required careful negotiation and preparation, and as time passed, 
flexibility was required. 
 
The researcher is an optimist and always considered the study was achievable. 
However, over time she underestimated the enormity of the task of running a 
complex RCT and working full-time. While she was able to keep all the balls 
juggling successfully the study proceeded well. Unfortunately, between November 
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2009 and October 2011 the researcher suffered a series of losses which 
included: her husband losing his job and relocating to Wales; both children 
leaving home; the sudden death of her father; and the deaths of two very close 
friends. While she does not wish to dwell on the detail of these losses, the 
cumulative emotional effect impacted on her ability to successfully juggle all the 
balls all of the time. This impacted solely on the distribution of the satisfaction with 
care questionnaires and therefore this data is not available, forming a deviation 
from the original protocol. 
 
Recovery came and her optimism returned, aided by the enthusiasm of the 
SBCN, supervisors and the knowledge that the research would contribute to 
HCP’s understanding of managing unmet need within a hospital follow-up setting. 
 
The limitations and strengths associated with this study reflect the challenges 
experienced undertaking a complex intervention within a real clinic environment.  
There were both practical and methodological issues which, as a novice, the 
researcher was aware of at different stages in the research process.   
 
From a practical perspective, identifying clinic space for the SBCN and support 
for her dictation following the clinic was a surprising obstacle. This was largely out 
of the researcher’s control and while passionate about her study, it took time to 
negotiate as it was not a priority. Between the training of the nurse, delays in 
receiving ethical permission and this issue, recruitment did not begin until 
November 2008, two years and five months after the researcher’s PhD started.   
Despite having worked in the NHS for over 20 years, the researcher displayed a 
naivety in expecting that the electronic patient records to identify patients would 
be easy to navigate. They were difficult to use, compounded by the introduction of 
a new system half-way through the study period and recruitment process. This 
required each patient to be identified individually, their survival status established 
and study details sent to large numbers of women. This was hugely time 
consuming and on-going for 18 months. In hindsight, the paperwork should have 
been sent out at least 12 weeks prior to the clinic, and may have reduced the 
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numbers of patients contacting the researcher after they had received their follow-
up and therefore ineligible to participate.   
Randomisation, central to the mechanics of a trial, was decided prior to the study 
commencing, indeed great thought went into how this would occur and how 
blinding of participants could be maximised. While the system worked well, 
contacting potential participants, getting their agreement to participate, 
randomisation and re-scheduling clinics appointments took longer than first 
thought. This was further compounded because the researcher was not able to 
give 100% of her time to the study due to working full-time. However the learning 
curve has been steep and rewarding, her skills in the use of statistical packages 
and interpretation of statistics have, and will be hugely beneficial in the future.  It 
has been quite a journey. 
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Appendix 2: Example of Medline search strategy (1996 - 2013) 
1 exp Breast Neoplasm/ 
2 (breast$ or mammary$).tw. 
3 (cancer or tumor$ or tumour$ or carcinoma$ or sarcoma$ or neoplasm$ or 
adenocarcinoma$ or metastasis or poly$).tw. 
4 2 and 3 
5 (breast adj mass).tw. 
6 (cystosarcoma adj Phylloides tumour)>tw. 
7 (carcinoma, intraductal, noninfiltrating).tw. 
8 (paget’s disease, mammary midline heading).tw. 
9 Or/4-8 
10 1 or 9 
11 Exp Neoplasm Recurrence, Local/ 
12 Recur.tw. 
13 relaps$.tw. 
14 or/11-13 
15 (patients$adj follow up).tw. 
16 (surveillance adj patient$).tw. 
17 Or/15-16 
18 Exp Diagnostic imaging/ 
19 Magnetic resonance imaging.tw. 
20 Positron emission tomography.tw. 
21 Exp RADIOGRAPHY/ 
22 x-ray.tw. 
23 ultraso$ 
24 mammogra$.tw. 
25 or/18-24 
26 10 and 17 and 24 
27 10 and 14 and 24 
28 10 and 17 
29 or/26-28 
30 Limit 29 to yr=1996-2013 
31 from 30 keep 1-10 
32 from 30 keep 1-200 
 Nursing and follow-up 
1 Exp Breast Cancer/ 
2 Follow.af. 
3 1 and 2 
4 Exp Cancer Services/exp cancer nursing/ 
5 4 and 2 
6 3 or 5  
 Needs assessment (major concept) 
1 exp*Needs Assessment/4288 
2 exp*neoplasms/ 
3 1 or 2 
4 Limit 3 to yr=1993-2013 
5 From 4  
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Appendix 3: Breast cancer needs questionnaire 
 
 
In the last month, 
what was your level of need for 
help with: 
No need Some need 
     
 
 
Not 
applicable 
 
Satisfied 
Low 
need 
Modera
te need 
High 
need 
1.  Coping with problems with your 
prosthesis 
 
1 2 3 4 5 
2.  Wanting more information about 
finding a good breast prothesis 
 
1 2 3 4 5 
3.  Wanting help in coping with the 
amount of breast that was 
removed 
 
1 2 3 4 5 
4.  Coping with changes to your 
self-image as a result of breast 
surgery 
 
1 2 3 4 5 
5.  Dealing with your partner’s 
reaction to your breasts 
 
1 2 3 4 5 
6.  Coping with fear about the 
reaction of future partner’s to 
your breasts. 
 
1 2 3 4 5 
7.  Coping with lymphoedema 
 
1 2 3 4 5 
8.  Coping with what having breast 
cancer might mean for your 
daughters or sisters 
 
1 2 3 4 5 
9.  Being informed about your 
daughters and/or sister’s risk of 
developing breast cancer 
 
1 2 3 4 5 
10.  Dealing with lack of energy or 
tiredness 
 
1 2 3 4 5 
11.  Pain or discomfort in the arm 
near to your surgery 
1 2 3 4 5 
12.  Pain or discomfort in the area of 
your affected breast 
1 2 3 4 5 
13.  Dealing with menopausal 
symptoms, which have occurred 
as a result of your treatment 
1 2 3 4 5 
14.  Dealing with anger and 
confusion about why this has 
happened to you 
1 2 3 4 5 
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15.  Dealing with fears about the 
cancer spreading or returning 
 
1 2 3 4 5 
16.  Trying to find meaning in this 
experience 
 
1 2 3 4 5 
17.  Coping with changes to your 
usual  
routine and lifestyle 
 
1 2 3 4 5 
18.  Dealing with the impact of 
cancer on your career 
 
1 2 3 4 5 
19.  Accepting changes in your 
appearance 
1 2 3 4 5 
20.  Coping with changes in your 
sexuality or to your sexual 
relationships 
 
1 2 3 4 5 
21.  Finding assistance for your 
partner to come to terms with 
your cancer 
 
1 2 3 4 5 
22.  Coping with the impact your 
cancer is having on your 
relationship (both for you and/or 
your partner) 
 
1 2 3 4 5 
23.  Coping with changes with others 
attitudes and behaviour towards 
you 
 
1 2 3 4 5 
24.  Finding a support group which 
addresses your particular needs 
 
1 2 3 4 5 
25.  Meeting other breast cancer 
survivors who are your age 
 
1 2 3 4 5 
26.  Being informed about the 
possible effects of the cancer on 
the length of your life 
 
1 2 3 4 5 
27.  Being informed about the 
causes, preventions and 
treatment of lymphoedema 
1 2 3 4 5 
28.  Being informed about the latest 
developments in treatment and 
prevention of breast cancer 
 
1 2 3 4 5 
29.  Being informed about insurance 
issues 
1 2 3 4 5 
30.  Being informed about the impact 
of cancer treatment on your 
1 2 3 4 5 
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fertility 
31.  Being informed about the 
causes and possible triggers of 
breast cancer 
1 2 3 4 5 
32.  Being informed about the impact 
of the cancer or treatment on 
your ability to breast-feed 
children 
1 2 3 4 5 
33.  Being informed about using 
contraception following 
treatment 
1 2 3 4 5 
34.  Receiving information and 
advice about your diet 
1 2 3 4 5 
35.  Receiving information which is 
specific to women of your age 
1 2 3 4 5 
36.  Feeling able to ask your cancer 
specialists for information about 
a range of issues not just 
medical issues 
1 2 3 4 5 
37.  Having one doctor who knows 
all about your condition, 
treatment and follow-up 
1 2 3 4 5 
38.  Being able to negotiate with 
your specialists about the 
frequency or length of follow-up 
appointments 
1 2 3 4 5 
39.  Being able to negotiate with 
your specialists about the 
location of your follow-up 
appointments (eg whether the 
appointments occur at the 
treatment centre or in a 
separate clinic) 
1 2 3 4 5 
40. Having access to health 
professionals (eg. general 
practitioners, dieticians, 
physiotherapists) who specialise 
in dealing with people who are 
cancer survivors (or people who 
are recovering from cancer) 
1 2 3 4 5 
 
 
Centre for Health Research & Psycho-oncology (2003) Recent Survivors of Breast 
Cancer Survey. 
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Appendix 4: HADS 
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Appendix 5: EORTC QLQ C30 and BR23 
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Appendix 6: Key Instruments used in Health related quality of life research in breast cancer       
Type of construct measured  
   
  
EORTC EORTC FACT-G FACT-B CARES POMS HADS SF-36 FLIC RSCL 
QLQ-C30 BR-23         
Physical functioning    5  2  4   10  4 
Role - physical    2  3  7   5 4 4 
Mental Health              
Psychological           3 4 8 
distress/adjustment    4 1 7 2 5      
anxiety          9 7    
depression         15 7    
anger-hostility         12     
anxiety re cancer, treatment    1   4    2  
anxiety in medical situations       8      
psychological well-being          2   
role-emotional      2  2   3   
social     2  6  14   2 2  
energy/fatigue    3  1  3 15  4  2 
cognitive     2    3 7     
sleep     1  1  1     2 
pain     2  1  4   2  1 
general health/global QOL   2 1 6 1    4 3  
Health change           1 2  
body image     2  1 3      
sexual interest, function/attractiveness  5 1 2 8     1 
clothing         3      
nausea/vomiting    2  2  6    2 2 
hair loss      2  1 1     1 
appetite/taste/dry mouth/swallowing 1 2   3     1 
other GI symptoms    2    1     3 
shortness of breath    1   1      1 
arm symptoms     3  1       
breast symptoms     4         
hot flashes     1         
ostomy/prosthesis problems       2      
other physical symptoms    1   4     8 
medical interaction      2  11      
patient compliance        4      
relationship with partner       18      
interaction with children       3      
dating problems        5      
employment concerns       7      
hardship due to cancer (self)   1    3    1  
hardship (family)            2  
Not scored         7     
Total items    30 23 34 10 139 65 14 36 22 38 
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Appendix 7: Data collection sheet  
 
Demographic and clinical characteristics of the participants in the study 
 
Age  
Surgery Mastectomy 
 Wide local excision 
Axillary surgery Sample 
 Clearance 
 Sentinal node biopsy 
Reconstruction Yes/no 
Time since diagnosis  
Side of primary Left 
 Right 
Pathological tumour size 0-0.9 
 1.0-1.9 
 2.0-2.9 
 >3.0 
Tumour grade 1 
 2 
 3 
 Unknown 
Histological type ductal 
 Lobular 
 Not reported 
Node status Positive 
 negative 
 unknown 
Her2 status Positive 
 Negative 
 Unknown 
ER status Positive 
 Negative 
 Unknown 
Adjuvant treatment None 
 Endocrine therapy 
 Chemotherapy 
 Radiotherapy 
 Herceptin 
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Appendix 8: Letter of invitation to take part in the study 
 
 
Dear …… 
 
You have an appointment to attend St John’s Hospital Breast Clinic in the next few 
weeks/months. 
 
We have become aware that many questions can arise leading up to and during the 
follow-up clinic appointment and we want to improve the care we provide. We are 
therefore undertaking a research study during this period to look at different ways of 
providing follow-up care to patients, within the breast clinic. 
 
Taking part in our research study would help us to improve our care and we would value 
your contribution. An information sheet about the study is provided. 
 
If you would be interested in taking part, complete the tear off slip below and send back 
in the stamped addressed envelope to Napier University to Sue Cruickshank who is co-
ordinating the study.  Alternatively you can phone her on 0131 455 5705.  A member of 
the research team will get back to you. This is not the consent form to participate in the 
study. 
 
Yours Sincerely 
 
Mr Mathew Barber, Consultant Surgeon 
Dr Frances Yuille, Consultant Clinical Oncologist 
Rosie Small, Breast Care Nurse Specialist 
Sue Cruickshank, Researcher, Napier University 
 
Name: 
 
Contact Details: 
 
I am interested in taking part in the follow-up study. 
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Appendix 9: Information for participants about the study 
 
        
 
 
 
Follow-up of breast cancer patients: a randomised controlled trial of a nursing 
intervention 
 
 
 
PATIENT INFORMATION SHEET 
 
You are being invited you to take part in a research study.  The study is being 
carried out by staff at Napier University, School of Nursing and the breast cancer 
team at St John’s Hospital, West Lothian.  Before you make a decision it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the information carefully and discuss it with 
family, friends, your GP or the independent person if you wish. Please ask your 
doctor or nurse if there is anything you do not understand or if you want more 
information. Take your time to decide. 
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Breast cancer 
services are 
undergoing 
significant 
changes, 
recognizing the 
need to adapt and 
 
 
 
Breast cancer 
services are 
undergoing 
significant 
changes, 
recognizing the 
need to adapt and 
respond to the 
complex needs of 
breast cancer 
patients. The way 
follow-up services 
are managed is 
being reviewed at 
 
 
r t r 
s r ic s r  
r i  
i ifi t 
, 
r i i  t  
 t  t  
Why is the study being done? 
Follow-up care has traditionally focused on the the chances of cancer returning. 
While this is very important, it does not always answer all the questions that 
women may have. Other research studies have found that nurses can provide 
useful follow-up care. This research aims to investigate whether offering women a 
chance to talk about the needs that are important to them, before they come to 
the clinic allows the time spent in the clinic to be more effective.   
 
How was I selected? 
You have been diagnosed with breast cancer and are being offered or have been 
having follow-up care   
 
How will you get in touch with me? 
The initial contact will be by your doctor or nurse. They will tell you about the 
study and if you agree, you will meet the researcher, Sue Cruickshank. 
 
What am I being asked to do? 
We want to compare two different ways of providing follow-up care to women 
following a diagnosis of breast cancer. Whichever one you are allocated, you will 
be asked to fill in some questionnaires about your concerns and your quality of 
life. 
 
Follow-up by the doctor: This is the standard follow-up care offered at St Johns 
hospital and is in common use in most breast services. You will see a doctor at 
regular intervals, undergo a clinical examination and have a mammogram yearly. 
You will be asked to fill in some questionnaires before the clinic appointment and 
at regular intervals which will only be seen by the researcher. 
 
Follow-up by the breast care nurse:  You will see a breast care nurse, undergo 
a clinical examination and have a mammogram yearly. Plus, you will be asked to 
fill in some questionnaires prior to your appointment.  This will give you an 
opportunity to describe your concerns. This information will be available to the 
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nurse during the clinic appointment and she will then put together a plan that best 
suits your needs. This may include referral to other health professionals, more 
information or some additional support.  She will contact you a month later to see 
how you are getting on.   
 
How will my follow-up be chosen? 
Everyone who agrees to take part in this research study will be allocated to one of 
two groups. Every patient has an equal chance of being in each group. It is 
important that the two groups of patients are as similar to each other as possible. 
This is because we need to be sure that if one group fares better than the other, it 
is because of the follow-up, and not because the groups are different from each 
other in some way. The only way to make sure that the groups of patients are as 
similar as possible is to allocate patients to a group at random. A computer 
programme is used to make sure it is done properly. We do not use any 
information about you or your breast cancer to allocate you to one of the groups. 
 
We will look at how both groups get on and compare them. This will tell us which 
way is better to provide follow-up care.  
 
What if I do not wish to take part? 
If you do not wish to take part in this research, you will be offered the usual 
follow-up care delivered by the doctor. 
 
What will happen to me if I take part? 
If you agree to take part in this research, you will be asked to fill in some 
questionnaires before coming to the clinic. Before every appointment you will be 
sent another one. You will also be asked to fill in some short questionnaire 
booklets asking about your quality of life and general health, before attending the 
follow-up appointment and then at 12 months 
 
The information will be kept and analysed anonymously. However, if we find that 
those in the doctor group have scored a particularly high score on either, the 
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anxiety and depression scale then with your permission we will inform your doctor 
or GP.   
 
If you decide to take part you are still free to withdraw at any time andwithout 
giving a reason. This will not affect the standard of care you receive. 
 
What will happen to the results of the research study? 
The results will be published in a professional journal. You will not be identified in 
any report or publication. We will write to you when the results are known to ask if 
you would like to see them. The letter will explain how to get a copy. The 
anonymous data or part of the data from the quality of life questionnaire will be 
passed onto the EORTC Quality of Life Group. 
 
Confidentiality 
Your medical notes will need to be seen by authorised members of the research 
team, so that they can collect and check information needed for this research 
study. Your name, date of birth and NHS number will be passed to the research 
nurse. You will be given a unique registration number, which will be used together 
with your initials and date of birth on forms that the Research Staff uses. All 
information about you will be treated as strictly confidential and nothing that might 
identify you will be seen by anyone else. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you decide to take part, you 
will be asked to sign a consent form. You will be given a copy of the consent form 
to keep, together with this information sheet. Your GP will be told if you are taking 
part in this research, unless you specifically request that he/she is not told.   
 
What are the benefits and risks of taking part? 
We hope that the information we gain will benefit patients who attend follow-up in 
the future but here is no guarantee that you as an individual will benefit directly 
from taking part.  
 
Thank you for reading this 
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Researcher 
Susanne (Sue) Cruickshank 
Lecturer in Cancer Nursing 
School of Nursing, Midwifery and Social Care 
Napier University 
74 Canaan Lane 
Edinburgh 
EH9 2TB 
Tel: 0131 455 5705 (answer phone) 
Email: s.cruickshank@napier.ac.uk 
 
If you wish to speak to someone independent of the research team you can 
contact:  
Juliet MacArthur 
Senior Nurse – Research 
NHS Lothian 
Western General Hospital 
Crewe Road 
Edinburgh 
Tel: 0131 537 2090 
Email: Juliet.MacArthur@luht.scot.nhs.uk 
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Appendix 10  -  Consent form 
      
 
 
Patient Identification Number for this study: 
 
Consent Form for patients 
 
 
Title of study: Follow up care of breast cancer patients: a randomised 
controlled trial of a nursing intervention 
 
Name:            
 
Address:            
 
            
 
 
I confirm I have read and understood the information 
 
I confirm I have had an opportunity to ask questions and discuss the study 
before taking part. 
 
I confirm that my participation is voluntary and that I am aware I may withdraw 
from the study at any point, without explanation and with no adverse affect to 
the care I receive 
 
I understand that sections of my medical notes will be looked at by members 
of the research team.  
 
I agree to take part in the above study 
 
 
Name:                Date:     
 
Signature:           Date:    
   
 
Researcher’s signature:        Date:    
 
One copy to researcher, one copy for participant, 1 copy for hospital notes 
The participants General Practitioner will be notified of inclusion in the study 
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Appendix 11: Exploratory factor analysis results of BCNQ: rotated 
component matrix 
  Component* 
1 2 3 4 5 
Coping with the impact your cancer is having on 
your relationship (both for you and/or your 
partner) 
.873 
    
Accepting changes to your appearance .821 
    
Meeting other breast cancer survivors who are 
your age 
.728 
  
.330 
 
Coping with changes with others attitudes and 
behaviour towards you 
.706 .500 
   
Coping with changes in your sexuality or to your 
sexual relationships 
.696 
    
Finding assistance for your partner to come to 
terms with your cancer 
.694 .306 
   
Coping with changes to your usual routine and 
lifestyle 
.655 .470 
 
.382 
 
Dealing with anger and confusion about why this 
has happened to you 
.617 .549 
   
Coping with changes to your self-image as a 
result of breast cancer 
.610 .439 
   
Dealing with fears about the cancer spreading or 
returning 
.591 .379 .304 
  
Coping with fear about the reaction of future 
partner's to your breasts 
.555 
 
.319 
  
Dealing with the impact of cancer on your career .517 
    
Being informed about using contraception 
following treatment 
.501 
  
.337 
 
Dealing with lack of energy or tiredness .472 .461 
   
Being informed about the impact of the cancer 
treatment on your ability to breast-feed children      
Having one doctor who knows all about your 
condition, treatment and follow-up      
Being able to negotiate with your specialists 
about the frequency or length of follow-up 
appointments 
 
.764 
   
Wanting more information about finding a good 
breast protesis  
.685 
   
Coping with problems with your prosthesis 
 
.681 
   
Having access to health professionals (eg 
general practitioners, dieticians. physiotherapists) 
who specialise in dealing with people who are 
cancer survivors (or people who are recovering 
from cancer) 
 
.660 
 
.426 
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  Component* 
1 2 3 4 5 
Feeling able to ask your cancer specialists for 
information about a range of issues not just 
medical issues 
 
.648 
   
Trying to find meaning in this experience .581 .641 
   
Being able to negotiate with your specialists 
about the location of your follow-up appointments 
(e.g. whether the appointments occur at the 
treatment centre or in a separate clinic) 
 
.618 
 
.312 
 
Being informed about the possible effects of the 
cancer on the length of your life  
.540 
 
.343 
 
Wanting help in coping with amount of breast that 
was removed   
.667 
  
Coping with lymphoedema 
  
.659 
  
Pain or discomfort in the arm near to your surgery .336 
 
.637 
  
Pain or discomfort in the area of your affected 
breast 
.400 
 
.611 
  
Dealing with your partner's reaction to your 
breasts 
.342 
 
.578 
  
Being informed about the causes, preventions 
and treatment of lymphoedema  
.433 .502 .330 
 
Dealing with menopausal symptoms, which have 
occurred as a result of your treatment   
.404 
  
Receiving information which is specific to women 
of your age    
.782 .312 
Receiving information and advice about your diet 
   
.731 
 
Being informed about the causes and possible 
triggers of breast cancer    
.540 .491 
Being informed about your daughters and/or 
sister's risk of developing breast cancer  
.384 
 
.448 
 
Coping with what having breast cancer might 
mean for your daughters or sisters     
.882 
Being informed about the impact of cancer 
treatment on your fertility     
.864 
Being informed about insurance issues .481 
   
.513 
Being informed about the latest developments in 
treatment and prevention of breast cancer  
.374 .418 .459 .470 
Extraction Method: Principal Component Analysis  
Rotation Method: Varimax with Kaiser Normalization 
* Rotation converged in 12 iterations. 
 
